



(51) International Patent Classification:

A61K 47/60 (2017.01) C07H 3/04 (2006.01)
 A61K 47/68 (2017.01) C07H 3/02 (2006.01)
 A61P 35/00 (2006.01) C07H 17/00 (2006.01)
 C07D 403/04 (2006.01) C07D 495/14 (2006.01)
 C07D 471/04 (2006.01) C07D 487/04 (2006.01)

(21) International Application Number:

PCT/IB2022/000772

(22) International Filing Date:

20 December 2022 (20.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/292,101 21 December 2021 (21.12.2021) US

(71) Applicant: INTOCELL, INC. [KR/KR]; 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR).


(72) Inventors: PARK, Taekyo; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). REW, Yosup; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). KIM, Sunyoung; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). JUNG, Doohwan; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). SEO, Donghoon; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). LEE, Sangkwang; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). HA, Jihyeon; Intocell, Inc.,

101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). CHOI, Jihye; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). JEON, Cheolmin; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). JEONG, Myeonghwa; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). KIM, Hyewon; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). YANG, Eun, Hye; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). KIM, Ya, Gob; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). LEE, Chohee; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). LEE, Hyang, Sook; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). SEO, Beomseok; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). SONG, Jina; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). KIM, Sena; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR). YOO, Jae, Do; Intocell, Inc., 101, Sinildong-ro, Daedeok-gu, Daejeon, 34324 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF

Fig. 1A



(57) Abstract: The present disclosure is directed toward drugs and toxins functionalized by at least one saccharide, sulfate or sulfonate; drug conjugates comprising said drugs or toxins and a cleavable linker; and targeted conjugates comprising said drugs or toxins, cleavable linkers, and targeting moieties. The present disclosure also relates to methods of treating cancers, auto-immune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS


This application claims the benefit of priority to US Provisional Patent Application No. 63/292,101, filed December 21, 2021. The entirety of this application is incorporated herein by reference.

BACKGROUND


Cleavable drug conjugates have the potential to combine the binding specificity of antibodies or other targeting groups with the potency of chemotherapeutic agents. Since targeting allows a drug to be accurately delivered to a target cancer cell and released under specific conditions while minimizing collateral damage to healthy cells, this technology increases the efficacy of a therapeutic agent and decreases the risk of an adverse reaction. However, conventional treatments show non-selective uptake of drugs into normal cells and cancer cells, and their therapeutic effects are not significant. The non-selective uptake is mainly due to the hydrophobicity of linker-drugs, and although studies are being conducted to lower the hydrophobicity of linker-drugs, so far their success is limited.

SUMMARY OF THE DISCLOSURE

In certain aspects, provided herein are drug conjugates comprising a compound represented by formula (VII) or (VIII) and a linker group:



(VII); or



(VIII);

or a pharmaceutically acceptable salt thereof;

wherein:

A is a heterocycle;

each R^a and R^b are independently halogen, amino, hydroxyl, acetyl, hydroxyalkyl, alkoxy,

5 cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

two geminal R^b are optionally taken together to form an oxo or =CH₂; or two R^b, together with the intervening atoms, optionally complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

10 R^c is sulfonate, sulfate, hydroxyl, amino, or thiol;

R^d is -L^{''}-Gly, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

provided that at least one R^c is sulfonate or sulfate, or at least one R^d is -L^{''}-Gly;

R^e is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

15 m is an integer selected from 0-3;

n is an integer selected from 0-8, as valency permits;

ring Cy is selected from aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

== is a single bond or a double bond;

X' is halogen;

20 X'' is -NR-, -S-, or -O-;

R is hydrogen or alkyl;

each R^{a''} and R^{b''} are independently halogen, amino, hydroxyl, alkoxy, acetyl, hydroxyalkyl, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or -(L''')_r-X''-Gly;

25 d is an integer selected from 0-4;

r is an integer from 0-1;

each L''' is a bond or a linker,

R^{e''} is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

p is an integer selected from 0-4;

30 DBD is a DNA binding domain;



L'' is a bond or a linker; and

Gly is a monosaccharide, disaccharide, or oligosaccharide.


In certain aspects, provided herein are targeted drug conjugates comprising the drug conjugate comprising compounds of the present disclosure, a linker group, and a targeting moiety.

In certain embodiments, the targeted drug conjugate is a compound represented by

5 Formula (XII), (XIII) or (XIV):



10




or a pharmaceutically acceptable salt thereof;

wherein TM is a targeting moiety.

In certain aspects, provided herein are drug conjugates comprising an active agent and a linking group; wherein the active agent is substituted with a polar group. In some embodiments, the polar group is selected from a saccharide, sulfate, or sulfonate.

In some embodiments, drug conjugates comprising an active agent and a linking group are the drug conjugates of Formula (I):



or a pharmaceutically acceptable salt thereof;

wherein:

Z' is a coupling group;

Ar is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

Y' is $-(CR^b)_yN(R^a)-$, $-(CR^b)_yO-$, or $-(CR^b)_yS-$, positioned such that the N, O, or S atom is attached to TG if y is 1;

TG is a triggering group that, when activated, generates an N, O, or S atom capable of reacting with the SO_2 to displace $(Q)_q-(L')_w$ and form a 5- to 6-membered ring

including X- SO_2 and the intervening atoms of Ar;

X is $-O-$, $-C(R^b)_2-$, or $-N(R^c)-$;

L' is a spacer moiety that if present, is attached to the SO_2 via a heteroatom selected from O, S, and N, and is selected such that cleavage of the bond between L' and SO_2 promotes release of the active agent;


each Q is independently an active agent substituted with a saccharide, a sulfate, or a sulfonate;

q is an integer selected from 1 to 3;


w and y are each independently 0 or 1; and

R^a , R^b and R^c are each independently hydrogen or C_{1-6} alkyl; or two R^b , together with the atom to which they are attached, complete a 3- to 5-membered ring; provided that when w is 0, q is 1.

In certain embodiments, the drug conjugate is a compound of Formula (IIIa) or (IIIb):




(IIIa); or



(IIIb);

5 or a pharmaceutically acceptable salt thereof.


In further embodiments, the drug conjugate is a compound represented by Formula (V):



(V);


10 or a pharmaceutically acceptable salt thereof.

In further aspects, provided herein are targeted drug conjugates of Formula (VI), comprising a targeting moiety conjugated to any one of the drug conjugates of the present disclosure:



wherein TM is a targeting moiety.

In yet further aspects, provided herein are targeted drug conjugates of Formula (VIb) comprising a targeting moiety conjugated to the drug conjugates of the present disclosure:




wherein:

TM is a targeting moiety;

10 R is hydrogen or a hydroxy protection group;

X is -C(O)-, -NH-, -O-, or -S-;

Q is an active agent substituted with a saccharide, a sulfonate, or a sulfate;





n is an integer selected from 0 or 1;

15 Y is hydrogen, haloC₁-C₈alkyl, halogen, cyano or nitro; z is an integer selected from 1-3, and

Y may be the same or different from each other, if z is an integer of not less than 2;

z1 is an integer selected from 0 or 1;



20 W_{a1} and W_{a2} are each independently -NH-, -C(=O)-, or -CH₂-;

W_{a3} and W_{a4} are each independently -NH-, -C(=O)-, -CH₂-, -C(=O)NH-, -NHC(=O)-, or triazolylenes;

W_{b1} is an amide bond or triazolylene;

L is an amino acid, peptide, or amide bond as a linker connecting W_{a2} and Z;

Z is a single bond, $-W_{a5}-(CH_2)_{a2}-W_{b2}-(CH_2)_{a3}-W_{a6}-$, or $-W_{a7}-(CH_2)_{a4}-CR'R''-X'''-$;

R' is C_1 - C_8 alkyl or $TM-W_{a8}-Q_3-W_{c1}-(CH_2)_{a5}-$;

R'' is $TM-W_{a8}-Q_3-W_{c1}-(CH_2)_{a5}-$;

5 Q_1 and Q_3 are each independently $-(CH_2)_{a6}-(X_1CH_2CH_2)_{b1}-(CH_2)_{a7}-$;

X_1 and X_3 are each independently $-O-$, $-S-$, $-NH-$, or $-CH_2-$;

X''' is $-NHC(=O)-(CH_2)_{a8}-W_{a9}-$ or $-C(=O)NH-(CH_2)_{a8}-W_{a9}-$;

W_{a5} , W_{a6} , W_{a7} , W_{a8} , and W_{a9} are each independently $-NH-$, $-C(=O)-$, or $-CH_2-$;

W_{b2} is an amide bond or triazolyne;

10 W_{c1} is $-NHC(=O)-$ or $-C(=O)NH-$;

Q_2 is a saturated or unsaturated alkylene, which is linear or branched with a carbon number of 1 to 50, satisfying any one of (i) to (iii) below;

(i) at least one $-CH_2-$ in the alkylene is substituted with one or more heteroatoms selected from $-NH-$, $-C(=O)-$, $-O-$, and $-S-$,

15 (ii) at least one arylene or heteroarylene is included in the alkylene,


(iii) the alkylene is further substituted with one or more selected from the group consisting of C_1 - C_{20} alkyl, C_6 - C_{20} aryl, C_1 - C_8 alkyl, $-(CH_2)_{s1}COOR_3$, $-(CH_2)_{s1}COR_3$, $-(CH_2)_{s2}CONR_4R_5$, and $-(CH_2)_{s2}NR_4R_5$;

arylene or heteroarylene of (ii) above may be further substituted with nitro;

20 R_3 , R_4 , and R_5 are each independently hydrogen or C_1 - C_{15} alkyl;

X_2 is $-O-$, $-S-$, $-NH-$, or $-CH_2-$;

U_1 is bound to B' in the position of asterisk (*) with a linking group selected from the following structures:




25 R is C_1 - C_{10} alkyl, C_6 - C_{20} aryl or C_2 - C_{20} heteroaryl;

TM and B' are each independently a ligand or a protein having properties selectively targeting a particular organ with a drug, a tissue or a cell, that is, properties binding to a receptor; a1, a2, a3, a4, a5, a6, a8, b1, p1, p2, p3 and p4 are each independently an integer selected from 1-10;

- 5 a7, y, s1, s2 and s4 are each independently an integer selected from 0-10; and
R₁ and R₂ are each independently hydrogen, C₁-C₈ alkyl or C₃-C₈ cycloalkyl.

In yet further aspects, provided herein are targeted drug conjugates of Formula (VIc) comprising a targeting moiety conjugated to the drug conjugates of the present disclosure:



10 (VIc);

wherein:

TM is a targeting moiety;

G is a glucuronic acid moiety or a derivative thereof;

Q is an active agent substituted with a saccharide, a sulfonate or a sulfate;

- 15 W is an electron withdrawing group;


Z is hydrogen, C₁-C₈ alkyl, halogen, cyano, or nitro;

n is an integer selected from 1-3, and when n is an integer of 2 or more, each of the Z(s) are the same as or different from each other;

L is a linker connecting TM and W; and

- 20 R₁ and R₂ are each independently hydrogen, C₁-C₈ alkyl, or C₃-C₈ cycloalkyl

In certain aspects, provided herein are targeted drug conjugate of Formula (VIId) comprising a targeting moiety conjugated to the drug conjugate of the present disclosure:



- 25 wherein TM is a targeting moiety;

L₁ is ligand moiety;


Q is an active agent substituted with a saccharide, a sulfonate or a sulfate;

-A_a-W_w-Y_y- is linker moiety;

A is an optional stretcher moiety;

- 30 a is an integer selected from 0-3;

each W is independently a glucuronide unit having one of the formula:



Su is a sugar moiety;

each R is independently hydrogen, halogen, -CN, or -NO₂;


5 w is an integer selected from 1-2;

Y is an optional self-immolative spacer moiety;


y is an integer selected from 0-2; and

p is an integer selected from 1-20.

In still further aspects, provided herein are compounds of Formula (VII) or (VIII):



(VII); or



(VIII);

or a pharmaceutically acceptable salt thereof;

15 wherein:

A is a heterocycle;

each R^{a'} and R^{b'} are independently halogen, amino, hydroxyl, acetyl, hydroxyalkyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

two geminal R^{b'} are optionally taken together to form an oxo or =CH₂; or two R^{b'}, together with the intervening atoms, optionally complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^{c'} is sulfonate, sulfate, hydroxyl, amino, or thiol;

- 5 R^{d'} is -L''-Gly, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

provided that at least one R^{c'} is sulfonate or sulfate, or at least one R^{d'} is -L''-Gly;

R^{e'} is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

m is an integer selected from 0-3;

- 10 n is an integer selected from 0-8, as valency permits;

ring Cy is selected from aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

=== is a single bond or a double bond;

X' is halogen;

X'' is -NR-, -S-, or -O-;

- 15 each R^{a''} and R^{b''} are independently halogen, amino, hydroxyl, alkoxy, acetyl, hydroxyalkyl, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or -(L''')_r-X''-Gly;

d is an integer selected from 0-4;

r is an integer selected from 0-1;

- 20 each L''' is a bond or a linker,

R^{e''} is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;


p is an integer selected from 0-4;

DBD is a DNA binding domain;

L'' is a bond or a linker; and

- 25 Gly is a monosaccharide, disaccharide, or oligosaccharide.


In certain embodiments, the compound is a compound of Formula (VII):



(VII);



or a pharmaceutically acceptable salt thereof.


- 30 In further embodiments, the compound is a compound of formula (VIII):



or a pharmaceutically acceptable salt thereof.

In certain aspects, provided herein are drug conjugates comprising any one of the disclosed compounds and a linker group. In certain embodiments, the drug conjugate is a compound of formula (IX), (X), or (XI):





or a pharmaceutically acceptable salt thereof;

wherein:

5 Z' is a coupling group;

Ar is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

Y' is $-(CR^{b_2})_yN(R^a)-$, $-(CR^{b_2})_yO-$, or $-(CR^{b_2})_yS-$, positioned such that the N, O, or S atom is attached to TG if y is 1;

10 TG is a triggering group that, when activated, generates an N, O, or S atom capable of reacting with the SO_2 to displace $(Q)_q-(L')_w$ and form a 5- to 6-membered ring including X- SO_2 and the intervening atoms of Ar;

X is $-O-$, $-C(R^b)_2-$, or $-N(R^c)-$;

L' is a spacer moiety that if present, is attached to the SO_2 via a heteroatom selected from O, S, and N, and is selected such that cleavage of the bond between L' and SO_2 promotes

15 release of the active agent;

w is an integer selected from 0-1;

r is an integer from 0-1;

Z^2 is a linking group;

Z^3 is a linking group;




20 R^a , R^b and R^c are each independently hydrogen, or lower alkyl;

y is an integer selected from 0-1;

t is an integer from 1-5; and

e is an integer from 1-5.

In further aspects, provided herein are targeted drug conjugates comprising any one of the drug conjugates provided herein and a targeting moiety. In certain embodiments, the drug conjugate is a compound of formula (XII), (XIII) or (XIV):



or a pharmaceutically acceptable salt thereof;
wherein TM is a targeting moiety.

In yet further aspects, provided herein are methods of treating a cancer, comprising administering any one of the compounds, drug conjugates, targeted drug conjugates, or

pharmaceutically compositions provided herein to a subject in need thereof. In certain embodiments, the cancer is selected from leukemia, lymphoma, breast cancer, colon cancer, ovarian cancer, bladder cancer, prostate cancer, glioma, lung cancer, bronchial cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, urinary bladder cancer, kidney cancer, renal pelvis cancer, oral cavity cancer, pharynx cancer, uterine corpus cancer, or melanoma.

In still further aspects, provided herein are methods of treating autoimmune diseases or inflammatory diseases, comprising administering any one of the compounds, drug conjugates, targeted drug conjugates, or pharmaceutically compositions provided herein to a subject in need thereof. In certain embodiments, the autoimmune diseases or the inflammatory disease is selected from B-cell mediated autoimmune diseases or inflammatory diseases, for example, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP), Waldenstrom's hypergammaglobulinaemia, Sjogren's syndrome, multiple sclerosis (MS), or lupus nephritis.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1A shows the *in vivo* efficacy of T-2-AB, T-3-AB, and T-4-AB in the JIMT-1 xenograft model.

Fig. 1B shows the *in vivo* efficacy of T-103-AB, T-104-AB, T-116-AB, and T-117-AB in the JIMT-1 xenograft model.

Fig. 2A shows the plasma stability of seco-MCBI-HAI duocarmycin payloads where A indicates the unsubstituted toxin-linker conjugate, and B indicates the glyco-substituted toxin-linker conjugate.

Fig. 2B shows the plasma stability of seco-DUBA duocarmycin payloads where C indicates the unsubstituted toxin-linker conjugate, and D indicates the glyco-substituted toxin-linker conjugate.

DETAILED DESCRIPTION OF THE DISCLOSURE

Provided herein are compounds, drug conjugates, and targeted drug conjugates which are useful for the treatment of cancer and/or autoimmune diseases or inflammatory diseases. The compounds, the drug conjugates, and targeted drug conjugates may be derived from generally toxin payloads which have been modified with a saccharide, a sulfate, or sulfonate.

The compounds, the drug conjugates, and targeted drug conjugates may significantly reduce non-specific uptake of drugs.

Some components of the technology disclosed herein, including cleavable linker technologies and targeting moieties, are further described in WO 2019/008441, WO 2019/229536, WO 2020/141459, WO 2020/141460, PCT/IB2021/000445, US 16,472,983, US 14,898,932, and US 11,996,009 each of which is incorporated herein by reference in its entirety.

Definitions

Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of, chemistry, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, pharmacology, genetics and protein and nucleic acid chemistry, described herein, are those well known and commonly used in the art.

The methods and techniques of the present disclosure are generally performed, unless otherwise indicated, according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout this specification. See, e.g. "Principles of Neural Science", McGraw-Hill Medical, New York, N.Y. (2000); Motulsky, "Intuitive Biostatistics", Oxford University Press, Inc. (1995); Lodish et al., "Molecular Cell Biology, 4th ed.", W. H. Freeman & Co., New York (2000); Griffiths et al., "Introduction to Genetic Analysis, 7th ed.", W. H. Freeman & Co., N.Y. (1999); and Gilbert et al., "Developmental Biology, 6th ed.", Sinauer Associates, Inc., Sunderland, MA (2000).

Chemistry terms used herein, unless otherwise defined herein, are used according to conventional usage in the art, as exemplified by "The McGraw-Hill Dictionary of Chemical Terms", Parker S., Ed., McGraw-Hill, San Francisco, C.A. (1985).

All of the above, and any other publications, patents and published patent applications referred to in this application are specifically incorporated by reference herein. In case of conflict, the present specification, including its specific definitions, will control.

The term "agent" is used herein to denote a chemical compound (such as an organic or inorganic compound, a mixture of chemical compounds), a biological macromolecule (such as a nucleic acid, an antibody, including parts thereof as well as humanized, chimeric and human antibodies and monoclonal antibodies, a protein or portion thereof, e.g., a peptide, a lipid, a

carbohydrate), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues. Agents include, for example, agents whose structure is known, and those whose structure is not known. The ability of such agents to inhibit AR or promote AR degradation may render them suitable as “therapeutic agents” in the methods and compositions of this disclosure.

A “patient,” “subject,” or “individual” are used interchangeably and refer to either a human or a non-human animal. These terms include mammals, such as humans, primates, livestock animals (including bovines, porcines, etc.), companion animals (e.g., canines, felines, etc.) and rodents (e.g., mice and rats).

“Treating” a condition or patient refers to taking steps to obtain beneficial or desired results, including clinical results. As used herein, and as well understood in the art, “treatment” is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.

The term “preventing” is art-recognized, and when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition. Thus, prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant amount.

“Administering” or “administration of” a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art. For example, a compound or an agent can be administered, intravenously, arterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, ocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., through a skin duct). A compound or agent can also

appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g., patches and pumps, or formulations, which provide for the extended, slow or controlled release of the compound or agent. Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.

5 Appropriate methods of administering a substance, a compound or an agent to a subject will also depend, for example, on the age and/or the physical condition of the subject and the chemical and biological properties of the compound or agent (e.g., solubility, digestibility, bioavailability, stability and toxicity). In some embodiments, a compound or an agent is administered orally, e.g., to a subject by ingestion. In some embodiments, the orally
10 administered compound or agent is in an extended release or slow release formulation, or administered using a device for such slow or extended release.

As used herein, the phrase “conjoint administration” refers to any form of administration of two or more different therapeutic agents such that the second agent is administered while the previously administered therapeutic agent is still effective in the body
15 (e.g., the two agents are simultaneously effective in the patient, which may include synergistic effects of the two agents). For example, the different therapeutic compounds can be administered either in the same formulation or in separate formulations, either concomitantly or sequentially. Thus, an individual who receives such treatment can benefit from a combined effect of different therapeutic agents.

20 A “therapeutically effective amount” or a “therapeutically effective dose” of a drug or agent is an amount of a drug or an agent that, when administered to a subject will have the intended therapeutic effect. The full therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations. The
25 precise effective amount needed for a subject will depend upon, for example, the subject’s size, health and age, and the nature and extent of the condition being treated, such as cancer or MDS. The skilled worker can readily determine the effective amount for a given situation by routine experimentation.

As used herein, the terms “optional” or “optionally” mean that the subsequently
30 described event or circumstance may occur or may not occur, and that the description includes instances where the event or circumstance occurs as well as instances in which it does not. For example, “optionally substituted alkyl” refers to the alkyl may be substituted as well as where the alkyl is not substituted.

It is understood that substituents and substitution patterns on the compounds of the present disclosure can be selected by one of ordinary skilled person in the art to result chemically stable compounds which can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a
5 substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.

As used herein, the term “optionally substituted” refers to the replacement of one to six hydrogen atoms in a given structure with a specified substituent including, but not limited to: hydroxyl, hydroxyalkyl, alkoxy, halogen, alkyl, nitro, silyl, acyl, acyloxy, aryl, cycloalkyl,
10 heterocyclyl, amino, aminoalkyl, cyano, haloalkyl, haloalkoxy, -OCO-CH₂-O-alkyl, -OP(O)(O-alkyl)₂ or -CH₂-OP(O)(O-alkyl)₂. Preferably, “optionally substituted” refers to the replacement of one to four hydrogen atoms in a given structure with the substituents mentioned above. More preferably, one to three hydrogen substituents are replaced by the substituents as mentioned above. It is understood that the substituent can be further substituted.

As used herein, the term “alkyl” refers to saturated aliphatic groups, including but not limited to C₁-C₁₀ straight-chain alkyl groups or C₁-C₁₀ branched-chain alkyl groups. Preferably, the “alkyl” group refers to C₁-C₆ straight-chain alkyl groups or C₁-C₆ branched-chain alkyl groups. Most preferably, the “alkyl” group refers to C₁-C₄ straight-chain alkyl groups or C₁-C₄ branched-chain alkyl groups. Examples of “alkyl” include, but are not limited
20 to, methyl, ethyl, 1-propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, 1-pentyl, 2-pentyl, 3-pentyl, neo-pentyl, 1-hexyl, 2-hexyl, 3-hexyl, 1-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 1-octyl, 2-octyl, 3-octyl or 4-octyl and the like. The “alkyl” group may be optionally substituted.

The term “acyl” is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)-, preferably alkylC(O)-.

The term “acylamino” is art-recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the formula hydrocarbylC(O)NH-.

The term “acyloxy” is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)O-, preferably alkylC(O)O-.

The term “alkoxy” refers to an alkyl group having an oxygen attached thereto.
30 Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.

The term “alkoxyalkyl” refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O-alkyl.

The term “alkyl” refers to saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl-substituted

cycloalkyl groups, and cycloalkyl-substituted alkyl groups. In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C₁₋₃₀ for straight chains, C₃₋₃₀ for branched chains), and more preferably 20 or fewer. The term “lower alkyl” refers to the alkyl group with 1-6 carbon atoms.


Moreover, the term “alkyl” as used throughout the specification, examples, and claims is intended to include both unsubstituted and substituted alkyl groups, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc.

The term “C_{x-y}” or “C_x-C_y”, when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain. C₀alkyl indicates a hydrogen where the group is in a terminal position, a bond if internal. A C₁₋₆alkyl group, for example, contains from one to six carbon atoms in the chain.

The term “alkylamino”, as used herein, refers to an amino group substituted with at least one alkyl group.


The term “alkylthio”, as used herein, refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkylS-

The term “amide”, as used herein, refers to a group



wherein R⁹ and R¹⁰ each independently represent a hydrogen or hydrocarbyl group, or R⁹ and R¹⁰ taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.

The terms “amine” and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by




wherein R⁹, R¹⁰, and R^{10'} each independently represent a hydrogen or a hydrocarbyl group, or R⁹ and R¹⁰ taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.

The term “aminoalkyl”, as used herein, refers to an alkyl group substituted with an amino group.

The term “aralkyl”, as used herein, refers to an alkyl group substituted with an aryl group.

5 The term “aryl” as used herein include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon. Preferably the ring is a 5- to 7-membered ring, more preferably a 6-membered ring. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be
10 cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.

The term “carbamate” is art-recognized and refers to a group



wherein R⁹ and R¹⁰ independently represent hydrogen or a hydrocarbonyl group.

15 The term “carbocyclalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.

The term “carbocycle” includes 5-7 membered monocyclic and 8-12 membered bicyclic rings. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated and aromatic rings. Carbocycle includes bicyclic molecules in which one, two or three or more
20 atoms are shared between the two rings. The term “fused carbocycle” refers to a bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring. Each ring of a fused carbocycle may be selected from saturated, unsaturated and aromatic rings. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Any combination of
25 saturated, unsaturated and aromatic bicyclic rings, as valence permits, is included in the definition of carbocyclic. Exemplary “carbocycles” include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene and adamantane. Exemplary fused carbocycles include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-1H-
30 indene and bicyclo[4.1.0]hept-3-ene. “Carbocycles” may be substituted at any one or more positions capable of bearing a hydrogen atom.

The term “carbocyclalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.

The term “carbonate” is art-recognized and refers to a group $-\text{OCO}_2-$.

5 The term “carboxy”, as used herein, refers to a group represented by the formula $-\text{CO}_2\text{H}$.

The term “ester”, as used herein, refers to a group $-\text{C}(\text{O})\text{OR}^9$ wherein R^9 represents a hydrocarbyl group.

10 The term “ether”, as used herein, refers to a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O-. Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O-heterocycle and aryl-O-heterocycle. Ethers include “alkoxyalkyl” groups, which may be represented by the general formula alkyl-O-alkyl.

15 The terms “halo” and “halogen” as used herein means halogen and includes chloro (Cl), fluoro (F), bromo (Br), and iodo (I).

The terms “hetaralkyl” and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group.

20 The terms “heteroaryl” and “hetaryl” include substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms “heteroaryl” and “hetaryl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocycls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, 25 oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.

The term “heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.

30 The term “heterocyclalkyl”, as used herein, refers to an alkyl group substituted with a heterocycle group.

The terms “heterocycl”, “heterocycle”, and “heterocyclic” refer to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10-membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms

“heterocyclyl” and “heterocyclic” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryl, and/or heterocyclyls. Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.

The term “hydrocarbyl”, as used herein, refers to a group that is bonded through a carbon atom that does not have a =O or =S substituent, and typically has at least one carbon-hydrogen bond and a primarily carbon backbone, but may optionally include heteroatoms. Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and even trifluoromethyl are considered to be hydrocarbyl for the purposes of this application, but substituents such as acetyl (which has a =O substituent on the linking carbon) and ethoxy (which is linked through oxygen, not carbon) are not. Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.


The term “hydroxyalkyl”, as used herein, refers to an alkyl group substituted with a hydroxy group.

The term “lower” when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer atoms in the substituent, preferably six or fewer. A “lower alkyl”, for example, refers to an alkyl group that contains ten or fewer carbon atoms, preferably six or fewer. In certain embodiments, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example, the atoms within the aryl group are not counted when counting the carbon atoms in the alkyl substituent).

The terms “polycyclyl”, “polycycle”, and “polycyclic” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryl, and/or heterocyclyls) in which two or more atoms are common to two adjoining rings, e.g., the rings are “fused rings”. Each of the rings of the polycycle can be substituted or unsubstituted. In certain embodiments, each ring of the polycycle contains from 3 to 10 atoms in the ring, preferably from 5 to 7.

The term “sulfate” is art-recognized and refers to the group $-\text{OSO}_3\text{H}$, or a pharmaceutically acceptable salt thereof.

The term “sulfonamide” is art-recognized and refers to the group represented by the general formulae



wherein R⁹ and R¹⁰ independently represents hydrogen or hydrocarbonyl.

The term “sulfoxide” is art-recognized and refers to the group –S(O)–.

The term “sulfonate” is art-recognized and refers to the group SO₃H, or a
 5 pharmaceutically acceptable salt thereof.

The term “bisulfite” is art-recognized and refers to the group –OS(O)OH, or a pharmaceutically acceptable salt thereof.

The term “sulfate” is art-recognized and refers to the group –OSO₃H, or a pharmaceutically acceptable salt thereof.

10 The term “sulfone” is art-recognized and refers to the group –S(O)₂–.


The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable
 15 compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The
 20 permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this disclosure, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an
 25 alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties
 30 substituted on the hydrocarbon chain can themselves be substituted, if appropriate.

The term “thioalkyl”, as used herein, refers to an alkyl group substituted with a thiol group.

The term “thioester”, as used herein, refers to a group $-C(O)SR^9$, or $-SC(O)R^9$, wherein R^9 represents a hydrocarbyl.

The term “thioether”, as used herein, is equivalent to an ether, wherein the oxygen is replaced with a sulfur.

5 The term “urea” is art-recognized and may be represented by the general formula



wherein R^9 and R^{10} independently represent hydrogen or a hydrocarbyl.

The term “modulate” as used herein includes the inhibition or suppression of a function or activity (such as cell proliferation) as well as the enhancement of a function or activity.

10 “Pharmaceutically acceptable salt” or “salt” is used herein to refer to an acid addition salt or a basic addition salt which is suitable for or compatible with the treatment of patients.

The term “pharmaceutically acceptable acid addition salt” as used herein means any non-toxic organic or inorganic salt of any base compounds represented by Formula I. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, 15 sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids that form suitable salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p-toluene sulfonic and 20 methanesulfonic acids. Either the mono or di-acid salts can be formed, and such salts may exist in either a hydrated, solvated or substantially anhydrous form. In general, the acid addition salts of compounds of Formula I are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection of the appropriate salt will be known to one skilled in the art. Other 25 non-pharmaceutically acceptable salts, e.g., oxalates, may be used, for example, in the isolation of compounds of the disclosure for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.

The term “pharmaceutically acceptable basic addition salt” as used herein means any non-toxic organic or inorganic base addition salt of any acid compounds represented by 30 Formula I or any of their intermediates. Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide. Illustrative organic bases which form suitable salts include aliphatic, alicyclic, or aromatic organic amines

such as methylamine, trimethylamine and picoline or ammonia. The selection of the appropriate salt will be known to a person skilled in the art.

Many of the compounds useful in the methods and compositions of this disclosure have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30. The disclosure contemplates all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds, salts, prodrugs or mixtures thereof (including all possible mixtures of stereoisomers). See, e.g., WO 01/062726.

In certain embodiments, compounds of the disclosure may be racemic. In certain embodiments, compounds of the disclosure may be enriched in one enantiomer. For example, a compound of the disclosure may have greater than about 30% ee, 40% ee, 50% ee, 60% ee, 70% ee, 80% ee, 90% ee, 95% ee, 96% ee, 97% ee, 98% ee, 99% ee, or greater ee.

As is generally understood in the art, single bonds drawn without stereochemistry do not indicate the stereochemistry of the compound. The compound of formula I provides an example of a compound for which no stereochemistry is indicated.

In certain embodiments, a composition or compound of the disclosure may be enriched to provide predominantly one enantiomer of a compound. An enantiomerically enriched composition or compound may comprise, for example, at least 60 mol percent of one enantiomer, or more preferably at least 75, 90, 95, or even 99 mol percent. In certain embodiments, the compound enriched in one enantiomer is substantially free of the other enantiomer, wherein substantially free means that the substance in question makes up less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1% as compared to the amount of the other enantiomer, e.g., in the composition or compound mixture. For example, if a composition or compound contains 98 grams of a first enantiomer and 2 grams of a second enantiomer, it would be said to contain 98 mol percent of the first enantiomer and only 2 mol% of the second enantiomer.

Furthermore, certain compounds which contain alkenyl groups may exist as Z (zusammen) or E (entgegen) isomers. In each instance, the disclosure includes both mixture and separate individual isomers.

Some of the compounds may also exist in tautomeric forms. Such forms, although not explicitly indicated in the formulae described herein, are intended to be included within the scope of the present disclosure.

“Prodrug” or “pharmaceutically acceptable prodrug” refers to a compound that is metabolized, for example hydrolyzed or oxidized, in the host after administration to form the

compound of the present disclosure (e.g., compounds of formula I). Typical examples of prodrugs include compounds that have biologically labile or cleavable (protecting) groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to produce the active compound. Examples of prodrugs using ester or phosphoramidate as biologically labile or cleavable (protecting) groups are disclosed in U.S. Patents 6,875,751, 7,585,851, and 7,964,580, the disclosures of which are incorporated herein by reference. The prodrugs of this disclosure are metabolized to produce a compound of Formula I. The present disclosure includes within its scope, prodrugs of the compounds described herein. Conventional procedures for the selection and preparation of suitable prodrugs are described, for example, in “Design of Prodrugs” Ed. H. Bundgaard, Elsevier, 1985.

The term “Log of solubility”, “LogS” or “logS” as used herein is used in the art to quantify the aqueous solubility of a compound. The aqueous solubility of a compound significantly affects its absorption and distribution characteristics. A low solubility often goes along with a poor absorption. LogS value is a unit stripped logarithm (base 10) of the solubility measured in mol/liter.

The term “glycosyl” as used herein refers to a monovalent substituent formed from any natural sugar, a metabolite/catabolite thereof, a prodrug thereof, or a combination thereof. The term includes both linear and branched forms of oligosaccharides and polysaccharides, as well as alpha and beta configurations or any combination thereof. Preferred chain lengths of polysaccharides are one or two (i.e., mono- or disaccharides). In certain preferred embodiments, a glycosyl refers to a substituent formed from a glucose, a fucose, a galactose, a mannose, a xylose, a galatosamine, a glucuronic acid, a galacturonic acid, a manuric acid, a sialic acid, iduronic acid, neuraminic acid, derivatives thereof, or a combination thereof.

Toxin Payloads


Many toxin payloads are suitable for use in the presently disclosed conjugates. In certain embodiments, the toxin payload is selected from a chemotherapeutic agent substituted with a saccharide, a sulfate, or a sulfonate or a toxin substituted with a saccharide, a sulfate, or a sulfonate. In further embodiments, the active agent is a chemotherapeutic agent substituted with a saccharide, a sulfate, or a sulfonate. In yet further embodiments, the toxin payload is independently selected from an immunomodulatory compound substituted with a

saccharide, a sulfate, or a sulfonate, an anticancer agent substituted with a saccharide, a sulfate, or a sulfonate, an antiviral agent substituted with a saccharide, a sulfate, or a sulfonate, an antibacterial agent substituted with a saccharide, a sulfate, or a sulfonate, an antifungal agent substituted with a saccharide, a sulfate, or a sulfonate, or an antiparasitic agent substituted with a saccharide, a sulfate, or a sulfonate.


In still further embodiments, the toxin payload is independently selected from a benzodiazepine substituted with a saccharide, a sulfate, or a sulfonate, a duocarmycin substituted with a saccharide, a sulfate, or a sulfonate, an auristatin substituted with a saccharide, a sulfate, or a sulfonate, a tubulysine substituted with a saccharide, a sulfate, or a sulfonate, SN-38 substituted with a saccharide, a sulfate, or a sulfonate, PNU substituted with a saccharide, a sulfate, or a sulfonate, or an exatecan substituted with a saccharide, a sulfate, or a sulfonate, amanitin substituted with a saccharide, a sulfate, or a sulfonate.

In still further embodiments, the toxin payload may be functionalized at one or more functional groups selected from $-C(O)-$, $-O-$, $-NH-$, $-S-$, and $-C(O)O-$. In further embodiments, said functional groups are functionalized by a saccharide, a sulfate, or a sulfonate. In some embodiments, the toxin payload may comprise a modified moiety bound to a saccharide through a functional group selected from ester, amide, thio, carbamate, oxime, hydrazone, and the like. In some implementations, the toxin payload may comprise a modified moiety bound to a polar group such as a sulfonate (see, e.g., WO 2006/111759 A1), a sulfate, a sulfite, and the like.

In still further aspects, provided herein are compounds of Formula (VII) or (VIII):



(VII); or



(VIII);

or a pharmaceutically acceptable salt thereof;

wherein:

A is a heterocycle;

each R^{a'} and R^{b'} are independently halogen, amino, hydroxyl, acetyl, hydroxyalkyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

two geminal R^{b'} are optionally taken together to form an oxo or =CH₂; or two R^{b'}, together with the intervening atoms, optionally complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^{c'} is sulfonate, sulfate, hydroxyl, amino, or thiol;

R^{d'} is -L''-Gly, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

provided that at least one R^{c'} is sulfonate or sulfate, or at least one R^{d'} is -L''-Gly;

R^{e'} is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

m is an integer selected from 0-3;

n is an integer selected from 0-8, as valency permits;

ring Cy is selected from aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

=== is a single bond or a double bond;

X' is halogen;

X'' is -NR-, -S-, or -O-;

each R^{a''} and R^{b''} are independently halogen, amino, hydroxyl, alkoxy, acetyl, hydroxyalkyl, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or -(L''')_r-X''-Gly;

d is an integer selected from 0-4;

r is an integer selected from 0-1;

each L''' is a bond or a linker,

R^{e''} is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

p is an integer selected from 0-4;


DBD is a DNA binding domain;

L'' is a bond or a linker; and

Gly is a monosaccharide, disaccharide, or oligosaccharide.


In certain embodiments, each L''' is a C₁₀-C₁₀₀ linear or branched, saturated, or unsaturated alkylene moiety, optionally comprising one or more double bonds and/or triple bonds. In further embodiments, each p and each d is independently an integer from 0-1.

In yet further embodiments, the compound is represented by Formula (VII):



or a pharmaceutically acceptable salt thereof.

- 5 In still further embodiments, A is 5- to 6-membered heterocycle. In certain embodiments, R^{c'} is hydroxyl. In further embodiments, R^{d'} is hydrogen, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl. In yet further embodiments, R^{d'} is L''-Gly. In still further embodiments, the compound is selected from:



or a pharmaceutically acceptable salt thereof;


wherein == is a single bond or a double bond.

- 15 In certain embodiments, R^{a'} is halogen, amino, hydroxyl, alkoxy, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 4- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl. In further embodiments, two geminal R^{b'} are taken together to form =CH₂. In yet further embodiments, two R^{b'}, together with the intervening atoms, complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. In still further embodiments, two R^{b'}, together with the intervening atoms, complete an aryl or heteroaryl. In
- 20 certain embodiments, two R^{b'}, together with the intervening atoms, complete an aryl.


In further embodiments, R^{c'} is hydrogen, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl. In yet further

embodiments, $R^{e'}$ is hydrogen, C_{1-6} alkyl, or C_{3-10} cycloalkyl. In still further embodiments, $R^{e'}$ is hydrogen.

In certain embodiments, the compound is selected from:




In further embodiments, the compound is represented by Formula (VIII):




10 or a pharmaceutically acceptable salt thereof.

In yet further embodiments, Cy is phenyl. In still further embodiments, Cy is pyrrolidine or pyrrole. In certain embodiments, the compound is represented by Formula (VIIIa) or (VIIIb):




15



(VIIIb);

or a pharmaceutically acceptable salt thereof.

In further embodiments, the DBD-(L''')_r-X''-Gly unit is selected from:



or a pharmaceutically acceptable salt thereof;

wherein:

Y'' is C or N;

10 X'' is selected from -NR-, -S-, or -O-;

R is hydrogen or alkyl;

r is an integer selected from 0-1;

each R^{b''} is independently halogen, amino, hydroxyl, acetyl, hydroxyalkyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl,

15 heteroaryl, or -(L''')_r-X''-Gly;





R^k is alkyl, preferably C₁-C₃ alkyl;

q is an integer selected from 0-3; and

== is a single bond or a double bond.

In yet further embodiments, the compound is represented by Formula (VIIIc),

20 (VIIId), (VIIIe), or (VIIIf):








or a pharmaceutically acceptable salt thereof.

10 In still further embodiments, each $R^{a''}$ is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and each $R^{b''}$ is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, C₁₋₆ alkyl, heteroalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 4- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl.


15 In certain embodiments, X' is Cl. In further embodiments, X' is Br. In still further embodiments, Y'' is C. In certain embodiments, Y'' is N. In further embodiments, $R^{e''}$ is

hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. In yet further embodiments, R^{e''} is hydrogen, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl. In still further embodiments, R^{e''} is hydrogen, C₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl. In certain embodiments, R^{e''} is hydrogen.

5 In certain embodiments, the compound is selected from:




10



or a pharmaceutically acceptable salt thereof.

In further embodiments, L''' is a bond. In yet further embodiments, L''' is a linker
5 selected from:



wherein:

R''' is hydrogen, halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, alkenyl, alkynyl,


10 =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and

each R''' is independently hydrogen, halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl,


heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and

h is an integer selected from 0-4, as valency permits.

In still further embodiments, L''' is




In certain embodiments, Gly is a monosaccharide. In further embodiments, Gly is a monosaccharide selected from glucose, glucuronic acid, fucose, and galactose. In yet further embodiments, Gly is




optionally wherein 1 or more of the -OH groups is masked by a protecting group.

In still further embodiments, Gly is




In certain embodiments, Gly is a disaccharide. In further embodiments, Gly is a disaccharide comprising glucose, glucuronic acid, fucose, galactose, or a combination thereof. In yet further embodiments, Gly is



optionally wherein 1 or more of the -OH groups is masked by a protecting group.


In certain embodiments, Gly is




In certain embodiments, X'' is coupled to Gly at the anomeric position.

Drug Conjugates

- 5 In certain aspects, provided herein are drug conjugates comprising a compound represented by Formula (VII) or (VIII) and a linker group:



(VII); or



(VIII);

or a pharmaceutically acceptable salt thereof;

wherein:

A is a heterocycle;

each R^{a'} and R^{b'} are independently halogen, amino, hydroxyl, acetyl, hydroxyalkyl, alkoxy,

- 15 cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

two geminal R^{b'} are optionally taken together to form an oxo or =CH₂; or two R^{b'}, together with the intervening atoms, optionally complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

$R^{c'}$ is sulfonate, sulfate, hydroxyl, amino, or thiol;

$R^{d'}$ is $-L''$ -Gly, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

provided that at least one $R^{c'}$ is sulfonate or sulfate, or at least one $R^{d'}$ is $-L''$ -Gly;

5 $R^{e'}$ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

m is an integer selected from 0-3;

n is an integer selected from 0-8, as valency permits;

ring Cy is selected from aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

$==$ is a single bond or a double bond;

10 X' is halogen;

X'' is $-NR-$, $-S-$, or $-O-$;

R is hydrogen or alkyl;

each $R^{a''}$ and $R^{b''}$ are independently halogen, amino, hydroxyl, alkoxy, acetyl, hydroxyalkyl, cyano, nitro, alkyl, alkenyl, alkynyl, $=O$, carboxyl, cycloalkyl, heterocycloalkyl, aryl,

15 heteroaryl, or $-(L''')_r-X''$ -Gly;

d is an integer selected from 0-4;

r is an integer from 0-1;

each L''' is a bond or a linker,

$R^{e''}$ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

20 p is an integer selected from 0-4;


DBD is a DNA binding domain;

L'' is a bond or a linker; and

Gly is a monosaccharide, disaccharide, or oligosaccharide.

In certain embodiments, each L''' is a C_{10} - C_{100} linear or branched, saturated, or
 25 unsaturated alkylene moiety, optionally comprising one or more double bonds and/or triple bonds. In further embodiments, each p and each d is independently an integer from 0-1.

In yet further embodiments, the drug conjugates includes a compound of Formula
 (VII):




(VII);

30

or a pharmaceutically acceptable salt thereof.

In still further embodiments, A is 5- to 6-membered heterocycle. In certain embodiments, R^{c'} is hydroxyl. In further embodiments, R^{d'} is hydrogen, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl.

- 5 In yet further embodiments, R^{d'} is L''-Gly. In still further embodiments, the compound is selected from:




or a pharmaceutically acceptable salt thereof;

- 10 wherein == is a single bond or a double bond.

- In certain embodiments, R^{a'} is halogen, amino, hydroxyl, alkoxy, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 4- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl. In further embodiments, two geminal R^{b'} are taken together to form =CH₂. In yet further embodiments, two R^{b'}, together with the intervening atoms, complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. In still further
 15 embodiments, two R^{b'}, together with the intervening atoms, complete an aryl or heteroaryl. In certain embodiments, two R^{b'}, together with the intervening atoms, complete an aryl.


- In further embodiments, R^{c'} is hydrogen, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl. In yet further
 20 embodiments, R^{c'} is hydrogen, C₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl. In still further embodiments, R^{c'} is hydrogen.

In certain embodiments, the compound is selected from:





or a pharmaceutically acceptable salt thereof.

In further embodiments, the compound is represented by Formula (VIII):




or a pharmaceutically acceptable salt thereof.

In yet further embodiments, Cy is phenyl. In still further embodiments, Cy is pyrrolidine or pyrrole. In certain embodiments, the compound is represented by Formula **(VIIIa)** or **(VIIIb)**:



or a pharmaceutically acceptable salt thereof.

In further embodiments, the DBD-(L''')_r-X''-Gly unit is selected from:



or a pharmaceutically acceptable salt thereof;

5 wherein:

Y'' is C or N;

X'' is selected from -NR-, -S-, or -O-;

R is hydrogen or alkyl;

r is an integer selected from 0-1;


10 each R^{b''} is independently halogen, amino, hydroxyl, acetyl, hydroxyalkyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or -(L''')_r-X''-Gly;


R^k is alkyl, preferably C₁-C₃ alkyl;

q is an integer selected from 0-3; and


15 === is a single bond or a double bond.

In yet further embodiments, the compound is represented by Formula (VIIIc), (VIIId), (VIIIe), or (VIIIf):






(VIII d);



(VIII e);




(VIII f);

or a pharmaceutically acceptable salt thereof.


In still further embodiments, each $R^{a''}$ is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and each $R^{b''}$ is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, C_{1-6} alkyl, heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 4- to 10-membered heterocycloalkyl, C_{6-10} aryl, or 5- to 10-membered heteroaryl. In certain preferred embodiments, at least one $R^{a''}$ is alkoxy, e.g. methoxy, ethoxy, or propoxy. In certain embodiments, X' is Cl. In further embodiments, X' is Br. In still further embodiments, Y'' is C. In certain embodiments, Y'' is N. In further embodiments, $R^{e''}$ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. In yet further embodiments, $R^{e''}$ is hydrogen, C_{1-6} alkyl, C_{3-10} cycloalkyl, 3- to 10-membered heterocycloalkyl, C_{6-10} aryl, or 5- to 10-membered heteroaryl. In still further embodiments, $R^{e''}$ is hydrogen, C_{1-6} alkyl, or C_{3-10} cycloalkyl. In certain embodiments, $R^{e''}$ is hydrogen.

In certain embodiments, at least one of $R^{a''}$ is at the 8- position. In further embodiments, p is 1, d is 0, and $R^{a''}$ is at the 8- position, that is, the compound is represented by formula (VIIIg) or (VIIIh):



5


(VIIIg);








(VIIIh);

or a pharmaceutically acceptable salt thereof. In certain embodiments, of formulas (VIIIg) or (VIIIh), $R^{a''}$ is alkoxy, e.g. methoxy, ethoxy, or propoxy, preferably methoxy. In certain such embodiments, the compound is selected from:

10






5

or a pharmaceutically acceptable salt thereof.


In further embodiments, L''' is a bond. In yet further embodiments, L''' is a linker selected from:




wherein:

$R^{a''''}$ is hydrogen, halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, alkenyl, alkynyl,
 5 $=O$, carboxyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
 each $R^{b''''}$ is independently hydrogen, halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl,
 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
 h is an integer selected from 0-4, as valency permits.

In still further embodiments, L''' is




In certain embodiments, Gly is a monosaccharide. In further embodiments, Gly is a
 monosaccharide selected from glucose, glucuronic acid, fucose, and galactose. In yet further
 embodiments, Gly is




optionally wherein 1 or more of the $-OH$ groups is masked by a protecting group.

In still further embodiments, Gly is




In certain embodiments, Gly is a disaccharide. In further embodiments, Gly is a disaccharide comprising glucose, glucuronic acid, fucose, galactose, or a combination thereof. In yet further embodiments, Gly is




optionally wherein 1 or more of the –OH groups is masked by a protecting group.

In certain embodiments, Gly is




In certain embodiments, X'' is coupled to Gly at the anomeric position.


In certain aspects, provided herein are drug conjugates comprising any one of the disclosed compounds and a linker group. In certain embodiments, the drug conjugate is a compound of formula (IX), (X), or (XI):



(IX);



(X); or



(XI);

or a pharmaceutically acceptable salt thereof;

wherein:

10 Z' is a coupling group;

Ar is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

Y' is $-(CR^{b_2})_yN(R^a)-$, $-(CR^{b_2})_yO-$, or $-(CR^{b_2})_yS-$, positioned such that the N, O, or S atom is attached to TG if y is 1;

TG is a triggering group that, when activated, generates an N, O, or S atom capable of reacting with the SO₂ to displace (Q)_q-(L')_w and form a 5- to 6-membered ring including X-SO₂ and the intervening atoms of Ar;

X is -O-, -C(R^b)₂-, or -N(R^c)-;

- 5 L' is a spacer moiety that if present, is attached to the SO₂ via a heteroatom selected from O, S, and N, and is selected such that cleavage of the bond between L' and SO₂ promotes release of the active agent;

w is an integer selected from 0-1;

r is an integer from 0-1;

- 10 Z² is a linking group;

Z³ is a linking group;


R^a, R^b and R^c are each independently hydrogen, or lower alkyl;

y is an integer selected from 0-1;

t is an integer from 1-5; and

- 15 e is an integer from 1-5.

In certain embodiments, Z³ is selected from:



wherein:

X⁵ is -O- or -NR^x-;


- 20 Y¹ is CR^y, or N;

R^x and R^y are each independently hydrogen or C₁₋₆ alkyl;


each *b* is independently an integer from 1-3; and

c is an integer from 1-5.

In further embodiments, Z³ is selected from:




In yet further embodiments, Z^2 is methylene. In still further embodiments, Z^2 is




wherein:

- 5 Y^5 is CR^{Y1} or N, provided that only one Y^5 is N;
 R^{Y1} is H, hydroxyl, amino, amido, or $(CH_2)_y(R^{Y1a})$;
 R^{Y1a} is amino (*e.g.*, secondary or tertiary amino), aryl (*e.g.*, phenyl), or heteroaryl; and
 y is an integer having a value of 1 to about 10.

In certain embodiments, Z^2 is




In further embodiments, Z^2 is:



wherein:


- Y^6 is CR^{Y2} or N;
 15 R^{Y2} is H or alkyl, preferably lower alkyl;
 R^{Z2} is $(CH_2)_z R^{Z2a}$;
 R^{Z2a} is amino (preferably tertiary amino), aryl (*e.g.*, phenyl), or heteroaryl; and
 z is an integer having a value of 0 to about 10.

In yet further embodiments, Z^2 is:



In further embodiments, Ar is aryl. In yet further embodiments, Ar is C₆₋₁₀ aryl. In still further embodiments, Ar is phenyl. In certain embodiments, Ar is heteroaryl. In further embodiments, Ar is 5- to 10-membered heteroaryl. In yet further embodiments, Y' is -
 (CR^b)_yN(R^a)- or -(CR^b)_yO-. In still further embodiments, Y' is -(CR^b)_yO-. In certain
 5 embodiments, y is 0. In further embodiments, y is 1. In yet further embodiments, X is -O-, C(R^b)(R^c)- or -N(R^c)-. In still further embodiments, X is -O-. In certain embodiments, L' is a spacer moiety, and forms an -O-, an -OC(O)-, an -OC(O)O-, a -NHC(O)O-, or an -OC(O)NH- linkage including the heteroatom of the active agent.

In certain embodiments, L' is selected from



wherein:

X⁴ is absent or forms an -O-, an -OC(O)-, an -OC(O)O-, or an -OC(O)NH- linkage including the heteroatom of Q;

15 X¹ is -O- or -NR^a-;

X² is -O-, -OC(O)-, -OC(O)O- or -OC(O)NH-;

X³ is -OC(=O)-;

w' is an integer having a value of 1, 2, 3, 4, or 5;

R⁹ and R¹⁰ are each independently hydrogen, alkyl, aryl, or heteroaryl, wherein alkyl, aryl,

20 and heteroaryl are unsubstituted or substituted with one or more substituents, *e.g.*, selected from alkyl, -(CH₂)_uNH₂, -(CH₂)_uNR^{u1}R^{u2}, and -(CH₂)_uSO₂R^{u3};

R^{u1}, R^{u2}, and R^{u3} are each independently hydrogen, alkyl, aryl, or heteroaryl; and


u is an integer having a value of 1 to about 10.

In yet further embodiments, L' is



In certain aspects, provided herein are drug conjugates comprising any one of the toxin payload compounds of the present disclosure (an active agent) and a linking group; wherein the active agent is substituted with a polar group. In some embodiments, the polar group is selected from a saccharide, sulfate, or sulfonate.

- 5 In some embodiments, drug conjugates comprising an active agent and a linking group are the drug conjugates of Formula (I):



or a pharmaceutically acceptable salt thereof;

wherein:

- 10 Z' is a coupling group;
 Ar is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;
 Y' is $-(\text{CR}^b)_y\text{N}(\text{R}^a)-$, $-(\text{CR}^b)_y\text{O}-$, or $-(\text{CR}^b)_y\text{S}-$, positioned such that the N, O, or S atom is attached to TG if y is 1;
 TG is a triggering group that, when activated, generates an N, O, or S atom capable of
 15 reacting with the SO_2 to displace $(Q)_q - (L')_w$ and form a 5- to 6-membered ring including $\text{X}-\text{SO}_2$ and the intervening atoms of Ar;
 X is $-\text{O}-$, $-\text{C}(\text{R}^b)_2-$, or $-\text{N}(\text{R}^c)-$;
 L' is a spacer moiety that if present, is attached to the SO_2 via a heteroatom selected from O, S, and N, and is selected such that cleavage of the bond between L' and SO_2 promotes
 20 release of the active agent;
 each Q is independently an active agent substituted with a saccharide, a sulfate, or a sulfonate;
 q is an integer selected from 1 to 3;
 w and y are each independently 0 or 1; and
 25 R^a , R^b and R^c are each independently hydrogen or C_{1-6} alkyl; or two R^b , together with the atom to which they are attached, complete a 3- to 5-membered ring;
 provided that when w is 0, q is 1.

In certain embodiments, each Q is independently selected from a chemotherapeutic agent substituted with a saccharide, a sulfate, or a sulfonate or a toxin substituted with a


saccharide, a sulfate, or a sulfonate. In further embodiments, the active agent is a
chemotherapeutic agent substituted with a saccharide, a sulfate, or a sulfonate. In yet further
embodiments, each Q is independently selected from an immunomodulatory compound
substituted with a saccharide, a sulfate, or a sulfonate, an anticancer agent substituted with a
5 saccharide, a sulfate, or a sulfonate, an antiviral agent substituted with a saccharide, a sulfate,
or a sulfonate, an antibacterial agent substituted with a saccharide, a sulfate, or a sulfonate, an
antifungal agent substituted with a saccharide, a sulfate, or a sulfonate, or an antiparasitic
agent substituted with a saccharide, a sulfate, or a sulfonate.

In still further embodiments, each Q is independently selected from a benzodiazepine
10 substituted with a saccharide, a sulfate, or a sulfonate, a duocarmycin substituted with a
saccharide, a sulfate, or a sulfonate, an auristatin substituted with a saccharide, a sulfate, or a
sulfonate, a tubulysine substituted with a saccharide, a sulfate, or a sulfonate, SN-38
substituted with a saccharide, a sulfate, or a sulfonate, PNU substituted with a saccharide, a
sulfate, or a sulfonate, or an exatecan substituted with a saccharide, a sulfate, or a sulfonate,
15 amanitin substituted with a saccharide, a sulfate, or a sulfonate.

In certain embodiments, Q may be a modified moiety bonded with a saccharide through
a linking group. In yet further embodiments, Q may be a modified moiety bonded with a
saccharide through a functional group selected from -C(O)-, -OH, -NH-, -SH, -COH, -COOH,
and the like. In still further embodiments, Q may be a modified moiety bonded with a
20 saccharide through a functional group selected from selected from ester, amide, thio,
carbamate, oxime, hydrazone, and the like.

In certain embodiments, Q may be comprising modified moiety bonded with a
saccharide through a functional group selected from ester, amide, thio, carbamate, oxime,
hydrazone, and the like. In yet further embodiments, Q may be comprising modified moiety
25 bonded with polar groups such as a sulfonate, a sulfate, a sulfite, and the like.

In certain embodiments, each Q is independently represented by:



wherein:

Z^2 is a linking group;


30 Z^3 is a linking group;

t is an integer from 1-5;


e is an integer from 1-5;

and each Q' is independently a modified benzodiazepine.

In further embodiments, each Q' is independently represented by formula (IIa) or (IIb):



(IIa); or



(IIb);

or a pharmaceutically acceptable salt thereof;

wherein:

each A is a heterocycle;

each R^{a'} is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl (preferably lower alkyl), alkenyl, alkynyl, cycloalkyl, aryl, or a heterocyclic ring, preferably a five- or six-membered ring; optionally, fused to or substituted with one or more aryl or heteroaryl rings;

each R^{b'} is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or a heterocyclic ring, preferably a five- or six-membered ring; optionally, fused to or substituted with one or more aryl or heteroaryl rings;

or two geminal R^{b'} are optionally taken together to form an oxo or =CH₂; or two R^{b'},

together with the intervening atoms, optionally complete a cycloalkyl,

heterocycloalkyl, aryl, or heteroaryl, optionally substituted with one or more of R^{f'}

each R^{f'} is independently halogen, hydroxyl, -O-Gly, cyano, nitro, alkyl, haloalkyl, cycloalkyl, carboxyl, amino, aminoalkyl (-CH₂NH₂, -CH₂NH(Me), or -CH₂N(Me)₂), aryl, or heteroaryl;

R^{c'} is sulfonate, sulfate, hydroxyl, amino, or thiol;

R^{d'} is -L'-Gly, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

provided that at least one $R^{c'}$ is sulfonate or sulfate, or at least one $R^{d'}$ is -L"-Gly;

m is an integer selected from 0-3;

n is an integer selected from 0-8, as valency permits; and

Gly is a glycosyl, preferably wherein Gly is a monosaccharide, disaccharide, or

oligosaccharide.


As will be understood, in formula (IIIb) one of the instances of $R^{b'}$ (or two germinal $R^{b'}$ taken together as described above), will serve as the attachment point to the remainder of

the conjugate (e.g., where Q is $Q'-(CH_2)_t-Z^2-(CH_2)_e-Q'^{-\frac{1}{2}}-$). Under the definitions provided below, the remainder of the conjugate may be understood as a substituent on that (or those) instance(s)


of $R^{b'}$. Such $R^{b'}$ instance(s) are thus selected from the substituents listed above that may be made bivalent, e.g. amino, alkoxy, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or a heterocyclic ring, preferably a five- or six-membered ring optionally, fused to or substituted with one or more aryl or heteroaryl rings. Where two geminal $R^{b'}$ taken together form the attachment point, they are likewise selected from potentially bivalent substituents, e.g. $=CH_2$; or they,

together with the intervening atoms, complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with one or more of $R^{f'}$ as further described herein.

In certain embodiments, the drug conjugate is represented by formula (IIIa) or (IIIb):



(IIIa); or



(IIIb);

or a pharmaceutically acceptable salt thereof.

In some embodiments herein, the drug conjugate is represented by formula (IIIa) or (IIIb) wherein:

each A is a heterocycle;

5 each R^{a'} is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl (preferably lower alkyl), alkenyl, alkynyl, cycloalkyl, aryl, or a heterocyclic ring, preferably a five- or six-membered ring; optionally, fused to or substituted with one or more aryl or heteroaryl rings;

10 each R^{b'} is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or a heterocyclic ring, preferably a five- or six-membered ring; optionally, fused to or substituted with one or more aryl or heteroaryl rings;

or two geminal R^{b'} are optionally taken together to form an oxo or =CH₂; or two R^{b'}, together with the intervening atoms, optionally complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with one or more of R^{f'}

15 each R^{f'} is independently halogen, hydroxyl, -O-Gly, cyano, nitro, alkyl, haloalkyl, cycloalkyl, carboxyl, amino, aminoalkyl (-CH₂NH₂, -CH₂NH(Me), or -CH₂N(Me)₂), aryl, or heteroaryl;

R^{c'} is sulfonate, sulfate, hydroxyl, amino, or thiol;

20 R^{d'} is -L^{''}-Gly, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

provided that at least one R^{c'} is sulfonate or sulfate, or at least one R^{d'} is -L^{''}-Gly;

m is an integer selected from 0-3;


n is an integer selected from 0-8, as valency permits; and

25 Gly is a glycosyl, preferably wherein Gly is a monosaccharide, disaccharide, or oligosaccharide.

In some embodiments herein, Formulae (IIIa) and (IIIb) are referred to as Formulae (IX) and (X), respectively, as will be apparent from their context.

In certain embodiments, A is 5- to 6-membered heterocycle. In further embodiments, R^{c'} is hydroxyl. In yet further embodiments, R^{c'} is sulfonate or sulfate. In still further
30 embodiments, R^{d'} is -L^{''}-Gly. In certain embodiments, R^{d'} is hydrogen.

In certain embodiments, each Q' is independently selected from:




- 5 or a pharmaceutically acceptable salt thereof;
wherein $\equiv$ is a single bond or a double bond.

In further embodiments, $R^{a'}$ is halogen, amino, hydroxyl, alkoxy, cyano, nitro, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 4- to 10-membered heterocycloalkyl, C_{6-10} aryl, or 5- to 10-membered heteroaryl. In yet further embodiments, one $R^{b'}$ is alkyl or two geminal $R^{b'}$ are taken together to form an alkenyl group. In still further embodiments, two $R^{b'}$, together with the intervening atoms, complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; preferably wherein the aryl or heteroaryl is a 6-membered aryl or heteroaryl, optionally substituted with one or more R^f .

In certain embodiments, two $R^{b'}$, together with the intervening atoms, complete an aryl or heteroaryl; preferably wherein the aryl or heteroaryl is a 6-membered aryl or heteroaryl, optionally substituted with one or more R^f . In further embodiments, two $R^{b'}$, together with the intervening atoms, complete an aryl. In yet further embodiments, two $R^{b'}$, together with the intervening atoms, complete a heteroaryl.

In certain embodiments, each Q' is independently selected from:




or a pharmaceutically acceptable salt thereof;

wherein $\equiv$ is a single bond or a double bond; and

wherein g is an integer from 0-4.

In certain embodiments, Z^3 is selected from:



wherein:


X^5 is -O- or -NR^x;

Y^1 is CR^y, or N;


R^y is hydrogen or C₁₋₆ alkyl;

- 5 each b is independently an integer from 1-3; and
c is an integer from 1-5.

In further embodiments, Z^3 is selected from:



In yet further embodiments, Z^2 is methylene. In still further embodiments, Z^2 is



10

wherein:


Y^5 is CR^{Y1} or N, provided that only one Y^5 is N;

R^{Y1} is H, hydroxyl, amino, amido, or (CH₂)_y(R^{Y1a});


R^{Y1a} is amino (*e.g.*, secondary or tertiary amino), aryl (*e.g.*, phenyl), or heteroaryl; and

- 15 y is an integer having a value of 1 to about 10.

In certain embodiments, Z^2 is



In further embodiments, Z^2 is:



- 20 wherein:

Y^6 is CR^{Y2} or N;

R^{Y2} is H or alkyl, preferably lower alkyl;


R^{Z2} is $(CH_2)_z R^{Z2a}$,

R^{Z2a} is amino (preferably tertiary amino), aryl (*e.g.*, phenyl), or heteroaryl; and


z is an integer having a value of 0 to about 10.

In yet further embodiments, Z^2 is:

5



In still further embodiments, each Q is independently a group of Formula (IV):



(IV);

or a pharmaceutically acceptable salt thereof;

10 wherein:

ring Cy is selected from aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

$==$ is a single bond or a double bond;

X' is halogen;

X'' is selected from $-NR-$, $-S-$, or $-O-$;

15 each $R^{a''}$ and $R^{b''}$ is independently halogen, amino, hydroxyl, alkoxy, acetyl, hydroxyalkyl, cyano, nitro, alkyl, alkenyl, alkynyl, $=O$, carboxyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or $-(L''')_r-X''-Gly$;

p is an integer selected from 0-4;

d is an integer selected from 0-4;

20 r is an integer from 0-1;

DBD is a DNA binding domain;

each L''' is a bond or a linker and


Gly is a monosaccharide, disaccharide, or oligosaccharide.

In yet further embodiments, each L''' is a C_{10} - C_{100} linear or branched, saturated, or


25 unsaturated alkylene moiety, optionally comprising one or more double bonds and/or triple

bonds. In still further embodiments, each p and each d is independently an integer from 0-1. In certain embodiments, Cy is phenyl. In further embodiments, Cy is pyrrolidine or pyrrole.

In certain embodiments, each Q is independently a group of Formula (IVa) or (IVb):




(IVa);



(IVb);

or a pharmaceutically acceptable salt thereof.

In further embodiments, the $\text{DBD}-(\text{L}''')_r\text{-X}''\text{-Gly}$ unit is selected from:



or a pharmaceutically acceptable salt thereof;

wherein:

Y'' is C or N;

X'' is selected from $-\text{NR}-$, $-\text{S}-$, or $-\text{O}-$;


each $\text{R}^{b''}$ is independently halogen, amino, hydroxyl, acetyl, hydroxyalkyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or $-(\text{L}''')_r\text{-X}''\text{-Gly}$;

R^k is alkyl or hydroxyalkyl, preferably $\text{C}_1\text{-C}_3$ alkyl;


q is an integer selected from 0-3; and

== is a single bond or a double bond.


In yet further embodiments, each Q is independently selected from a group of Formula (IVc), (IVd), (IVe), (IVf), (IVg), (IVh), (IVi), or (IVj).




(IVc);




(IVd);




(IVe);




(IVf);




(IVg);



(IVh);




(IVi);




(IVj);

or a pharmaceutically acceptable salt thereof.


In preferred embodiments, each Q is independently selected from a group of Formula (IVc), (IVd), (IVe), or (IVf):




(IVc);



(IVd);



(IVe);




5

(IVf);

or a pharmaceutically acceptable salt thereof.

In certain embodiments, the drug conjugate is represented by Formula (V):



(V);

10 or a pharmaceutically acceptable salt thereof;

wherein:

Z' is a coupling group;

Ar is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

Y' is $-(CR^{b_2})_yN(R^a)-$, $-(CR^{b_2})_yO-$, or $-(CR^{b_2})_yS-$, positioned such that the N, O, or S atom is

15 attached to TG if y is 1;

TG is a triggering group that, when activated, generates an N, O, or S atom capable of reacting with the SO₂ to displace (Q)_q-(L')_w and form a 5- to 6-membered ring including X-SO₂ and the intervening atoms of Ar;



X is -O-, -C(R^b)₂-, or -N(R^c)-;

- 5 L' is a spacer moiety that if present, is attached to the SO₂ via a heteroatom selected from O, S, and N, and is selected such that cleavage of the bond between L' and SO₂ promotes release of the active agent; and

r is an integer from 0-1.


10 In some embodiments herein, Formula (V) is referred to as Formula (XI), as will be apparent from the context.

In further embodiments, Cy is phenyl. In yet further embodiments, Cy is selected from pyrrolidine or pyrrole. In still further embodiments, the drug conjugate is represented by Formula (Va) or (Vb):



(Vb);

or a pharmaceutically acceptable salt thereof.

In certain embodiments, the DBD-(L''')_r-X''-Gly unit is selected from:

or a pharmaceutically acceptable salt thereof;

wherein:

Y'' is C or N;

each R^{b''} is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, heteroalkyl,
 10 alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;


R^k is alkyl or hydroxyalkyl, preferably C₁-C₃ alkyl;


q is an integer selected from 0-3; and

== is a single bond or a double bond.


In certain embodiments, the drug conjugate is selected from a group of Formula (Vc),

(Vd), (Ve), or (Vf):






(Vd);




(Ve);




(Vf);

or a pharmaceutically acceptable salt thereof.

In preferred embodiments, the drug conjugate is represented by formula (Vc) or (Vd):



(Vc); or



(Vd);






5 or a pharmaceutically acceptable salt thereof.


In certain embodiments, each $R^{a''}$ is independently hydrogen, halogen, amino, hydroxyl, alkoxy, acetyl, hydroxyalkyl, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or $-(L''')_r-X''-Gly$; and each $R^{b''}$ is independently hydrogen halogen, amino, hydroxyl, alkoxy, acetyl, hydroxyalkyl, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or $-(L''')_r-X''-Gly$.

10

In further embodiments, X' is Cl. In yet further embodiments, X' is Br. In still further embodiments, Y'' is C. In certain embodiments, Y'' is N.


In certain embodiments, Q is selected from:





or a pharmaceutically acceptable salt thereof.


In further embodiments, L''' is a bond. In yet further embodiments, L''' is a linker
5 selected from




wherein:

each $R^{a'''}$ is independently hydrogen, halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl,
10 alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
each $R^{b'''}$ is independently hydrogen, halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl,
heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
 h is an integer selected from 0-4, as valency permits; and
 $\sim$ is a point of connection to a neighboring functional group.

15 In still further embodiments, L''' is




In certain embodiments, Gly is a monosaccharide. In further embodiments, Gly is a monosaccharide selected from glucose, glucuronic acid, fucose, and galactose. In yet further embodiments, Gly is




optionally wherein 1 or more of the -OH groups is masked by a protecting group.

In still further embodiments, Gly is




In certain embodiments, Gly is a disaccharide. In further embodiments, Gly is a disaccharide comprising glucose, glucuronic acid, fucose, galactose, or a combination thereof. In yet further embodiments, Gly is




optionally wherein 1 or more of the -OH groups is masked by a protecting group.

In still further embodiments, Gly is



In certain embodiments, X'' or L'' is coupled to Gly at the anomeric position. In further embodiments, Ar is aryl. In yet further embodiments, Ar is C₆₋₁₀ aryl. In still further embodiments, Ar is phenyl. In certain embodiments, Ar is heteroaryl. In further
 5 embodiments, Ar is 5- to 10-membered heteroaryl. In yet further embodiments, Y' is -
 (CR^b₂)_yN(R^a)- or -(CR^b₂)_yO-. In still further embodiments, Y' is -(CR^b₂)_yO-. In certain
 embodiments, y is 0 or 1. In further embodiments, y is 1. In yet further embodiments, X is -
 O-, C(R^b)₂- or -N(R^c)-. In still further embodiments, X is -O-. In certain embodiments, L' is a
 spacer moiety, and forms an -O-, an -OC(O)-, an -OC(O)O- or an -OC(O)NH- linkage
 10 including the heteroatom of the active agent.

In certain embodiments, Q-(L')_w- is selected from



wherein:


- 15 X⁴ is absent or forms an -O-, an -OC(O)-, an -OC(O)O- or an -OC(O)NH- linkage including
 the heteroatom of Q;
 X¹ is -O- or -NR^a-;
 X² is -O-, -OC(O)-, -OC(O)O- or -OC(O)NH-;
 X³ is -OC(=O)-;
 20 w' is an integer having a value of 1, 2, 3, 4, or 5;

R^9 and R^{10} are each independently hydrogen, alkyl, aryl, or heteroaryl, wherein alkyl, aryl, and heteroaryl are unsubstituted or substituted with one or more substituents, *e.g.*, selected from alkyl, $-(CH_2)_uNH_2$, $-(CH_2)_uNR^{u1}R^{u2}$, and $-(CH_2)_uSO_2R^{u3}$;


R^{u1} , R^{u2} , and R^{u3} are each independently hydrogen, alkyl, aryl, or heteroaryl; and



5 u is an integer having a value of 1 to about 10.


In further embodiments, $Q-(L')_w-$ is selected from




In certain embodiments, the drug conjugate is selected from













,







,


















, and




;

or a pharmaceutically acceptable salt thereof.





In certain embodiments, the drug conjugate is not selected from:













T-2




T-4











- 5 In certain embodiments, the drug conjugate is not a compound disclosed in US2022/0047717.


Targeted Drug Conjugates

In certain aspects, provided herein are targeted drug conjugates comprising the drug conjugate comprising compounds of the present disclosure, a linker group, and a targeting moiety.

- 10 In certain embodiments, the targeted drug conjugate is a compound represented by Formula (XII), (XIII) or (XIV):




5






or a pharmaceutically acceptable salt thereof;
wherein TM is a targeting moiety.

10 In certain aspects, the drug conjugates of the present disclosure further comprise a targeting moiety. In further aspects, provided herein are targeted drug conjugates of Formula (VI), comprising a targeting moiety conjugated to any one of the drug conjugates of the present disclosure:



wherein TM is a targeting moiety.

In certain embodiments, the targeted drug conjugate is a compound of Formula (XII),
 5 (XIII) or (XIV):



10


(XIV);

or a pharmaceutically acceptable salt thereof;

wherein TM is a targeting moiety.

In yet further aspects, provided herein are targeted drug conjugates of Formula (VIb)

5 comprising a targeting moiety conjugated to the drug conjugates of the present disclosure:



(VIb);

wherein:

TM is a targeting moiety;

10 R is hydrogen or a hydroxy protection group;

X is -C(O)-, -NH-, -O-, or -S-;

Q is an active agent substituted with a saccharide, a sulfonate, or a sulfate;

T is $B' - U1 - (CH_2CH_2X_3)_{p4} - (CH_2)_{p3} - W_{a4} - Q_2 - W_{a3} - W_1$;

n is an integer selected from 0 or 1;

15 Y is hydrogen, haloC₁-C₈alkyl, halogen, cyano or nitro; z is an integer selected from 1-3, and

Y may be the same or different from each other, if z is an integer of not less than 2;

z₁ is an integer selected from 0 or 1;W₁ is $W_{a2} - (CH_2)_{a5} - W_{b1} - Q_1$;W₂ is $W_{a4} - Q_2 - W_{a3}$;20 W_{a1} and W_{a2} are each independently -NH-, -C(=O)-, or -CH₂-;W_{a3} and W_{a4} are each independently -NH-, -C(=O)-, -CH₂-, -C(=O)NH-, -NHC(=O)-, or triazolylen;W_{b1} is an amide bond or triazolylen;L is an amino acid, peptide, or amide bond as a linker connecting W_{a2} and Z;25 Z is a single bond, -W_{a5}-(CH₂)_{a2}-W_{b2}-(CH₂)_{a3}-W_{a6}-, or -W_{a7}-(CH₂)_{a4}-CR'R''-X'''-;

R' is C₁-C₈alkyl or TM-W_{a8}-Q₃-W_{c1}-(CH₂)_{a5}-;

R'' is TM-W_{a8}-Q₃-W_{c1}-(CH₂)_{a5}-;

Q₁ and Q₃ are each independently -(CH₂)_{a6}-(X₁CH₂CH₂)_{b1}-(CH₂)_{a7}-;

X₁ and X₃ are each independently -O-, -S-, -NH-, or -CH₂-;

5 X''' is -NHC(=O)-(CH₂)_{a8}-W_{a9}- or -C(=O)NH-(CH₂)_{a8}-W_{a9}-;

W_{a5}, W_{a6}, W_{a7}, W_{a8}, and W_{a9} are each independently -NH-, -C(=O)-, or -CH₂-;

W_{b2} is an amide bond or triazolyne;

W_{c1} is -NHC(=O)- or -C(=O)NH-;

10 Q₂ is a saturated or unsaturated alkylene, which is linear or branched with a carbon number of 1 to 50, satisfying any one of (i) to (iii) below;

(i) at least one -CH₂- in the alkylene is substituted with one or more heteroatoms selected from -NH-, -C(=O)-, -O-, and -S-;

(ii) at least one arylene or heteroarylene is included in the alkylene;


15 (iii) the alkylene is further substituted with one or more selected from the group consisting of C₁-C₂₀ alkyl, C₆-C₂₀ aryl, C₁-C₈ alkyl, -(CH₂)_{s1}COOR₃, -(CH₂)_{s1}COR₃, -(CH₂)_{s2}CONR₄R₅, and -(CH₂)_{s2}NR₄R₅;

arylene or heteroarylene of (ii) above may be further substituted with nitro;

R₃, R₄, and R₅ are each independently hydrogen or C₁-C₁₅ alkyl;

X₂ is -O-, -S-, -NH-, or -CH₂-;

20 U₁ is bound to B' in the position of asterisk (*) with a linking group selected from the following structures:



R is C₁-C₁₀ alkyl, C₆-C₂₀ aryl or C₂-C₂₀ heteroaryl;


25 TM and B' are each independently a ligand or a protein having properties selectively targeting a particular organ with a drug, a tissue or a cell, that is, properties binding to a receptor;

a1, a2, a3, a4, a5, a6, a8, b1, p1, p2, p3 and p4 are each independently an integer selected from 1-10;

a7, y, s1, s2 and s4 are each independently an integer selected from 0-10; and

R₁ and R₂ are each independently hydrogen, C₁-C₈ alkyl or C₃-C₈ cycloalkyl.


- 5 In yet further aspects, provided herein are targeted drug conjugates of Formula (VIc) comprising a targeting moiety conjugated to the drug conjugates of the present disclosure:



wherein:

- 10 TM is a targeting moiety;
 G is a glucuronic acid moiety or a derivative thereof;
 Q is an active agent substituted with a saccharide, a sulfonate or a sulfate;
 W is an electron withdrawing group;
 Z is hydrogen, C₁-C₈ alkyl, halogen, cyano, or nitro;
 15 n is an integer selected from 1-3, and when n is an integer of 2 or more, each of the Z(s) are the same as or different from each other;
 L is a linker connecting TM and W; and
 R₁ and R₂ are each independently hydrogen, C₁-C₈ alkyl, or C₃-C₈ cycloalkyl


- In certain aspects, provided herein are targeted drug conjugate of Formula (VIId)
 20 comprising a targeting moiety conjugated to the drug conjugate of the present disclosure:



wherein TM is a targeting moiety;

L₁ is ligand moiety;

- 25 Q is an active agent substituted with a saccharide, a sulfonate or a sulfate;
 -A_a-W_w-Y_y- is linker moiety;
 A is an optional stretcher moiety;
 a is an integer selected from 0-3;
 each W is independently a glucuronide unit having one of the formula:



Su is a sugar moiety;

each R is independently hydrogen, halogen, -CN, or -NO₂;

w is an integer selected from 1-2;

5 Y is an optional self-immolative spacer moiety;

y is an integer selected from 0-2; and

p is an integer selected from 1-20.


Release of the Active Agent

10 As described above, in certain embodiments, the compounds and conjugates disclosed herein are capable of dissociating one or more active agents through an intramolecular cyclization reaction following a chemical reaction that activates the triggering group. In certain embodiments, the chemical reaction is a physicochemical reaction and/or a biochemical reaction.

15 In some embodiments, the compounds and conjugates disclosed herein comprise a nucleophilic functional group (Y or Y') introduced at an atom on Ar adjacent to X (*e.g.*, O). Typically, the nucleophilic functional group is masked by a triggering group (TG), as further detailed below. Upon activation, the triggering group releases the nucleophilic functional group to react with the nearby SO₂ moiety in an intramolecular cyclization, ultimately releasing the
 20 one or more compounds of Formula (II), (IIa), or (IIb). In some such embodiments, one or more active agents are released through an intramolecular cyclization reaction after a chemical reaction, a physicochemical reaction and/or a biochemical reaction (see, for example, Reaction Scheme 1), or the active agent is released through 1,6-elimination or 1,4-elimination after the intramolecular cyclization reaction (see, for example, Reaction Scheme 2).

25 As an example, when Y is -Y'-TG and Q is an active agent directly conjugated to the SO₂ group, the active agent may be released by the mechanism shown in Reaction Scheme 1:


Reaction Scheme 1



When Q is $^*\text{-X}_1\text{-C}_6\text{H}_4\text{-CH}_2\text{-X}_2\text{-Q}_1$, Q^1 may be released by the mechanism shown in Reaction Scheme 2:

5

Reaction Scheme 2



In some embodiments, Q^1 when released is an active agent comprising at least one functional group selected from $-\text{C}(\text{O})-$, $-\text{OH}$, $-\text{NH}-$, $-\text{SH}$, $-\text{COH}$, and $-\text{COOH}$. According to these embodiments, as further described herein, Q^1 is conjugated to a compound as described herein by the $-\text{C}(\text{O})-$, $-\text{OH}$, $-\text{NH}-$, $-\text{SH}$, $-\text{COH}$, and $-\text{COOH}$, for instance through a functional group selected from ester, amide, thioester, carbamate, urea, oxime, hydrazone, *etc.* In some such embodiments, Q^2 is used in place of Q^1 , and Q^2 is an amine group-containing drug. In other embodiments, Q^2 is an active agent capable of binding with an ammonium unit. In still other embodiments, Q^2 is capable of being dissociated in its original form having an amine

group upon release of Q² release, wherein the active agent may be a drug, a toxin, an affinity ligand, a probe for detection, or a combination thereof.

In some embodiments, the compounds and conjugates disclosed herein are chemically and physiologically stable. In some such embodiments, the compounds and conjugates disclosed herein reach a desired target cell in a state wherein there is little dissociation of the active agent in the blood, thereby selectively releasing the drug.

Triggering Groups (TGs)

In some embodiments, the conjugates of the present disclosure include a triggering group (TG). TGs are groups capable of being cleaved, preferably selectively cleaved, by a chemical reaction, such as a biological reaction. Generally, triggering groups serve to mask the nucleophilic nature of the Y' group, thereby providing stability (*e.g.*, by preventing self-immolation or intramolecular cyclization prior to the conjugate reaching a target location or experiencing a predetermined trigger condition) to the compounds and conjugates disclosed herein. Upon activation, the triggering group releases the nucleophilic Y group and allows for self-immolation or intramolecular cyclization to occur, as described above.

In some embodiments, the TG comprises a sequence (such as a peptide sequence) or a moiety recognized by TEV, trypsin, thrombin, cathepsin B, cathepsin D, cathepsin K, caspase 1, matrix metalloproteinase (MMP), and the like, which can be hydrolyzed by an enzyme (*e.g.*, an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase, a ligase, *etc.*) and/or may include a moiety selected from a sulfate, a phosphodiester, a phospholipid, an ester, a β -galactose, a β -glucose, a fucose, an oligosugar, and the like.

In some embodiments, the TG comprises a reactive chemical moiety or functional group that can be cleaved under nucleophilic reagent conditions (*e.g.*, a silyl ether, a 2-N-acyl nitrobenzenesulfonamide, an unsaturated vinyl sulfide, a sulfonamide after activation, a malondialdehyde-indole derivative, a levulinoyl ester, a hydrazone, or an acyl hydrazone).

In some embodiments, the TG may comprise a reactive chemical moiety or functional group that can be cleaved under basic reagent conditions (*e.g.*, a 2-cyanoethyl ester, an ethylene glycolyl disuccinate, a 2-sulfonylethyl ester, an alkyl thioester, or a thiophenyl ester).

In some embodiments, the TG may comprise a reactive chemical moiety or functional group that can be cleaved by photo-irradiation (*e.g.*, 2-nitrobenzyl derivative, phenacyl ester, 8-quinolinylnyl benzenesulfonate, coumarin, phosphotriester, bis-arylhydrazone, or biman bi-thiopropionic acid derivative).

In some embodiments, the TG may comprise a reactive chemical moiety or functional group that can be cleaved by reducing agent conditions (*e.g.*, hydroxylamine, disulfide, levulinate, nitro, or 4-nitrobenzyl derivative).


In some embodiments, the TG may comprise a reactive chemical moiety or a functional group that can be cleaved using acidic conditions (*e.g.*, saccharides, tert-butylcarbamate analogue, dialkyl or diaryl dialkoxysilane, orthoester, acetal, aconityl, hydrazone, β -thiopropionate, phosphoramidate, imine, trityl, vinyl ether, polyketal, and alkyl 2-(diphenylphosphino)benzoate derivative; alkyl ester, 8-hydroxyquinoline ester, and picolinate ester).

In some embodiments, the TG may comprise a reactive chemical moiety or functional group that can be cleaved under oxidative conditions (*e.g.*, a boronate, a vicinal diol, paramethoxybenzyl derivative, or a selenium compound).

In certain preferred embodiments, the TG comprises a saccharide, which can be cleaved under acidic or enzymatic conditions. In certain preferred embodiments, the triggering group is $-\text{NO}_2$, which can be cleaved under reducing conditions. In certain preferred embodiments, the triggering group is a boronate, which can be cleaved under oxidative conditions. In certain preferred embodiments, the triggering group is an ester, which can be cleaved under acidic, basic, or enzymatic conditions. In certain preferred embodiments, the triggering group is a hydrazone, which can be cleaved under nucleophilic conditions or under acidic conditions. In certain preferred embodiments, the triggering group is a hydroxylamine, which can be cleaved under reducing conditions.


Saccharide Triggering Groups

In some embodiments, the compounds and conjugates disclosed herein comprise a saccharide triggering group, for instance a triggering group selected from:




wherein each R^{21} is independently hydrogen or is selected such that $O-R^{21}$ is a hydroxy protecting group (*e.g.*, acetyl); and R^{22} is hydrogen or lower alkyl (*e.g.*, C_1 – C_6 -alkyl). In certain embodiments, the hydroxy protecting group is capable of being used in organic synthesis, including but not limited to: methyl ether, methoxymethyl ether, methylthiomethyl ether, 2-methoxyethoxymethyl ether, bis(2-chloroethoxy)methyl ether, tetrahydropyranyl ether, 2-methoxytetrahydropyranyl ether, 4-methoxytetrahydropyranyl ether, 4-methoxytetrahydrothiopyranyl ether, tetrahydrofuranyl ether, 1-ethoxyethyl ether, 1-methyl-1-methoxyethyl ether, 2-(phenylselenyl)ethyl ether, *t*-butyl ether, allyl ether, benzyl ether, *o*-nitrobenzyl ether, triphenyl methyl ether, α -naphthylidiphenyl methyl ether, *p*-methoxyphenyldiphenylmethyl ether, 9-(9-phenyl-10-oxo)anthryl ether, trimethylsilyl ether, isopropyldimethylsilyl ether, *t*-butyldimethylsilyl ether, *t*-butyldiphenylsilyl ether, tribenzylsilyl ether, triisopropylsilyl ether, formate ester, acetate ester, trichloroacetate ester, phenoxyacetate ester, isobutyrate ester, pivaloate ester, adamantoate ester, benzoate ester, 2,4,6-trimethylbenzoate ester, methyl carbonate, 2,2,2-trichloroethyl carbonate, allyl carbonate, *p*-nitrophenyl carbonate, benzyl carbonate, *p*-nitrobenzyl carbonate, *S*-benzylthiocarbonate, *N*-phenylcarbamate, nitrate ester, 2,4-dinitrophenylsulfenate ester, *etc.*, but is not limited thereto.

In certain embodiments, TG is a monosaccharide. In further embodiments, TG is a monosaccharide selected from glucose, glucuronic acid, fucose, and galactose. In yet further embodiments, TG is




optionally wherein 1 or more of the $-OH$ groups is masked by a protecting group.

In still further embodiments, TG is




In certain embodiments, TG is a disaccharide. In further embodiments, TG is a disaccharide comprising glucose, glucuronic acid, fucose, galactose, or a combination thereof. In yet further embodiments, TG is



5 optionally wherein 1 or more of the –OH groups is masked by a protecting group.

In still further embodiments, TG is



In certain embodiments, Y' or L' is coupled to TG at the anomeric position.

10 Protecting Groups as Triggering Groups

In some embodiments, TG is a group that is capable of being cleaved by a chemical reaction, a physicochemical reaction, and/or a biological reaction. In certain embodiments, TG is a protecting group. In some such embodiments, the protecting group is an amine group protecting group, an alcohol protecting group, or a thiol protecting group.

15 Amine Protecting Groups

In certain embodiments, the amine protecting group is a general protecting group that is capable of being used in organic synthesis, including but not limited to: m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, alkyl carbamate, 9-fluorenylmethyl carbamate, 2,2,2-trichloroethyl carbamate, 2-trimethylsilylethyl carbamate (Teoc), t-butyl carbamate (Boc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), 8-quinolyl carbamate, N-hydroxypiperidiny carbamate, benzyl carbamate, p-methoxybenzyl carbamate,

20

p-nitrobenzyl carbamate, diphenyl methyl carbamate, acetamide, chloroacetamide, trichloroacetamide, phenylacetamide, benzamide, N-phthalimide, N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1-dimethylthiomethyleneamine, N-benzylideneamine, benzenesulfenamide, o-nitrobenzenesulfenamide, triphenylmethylsulfenamide, p-toluenesulfonamide, methanesulfonamide, *etc.*, but is not limited thereto.

Alcohol Protecting Groups

In certain embodiments, the alcohol protecting group is a general protecting group that is capable of being used in organic synthesis, including but not limited to: methyl ether, methoxymethyl ether (MOM ether), benzyloxymethyl ether (BOM ether), 2-(trimethylsilyl)ethoxymethyl ether (SEM ether), phenylthiomethyl ether (PTM ether), 2,2-dichloro-1,1-difluoroethyl ether, p-bromophenacyl ether, chloropropylmethyl ether, isopropyl ether, cyclohexyl ether, 4-methoxybenzyl, 2,6-dichlorobenzyl ether, 4-(dimethylaminocarbonyl)benzyl ether, 9-anthrylmethyl ether, 4-picolyl ether, methylthiomethyl ether (MTM ether), 2-methoxyethoxymethyl ether (MEM ether), bis(2-chloroethoxy)methyl ether, tetrahydropyranyl ether (THP ether), tetrahydrothiopyranyl ether, 4-methoxytetrahydropyranyl ether, 4-methoxytetrahydrothiopyranyl ether, tetrahydrofuranyl ether, 1-ethoxyethyl ether, 1-methyl-1-methoxyethyl ether, 2-(phenylselenyl)ethyl ether, t-butyl ether, allyl ether, benzyl ether, o-nitrobenzyl ether, triphenylmethyl ether, α -naphthylidiphenylmethyl ether, p-methoxyphenyldiphenylmethyl ether, 9-(9-phenyl-10-oxo)anthryl ether, trimethylsilyl ether (TMS ether), isopropyldimethylsilyl ether, t-butyldimethylsilyl ether (TBDMS ether), t-butyldiphenyl silyl ether, tribenzylsilyl ether, triisopropylsilyl ether, formate ester, acetate ester, trichloroacetate ester, phenoxyacetate ester, isobutyrate ester, pivaloate ester, adamantate ester, benzoate ester, 2,4,6-trimethylbenzoate(Mesitoate) ester, methyl carbonate, 2,2,2-trichloroethyl carbonate, allyl carbonate, p-nitrophenyl carbonate, benzyl carbonate, p-nitrobenzyl carbonate, S-benzyl thiocarbonate, N-phenylcarbamate, nitrate ester, 2,4-dinitrophenylsulfenate ester, dimethylphosphinyl ester (DMP ester), dimethylthiophosphinyl ester (MPT ester), aryl methanesulfonate, aryl toluenesulfonate, *etc.*, but is not limited thereto.

Thiol Protecting Groups

In certain embodiments, the thiol protecting group is capable of being used in organic synthesis, including but not limited to: S-benzyl thioether, S-p-methoxybenzyl thioether, S-o- or p-hydroxyl or acetoxymethyl thioether, S-p-nitrobenzyl thioether, S-4-picolyl thioether, S-2-picolyl N-oxide thioether, S-9-anthrylmethyl thioether, S-9-fluorenylmethyl thioether, S-

methoxymethyl monothioacetal, A-acetyl derivative, S-benzoyl derivative, S-(N-ethylcarbamate), S-(N-methoxymethylcarbamate), *etc.*, but is not limited thereto.

Coupling Groups from the Drug Conjugate to the Targeting Moiety (Linking Group)

In some embodiments, the compounds and conjugates disclosed herein comprise a linking group connecting each TM and Ar through covalent bonds. Typical linking groups are stable, non-hydrolyzable moieties, such as, for example a C₁₀–C₁₀₀ linear or branched, saturated or unsaturated alkylene. In certain embodiments, the linking unit satisfies at least two, and more preferably at least three, out of four of the following criteria:

(i) at least one -CH₂- in the alkylene moiety is replaced by one or more heteroatoms selected from -NH-, -C(=O), -O-, -S- and -P-;

(ii) at least one heteroarylene is included in the alkylene moiety;

(iii) at least one amino acid moiety, sugar bond, peptide bond, or amide bond is included in the alkylene moiety; and

(iv) the alkylene may be further substituted with one or more substituents selected from the group consisting of C₁–C₂₀ alkyl, C₆–C₂₀ aryl C₁–C₈ alkyl, -(CH₂)_sCOOH, and -(CH₂)_pNH₂, wherein s is an integer having a value of 0 to 10, and p is an integer having a value of 1 to about 10.

In certain embodiments, the linking unit comprises at least two, and more preferably at least three, of the following:

(i) at least one heteroatom selected from -NH-, -C(=O), -O-, -S- and -P-;

(ii) at least one heteroarylene;

(iii) at least one amino acid moiety, sugar bond, peptide bond, or amide bond; and

(iv) the alkylene may be further substituted with one or more substituents selected from the group consisting of C₁–C₂₀ alkyl, C₆–C₂₀ aryl C₁–C₈ alkyl, -(CH₂)_sCOOH, and -(CH₂)_pNH₂, wherein s is an integer having a value of 0 to 10, and p is an integer having a value of 1 to about 10.


In other embodiments, the linking group connecting each TM and Ar comprises a functional group produced through a click chemical reaction.

In alternative embodiments, the linking unit comprises a reactive functional group capable of participating in a click chemical reaction.

A click chemical reaction is a reaction that can be performed under mild conditions, and is extremely selective for functional groups that are not commonly found in biological

molecules (*e.g.*, an azide group, an acetylene group, *etc.*). Accordingly, this reaction can be carried out in the presence of complex triggering groups, targeting moieties, *etc.* Further, click chemistry has high reaction specificity. For example, the click chemical reaction between an azide group and an acetylene group proceeds selectively without interference from other functional groups present in the molecule. For example, azide-acetylene click chemistry may afford a triazole moiety in high yield.


Thus, in some embodiments, the linking group connecting each TM and Ar comprises

















NR²³C(O)-, -NR²⁴SO₂-, or -SO₂NR²⁵-, R²¹ to R²⁵ may be each independently hydrogen, (C₁-C₆)alkyl, (C₁-C₆)alkyl(C₆-C₂₀)aryl, or (C₁-C₆)alkyl(C₃-C₂₀)heteroaryl, r may be an integer having a value of 1 to about 10, p may be an integer having a value of 0 to about 10, q may be an integer having a value of 1 to about 10, and L'' may be a single bond.


Various linking groups are suitable for use with the presently disclosed drug conjugates.

When a targeting moiety is not present (*i.e.*, the drug conjugate is not a targeted drug conjugate), the linking group comprises a terminal reactive functional moiety that can react with a targeting moiety. In some embodiments, Z' is selected from









5 wherein:

R^{Za} is H or methyl;

R^{Zb} is $-OH$, $=O$, or $=NHOH$;


n and m are each independently integer selected from 1-10;

x is integer selected from 1-2;




10 $\text{---}\text{Z}'\text{---}$ represents the bond between Z' and the drug conjugate;

$\text{---}\text{---}$ a single bond or a double bond;





Z'' is selected from









15 In further embodiments, when a targeting moiety is present (i.e., the drug conjugate is a targeted drug conjugate), the linking group links the conjugate to the targeting moiety. In some embodiments, Z' is selected from



5







wherein

R^{za} is H or methyl;

R^{zb} is $-\text{OH}$, $=\text{O}$, or $=\text{NHOH}$;

10 ----- a single bond or a double bond;


n and m are each independently an integer selected from 1-10;

x is an integer selected from 1-2;

a'' represents the bond between Z' and the drug conjugate;

b'' represents the bond between Z' and TM; and

15 Z'' is selected from



Targeting Moieties

The compounds and conjugates of the present disclosure can further comprise one or more ligand or targeting moiety, TM. In some embodiments, the ligand or targeting moiety is any molecular recognition element, which can undergo a specific interaction with at least one other molecular through, *e.g.*, noncovalent bonding such as hydrogen bonding, metal coordination, hydrophobic forces, van der Waals forces, π - π interactions, halogen bonding, electrostatic, and/or electromagnetic effects. In certain embodiments, TM is selected from a nanoparticle, an immunoglobulin, a nucleic acid, a protein, an oligopeptide, a polypeptide, an antibody, a fragment of an antigenic polypeptide, a repebody, and the like.

The compounds and conjugates of the present disclosure may comprise one or more targeting moieties. In certain embodiments, the targeting moiety is a nanoparticle, an immunoglobulin, a nucleic acid, a protein, an oligopeptide, a polypeptide, an antibody, a fragment of an antigenic polypeptide, or a repebody. In further embodiments, the targeting moiety is an antibody selected from an intact polyclonal antibody, an intact monoclonal antibody, an antibody fragment, a single chain Fv (scFv) mutant, a multispecific antibody, a bispecific antibody, a chimeric antibody, a humanized antibody, a human antibody, a fusion protein comprising an antigenic determinant portion of an antibody, and other modified immunoglobulin molecules comprising antigen recognition sites.

In yet further embodiments, the antibody is selected from Muromonab-CD3, Abciximab, Rituximab, Daclizumab, Palivizumab, Infliximab, Trastuzumab (herceptin), Etanercept, Basiliximab, Gemtuzumab ozogamicin, Alemtuzumab, Ibritumomab tiuxetan, Adalimumab, Alefacept, Omalizumab, Efalizumab, Tositumomab-I¹³¹, Cetuximab, Bevacizumab, Natalizumab, Ranibizumab, Panitumumab, Eculizumab, Rilonacept, Certolizumab pegol, Romiplostim, AMG-531, CNTO-148, CNTO-1275, ABT-874, LEA-29Y, Belimumab, TACI-Ig, Second generation anti-CD20, ACZ-885, Tocilizumab, Atlizumab, Mepolizumab, Pertuzumab, Humax CD20, Tremelimumab (CP-675 206), Ticilimumab, MDX-010, IDEC-114, Inotuzumab ozogamycin, HuMax EGFR, Aflibercept, HuMax-CD4, Ala-Ala, ChAglyCD3, TRX4, Catumaxomab, IGN101, MT-201, Pregovomab, CH-14.18, WX-G250, AMG-162, AAB-001, Motavizumab, MEDI-524, Efumgumab, Aurograb, Raxibacumab, Third generation anti-CD20, LY2469298, and Veltuzumab.

In some embodiments, TM comprises two or more independently selected natural amino acids or non-natural amino acids conjugated by covalent bonds (*e.g.*, peptide bonds),

and the peptide may include 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more natural amino acids or non-natural amino acids that are conjugated by peptide bonds. In some embodiments, the ligand comprises shorter amino acid sequences (*e.g.*, fragments of natural proteins or synthetic polypeptide fragments) as well as full-length proteins (*e.g.*, pre-engineered proteins).

In some embodiments, TM is selected from an antibody, a hormone, a drug, an antibody analogue (*e.g.*, non-IgG), protein, an oligopeptide, a polypeptide, *etc.*, which bind to a receptor. In certain embodiments, TM selectively targets the drug in a specific organ, tissue, or cell. In other embodiments, TM specifically binds to a receptor over-expressed in cancer cells as compared to normal cells, and may be classified into a monoclonal antibody (mAb) or an antibody fragment and a low-molecular non-antibody. Preferably, TM is selected from peptides, tumor cell-specific peptides, tumor cell-specific aptamers, tumor cell-specific carbohydrates, tumor cell-specific monoclonal antibodies, polyclonal antibodies, and antibody fragments that are identified in a library screen.

Exemplary ligands or targeting moieties include, but are not limited to, carnitine, inositol, lipoic acid, pyridoxal, ascorbic acid, niacin, pantothenic acid, folic acid, riboflavin, thiamine, biotin, vitamin B₁₂, other water-soluble vitamins (vitamin B), fat-soluble vitamins (vitamin A, D, E, K), RGD (Arg-Gly-Asp), NGR (Asn-Gly-Arg), transferrin, VIP (vasoactive intestinal peptide) receptor, APRPG (Ala-Pro-Arg-Pro-Gly) peptide, TRX-20 (thioredoxin-20), integrin, nucleolin, aminopeptidase N (CD13), endoglin, vascular epithelial growth factor receptor, low density lipoprotein receptor, transferrin receptor, somatostatin receptor, bombesin, neuropeptide Y, luteinizing hormone releasing hormone receptor, folic acid receptor, epidermal growth factor receptor, transforming growth factor, fibroblast growth factor receptor, asialoglycoprotein receptor, galectin-3 receptor, E-selectin receptor, hyaluronic acid receptor, prostate-specific membrane antigen (PSMA), cholecystokinin A receptor, cholecystokinin B receptor, discoidin domain receptor, mucin receptor, opioid receptor, plasminogen receptor, bradykinin receptor, insulin receptor, insulin-like growth factor receptor, angiotensin AT1 receptor, angiotensin AT2 receptor, granulocyte macrophage colony stimulating factor receptor (GM-CSF receptor), galactosamine receptor, sigma-2 receptor, delta-like 3 (DLL-3), aminopeptidase P, melanotransferrin, leptin, tetanus toxin Tet1, tetanus toxin G23, RVG (Rabies Virus Glycoprotein) peptide, HER2 (human epidermal growth factor receptor 2), GPNMB (glycoprotein non-metastatic b), Ley, CA6, CanAng, SLC44A4 (Solute carrier family 44 member 4), CEACAM5 (Carcinoembryonic antigen-related cell adhesion

molecule 5), Nectin-4, Carbonic Anhydrase 9, TNNB2, 5T4, CD30, CD37, CD74, CD70, PMEL17, EphA2(EphrinA2 receptor), Trop-2, SC-16, Tissue factor, ENPP-3(AGS-16), SLITRK6 (SLIT and NTRK like family member 6), CD27, Lewis Y antigen, LIV1, GPR161 (G Protein-Coupled Receptor 161), PBR (peripheral-type benzodiazepine receptor), MERTK (Mer receptor tyrosine kinase) receptor, CD71, LLT1 (Lectin-like transcript 1 or CLED2D), interleukin-22 receptor, sigma 1 receptor, peroxisome proliferator-activated receptor, DLL3, C4.4a, cKIT, EphrinA, CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), FGFR2b (fibroblast growth factor receptor 2b), N-acetylcholine receptor, gonadotropin releasing hormone receptor, gastrin-releasing peptide receptor, bone morphogenetic protein receptor-type 1B (BMPRI1B), E16 (LAT1, SLC7A5), STEAP1 (six transmembrane epithelial antigen of prostate), 0772P (CA125, MUC16), MPF (MSLN, mesothelin), Napi3b (SLC34A2), Sema5b (semaphorin 5b), ETBR(Endothelin type B receptor), MSG783(RNF124), STEAP2 (six transmembrane epithelial antigen of prostate 2), TrpM4 (transient receptor potential cation 5 channel, subfamily M, member 4), CRIPTO (teratocarcinoma-derived growth factor), CD21, CD79b, FcRH2 (IFGP4), HER2 (ErbB2), NCA (CEACM6), MDP (DPEP1), IL20R-alpha (IN20Ra), Brevican (BCAN), EphB2R, ASLG659 (B7h), CD276, PSCA (prostate stem cell antigen precursor), GEDA, BAFF-R (BR3), CD22 (BL-CAM), CD79a, CXCR5, HLA-DOB, P2X5, CD72, LY64, FcRH1, IRTA2, TENB2, SSTR2, SSTR5, SSTR1, SSTR3, SSTR4, ITGAV (Integrin, alpha 5), ITGB6 (Integrin, beta 6), MET, MUC1, EGFRvIII, CD33, CD19, IL2RA (interleukin 2 receptor, alpha), AXL, BCMA, CTA (cancer testis antigens), CD174, CLEC14A, GPR78, CD25, CD32, LGR5 (GPR49), CD133 (Prominin), ASG5, ENPP3 (ectonucleotide Pyrophosphatase/Phosphodiesterase 3), PRR4 (proline-rich protein 4), GCC (guanylate cyclase 2C), Liv-1 (SLC39A6), CD56, CanAg, TIM-1, RG-1, B7-H4, PTK7, CD138, Claudins, Her3 (ErbB3), RON (MST1R), CD20, TNC (Tenascin C), FAP, DKK-1, CD52, CS1 (SLAMF7), Annexin A1, V-CAM, gp100, MART-1, MAGE-1 (melanoma antigen-encoding gene-1), MAGE-3 (melanoma-associated antigen 3), BAGE, GAGE-1, MUM-1(multiple myeloma oncogene 1), CDK4, TRP-1(gp75), TAG-72 (tumor-associated glycoprotein-72), ganglioside GD2, GD3, GM2, GM3, VEP8, VEP9, My1, VIM-D5, D156-22, OX40, RNAK, PD-L1, TNFR1, TNFR2, *etc.*

30 Targets

In some embodiments, the target or targets of the molecular recognition element are specifically associated with one or more particular cell or tissue types. In some embodiments, targets are specifically associated with one or more particular disease states. In some

embodiments, targets are specifically associated with one or more particular developmental stages. For example, a cell type specific marker is typically expressed at levels at least 2 fold greater in that cell type than in a reference population of cells. In some embodiments, the cell type specific marker is present at levels at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, at least 10 fold, at least 50 fold, at least 100 fold, or at least 1,000 fold greater than its average expression in a reference population. Detection or measurement of a cell type specific marker may make it possible to distinguish the cell type or types of interest from cells of many, most, or all other types. In some embodiments, a target can comprise a protein, a carbohydrate, a lipid, and/or a nucleic acid, as described herein.

In some embodiments, a substance is considered to be “targeted” if it specifically binds to a targeting moiety, such as a nucleic acid targeting moiety. In some embodiments, a targeting moiety, such as a nucleic acid targeting moiety, specifically binds to a target under stringent conditions.

In certain embodiments, the conjugates and compounds described herein comprise a targeting moiety that specifically binds to one or more targets (*e.g.*, antigens) associated with an organ, tissue, cell, extracellular matrix component, and/or intracellular compartment. In some embodiments, the conjugates and compounds described herein comprise a targeting moiety that specifically binds to targets associated with a particular organ or organ system. In some embodiments, the conjugates and compounds described herein comprise a targeting moiety that specifically binds to one or more intracellular targets (*e.g.*, organelle, intracellular protein). In some embodiments, the conjugates and compounds described herein comprise a targeting moiety which specifically binds to targets associated with diseased organs, tissues, cells, extracellular matrix components, and/or intracellular compartments. In some embodiments, the conjugates and compounds described herein comprise a targeting moiety that specifically binds to targets associated with particular cell types (*e.g.*, endothelial cells, cancer cells, malignant cells, prostate cancer cells, *etc.*).

In some embodiments, the conjugates and compounds described herein comprise a targeting moiety that binds to a target that is specific for one or more particular tissue types (*e.g.*, liver tissue *vs.* prostate tissue). In some embodiments, the conjugates and compounds described herein comprise a targeting moiety that binds to a target that is specific for one or more particular cell types (*e.g.*, T cells *vs.* B cells). In some embodiments, the conjugates and compounds described herein comprise a targeting moiety that binds to a target that is specific for one or more particular disease states (*e.g.*, tumor cells *vs.* healthy cells). In some

embodiments, the conjugates and compounds described herein comprise a targeting moiety that binds to a target that is specific for one or more particular developmental stages (*e.g.*, stem cells *vs.* differentiated cells).

In some embodiments, a target may be a marker that is exclusively or primarily associated with one or a few cell types, with one or a few diseases, and/or with one or a few developmental stages. A cell type specific marker is typically expressed at levels at least 2 fold greater in that cell type than in a reference population of cells which may consist, for example, of a mixture containing cells from a plurality (*e.g.*, 5–10 or more) of different tissues or organs in approximately equal amounts. In some embodiments, the cell type specific marker is present at levels at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, at least 10 fold, at least 50 fold, at least 100 fold, or at least 1000 fold greater than its average expression in a reference population. Detection or measurement of a cell type specific marker may make it possible to distinguish the cell type or types of interest from cells of many, most, or all other types.

In some embodiments, a target comprises a protein, a carbohydrate, a lipid, and/or a nucleic acid. In some embodiments, a target comprises a protein and/or characteristic portion thereof, such as a tumor marker, integrin, cell surface receptor, transmembrane protein, intercellular protein, ion channel, membrane transporter protein, enzyme, antibody, chimeric protein, glycoprotein, *etc.* In some embodiments, a target comprises a carbohydrate and/or characteristic portion thereof, such as a glycoprotein, sugar (*e.g.*, monosaccharide, disaccharide, polysaccharide), glycocalyx (*i.e.*, the carbohydrate-rich peripheral zone on the outside surface of most eukaryotic cells), *etc.* In some embodiments, a target comprises a lipid and/or characteristic portion thereof, such as an oil, fatty acid, glyceride, hormone, steroid (*e.g.*, cholesterol, bile acid), vitamin (*e.g.*, vitamin E), phospholipid, sphingolipid, lipoprotein, *etc.* In some embodiments, a target comprises a nucleic acid and/or characteristic portion thereof, such as a DNA nucleic acid; RNA nucleic acid; modified DNA nucleic acid; modified RNA nucleic acid; nucleic acid that includes any combination of DNA, RNA, modified DNA, and modified RNA.

Numerous markers are known in the art. Typical markers include cell surface proteins, *e.g.*, receptors. Exemplary receptors include, but are not limited to, the transferrin receptor; LDL receptor; growth factor receptors such as epidermal growth factor receptor family members (*e.g.*, EGFR, Her2, Her3, Her4) or vascular endothelial growth factor receptors, cytokine receptors, cell adhesion molecules, integrins, selectins, and CD molecules. The

marker can be a molecule that is present exclusively or in higher amounts on a malignant cell, *e.g.*, a tumor antigen.

Antibody-Drug Conjugates (ADCs)

5 In some embodiments, TM is an antibody, and Q is a drug. Accordingly, the compounds and conjugates disclosed herein may be used to conjugate an antibody to a drug moiety to form targeted drug conjugates which are antibody-drug conjugates (ADC). Antibody-drug conjugates (ADCs), like other targeted drug conjugates, may increase therapeutic efficacy in treating disease, *e.g.*, cancer, due to the ability of the ADC to selectively deliver one or more
10 drug moiety(s) to target tissues, such as a tumor-associated antigen. Thus, in certain embodiments, the disclosure provides ADCs for therapeutic use, *e.g.*, treatment of cancer.

ADCs of the disclosure comprise an antibody linked to one or more drug moieties. The specificity of the ADC is defined by the specificity of the antibody. In one embodiment, an antibody is linked to one or more cytotoxic drug(s), which is delivered internally to a cancer
15 cell.

Examples of drugs that may be used in the ADC of the disclosure are provided below. The terms “drug”, “agent”, and “drug moiety” are used interchangeably herein. The terms “linked” and “conjugated” are also used interchangeably herein and indicate that the antibody and moiety are covalently linked.

20 In certain aspects, the present disclosure is directed to ADCs, compositions comprising ADCs, methods of treating, and methods of formulating ADC compositions. ADCs comprise an antibody, or an antibody fragment, conjugated to a cytotoxic compound. In some embodiments, the cytotoxic compound is conjugated to an antibody via a linker. In other embodiments, the cytotoxic compound is linked directly to the antibody. The types of
25 antibodies, linkers, and cytotoxic compounds encompassed by this disclosure are described below.

Antibodies

The antibody of an ADC may be any antibody that binds, typically but not necessarily specifically, an antigen expressed on the surface of a target cell of interest. The antigen need
30 not, but in some embodiments, is capable of internalizing an ADC bound thereto into the cell. Target cells of interest may include cells where induction of apoptosis is desirable. Target antigens may be any protein, glycoprotein, polysaccharide, lipoprotein, *etc.* expressed on the target cell of interest, but will typically be proteins that are either uniquely expressed on the

target cell and not on normal or healthy cells, or that are over-expressed on the target cell as compared to normal or healthy cells, such that the ADCs selectively target specific cells of interest, such as, for example, tumor cells. As will be appreciated by skilled artisans, the specific antigen, and hence antibody, selected will depend upon the identity of the desired target cell of interest. In specific embodiments, the antibody of the ADC is an antibody suitable for administration to humans.

Antibodies (Abs) and immunoglobulins (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific target, immunoglobulins include both antibodies and other antibody-like molecules which lack target specificity. Native antibodies and immunoglobulins are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains. Each light chain has a variable domain at one end (VL) and a constant domain at its other end.

References to “VH” refer to the variable region of an immunoglobulin heavy chain of an antibody, including the heavy chain of an Fv, scFv, or Fab. References to “VL” refer to the variable region of an immunoglobulin light chain, including the light chain of an Fv, scFv, dsFv or Fab.

The term “antibody” herein is used in the broadest sense and refers to an immunoglobulin molecule that specifically binds to, or is immunologically reactive with, a particular antigen, and includes polyclonal, monoclonal, genetically engineered and otherwise modified forms of antibodies, including but not limited to murine, chimeric antibodies, humanized antibodies, heteroconjugate antibodies (*e.g.*, bispecific antibodies, diabodies, triabodies, and tetrabodies), and antigen binding fragments of antibodies, including *e.g.*, Fab’, F(ab’)2, Fab, Fv, rIgG, and scFv fragments. The term “scFv” refers to a single chain Fv antibody in which the variable domains of the heavy chain and the light chain from a traditional antibody have been joined to form one chain.

Antibodies may be murine, human, humanized, chimeric, or derived from other species. An antibody is a protein generated by the immune system that is capable of recognizing and binding to a specific antigen. (Janeway, C., Travers, P., Walport, M., Shlomchik (2001) *Immuno Biology*, 5th Ed., Garland Publishing, New York). A target antigen generally has numerous binding sites, also called epitopes, recognized by CDRs on multiple antibodies. Each antibody that specifically binds to a different epitope has a different structure. Thus, one antigen may have more than one corresponding antibody. An antibody includes a full-length

immunoglobulin molecule or an immunologically active portion of a full-length immunoglobulin molecule, *i.e.*, a molecule that contains an antigen binding site that immunospecifically binds an antigen of a target of interest or part thereof, such targets including but not limited to, cancer cell or cells that produce autoimmune antibodies associated with an autoimmune disease. The immunoglobulin disclosed herein can be of any type (*e.g.*, IgG, IgE, IgM, IgD, and IgA), class (*e.g.*, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. The immunoglobulins can be derived from any species. In one aspect, however, the immunoglobulin is of human, murine, or rabbit origin.

The term “antibody fragment” refers to a portion of a full-length antibody, generally the target binding or variable region. Examples of antibody fragments include Fab, Fab', F(ab')₂ and Fv fragments. An “Fv” fragment is the minimum antibody fragment that contains a complete target recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in a tight, non-covalent association (VH-VL dimer). It is in this configuration that the three CDRs of each variable domain interact to define a target binding site on the surface of the VH-VL dimer. Often, the six CDRs confer target binding specificity to the antibody. However, in some instances even a single variable domain (or half of an Fv comprising only three CDRs specific for a target) can have the ability to recognize and bind target. “Single-chain Fv” or “scFv” antibody fragments comprise the VH and VL domains of an antibody in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for target binding. “Single domain antibodies” are composed of a single VH or VL domains which exhibit sufficient affinity to the target. In a specific embodiment, the single domain antibody is a camelized antibody (see, *e.g.*, Riechmann, 1999, Journal of Immunological Methods 231:25-38).

The Fab fragment contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. F(ab') fragments are produced by cleavage of the disulfide bond at the hinge cysteines of the F(ab')₂ pepsin digestion product. Additional chemical couplings of antibody fragments are known to those of ordinary skill in the art.

Both the light chain and the heavy chain variable domains have complementarity determining regions (CDRs), also known as hypervariable regions. The more highly conserved portions of variable domains are called the framework (FR). As is known in the art, the amino acid position/boundary delineating a hypervariable region of an antibody can vary, depending on the context and the various definitions known in the art. Some positions within a variable domain may be viewed as hybrid hypervariable positions in that these positions can be deemed to be within a hypervariable region under one set of criteria while being deemed to be outside a hypervariable region under a different set of criteria. One or more of these positions can also be found in extended hypervariable regions. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the target binding site of antibodies (see Kabat *et al.*, Sequences of Proteins of Immunological Interest (National Institute of Health, Bethesda, Md. 1987). As used herein, numbering of immunoglobulin amino acid residues is done according to the immunoglobulin amino acid residue numbering system of Kabat *et al.*, unless otherwise indicated.

In certain embodiments, the antibodies of the ADCs of the present disclosure are monoclonal antibodies. The term “monoclonal antibody” (mAb) refers to an antibody that is derived from a single copy or clone, including *e.g.*, any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. Preferably, a monoclonal antibody of the disclosure exists in a homogeneous or substantially homogeneous population. Monoclonal antibody includes both intact molecules, as well as, antibody fragments (such as, for example, Fab and F(ab')₂ fragments), which are capable of specifically binding to a protein. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation of the animal, and may have less non-specific tissue binding than an intact antibody (Wahl *et al.*, 1983, *J. Nucl. Med* 24:316). Monoclonal antibodies useful with the present disclosure can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. The antibodies of the disclosure include chimeric, primatized, humanized, or human antibodies.

While in most instances antibodies are composed of only the genetically-encoded amino acids, in some embodiments non-encoded amino acids may be incorporated at specific. Examples of non-encoded amino acids that may be incorporated into antibodies for use in controlling stoichiometry and attachment location, as well as methods for making such modified antibodies are discussed in Tian *et al.*, 2014, *Proc Nat'l Acad Sci USA* 111(5):1766-1771 and Axup *et al.*, 2012, *Proc Nat'l Acad Sci USA* 109(40):16101-16106 the entire contents of which are incorporated herein by reference.

In certain embodiments, the antibody of the ADCs described herein is a chimeric antibody. The term “chimeric” antibody as used herein refers to an antibody having variable sequences derived from a non-human immunoglobulin, such as rat or mouse antibody, and human immunoglobulin constant regions, typically chosen from a human immunoglobulin template. Methods for producing chimeric antibodies are known in the art. *See, e.g.,* Morrison, 1985, *Science* 229(4719):1202-7; Oi *et al.*, 1986, *BioTechniques* 4:214-221; Gillies *et al.*, 1985, *J. Immunol. Methods* 125:191-202; U.S. Pat. Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entireties.

In certain embodiments, the antibody of the ADCs described herein is a humanized antibody. “Humanized” forms of non-human (*e.g.*, murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other target-binding subdomains of antibodies), which contain minimal sequences derived from non-human immunoglobulin. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin consensus sequence. Methods of antibody humanization are known in the art. *See, e.g.,* Riechmann *et al.*, 1988, *Nature* 332:323-7; U.S. Pat. Nos. 5,530,101; 5,585,089; 5,693,761; 5,693,762; and U.S. Pat. No. 6,180,370 to Queen *et al.*; EP239400; PCT publication WO 91/09967; U.S. Pat. No. 5,225,539; EP592106; EP519596; Padlan, 1991, *Mol. Immunol.*, 28:489-498; Studnicka *et al.*, 1994, *Prot. Eng.* 7:805-814; Roguska *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91:969-973; and U.S. Pat. No. 5,565,332, all of which are hereby incorporated by reference in their entireties.

In certain embodiments, the antibody of the ADCs described herein is a human antibody. Completely “human” antibodies can be desirable for therapeutic treatment of human patients. As used herein, “human antibodies” include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins. Human antibodies can be made by a variety of methods known in the art including phage display methods using antibody libraries derived from human immunoglobulin sequences. *See* U.S. Pat. Nos. 4,444,887 4,716,111, 6,114,598, 6,207,418, 6,235,883, 7,227,002, 8,809,151 and U.S. Published Application No. 2013/189218, the contents of which are incorporated herein by reference in their entireties.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. See, *e.g.*, U.S. Pat. Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; 5,939,598; 7,723,270; 8,809,051 and
5 U.S. Published Application No. 2013/117871, which are incorporated by reference herein in their entireties. In addition, companies such as Medarex (Princeton, N.J.), Astellas Pharma (Deerfield, Ill.), and Regeneron (Tarrytown, N.Y.) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above. Completely human antibodies that recognize a selected epitope can be generated using a
10 technique referred to as “guided selection.” In this approach a selected non-human monoclonal antibody, *e.g.*, a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope (Jespers *et al.*, 1988, *Biotechnology* 12:899-903).

In certain embodiments, the antibody of the ADCs described herein is a primatized antibody. The term “primatized antibody” refers to an antibody comprising monkey variable
15 regions and human constant regions. Methods for producing primatized antibodies are known in the art. See, *e.g.*, U.S. Pat. Nos. 5,658,570; 5,681,722; and 5,693,780, which are incorporated herein by reference in their entireties.

In certain embodiments, the antibody of the ADCs described herein is a bispecific antibody or a dual variable domain antibody (DVD). Bispecific and DVD antibodies are
20 monoclonal, often human or humanized, antibodies that have binding specificities for at least two different antigens. DVDs are described, for example, in U.S. Pat. No. 7,612,181, the disclosure of which is incorporated herein by reference.

In certain embodiments, the antibody of the ADCs described herein is a derivatized antibody. For example, but not by way of limitation, derivatized antibodies are typically
25 modified by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, *etc.* Any of numerous chemical modifications can be carried out by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, *etc.* Additionally, the derivative can contain one or more non-natural
30 amino acids, *e.g.*, using ambrx technology (*see, e.g.*, Wolfson, 2006, *Chem. Biol.* 13(10):1011-2).

In certain embodiments, the antibody of the ADCs described herein has a sequence that has been modified to alter at least one constant region-mediated biological effector function relative to the corresponding wild type sequence. For example, in some embodiments, the

antibody can be modified to reduce at least one constant region-mediated biological effector function relative to an unmodified antibody, *e.g.*, reduced binding to the Fc receptor (FcR). FcR binding can be reduced by mutating the immunoglobulin constant region segment of the antibody at particular regions necessary for FcR interactions (*see, e.g.*, Canfield and Morrison, 1991, *J. Exp. Med* 173:1483-1491; and Lund *et al.*, 1991, *J. Immunol.* 147:2657-2662).

In certain embodiments, the antibody of the ADCs described herein is modified to acquire or improve at least one constant region-mediated biological effector function relative to an unmodified antibody, *e.g.*, to enhance FcγR interactions (*see, e.g.*, US 2006/0134709). For example, an antibody with a constant region that binds FcγRIIA, FcγRIIB and/or FcγRIIIA with greater affinity than the corresponding wild type constant region can be produced according to the methods described herein.

In certain specific embodiments, the antibody of the ADCs described herein is an antibody that binds tumor cells, such as an antibody against a cell surface receptor or a tumor-associated antigen (TAA). In attempts to discover effective cellular targets for cancer diagnosis and therapy, researchers have sought to identify transmembrane or otherwise tumor-associated polypeptides that are specifically expressed on the surface of one or more particular type(s) of cancer cell as compared to on one or more normal non-cancerous cell(s). Often, such tumor-associated polypeptides are more abundantly expressed on the surface of the cancer cells as compared to the surface of the no-cancerous cells. Such cell surface receptor and tumor-associated antigens are known in the art, and can prepared for use in generating antibodies using methods and information which are well known in the art.

Exemplary Cell Surface Receptors and TAAs

Examples of cell surface receptor and TAAs to which the antibody of the ADCs described herein may be targeted include, but are not limited to, the various receptors and TAAs listed below in Table 1. For convenience, information relating to these antigens, all of which are known in the art, is listed below and includes names, alternative names, Genbank accession numbers and primary reference(s), following nucleic acid and protein sequence identification conventions of the National Center for Biotechnology Information (NCBI). Nucleic acid and protein sequences corresponding to the listed cell surface receptors and TAAs are available in public databases such as GenBank.

Table I.

4-1BB
5AC
5T4
Alpha-fetoprotein
angiopoietin 2
ASLG659
TCL1
BMPR1B
Brevican (BCAN, BEHAB)
C2-42 antigen
C5
CA-125
CA-125 (imitation)
CA-IX (Carbonic anhydrase 9)
CCR4
CD140a
CD152
CD19
CD20
CD200
CD21 (C3DR) 1)
CD22 (B-cell receptor CD22-B isoform)
CD221
CD23 (gE receptor)
CD28
CD30 (TNFRSF8)
CD33
CD37
CD38 (cyclic ADP ribose hydrolase)
CD4
CD40
CD44 v6
CD51
CD52
CD56
CD70
CD72 (Lyb-2, B-cell differentiation antigen CD72)
CD74
CD79a (CD79A, CD79 α , immunoglobulin-associated α) Genbank accession No. NP_001774.10)
CD79b (CD79B, CD79 β , B29)
CD80
CEA
CEA-related antigen
ch4D5
CLDN18.2
CRIPTO (CR, CR1, CRGF, TDGF1 teratocarcinoma-derived growth factor)

CTLA-4
CXCR5
DLL4
DR5
E16 (LAT1, SLC7A5) EGFL7
EGFR
EpCAM
EphB2R (DRT, ERK, Hek5, EPHT3, Tyro5)
Episialin
ERBB3
ETBR (Endothelin type B receptor)
FCRH1 (Fc receptor-like protein 1)
FcRH2 (IFGP4, IRTA4, SPAP1, SPAP1B, SPAP1C, SH2 domain containing phosphatase anchor protein)
Fibronectin extra domain-B
Folate receptor 1
Frizzled receptor
GD2
GD3 ganglioside
GEDA
GPNMB
HER1
HER2 (ErbB2)
HER2/neu
HER3
HGF
HLA-DOB
HLA-DR
Human scatter factor receptor kinase
IGF-1 receptor
IgG4
IL-13
IL20R α (IL20Ra, ZCYTOR7)
IL-6
ILGF2
ILFR1R
integrin α
integrin $\alpha 5\beta 1$
integrin $\alpha v\beta 3$
IRTA2 (Immunoglobulin superfamily receptor translocation associated 2, Gene Chromosome 1q21)
Lewis-Y antigen
LY64 (RP105)
MCP-1
MDP (DPEP1)
MPF (MSLN, SMR, mesothelin, megkaryocyte potentiating factor)
MS4A1

MSG783 (RNF124, hypothetical protein FLJ20315)
MUC1
Mucin CanAg
Napi3 (NAPI-3B, NPTIb, SLC34A2, type II sodium-dependent phosphate transporter 3b)
NCA (CEACAM6)
P2X5 (Purinergic receptor P2X ligand-gated ion channel 5)
PD-1
PDCD1
PDGF-R α
Prostate specific membrane antigen
PSCA (Prostate stem cell antigen precursor)
PSCA hlg
RANKL
RON
SDC1
Sema 5b
SLAMF7 (CS-1)
STEAP1
STEAP2 (HGNC_8639, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1)
TAG-72
TEM1
Tenascin C
TENB2, (TMEFF2, tomoregulin, TPEF, HPP1, TR)
TGF- β
TRAIL-E2
TRAIL-R1
TRAIL-R2
TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel subfamily M, member 4)
TA CTAA16.88
TWEAK-R
TYRP1 (glycoprotein 75)
VEGF
VEGF-A
EGFR-1
VEGFR-2
Vimentin

Exemplary Antibodies

Exemplary antibodies to be used with ADCs of the disclosure include but are not limited to 3F8 (GD2), Abagovomab (CA-125 (imitation)), Adecatumumab (EpCAM), Afutuzumab (CD20), Alacizumab pegol (VEGFR2), ALD518 (IL-6), Alemtuzumab (CD52), Altumomab pentetate (CEA), Amatuximab (Mesothelin), Anatumomab mafenatox (TAG-72), Apolizumab (HLA-DR), Arcitumomab (CEA), Bavituximab (Phosphatidylserine),

Bectumomab (CD22), Belimumab (BAFF), Besilesomab (CEA-related antigen), Bevacizumab (VEGF-A), Bivatuzumab mertansine (CD44 v6), Blinatumomab (CD19), Brentuximab vedotin ((CD30 (TNFRSF8)), Cantuzumab mertansine (Mucin CanAg), Cantuzumab ravtansine (MUC1), Capromab pendetide (Prostatic carcinoma cells), Carlumab (MCP-1), Catumaxomab (EpCAM, CD3), CC49 (Tag-72), cBR96-DOX ADC (Lewis-Y antigen), Cetuximab (EGFR), Citatuzumab bogatox (EpCAM), Cixutumumab (IGF-1 receptor), Clivatuzumab tetraxetan(MUC1), Conatumumab (TRAIL-E2), Dacetuzumab (CD40), Dalotuzumab (Insulin-like growth factor 1 receptor), Deratumumab ((CD38 (cyclic ADP ribose hydrolase)), Demcizumab (DLL4), Denosumab (RANKL), Detumomab (B-lymphoma cell), Drozitumab (DR5), Dusigitumab (ILGF2), Ecomeximab (D3 ganglioside), Eculizumab (C5), Edrecolomab (EpCAM), Elotuzumab (SLAMF7), Elsilimomab (IL-6), Enavatuzumab (TWEAK receptor), Enoticumab (DLL4), Ensituximab (5AC), Epitumomab cituxetan (Episialin), Epratuzumab (CD22), Ertumaxomab ((HER2/neu, CD3)), Etancizumab (Integrin $\alpha\beta 3$), Farletuzumab (Folate receptor 1), FBTA05 (CD20), Ficlaturuzumab (HGF), Figitumumab (IGF-1 receptor), Flanvotumab ((TYRP1 (glycoprotein 75)), Fresolimumab (TGF-1), Galiximab (CD80), Ganitumab (IGF-I), Gemtuzumab ozogamicin (CD33), Girentuximab ((Carbonic anhydrase 9 (CA-IX)), Glembatumumab vedotin (GPNMB), Ibritumomab tiuxetan (CD20) Icrucumab (VEGFR-1), Igovomab (CA-125), IMAB362 (CLDN18.2), Imgatuzumab (EGFR), Indatuximab ravtansine (SDC1), Intetumumab (CD51), Inotuzumab ozogamicin (CD22), Ipilimumab (CD152), Iratumumab ((CD30 (TNFRSF8)), Labetuzumab (CEA), Lambrolizumab (PDCD1), Lexatumumab (TRAIL-R2), Lintuzumab (CD33), Lorvotuzumab mertansine (CD56), Lucatumumab (CD40), Lumiliximab ((CD23 (IgE receptor)), Mapatumumab (TRAIL-R1), Margetuximab (ch4DS), Matuzumab (EGFR), Milatuzumab (CD74), Mitumomab (GD3 ganglioside), Mogamulizumab (CCR4), Moxetumomab pasudotox (CD22), Nacolomab tafenatox (C2-42 antigen), Naptumomab estafenatox (5T4), Narnatumab (RON), Natalizumab (integrin $\alpha 4$), Necitumumab (EGFR), Nesvacumab (angiopoietin 2), Nimotuzumab (EGFR), Nivolumab (IgG4), Ocaratuzumab (CD20), Ofatumumab (CD20), Olaratumab (PDGF-R α), Onartuzumab (Human scatter factor receptor kinase), Ontuxizumab (TEM1), Oportuzumab monato (EpCAM), Oregovomab (CA-125), Otlertuzumab (CD37), Panitumumab (EGFR) Pankomab (Tumor specific glycosylation of MUC1), Parsatuzumab (EGFL7), Patritumab (HER3), Pentumomab (MUC1), Pertuzumab (HER2/neu), Pidilizumab (PD-1), Pinatuzumab vedotin (CD22), Pritumumab (Vimentin), Racotumomab (N-glycolylneuraminic acid), Radretumab (Fibronectin extra domain-B), Ramucirumab (VEGFR2), Rilotumumab (HGF), Rituximab (CD20), Robatumumab (IGF-1 receptor),

Samalizumab (CD200), Satumomab pendetide (TAG-72), Seribantumab (ERBB3),
 Sibrotuzumab (FAP), SGN-CD19A (CD19), SGN-CD33A (CD33), Siltuximab (IL-6),
 Solitomab (EpCAM), Sonepcizumab (Sphingosine-1-phosphate), Tabalumb (BAFF),
 Tacatuzumab tetraxetan (Alpha-fetoprotein), Taplitumomab paptox (CD19), Tenatumomab
 5 (Tenascin C), Teprotumumab (CD221), TGN1412 (CD28), Ticilimumab (CTLA-4),
 Tigatuzumab (TRAIL-R2), TNX-650 (IL-13), Tovetumab (CD40a), Trastuzumab
 (HER2/neu), TRBS07 (GD2), Tremelimumab (CTLA-4), Tucotuzumab celmoleukin
 (EpCAM), Ublituximab (MS4A), Urelumab (4-1BB), Vandetanib (VEGF), Vantictumab
 (Frizzled receptor), Volociximab (integrin $\alpha 5\beta 1$), Vorsetuzumab mafodotin (CD70),
 10 Votumumab (Tumor antigen CTAA16.88), Zalutumumab (EGFR), Zanolimumab (CD4), and
 Zatuximab (HER1).

Methods of Making Antibodies

The antibody of an ADC can be prepared by recombinant expression of
 15 immunoglobulin light and heavy chain genes in a host cell. For example, to express an antibody
 recombinantly, a host cell is transfected with one or more recombinant expression vectors
 carrying DNA fragments encoding the immunoglobulin light and heavy chains of the antibody
 such that the light and heavy chains are expressed in the host cell and, optionally, secreted into
 the medium in which the host cells are cultured, from which medium the antibodies can be
 20 recovered. Standard recombinant DNA methodologies are used to obtain antibody heavy and
 light chain genes, incorporate these genes into recombinant expression vectors and introduce
 the vectors into host cells, such as those described in Molecular Cloning; A Laboratory Manual,
 Second Edition (Sambrook, Fritsch and Maniatis (eds), Cold Spring Harbor, N. Y., 1989),
 Current Protocols in Molecular Biology (Ausubel, F. M. *et al.*, eds., Greene Publishing
 25 Associates, 1989) and in U.S. Pat. No. 4,816,397.

In one embodiment, the Fc variant antibodies are similar to their wild-type equivalents
 but for changes in their Fc domains. To generate nucleic acids encoding such Fc variant
 antibodies, a DNA fragment encoding the Fc domain or a portion of the Fc domain of the wild-
 type antibody (referred to as the “wild-type Fc domain”) can be synthesized and used as a
 30 template for mutagenesis to generate an antibody as described herein using routine mutagenesis
 techniques; alternatively, a DNA fragment encoding the antibody can be directly synthesized.

Once DNA fragments encoding wild-type Fc domains are obtained, these DNA
 fragments can be further manipulated by standard recombinant DNA techniques, for example,

to convert the constant region genes to full-length antibody chain genes. In these manipulations, a CH-encoding DNA fragment is operatively linked to another DNA fragment encoding another protein, such as an antibody variable region or a flexible linker. The term “operatively linked,” as used in this context, is intended to mean that the two DNA fragments are joined such that the amino acid sequences encoded by the two DNA fragments remain in-frame.

To express the Fc variant antibodies, DNAs encoding partial or full-length light and heavy chains, obtained as described above, are inserted into expression vectors such that the genes are operatively linked to transcriptional and translational control sequences. In this context, the term “operatively linked” is intended to mean that an antibody gene is ligated into a vector such that transcriptional and translational control sequences within the vector serve their intended function of regulating the transcription and translation of the antibody gene. The expression vector and expression control sequences are chosen to be compatible with the expression host cell used. A variant antibody light chain gene and the antibody heavy chain gene can be inserted into separate vectors or, more typically, both genes are inserted into the same expression vector.

The antibody genes are inserted into the expression vector by standard methods (*e.g.*, ligation of complementary restriction sites on the antibody gene fragment and vector, or blunt end ligation if no restriction sites are present). Prior to insertion of the variant Fc domain sequences, the expression vector can already carry antibody variable region sequences. Additionally or alternatively, the recombinant expression vector can encode a signal peptide that facilitates secretion of the antibody chain from a host cell. The antibody chain gene can be cloned into the vector such that the signal peptide is linked in-frame to the amino terminus of the antibody chain gene. The signal peptide can be an immunoglobulin signal peptide or a heterologous signal peptide (*i.e.*, a signal peptide from a non-immunoglobulin protein).

In addition to the antibody chain genes, the recombinant expression vectors carry regulatory sequences that control the expression of the antibody chain genes in a host cell. The term “regulatory sequence” is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals) that control the transcription or translation of the antibody chain genes. Such regulatory sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185 (Academic Press, San Diego, Calif., 1990). It will be appreciated by those skilled in the art that the design of the expression vector, including the selection of regulatory sequences may depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, *etc.* Suitable regulatory sequences for mammalian host cell expression include viral elements that direct high

levels of protein expression in mammalian cells, such as promoters and/or enhancers derived from cytomegalovirus (CMV) (such as the CMV promoter/enhancer), Simian Virus 40 (SV40) (such as the SV40 promoter/enhancer), adenovirus, (*e.g.*, the adenovirus major late promoter (AdMLP)) and polyoma. For further description of viral regulatory elements, and sequences thereof, see, *e.g.*, U.S. Pat. No. 5,168,062 by Stinski, U.S. Pat. No. 4,510,245 by Bell *et al.*, and U.S. Pat. No. 4,968,615 by Schaffner *et al.*

In addition to the antibody chain genes and regulatory sequences, the recombinant expression vectors can carry additional sequences, such as sequences that regulate replication of the vector in host cells (*e.g.*, origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (*see, e.g.*, U.S. Pat. Nos. 4,399,216, 4,634,665 and 5,179,017, all to Axel *et al.*). For example, typically the selectable marker gene confers resistance to drugs, such as G418, puromycin, blasticidin, hygromycin or methotrexate, on a host cell into which the vector has been introduced. Suitable selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in DHFR– host cells with methotrexate selection/amplification) and the neo gene (for G418 selection). For expression of the light and heavy chains, the expression vector(s) encoding the heavy and light chains is transfected into a host cell by standard techniques. The various forms of the term “transfection” are intended to encompass a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, *e.g.*, electroporation, lipofection, calcium-phosphate precipitation, DEAE-dextran transfection, and the like.

It is possible to express the antibodies in either prokaryotic or eukaryotic host cells. In certain embodiments, expression of antibodies is performed in eukaryotic cells, *e.g.*, mammalian host cells, for optimal secretion of a properly folded and immunologically active antibody. Exemplary mammalian host cells for expressing the recombinant antibodies include Chinese Hamster Ovary (CHO cells) (including DHFR– CHO cells, described in Urlaub and Chasin, 1980, *Proc. Natl. Acad. Sci. USA* 77:4216-4220, used with a DHFR selectable marker, *e.g.*, as described in Kaufman and Sharp, 1982, *Mol. Biol.* 159:601-621), NS0 myeloma cells, COS cells, 293 cells and SP2/0 cells. When recombinant expression vectors encoding antibody genes are introduced into mammalian host cells, the antibodies are produced by culturing the host cells for a period of time sufficient to allow for expression of the antibody in the host cells or secretion of the antibody into the culture medium in which the host cells are grown. Antibodies can be recovered from the culture medium using standard protein purification

methods. Host cells can also be used to produce portions of intact antibodies, such as Fab fragments or scFv molecules.

In some embodiments, the antibody of an ADC can be a bifunctional antibody. Such antibodies, in which one heavy and one light chain are specific for one antigen and the other heavy and light chain are specific for a second antigen, can be produced by crosslinking an antibody to a second antibody by standard chemical crosslinking methods. Bifunctional antibodies can also be made by expressing a nucleic acid engineered to encode a bifunctional antibody.

In certain embodiments, dual specific antibodies, *i.e.* antibodies that bind one antigen and a second, unrelated antigen using the same binding site, can be produced by mutating amino acid residues in the light chain and/or heavy chain CDRs. Exemplary second antigens include a proinflammatory cytokine (such as, for example, lymphotoxin, interferon- γ , or interleukin-1). Dual specific antibodies can be produced, *e.g.*, by mutating amino acid residues in the periphery of the antigen binding site (*see, e.g.*, Bostrom *et al.*, 2009, *Science* 323:1610-1614). Dual functional antibodies can be made by expressing a nucleic acid engineered to encode a dual specific antibody.

Antibodies can also be produced by chemical synthesis (*e.g.*, by the methods described in *Solid Phase Peptide Synthesis*, 2nd ed., 1984 The Pierce Chemical Co., Rockford, Ill.). Antibodies can also be generated using a cell-free platform (*see, e.g.*, Chu *et al.*, *Biochemistry* No. 2, 2001 (Roche Molecular Biologicals)).

Methods for recombinant expression of Fc fusion proteins are described in Flanagan *et al.*, *Methods in Molecular Biology*, vol. 378: Monoclonal Antibodies: Methods and Protocols.

Once an antibody has been produced by recombinant expression, it can be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (*e.g.*, ion exchange, affinity, particularly by affinity for antigen after Protein A or Protein G selection, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.

Once isolated, an antibody can, if desired, be further purified, *e.g.*, by high performance liquid chromatography (*see, e.g.*, Fisher, *Laboratory Techniques In Biochemistry And Molecular Biology* (Work and Burdon, eds., Elsevier, 1980)), or by gel filtration chromatography on a Superdex™ 75 column (Pharmacia Biotech AB, Uppsala, Sweden).

General method for preparing antibodies

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a given target, such as, for example, B7-H3, a tumor associated antigen or other target, or against derivatives, fragments, analogs homologs or orthologs thereof. (See, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference).

Antibodies can be purified by well-known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

In some embodiments, the antibodies which may be used in embodiments disclosed herein are monoclonal antibodies. Monoclonal antibodies are generated, for example, by using the procedures set forth in the Examples provided herein. Antibodies are also generated, e.g., by immunizing BALB/c mice with combinations of cell transfectants expressing high levels of a given target on their surface. Hybridomas resulting from myeloma/B cell fusions are then screened for reactivity to the selected target.

Monoclonal antibodies are prepared, for example, using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized *in vitro*.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed.

The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of monoclonal antibodies. (See Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63)).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). Moreover, in therapeutic applications of monoclonal antibodies, it is important to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. (See Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

Monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies can be readily isolated and sequenced using conventional procedures (*e.g.*, by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (*see* U.S. Patent No. 4,816,567; Morrison, *Nature* 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody, or can be substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody.

Monoclonal antibodies which may be used in embodiments disclosed here include humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization is performed, *e.g.*, by following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeven et al., *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539). In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies also comprise, *e.g.*, residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody includes substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also includes

at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).

Fully human antibodies are antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs arise from human genes. Such antibodies are termed “human antibodies” or “fully human antibodies” herein. Monoclonal antibodies can be prepared by using trioma technique; the human B-cell hybridoma technique (*see* Kozbor, et al., 1983 Immunol Today 4: 72); and the EBV hybridoma technique to produce monoclonal antibodies (*see* Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Monoclonal antibodies may be utilized and may be produced by using human hybridomas (*see* Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus *in vitro* (*see* Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries. (*See* Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, *e.g.*, mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al., Bio/Technology 10, 779-783 (1992); Lonberg et al., Nature 368 856-859 (1994); Morrison, Nature 368, 812-13 (1994); Fishwild et al, Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).

Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (*See* PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement

of the modifications. An example of such a nonhuman animal is a mouse termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a
5 preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv (scFv) molecules.

10 An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method, which includes deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged
15 immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

One method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. This method includes introducing an expression vector
20 that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically
25 relevant epitope on an immunogen and a correlative method for selecting an antibody that binds specifically to the relevant epitope with high affinity are disclosed in U.S. publication U.S. 2003/009212.

The antibody can be expressed by a vector containing a DNA segment encoding the single chain antibody described above.

30 These can include vectors, liposomes, naked DNA, adjuvant-assisted DNA, gene gun, catheters, *etc.* Vectors include chemical conjugates such as described in WO 93/64701, which has targeting moiety (*e.g.*, a ligand to a cellular surface receptor), and a nucleic acid binding moiety (*e.g.*, polylysine), viral vector (*e.g.*, a DNA or RNA viral vector), fusion proteins such as described in U.S. Patent No. 7,186,697 which is a fusion protein containing a target moiety

(*e.g.*, an antibody specific for a target cell) and a nucleic acid binding moiety (*e.g.*, a protamine), plasmids, phage, etc. The vectors can be chromosomal, non-chromosomal or synthetic.

Preferred vectors include viral vectors, fusion proteins and chemical conjugates.

- 5 Retroviral vectors include moloney murine leukemia viruses. DNA viral vectors are preferred. These vectors include pox vectors such as orthopox or avipox vectors, herpesvirus vectors such as a herpes simplex I virus (HSV) vector (*see* Geller, A. I. et al., J. Neurochem, 64:487 (1995); Lim, F., et al., in DNA Cloning: Mammalian Systems, D. Glover, Ed. (Oxford Univ. Press, Oxford England) (1995); Geller, A. I. et al., Proc Natl. Acad. Sci.: U.S.A. 90:7603 (1993);
- 10 Geller, A. I., et al., Proc Natl. Acad. Sci USA 87:1149 (1990), Adenovirus Vectors (*see* LeGal LaSalle et al., Science, 259:988 (1993); Davidson, et al., Nat. Genet 3:219 (1993); Yang, et al., J. Virol. 69:2004 (1995) and Adeno-associated Virus Vectors (*see* Kaplitt, M. G. et al., Nat. Genet. 8:148 (1994).

- Pox viral vectors introduce the gene into the cells cytoplasm. Avipox virus vectors
- 15 result in only a short-term expression of the nucleic acid. Adenovirus vectors, adeno-associated virus vectors and herpes simplex virus (HSV) vectors are preferred for introducing the nucleic acid into neural cells. The adenovirus vector results in a shorter-term expression (about 2 months) than adeno-associated virus (about 4 months), which in turn is shorter than HSV vectors. The particular vector chosen will depend upon the target cell and the condition being
- 20 treated. The introduction can be by standard techniques, *e.g.*, infection, transfection, transduction or transformation. Examples of modes of gene transfer include *e.g.*, naked DNA, CaPO₄ precipitation, DEAE dextran, electroporation, protoplast fusion, lipofection, cell microinjection, and viral vectors.

- The vector can be employed to target essentially any desired target cell. For example,
- 25 stereotaxic injection can be used to direct the vectors (*e.g.*, adenovirus, HSV) to a desired location. Additionally, the particles can be delivered by intracerebroventricular (icv) infusion using a minipump infusion system, such as a SynchroMed Infusion System. A method based on bulk flow, termed convection, has also proven effective at delivering large molecules to extended areas of the brain and may be useful in delivering the vector to the target cell. (*See*
- 30 Bobo et al., Proc. Natl. Acad. Sci. USA 91:2076-2080 (1994); Morrison et al., Am. J. Physiol. 266:292-305 (1994)). Other methods that can be used include catheters, intravenous, parenteral, intraperitoneal and subcutaneous injection, and oral or other suitable routes of administration.

Bispecific antibodies are antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for a target such as B7-H3 or any fragment thereof. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

5 Many methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce
10 a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., *EMBO J.*, 10:3655-3659 (1991).

Bispecific and/or monovalent antibodies which may be used in embodiments disclosed
15 herein can be made using any of a variety of art-recognized techniques, including those disclosed in application WO 2012/023053, filed August 16, 2011, the contents of which are hereby incorporated by reference in their entirety. The methods described in WO 2012/023053 generate bispecific antibodies that are identical in structure to a human immunoglobulin. This type of molecule is composed of two copies of a unique heavy chain polypeptide, a first light
20 chain variable region fused to a constant Kappa domain and second light chain variable region fused to a constant Lambda domain. Each combining site displays a different antigen specificity to which both the heavy and light chain contribute. The light chain variable regions can be of the Lambda or Kappa family and are preferably fused to a Lambda and Kappa constant domains, respectively. This is preferred in order to avoid the generation of non-natural
25 polypeptide junctions. However it is also possible to obtain bispecific antibodies which may be used in embodiments disclosed herein by fusing a Kappa light chain variable domain to a constant Lambda domain for a first specificity and fusing a Lambda light chain variable domain to a constant Kappa domain for the second specificity. The bispecific antibodies described in WO 2012/023053 are referred to as IgGκλ antibodies or “κλ bodies,” a new fully human
30 bispecific IgG format. This κλ-body format allows the affinity purification of a bispecific antibody that is undistinguishable from a standard IgG molecule with characteristics that are undistinguishable from a standard monoclonal antibody and, therefore, favorable as compared to previous formats.

An essential step of the method is the identification of two antibody Fv regions (each composed by a variable light chain and variable heavy chain domain) having different antigen specificities that share the same heavy chain variable domain. Numerous methods have been described for the generation of monoclonal antibodies and fragments thereof. (*See, e.g.,*

5 Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Fully human antibodies are antibody molecules in which the sequence of both the light chain and the heavy chain, including the CDRs 1 and 2, arise from human genes. The CDR3 region can be of human origin or designed by synthetic means. Such antibodies are termed “human antibodies”, or

10 “fully human antibodies” herein. Human monoclonal antibodies can be prepared by using the trioma technique; the human B-cell hybridoma technique (*see* Kozbor, et al., 1983 Immunol Today 4: 72); and the EBV hybridoma technique to produce human monoclonal antibodies (*see* Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized and may be produced by using human

15 hybridomas (*see* Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus *in vitro* (*see* Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

Monoclonal antibodies are generated, *e.g.*, by immunizing an animal with a target antigen or an immunogenic fragment, derivative or variant thereof. Alternatively, the animal is

20 immunized with cells transfected with a vector containing a nucleic acid molecule encoding the target antigen, such that the target antigen is expressed and associated with the surface of the transfected cells. A variety of suitable techniques for producing xenogenic non-human animals are well-known in the art. For example, see U.S. Pat. No. 6,075,181 and No. 6,150,584, which is hereby incorporated by reference in its entirety.

25 Alternatively, the antibodies are obtained by screening a library that contains antibody or antigen binding domain sequences for binding to the target antigen. This library is prepared, *e.g.*, in bacteriophage as protein or peptide fusions to a bacteriophage coat protein that is expressed on the surface of assembled phage particles and the encoding DNA sequences contained within the phage particles (*i.e.*, “phage displayed library”).

30 Hybridomas resulting from myeloma/B cell fusions are then screened for reactivity to the target antigen. Monoclonal antibodies are prepared, for example, using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies

that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized *in vitro*.

Although not strictly impossible, the serendipitous identification of different antibodies having the same heavy chain variable domain but directed against different antigens is highly unlikely. Indeed, in most cases the heavy chain contributes largely to the antigen binding surface and is also the most variable in sequence. In particular the CDR3 on the heavy chain is the most diverse CDR in sequence, length and structure. Thus, two antibodies specific for different antigens will almost invariably carry different heavy chain variable domains.

The methods disclosed in application U.S. Patent No. 9,926,382 overcomes this limitation and greatly facilitates the isolation of antibodies having the same heavy chain variable domain by the use of antibody libraries in which the heavy chain variable domain is the same for all the library members and thus the diversity is confined to the light chain variable domain. Such libraries are described, for example, in U.S. Patent Nos. 8,921,281 and Application WO 2011/084255, each of which is hereby incorporated by reference in its entirety. However, as the light chain variable domain is expressed in conjunction with the heavy variable domain, both domains can contribute to antigen binding. To further facilitate the process, antibody libraries containing the same heavy chain variable domain and either a diversity of Lambda variable light chains or Kappa variable light chains can be used in parallel for *in vitro* selection of antibodies against different antigens. This approach enables the identification of two antibodies having a common heavy chain but one carrying a Lambda light chain variable domain and the other a Kappa light chain variable domain that can be used as building blocks for the generation of a bispecific antibody in the full immunoglobulin format. The bispecific antibodies which may be used in embodiments disclosed herein can be of different Isotypes and their Fc portion can be modified in order to alter the bind properties to different Fc receptors and in this way modify the effectors functions of the antibody as well as its pharmacokinetic properties. Numerous methods for the modification of the Fc portion have been described and are applicable to antibodies which may be used in embodiments disclosed herein. (see for example Strohl, WR Curr Opin Biotechnol 2009 (6):685-91; U.S. Pat. No. 6,528,624; PCT/US2009/0191199 filed Jan 9, 2009).

The common heavy chain and two different light chains are co-expressed into a single cell to allow for the assembly of a bispecific antibody which may be used in embodiments disclosed herein. If all the polypeptides get expressed at the same level and get assembled equally well to form an immunoglobulin molecule then the ratio of monospecific (same light chains) and bispecific (two different light chains) should be 50%. However, it is likely that

different light chains are expressed at different levels and/or do not assemble with the same efficiency. Therefore, a means to modulate the relative expression of the different polypeptides is used to compensate for their intrinsic expression characteristics or different propensities to assemble with the common heavy chain. This modulation can be achieved via promoter strength, the use of internal ribosome entry sites (IRES) featuring different efficiencies or other types of regulatory elements that can act at transcriptional or translational levels as well as acting on mRNA stability. Different promoters of different strength could include CMV (Immediate-early Cytomegalovirus virus promoter); EF1-1 α (Human elongation factor 1 α -subunit promoter); Ubc (Human ubiquitin C promoter); SV40 (Simian virus 40 promoter). Different IRES have also been described from mammalian and viral origin. (See *e.g.*, Hellen CU and Sarnow P. *Genes Dev* 2001 15: 1593–612). These IRES can greatly differ in their length and ribosome recruiting efficiency. Furthermore, it is possible to further tune the activity by introducing multiple copies of an IRES (Stephen et al. 2000 *Proc Natl Acad Sci USA* 97: 1536-1541). The modulation of the expression can also be achieved by multiple sequential transfections of cells to increase the copy number of individual genes expressing one or the other light chain and thus modify their relative expressions. The Examples provided herein demonstrate that controlling the relative expression of the different chains is critical for maximizing the assembly and overall yield of the bispecific antibody.

The co-expression of the heavy chain and two light chains generates a mixture of three different antibodies into the cell culture supernatant: two monospecific bivalent antibodies and one bispecific bivalent antibody. The latter has to be purified from the mixture to obtain the molecule of interest. The method described herein greatly facilitates this purification procedure by the use of affinity chromatography media that specifically interact with the Kappa or Lambda light chain constant domains such as the CaptureSelect Fab Kappa and CaptureSelect Fab Lambda affinity matrices (BAC BV, Holland). This multi-step affinity chromatography purification approach is efficient and generally applicable to antibodies which may be used in embodiments disclosed herein. This is in sharp contrast to specific purification methods that have to be developed and optimized for each bispecific antibodies derived from quadromas or other cell lines expressing antibody mixtures. Indeed, if the biochemical characteristics of the different antibodies in the mixtures are similar, their separation using standard chromatography technique such as ion exchange chromatography can be challenging or not possible at all.

Other suitable purification methods include those disclosed in US2013/0317200, the contents of which are hereby incorporated by reference in their entirety.

In other embodiments of producing bispecific antibodies, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., *Methods in Enzymology*, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface includes at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (*e.g.*, tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (*e.g.*, alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., *J. Immunol.* 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The “diabody” technology described by Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L)

by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen which may be used in embodiments disclosed herein. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (*e.g.*, CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

Heteroconjugate antibodies are also within the scope of the present disclosure. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (*see* U.S. Patent No. 4,676,980), and for treatment of HIV infection (*see* WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared *in vitro* using synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptopbutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

It can be desirable to modify the antibodies which may be used in embodiments disclosed herein with respect to effector function, so as to enhance, *e.g.*, the effectiveness of the antibody in treating cancer and/or other diseases and disorders associated with aberrant B7-H3 expression and/or activity. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). (*See*

Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992)). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. (See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989)).

5 Conjugated Antibodies

The disclosure also pertains to conjugated antibodies, also referred to herein as immunoconjugates, comprising an antibody or antigen-binding fragment thereof conjugated to a cytotoxic agent such as a toxin (*e.g.*, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (*i.e.*, a radioconjugate).

10 In some embodiments, the toxin is a microtubule inhibitor or a derivative thereof. In some embodiments, the toxin is a dolastatin or a derivative thereof. In some embodiments, the toxin is auristatin E, auristatin F, AFP, MMAF, MMAE, MMAD, DMAF, or DMAE. In some embodiments, the toxin is a maytansinoid or maytansinoid derivative. In some embodiments, the toxin is DM1 or DM4. In some embodiments, the toxin is a nucleic acid damaging toxin.

15 In some embodiments, the toxin is a duocarmycin or derivative thereof. In some embodiments, the toxin is a calicheamicin or a derivative thereof. In some embodiments, the agent is a pyrrolobenzodiazepine or a derivative thereof. In some embodiments, the agent is an exatecane or a derivative thereof. In some embodiments, the agent is an amanitin or a derivative thereof.

Enzymatically active toxins and fragments thereof that can be used include diphtheria

20 A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of

25 radionuclides are available for the production of radioconjugated antibodies. Examples include ^{212}Bi , ^{131}I , ^{131}In , ^{90}Y , and ^{186}Re .

Conjugates of the antibody and cytotoxic agent can be made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis-(p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-

30

2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. (See WO94/11026).

5 Those of ordinary skill in the art will recognize that a large variety of possible moieties can be coupled to the resultant antibodies which may be used in embodiments disclosed herein. (See, for example, "Conjugate Vaccines", Contributions to Microbiology and Immunology, J. M. Cruse and R. E. Lewis, Jr (eds), Carger Press, New York, (1989), the entire contents of which are incorporated herein by reference).

10 Coupling may be accomplished by any chemical reaction that will bind the two molecules so long as the antibody and the other moiety retain their respective activities. This linkage can include many chemical mechanisms, for instance covalent binding, affinity binding, intercalation, coordinate binding and complexation. The preferred binding is, however, covalent binding. Covalent binding can be achieved either by direct condensation of
15 existing side chains or by the incorporation of external bridging molecules. Many bivalent or polyvalent linking agents are useful in coupling protein molecules, such as the antibodies of the present disclosure, to other molecules. For example, representative coupling agents can include organic compounds such as thioesters, carbodiimides, succinimide esters, diisocyanates, glutaraldehyde, diazobenzenes and hexamethylene diamines. This listing is not
20 intended to be exhaustive of the various classes of coupling agents known in the art but, rather, is exemplary of the more common coupling agents. (See Killen and Lindstrom, Jour. Immun. 133:1335-2549 (1984); Jansen et al., Immunological Reviews 62:185-216 (1982); and Vitetta et al., Science 238:1098 (1987)).

Suitable linkers are described in the literature. (See, for example, Ramakrishnan, S. et
25 al., Cancer Res. 44:201-208 (1984) describing use of MBS (M-maleimidobenzoyl-N-hydroxysuccinimide ester). See also, U.S. Patent No. 5,030,719, describing use of halogenated acetyl hydrazide derivative coupled to an antibody by way of an oligopeptide linker. Particularly preferred linkers include: (i) EDC (1-ethyl-3-(3-dimethylamino-propyl) carbodiimide hydrochloride; (ii) SMPT (4-succinimidylloxycarbonyl-alpha-methyl-alpha-(2-
30 pyridyl-dithio)-toluene (Pierce Chem. Co., Cat. (21558G); (iii) SPDP (succinimidyl-6 [3-(2-pyridyldithio) propionamido]hexanoate (Pierce Chem. Co., Cat #21651G); (iv) Sulfo-LC-SPDP (sulfosuccinimidyl 6 [3-(2-pyridyldithio)-propionamide] hexanoate (Pierce Chem. Co. Cat. #2165-G); and (v) sulfo-NHS (N-hydroxysulfo-succinimide: Pierce Chem. Co., Cat. #24510) conjugated to EDC.

The linkers described above contain components that have different attributes, thus leading to conjugates with differing physio-chemical properties. For example, sulfo-NHS esters of alkyl carboxylates are more stable than sulfo-NHS esters of aromatic carboxylates. NHS-ester containing linkers are less soluble than sulfo-NHS esters. Further, the linker SMPT
5 contains a sterically hindered disulfide bond, and can form conjugates with increased stability. Disulfide linkages, are in general, less stable than other linkages because the disulfide linkage is cleaved *in vitro*, resulting in less conjugate available. Sulfo-NHS, in particular, can enhance the stability of carbodimide couplings. Carbodimide couplings (such as EDC) when used in conjunction with sulfo-NHS, forms esters that are more resistant to hydrolysis than the
10 carbodimide coupling reaction alone.

The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody can be prepared by any suitable methods, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with
15 enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody
20 of the present disclosure can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction.

Use of anti-B7-H3 antibodies

It will be appreciated that administration of therapeutic entities in accordance with the disclosure will be administered with suitable carriers, excipients, and other agents that are
25 incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences (15th ed, Mack Publishing Company, Easton, PA (1975)), particularly Chapter 87 by Blaug, Seymour, therein. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid
30 (cationic or anionic) containing vesicles (such as Lipofectin™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures may be appropriate in treatments and therapies in

accordance with the present disclosure, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. *See also* Baldrick P. "Pharmaceutical excipient development: the need for preclinical guidance." *Regul. Toxicol Pharmacol.* 32(2):210-8 (2000), Wang W. "Lyophilization and development of solid protein pharmaceuticals." *Int. J. Pharm.* 203(1-2):1-60 (2000), Charman WN "Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts." *J Pharm Sci.* 89(8):967-78 (2000), Powell *et al.* "Compendium of excipients for parenteral formulations" *PDA J Pharm Sci Technol.* 52:238-311 (1998) and the citations therein for additional information related to formulations, excipients and carriers well known to pharmaceutical chemists.

Therapeutic formulations of the disclosure, which include a conjugate of the disclosure, are used to treat or alleviate a symptom associated with a cancer, such as, by way of non-limiting example, leukemias, lymphomas, breast cancer, colon cancer, ovarian cancer, bladder cancer, prostate cancer, glioma, lung & bronchial cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, urinary bladder cancer, kidney and renal pelvis cancer, oral cavity & pharynx cancer, uterine corpus cancer, and/or melanoma The present disclosure also provides methods of treating or alleviating a symptom associated with a cancer. A therapeutic regimen can include identifying a subject, *e.g.*, a human patient suffering from (or at risk of developing) a cancer, *e.g.*, using standard methods.

Therapeutic formulations of the disclosure, which include a conjugate of the disclosure that recognizes B7-H3 and, optionally, a second target can be used to treat or alleviate a symptom associated with an autoimmune disease and/or inflammatory disease, such as, for example, B-cell mediated autoimmune diseases and/or inflammatory diseases, including by way of non-limiting example, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP), Waldenstrom's hypergammaglobulinaemia, Sjogren's syndrome, multiple sclerosis (MS), and/or lupus nephritis.

Efficaciousness of treatment can be determined in association with any suitable method for diagnosing or treating the particular immune-related disorder. Alleviation of one or more symptoms of the immune-related disorder indicates that the conjugate confers a clinical benefit.

Conjugates directed against a target such as B7-H3, a tumor associated antigen or other antigen may be used in methods relating to the localization and/or quantitation of these targets, *e.g.*, for use in measuring levels of these targets within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). For example, conjugates specific for any of these targets, or derivative, fragment, analog or homolog thereof, that

contain the antibody derived antigen-binding domain, can be utilized as pharmacologically active compounds (referred to hereinafter as “Therapeutics”).

A conjugate of the disclosure can be used to isolate a particular target using standard techniques, such as immunoaffinity, chromatography or immunoprecipitation. Conjugates of the disclosure can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Conjugates of the disclosure may be used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology associated with aberrant expression or activation of a given target in a subject. A conjugate preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Administration of the conjugate may abrogate or inhibit or interfere with the signaling function of the target. Administration of the conjugate may abrogate or inhibit or interfere with the binding of the target with an endogenous ligand to which it naturally binds.

A therapeutically effective amount of a conjugate of the disclosure relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target and/or the effect of an active agent conjugated to the antibody. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen and/or the potency of the active agent, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of a conjugate of the disclosure may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to

about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.

Conjugates of the disclosure can be administered for the treatment of a variety of diseases and disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington: The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa.: 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.

The formulation can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.

The formulations to be used for *in vivo* administration are preferably sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, *e.g.*, films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate

and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.

A conjugate according to the disclosure can be used as an agent for detecting the presence of a given target (or a protein fragment thereof) in a sample. In some embodiments, the conjugate contains a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, F_{ab}, scFv, or F_{(ab)2}) can be used. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term “biological sample”, therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the disclosure can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of an analyte mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in “ELISA: Theory and Practice: Methods in Molecular Biology”, Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995; “Immunoassay”, E. Diamandis and T. Christopoulos, Academic Press, Inc., San Diego, CA, 1996; and “Practice and Theory of Enzyme Immunoassays”, P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, *in vivo* techniques for detection of an analyte protein include introducing into a subject a labeled anti-analyte conjugate. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

Pharmaceutical compositions

In certain aspects, provided herein are pharmaceutical compositions comprising the compounds, drug conjugates, or targeted drug conjugates of the present disclosure.

The antibody-drug conjugate may be used to transfer the active agent to a target cell of a subject to treat the subject using any suitable method of preparing a composition. In some aspects, the disclosure relates to a composition (*e.g.*, a pharmaceutical composition) comprising an antibody-drug conjugate as described herein.

The compositions and methods of the present disclosure may be utilized to treat an individual in need thereof. In certain embodiments, the individual is a mammal such as a human, or a non-human mammal. When administered to an animal, such as a human, the composition or the compound is preferably administered as a pharmaceutical composition comprising, for example, a compound of the disclosure and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters. In preferred embodiments, when such pharmaceutical compositions are for human administration, particularly for invasive routes of administration (i.e., routes, such as injection or implantation, that circumvent transport or diffusion through an epithelial barrier), the aqueous solution is pyrogen-free, or substantially pyrogen-free. The excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs. The pharmaceutical composition can be in dosage unit form such as lyophile for reconstitution, powder, solution, injection or the like.

A pharmaceutically acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize, increase solubility or to increase the absorption of a compound such as a compound of the disclosure. Such physiologically acceptable agents include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients. The choice of a pharmaceutically acceptable carrier, including a physiologically acceptable agent, depends, for example, on the route of administration of the composition. The preparation or pharmaceutical composition can be a selfemulsifying drug delivery system or a selfmicroemulsifying drug delivery system. The pharmaceutical composition (preparation) also can be a liposome or other polymer matrix, which can have incorporated therein, for example, a compound of the disclosure. Liposomes, for example, which comprise phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

A pharmaceutical composition (preparation) can be administered to a subject by any of a number of routes of administration. For example, a compound may be simply dissolved or suspended in sterile water. Details of appropriate routes of administration and compositions suitable for same can be found in, for example, U.S. Pat. Nos. 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, as well as in patents cited therein.

The formulations may conveniently be presented in unit dosage form and may be prepared by any suitable method in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.

Methods of preparing these formulations or compositions include the step of bringing into association an active compound, such as a compound of the disclosure, with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present disclosure with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intraocular (such as intravitreal), intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion. Pharmaceutical compositions suitable for parenteral administration comprise one or more active compounds in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

Examples of suitable aqueous and nonaqueous carriers that may be employed in the pharmaceutical compositions of the disclosure include water, ethanol, polyols (such as

glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsulated matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.

For use in the methods of this disclosure, active compounds can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.

Methods of introduction may also be provided by rechargeable or biodegradable devices. Various slow release polymeric devices have been developed and tested *in vivo* in recent years for the controlled delivery of drugs, including proteinaceous biopharmaceuticals. A variety of biocompatible polymers (including hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of a compound at a particular target site.

Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

5 The selected dosage level will depend upon a variety of factors including the activity of the particular compound or combination of compounds employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound(s) being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound(s) employed, the age, sex, 10 weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the therapeutically effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the pharmaceutical composition or 15 compound at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. By “therapeutically effective amount” is meant the concentration of a compound that is sufficient to elicit the desired therapeutic effect. It is generally understood that the effective amount of the compound will vary according to the weight, sex, age, and medical history of the subject. Other factors 20 which influence the effective amount may include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the compound, and, if desired, another type of therapeutic agent being administered with the compound of the disclosure. A larger total dose can be delivered by multiple administrations of the agent. Many methods to determine efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) 25 Harrison's Principles of Internal Medicine 13 ed., 1814-1882, herein incorporated by reference).

In general, a suitable daily dose of an active compound used in the compositions and methods of the disclosure will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors 30 described above.

The patient receiving this treatment may be any animal in need, including primates, in particular humans; and other mammals such as equines, cattle, swine, sheep, cats, and dogs; poultry; and pets in general.

In certain embodiments, compounds of the disclosure may be used alone or conjointly administered with another type of therapeutic agent.

Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, 5 flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl 10 palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

Compositions may be prepared in an injectable form, either as a liquid solution or as a suspension. Solid forms suitable for injection may also be prepared, *e.g.*, as emulsions, or with 15 the antibody-drug conjugate encapsulated in liposomes. Antibody-drug conjugates may be combined with a pharmaceutically acceptable carrier, which includes any carrier that does not induce the production of antibodies harmful to the subject receiving the carrier. Suitable carriers typically comprise large macromolecules that are slowly metabolized, for example, proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino 20 acid copolymers, lipid aggregates, and the like.

The compositions may also contain diluents, for example, water, saline, glycerol, and ethanol. Auxiliary substances, for example, wetting or emulsifying agents, pH buffering substances, and the like may also be present therein. The compositions may be parenterally administered by injection, wherein such injection may be either subcutaneous or intramuscular 25 injection. In some embodiments, a composition may be administered into a tumor. The composition may be inserted (*e.g.*, injected) into a tumor. Additional formulations are suitable for other forms of administration, such as suppository or oral administration. Oral compositions may be administered as a solution, suspension, tablet, pill, capsule, or sustained release formulation.

30 The compositions may be administered in a manner compatible with a dose and a formulation. The composition preferably comprises a therapeutically effective amount of the antibody-drug conjugate. A dose may vary, depending on the subject to be treated, the subject's health and physical conditions, a degree of protection to be desired, and other relevant factors. The exact amount of an active ingredient (*e.g.*, the antibody-drug conjugate) may depend on

the judgment of a doctor. For example, a therapeutically effective amount of the antibody-drug conjugate or composition containing the same may be administered to a patient suffering from a cancer or tumor to treat the cancer or tumor.

The antibody-drug conjugate according to the present disclosure or the composition containing the same may be administered in the form of a pharmaceutically acceptable salt thereof. In some embodiments, the antibody-drug conjugate according to the present disclosure or the composition containing the same may be administered with a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, and/or a pharmaceutically acceptable additive. The effective amount and the type of the pharmaceutically acceptable salt, excipient and additive may be measured using standard methods (*see, e.g.*, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 18th Edition, 1990).

In some embodiments, the disclosure relates to a method of treating cancer in a subject, comprising administering a pharmaceutical composition comprising an antibody-drug conjugate as described herein to the subject. In preferred embodiments, the subject is a mammal. For example, the subject may be selected from rodents, lagomorphs, felines, canines, porcines, ovines, bovines, equines, and primates. In certain preferred embodiments, the subject is a human.

The conjugates of the disclosure (also referred to herein as “active compounds”), and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the conjugate and a pharmaceutically acceptable carrier. As used herein, the term “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, ringer's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the disclosure is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*,

intravenous, intradermal, and subcutaneous administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case

of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

In certain embodiments, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to suitable methods, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the disclosure are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Methods of Treatment

The compounds and conjugates disclosed herein may be used in methods to induce apoptosis in cells.

Dysregulated apoptosis has been implicated in a variety of diseases, including, for example, autoimmune disorders (*e.g.*, systemic lupus erythematosus, rheumatoid arthritis, graft-versus-host disease, myasthenia gravis, or Sjögren's syndrome), chronic inflammatory conditions (*e.g.*, psoriasis, asthma or Crohn's disease), hyperproliferative disorders (*e.g.*, breast cancer, lung cancer), viral infections (*e.g.*, herpes, papilloma, or HIV), and other

conditions, such as osteoarthritis and atherosclerosis. The compounds, conjugates, and compositions described herein may be used to treat or ameliorate any of these diseases. Such treatments generally involve administering to a subject suffering from the disease an amount of a compound, conjugate, or composition described herein sufficient to provide therapeutic benefit. The identity of the antibody of the compound, conjugate, or composition administered will depend upon the disease being treated—thus the antibody should bind a cell-surface antigen expressed in the cell type where inhibition would be beneficial. The therapeutic benefit achieved will also depend upon the specific disease being treated. In certain instances, the compounds and compositions disclosed herein may treat or ameliorate the disease itself, or symptoms of the disease, when administered as monotherapy. In other instances, the compounds and compositions disclosed herein may be part of an overall treatment regimen including other agents that, together with the inhibitor or the compounds and compositions disclosed herein, treat or ameliorate the disease being treated, or symptoms of the disease. Agents useful to treat or ameliorate specific diseases that may be administered adjunctive to, or with, the compounds and compositions disclosed herein will be apparent to those of skill in the art.

Although absolute cure is always desirable in any therapeutic regimen, achieving a cure is not required to provide therapeutic benefit. Therapeutic benefit may include halting or slowing the progression of the disease, regressing the disease without curing, and/or ameliorating or slowing the progression of symptoms of the disease. Prolonged survival as compared to statistical averages and/or improved quality of life may also be considered therapeutic benefit.

One particular class of diseases that involve dysregulated apoptosis and that are significant health burden world-wide are cancers. In a specific embodiment, the compounds and compositions disclosed herein may be used to treat cancers. The cancer may be, for example, solid tumors or hematological tumors. Cancers that may be treated with the compounds and compositions disclosed herein include, but are not limited to bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer and spleen cancer. The compounds and compositions disclosed herein may be especially beneficial in

the treatment of cancers because the antibody can be used to target the tumor cell specifically, thereby potentially avoiding or ameliorating undesirable side-effects and/or toxicities that may be associated with systemic administration of unconjugated inhibitors. One embodiment pertains to a method of treating a disease involving dysregulated intrinsic apoptosis,

5 comprising administering to a subject having a disease involving dysregulated apoptosis an amount of a compound and composition disclosed herein effective to provide therapeutic benefit, wherein the ligand of the compounds and compositions disclosed herein binds a cell surface receptor on a cell whose intrinsic apoptosis is dysregulated. One embodiment pertains to a method of treating cancer, comprising administering to a subject having cancer a
10 compound and composition disclosed herein, wherein the ligand is capable of binding a cell surface receptor or a tumor associated antigen expressed on the surface of the cancer cells, in an amount effective to provide therapeutic benefit.

In the context of tumorigenic cancers, therapeutic benefit, in addition to including the effects discussed above, may also specifically include halting or slowing progression of
15 tumor growth, regressing tumor growth, eradicating one or more tumors and/or increasing patient survival as compared to statistical averages for the type and stage of the cancer being treated. In one embodiment, the cancer being treated is a tumorigenic cancer.

The compounds and conjugates disclosed herein may be administered as monotherapy to provide therapeutic benefit, or may be administered adjunctive to, or with, other
20 chemotherapeutic agents and/or radiation therapy. Chemotherapeutic agents to which the compounds and compositions disclosed herein may be utilized as adjunctive therapy may be targeted (for example, ADCs, protein kinase inhibitors, *etc.*) or non-targeted (for example, non-specific cytotoxic agents such as radionucleotides, alkylating agents and intercalating agents). Non-targeted chemotherapeutic agents with which the compounds and compositions
25 disclosed herein may be adjunctively administered include, but are not limited to, methotrexate, taxol, L-asparaginase, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbazine, topotecan, nitrogen mustards, Cytosan, etoposide, 5-fluorouracil, BCNU, irinotecan, camptothecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin,
30 plicamycin, mitoxantrone, asparaginase, vinblastine, vincristine, vinorelbine, paclitaxel, calicheamicin, and docetaxel.

The compounds and conjugates disclosed herein that may not be effective as monotherapy to treat cancer may be administered adjunctive to, or with, other chemotherapeutic agents or radiation therapy to provide therapeutic benefit. One embodiment pertains to a method in which a compound or composition disclosed herein is administered in an amount effective to sensitize the tumor cells to standard chemotherapy and/or radiation therapy. Accordingly, in the context of treating cancers, “therapeutic benefit” includes administering the compounds and compositions disclosed herein adjunctive to, or with, chemotherapeutic agents and/or radiation therapy, either in patients who have not yet begun such therapy or who have but have not yet exhibited signs of resistance, or in patients who have begun to exhibit signs of resistance, as a means of sensitizing the tumors to the chemo and/or radiation therapy.

In some aspects, the present disclosure provides pharmaceutical compositions comprising an antibody drug conjugate as described herein, optionally further comprising a therapeutically effective amount of a chemotherapeutic agent.

In certain aspects, provided herein are methods of treating a cancer, comprising administering one or more of the compounds, drug conjugates, targeted drug conjugates, or pharmaceutical compositions of the present disclosure to a subject in need thereof.


In certain embodiments, the cancer is selected from leukemia, lymphoma, breast cancer, colon cancer, ovarian cancer, bladder cancer, prostate cancer, glioma, lung cancer, bronchial cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, urinary bladder cancer, kidney cancer, renal pelvis cancer, oral cavity cancer, pharynx cancer, uterine corpus cancer, or melanoma.

In further aspects, provided herein are methods of treating autoimmune diseases or inflammatory diseases, comprising administering one or more of the compounds, drug conjugates, targeted drug conjugates, or pharmaceutical compositions of the present disclosure to a subject in need thereof.

In certain embodiments, the autoimmune disease or the inflammatory disease is selected from B-cell mediated autoimmune diseases or inflammatory diseases, for example, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP), Waldenstrom’s hypergammaglobulinaemia, Sjogren’s syndrome, multiple sclerosis (MS), or lupus nephritis.

Hereinafter, configurations of the present disclosure will be described in detail through Examples, but the following Examples are only to assist in understanding of the present

disclosure. The scope of the present disclosure is not limited thereto. Further, unless specifically described otherwise, the reagent, solvent, and starting material described in the specification can be easily obtained from a commercial supplier.

EXAMPLES**Example 1: Preparation of Compound L-1****Preparation of compound L-1-1**

- 5 To a solution of dimethyl 5-hydroxyisophthalate (5 g, 23.79 mmol) in dry THF (300 mL) was added LAH (3.6g, 95.15 mmol) dropwise at -78 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 17 hours. After the reaction was completed, 15% NaOH solution (4 mL), H₂O (8 mL) and EA (100 mL) were added and then the reaction mixture was stirred for 1 hour. The mixture was filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound L-1-1 (3.02 g, 82%).

¹H NMR (400 MHz, DMSO-d₆) δ 9.21 (s, 1H), 6.66 (s, 1H), 6.58 (s, 2H), 5.07 (t, J = 6.0 Hz, 2H), 4.38 (d, J = 4.6 Hz, 4H)

Preparation of compound L-1-2

- 15 Compound L-1-1 (2 g, 12.97 mmol) was dissolved in HBr (5.0 mL, 33% in AcOH) under N₂ atmosphere. After stirring at 60 °C for 18 hours, the reaction was quenched by addition of NaHCO₃ solution (pH~8). And then distilled water (50 mL) and EA (100 mL $\times$ 2) were added in reaction mixture. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound L-1-2 (2.9 g, 80%).

¹H NMR (400 MHz, CDCl₃) δ 6.99 (s, 1H), 6.81 (s, 2H), 4.85 (s, 1H), 4.41 (s, 2H).

Preparation of compound L-1-3

- 25 To a solution of compound L-1-2 (1.0 g, 3.57 mmol) in DCM (35 mL) was added TEA (0.45 mL, 3.21 mmol) at room temperature under N₂ atmosphere. SO₂F₂ gas was introduced via a

balloon, and the mixture was stirred at room temperature for 1 hours. Then mixture was washed with DCM (50 mL) and water (30 mL) were added. The organic layer was washed with NaHCO₃ aqueous solution, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain


5 compound L-5 (941.7 mg, 73 %).

Preparation of Compound L-1

To a solution of compound L-1-2 (100 mg, 0.36 mmol) in dry DCM (3 mL) was added imidazole (27 mg, 0.39 mmol) and TBDMS-Cl (59 mg, 0.39 mmol) at room temperature under N₂ atmosphere. After stirring for 16 hours, distilled water (50 mL) and EA (100 mL) were added in reaction mixture. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound L-1 (110 mg, 79%).

¹H NMR (400 MHz, CDCl₃) δ 7.00 (s, 1H), 6.80 (s, 2H), 4.41 (s, 4H), 0.99 (s, 9H), 0.21

Example 2: Preparation of Compound L-2



Preparation of compound L-2-1

A homogeneous solution of 11-azido-3,6,9-trioxaundecan-1-amine (Aldrich, CAS 134179-38-7, 5.0 g, 22.9 mmol) in 1,4-dioxane (100 mL) and H₂O (25 mL) at room temperature under N₂ atmosphere was treated with NaHCO₃ (3.8 g, 45.8 mmol, 2.0 eq.) and BOC₂O (6.0 g, 27.5 mmol, 1.2 eq.) and then stirred for 6 hours. The reaction was quenched with water (50 mL) and extracted with DCM (100 mL x 3). The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (1 % to 3 % MeOH in DCM) to obtain compound L-2-1 (7.2 g, 99 %) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 5.03 (brs, 1H), 3.72 - 3.60 (m, 10H), 3.98 - 3.52 (m, 1H), 3.43 - 3.36 (m, 1H), 3.35 - 3.24 (m, 1H), 1.26 (s, 9H).

EI-MS m/z: 319 (M⁺+1).

Preparation of compound L-2-2


To a solution of compound L-8 (2 g, 6.282 mmol) in DMF (25 mL) was added sodium hydride (301 mg, 12.56 mmol, 60%) at 0 °C under N₂ atmosphere. After 10 minutes, iodomethane (3.9 mL, 62.82 mmol) was added at same temperature under N₂ atmosphere. The reaction was stirred at room temperature for 3 hours under N₂ atmosphere. After the reaction was completed, the reaction mixture was quenched 2N HCl (10 mL) and extracted with EA (500 mL X 3). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. Producing compound L-2-2 (3.3 g, quant) as yellow oil, which was used without further purification.

¹H NMR (400 MHz, CDCl₃) δ 3.70 – 3.62 (m, 12H), 3.4 (t, *J* = 5.2 Hz, 4H), 2.91(s, 3H), 1.46 (s, 9H).

Preparation of compound L-2

To a solution of compound L-2-2 (3.3 g, 6.282 mmol) in CH₂Cl₂ (70 mL) was added 4N HCl in dioxane (25ml) at 0 °C under N₂ atmosphere. The reaction was stirred at 0 °C for 1 hour under N₂ atmosphere. After the reaction was completed, the reaction mixture concentrated under reduced pressure. Producing compound L-2 (1.8 g, 100%) as yellow oil, which was used without further purification.

¹H NMR (400 MHz, CDCl₃) δ 3.92 (t, *J* = 4.8 Hz, 2H), 3.73 – 3.69 (m, 10H), 3.45 (t, *J* = 5.2 Hz, 2H), 3.22 – 3.16 (m, 2H), 2.77 (t, *J* = 5.6 Hz, 3H), 2.35 (brs, 1H).

Example 3: Preparation of Compound L-3

Preparation of compound L-3-1

To a solution of Hexaethylene glycol (5.0g, 18.0mmol) in anhydrous THF (20 mL) at 0°C under N₂ atmosphere was treated with 1M t-BuOK (9.4 mL, 4.9 mmol), propargyl bormide (1.0 mL, 9.4 mmol). The reaction mixture was allowed to warm up to room temperature and stirred overnight. The mixture was extracted with EA (50 mL X 2), H₂O (20 mL). The

organic layer was dry over with Na₂SO₄, filtered and concentrated under reduced pressure.

The residue was purified by chromatography to obtain compound L-3-1 (2.4 g, 80%).

¹H NMR (400 Hz, CDCl₃) δ 4.21 (s, 2H), 3.7-3.6 (m, 24H), 3.05 (brs, 1H), 2.43 (s, 1H).

5 Preparation of compound L-3-2

A clear solution of compound L-3-1 (4.23 g, 13.2 mmol) in anhydrous DCM (45 mL) at room temperature under N₂ atmosphere was treated with TEA (4.78 mL, 34.32 mmol, 2.6 eq), pTs-Cl (5.03 g, 26.40 mmol, 2.0 eq) and stirred overnight. The reaction was diluted with water (50 mL) and extracted with DCM (100 mL $\times$ 2). The obtained organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound L-3-2 as colorless oil (6.09 g, 97 %).

¹H NMR (400 Hz, CDCl₃) δ 7.80 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.8 Hz, 2H), 4.22- 4.20 (m, J =, 2H), 4.16 (t, J = 4.8 Hz, 2H), 3.93 - 3.58 (m, 22H), 2.45 (s, 3H); EI-MS m/z : 475

(M⁺+1).


Preparation of compound L-3-3

A clear solution of compound L-3-2 (6.09 g, 12.83 mmol) in DMF (45 mL) at room temperature under N₂ atmosphere was treated with NaN₃ (1.25 mg, 19.25 mmol, 1.5 eq) and stirred overnight. The reaction was diluted with water (50 mL) and extracted with DCM (100 mL $\times$ 3). The obtained organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (HeX : EA = 1 : 4) to obtain compound L-3-3 as wellowish oil (3.52 g, 79 %).

¹H NMR (400 Hz, CDCl₃) δ 4.23 – 4.22 (m 2H), 3.80 - 3.62 (m, 22H), 3.44 – 3.38 (m, 2H), 2.46 – 2.42 (m, 1H)

Preparation of compound L-3

A clear solution of compound L-3-3 (3.52 g, 10.19 mmol) in EA (24 mL), ether (24 mL) at 0 °C under N₂ atmosphere was treated with 5% HCl solution (48 mL), triphenylphosphine (3.47 g, 13.25 mmol) and stirred overnight. The mixture was diluted with H₂O (30 mL). The aqueous layer was extracted with DCM (100 mL $\times$ 3). The aqueous phase was concentrated under high vacuum to obtain compound L-3 (2.73 g, 75%); EI-MS m/z : 320 (M⁺+1).

Example 4: Preparation of Compound L-4**Preparation of compound L-4-1**

- 5 To a solution of hexaethylene glycol (5.0 g, 17.71 mmol) in anhydrous DCM (178 mL) at room temperature under N₂ atmosphere was treated with KI (294 mg, 1.77 mmol), Ag₂O (4.92 g, 19.48 mmol), p-TsCl (3.7 g, 19.48 mmol) and stirred overnight. The reaction mixture was filtered through CELITE®, and the CELITE® plug was washed with DCM (100mL). The filtrate was concentrated under reduced pressure. The residue was purified by column
- 10 chromatography to obtain compound L-4-1 (5.98 g, 73%).
- ¹H NMR (400 Hz, CDCl₃) δ 7.80 (d, *J* = 8.4 Hz, 2H), 7.35 (d, *J* = 8.4 Hz, 2H), 4.16 (t, *J* = 4.8 Hz, 2H), 3.71 - 3.58 (m, 22H), 2.88 (br, 1H), 2.45 (s, 3H).

Preparation of Compound L-4-2

- 15 To a solution of compound L-4-1 (5.98 g, 13.7 mmol) in DMF (30 mL) at room temperature under N₂ atmosphere was treated with NaN₃ (1.34 g, 20.55 mmol) and stirred for 1 hour 110 °C. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound L-4-2 (4.1 g, 97%).
- ¹H NMR (400 Hz, CDCl₃) δ 3.72 - 3.60 (m, 22H), 3.39 (t, *J* = 4.8 Hz, 2H), 2.78 (br, 1H).

Preparation of Compound L-4-3

- To a solution of compound L-4-2 (1.9 g, 6.18 mmol) in DCM (20 mL) at room temperature under N₂ atmosphere was treated with triethylamine (2.0 mL, 14.22 mmol), p-TsCl (2.4 g, 12.36 mmol) and stirred overnight. The reaction mixture was concentrated under reduced
- 25 pressure. The residue was purified by column chromatography to obtain a compound L-4-3 (2.58 g, 91%).
- ¹H NMR (400 Hz, CDCl₃) δ 7.80 (d, *J* = 8.4 Hz, 2H), 7.35 (d, *J* = 8.4 Hz, 2H), 4.16 (t, *J* = 4.8 Hz, 2H), 3.70 - 3.61 (m, 16H), 3.56 (s, 1H), 3.39 (t, *J* = 4.8 Hz, 2H), 2.45 (s, 3H).
- EI-MS *m/z*: 462 (M⁺+1).

Preparation of Compound L-4-4

To a solution of compound L-4-2 (1.0 g, 3.25 mmol) in EtOH (5 mL) at room temperature was treated with 5% Pd/C (1.04 g, 0.49 mmol) under H₂ atmosphere and stirred for 4 hours.

- 5 The mixture was filtered through CELITE® to remove Pd/C, and concentrated under reduced pressure. The residue was dissolved in DCM (25 mL). BOC₂O (852.1 mg, 3.9 mmol) was added and the resultant mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography to produce compound L-4-4 (330 mg, 28%).

10 ¹H NMR (400 Hz, CDCl₃) δ 5.19 (brs, 1H), 3.73 (t, *J* = 4.8 Hz, 2H), 3.67 (s, 12H), 3.63 - 3.60 (m, 6H), 3.54 (t, *J* = 5.2 Hz, 2H), 3.34 - 3.27 (m, 1H), 1.44 (s, 9H).

EI-MS *m/z*: 382 (M⁺+1).


Preparation of Compound L-4-5

- 15 To a solution of compound L-4-4 (450 mg, 1.18 mmol) in anhydrous THF (10 mL) under N₂ atmosphere at 0 °C was treated with NaH (60% dispersion in mineral oil, 47.2 mg, 1.18 mmol) and stirred for 20 minutes. To a solution of compound L-4-4 (544.5 mg, 1.18 mmol) was added thereto. The reaction was allowed to warm up to room temperature and stirred overnight. The reaction was allowed to cool, quenched with MeOH (5 mL) and concentrated
- 20 under reduced pressure. The residue was purified by column chromatography to obtain a compound L-4-5 (582.9 mg, 74%).

Preparation of compound L-4

- Compound L-4 (quant, colorless oil) was synthesized in a way similar to the preparation
- 25 method of compound L-3 of Example 3.

EI-MS *m/z*: 645(M⁺+1).

Example 5: Preparation of Compound Int-1 and Int-2

Preparation of compound Int-1-1

To a solution of vanillic acid (50.0 g, 0.30 mol) in MeOH (700 mL) was added dropwise SOCl₂ (207 mL, 2.85 mol) at 0 °C under N₂ atmosphere. After stirring for 15 hours at room temperature, the reaction was adjusted to have pH of 7 to 8 with saturated aqueous NaHCO₃ solution and then diluted with distilled water (100 mL) and EA (400 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-1-1 (54.2 g, quant).
¹H NMR (400 MHz, CDCl₃) δ 7.64 (dd, *J* = 6.4, 1.6 Hz, 1H), 7.55 (s, 1H), 6.94 (d, *J* = 8.4 Hz, 1H), 6.05 (s, 1H), 3.95 (s, 3H), 3.89 (s, 3H).

Preparation of compound Int-1-2

To a solution of compound Int-1-1 (54.2 g, 0.30 mol) in DMF (200 mL) at room temperature was treated with K₂CO₃ (61.6 g, 0.45 mol), benzyl bromide (39.0 mL, 0.33 mol) and stirred for 6 hours at 100°C. The reaction mixture was cooled to room temperature and diluted with distilled water (100 mL) and EA (400 mL). The organic layer was dried over with Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-1-2 (79.8 g, 98%).
¹H NMR (400 MHz, CDCl₃) δ 7.60 (dd, *J* = 6.4, 2.0 Hz, 1H), 7.56 (d, *J* = 2.0 Hz, 1H), 7.44 - 7.31 (m, 5H), 6.89 (d, *J* = 8.4 Hz, 1H), 5.22 (s, 2H), 3.94 (s, 3H), 3.88 (s, 3H).

Preparation of compound Int-1-3

To a solution Compound Int-1-2 (79.8 g, 0.29 mol) in acetic anhydride (550 mL) at 0 °C under N₂ atmosphere was portion-wise with copper (II) nitrate hemi-(pentahydrate) (75.0 g, 0.32 mol) and stirred for 6 hours at 0°C. The reaction mixture was quenched with ice water (800 mL). The solid was filtered and washed with distilled water (100 mL) and hexane (400 mL) to obtain compound Int-1-3 (85.5 g, 92%).
¹H NMR (400 MHz, CDCl₃) δ 7.52 (s, 1H), 7.45-7.35 (m, 5H), 7.08 (s, 1H), 5.22 (s, 2H), 3.98 (s, 3H), 3.91 (s, 3H).

Preparation of compound Int-1-4

To a solution of compound Int-1-3 (85.5 g, 0.27 mol) in THF (800 mL) and MeOH (300 mL) was added 2N NaOH (404 mL, 0.81 mol). After stirring for 5 hours at 65 °C, the reaction was cooled to room temperature and adjusted to have pH 2 by addition of 2N HCl solution, and

then extracted with distilled water (100 mL) and EA (300 mL X 2). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue solid was collected and washed with hexane to obtain compound Int-1-4 (79.2 g, 97%).

¹H NMR (400 MHz, DMSO-d₆) δ 7.69 (s, 1H), 7.47-7.35 (m, 5H), 7.03 (s, 1H), 5.24 (s, 2H),
5 3.91 (s, 3H).

Preparation of compound Int-1

To a solution of compound Int-1-4 (100 mg, 0.33 mmol) in anhydrous THF (500 μ L) and anhydrous DCM (1.5 mL) were slowly added dropwise oxalyl chloride (42.4 μ L) and 1 drop
10 of DMF at 0 °C under N₂ atmosphere. After stirring for 30 min, the reaction mixture was concentrated under reduced pressure. The compound Int-1 was used directly in the next step without further purification.

Preparation of compound Int-1-5

15 To a solution of compound Int-1-3 (5.0 g, 15.8 mmol) in DCM (300 mL) at 0°C under N₂ atmosphere was slowly dropwise solution of methane-sulfonic acid (50 mL) in DCM (100 mL) and stirred for 2 hours. The reaction mixture was quench with NaHCO₃ solution and extracted with H₂O (100 mL). The organic layer was dry over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to
20 obtain compound Int-1-5 (2.54g, 71%)

¹H NMR (400 MHz, CDCl₃) δ 7.48 (s, 1H), 7.14 (s, 1H), 6.05 (s, 1H), 4.02 (s, 3H), 3.89 (s, 3H).


Preparation of compound Int-1-6

25 To a solution of compound Int-1-5 (2.0 g, 8.8 mmol) in 1,4-dioxane (28 ml) under N₂ atmosphere was treated with 6N NaOH solution (4.4 ml, 26.4 mmol) and stirred for 4 hours at 40°C. The reaction mixture was allowed to cooled to 0°C, and acidified with 2N HCl. The mixture was extracted with EA/H₂O. The organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure and vacuum dry to obtain a white solid Int-1-6
30 (2.0 g, quant).

¹H NMR (400 MHz, DMSO-d₆) δ 10.60 (s, 1H), 7.305 (s, 1H), 7.24 (s, 1H), 3.89 (s, 3H)

Preparation of compound Int-2


To a solution of compound Int-1-6 (1.87 g, 8.77 mmol) in acetic anhydride (1.0 ml, 10.5 mmol) under N₂ atmosphere was treated with TEA (1.8 ml, 13.1 mmol), DMAP (0.2 g, 1.75 mmol) and stirred for 3.5 hours at room temperature. The reaction mixture was extracted with
 5 EA/H₂O. The organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure and vacuum dry to obtain a white solid Int-2 (2.2 g brown solid, 49%).
¹H NMR (400 MHz, DMSO-d₆): δ 7.981 (s, 1H), 7.451 (s, 1H), 3.933 (s, 3H), 2.294 (s, 3H).

Example 6: Preparation of Compound Int-TG1

Preparation of compound Int-TG1

β -D-galactose pentaacetate (Alfa, CAS 4163-60-4, 5.0 g, 12.81 mmol) was dissolved in 33% HBr in AcOH (20 mL) at 0 °C under N₂ atmosphere. The mixture was warmed to room temperature. After stirring at room temperature for 4 hours, the mixture was concentrated
 15 under reduced pressure, and then EA (1000 mL) and saturated aqueous sodium bicarbonate solution (1000 mL) were added. The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG1 (5.2 g, 99%).

¹H NMR (400 Hz, CDCl₃) δ 6.70 (d, J = 4.0 Hz, 1H), 5.52 (d, J = 2.4 Hz, 1H), 5.41 (dd, J =
 20 7.6, 2.8 Hz, 1H), 5.05 (dd, J = 6.4, 4.0 Hz, 1H), 4.49 (t, J = 6.4 Hz, 1H), 4.22 - 4.09 (m, 2H), 2.16 - 2.01 (m, 12H).

Example 7: Preparation of Compound Int-TG2


Preparation of compound Int-TG2

Compound Int-TG2 was synthesized via a similar method as described in Example 6.

Yield 80%

^1H NMR (400 MHz, CDCl_3) δ 6.654 (d, $J = 4.0\text{Hz}$, 1H), 5.627 (t, $J = 10.0\text{Hz}$, 1H), 5.252 (dd, $J = 10.4\text{Hz}$, 9.6Hz, 1H), 4.865 (dd, $J = 10.0\text{Hz}$, 4.0Hz, 1H), 4.593 (d, $J = 10.4\text{Hz}$, 1H), 3.777 (s, 3H), 2.113 (s, 3H), 2.071 (s, 3H), 2.065 (s, 3H)

5 Example 8: Preparation of Compound Int-TG3



Preparation of compound Int-TG3-1

To a solution of compound Int-TG1 (18.5 g, 45.0 mmol), 4-hydroxybenzaldehyde (5.0 g, 40.9 mmol) molecular sieve (10.0 g) in ACN (150 mL) at room temperature under N_2 atmosphere was treated with Ag_2O (38.0 g, 0.164 mol) and stirred for 3 hours. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG3-1 (16.0 g, 86%)

^1H NMR (400 MHz, CDCl_3) δ 9.93 (s, 1H), 7.86 (d, $J = 6.8\text{ Hz}$, 2H), 7.11 (d, $J = 6.8\text{ Hz}$, 2H), 5.52-5.47 (m, 2H), 5.18-5.14 (m, 2H), 4.24-4.11 (m, 3H), 2.19 (s, 3H), 2.07 (s, 6H), 2.02 (s, 3H).

Preparation of compound Int-TG3-2


To a solution of compound Int-TG3-1 (540 mg, 1.19 mmol) in anhydrous THF (15 mL) at 0 °C under N_2 atmosphere was treated with NaBH_4 (113 mg, 2.98 mmol) and stirred for 10 minutes at 0 °C. After stirring for 4 hours at room temperature, the reaction was diluted with H_2O and EA. The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography (EA:HEX=1:1) to obtain compound Int-TG3-2 (430 mg, 79%).

^1H NMR (400 MHz, CDCl_3) δ 7.30 (d, $J = 8.8\text{ Hz}$, 2H), 6.99 (d, $J = 8.8\text{ Hz}$, 2H), 5.51-5.54 (m, 2H), 5.11 (dd, $J = 10.8\text{ Hz}$, 1H), 5.03 (d, $J = 8.0\text{ Hz}$, 1H), 4.65 (d, $J = 5.6\text{ Hz}$, 2H), 4.25-4.04 (m, 3H), 2.19 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.01 (s, 3H).

Preparation of compound Int-TG3

To a solution of compound Int-TG3-2 (1.0g, 2.2mmol) in dry. DMF (6.0ml) at room temperature under N₂ atmosphere was treated with Bis(pentafluorophenylcarbonate) (1.3g, 3.3mmol) and stirred for 3 hours. The reaction mixture was extracted with EA (20 mL X2),
 5 H₂O(30 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure. The reaction mixture was purified by column chromatography to obtain compound Int-TG3 (1.4g, 98%). ¹H NMR (400 MHz, CDCl₃) : δ 7.384 (d, J = 8.8Hz, 2H), 7.039 (d, J = 8.4Hz, 2H), 5.529-5.465 (m, 2H), 5.280 (s, 2H), 5.141-5.068 (m, 2H), 4.262-4.070 (m, 4H), 2.195 (s, 3H), 2.078 (s, 3H), 2.073 (s, 3H), 2.025 (s, 3H).

10

Example 9: Preparation of Compound Int-TG4 and Int-TG4a

Compound Int-TG4-1(Yield 72%) was synthesized via a similar method as described in

15 Example 8.

¹H NMR (400 MHz, CDCl₃) δ 9.93 (s, 1H), 7.86 (d, J = 6.8 Hz, 2H). 7.11 (d, J = 6.8 Hz, 2H), 5.52-5.47 (m, 2H), 5.18-5.14 (m, 2H), 4.24-4.11 (m, 3H), 2.19 (s, 3H), 2.07(s, 6H), 2.02 (s, 3H).

20 Preparation of compound Int-TG4-2

To a solution of compound Int-TG4-1 (2.06 g, 4.70 mmol) in DCM (50 mL) at 0 °C under N₂ atmosphere was dropwise with solution of NaBH₄ (191 mg, 5.04 mmol) in methanol (50 mL) and stirred 30 minutes. The reaction mixture was diluted with a saturated aqueous solution of ammonium chloride (263 mL), and the aqueous layer was extracted sequentially using
 25 dichloromethane (88 mL X 3) and ethyl acetate (88 mL X 3). The organic layer was dried

over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give (2.02 g, 98%) as white foam. The product was used in the next step without further purification to obtain compound Int-TG4-2.

¹H NMR (400 MHz, CDCl₃) δ 7.31 (d, *J* = 8.8 Hz, 2H), 6.99 (d, *J* = 8.8 Hz, 2H), 5.35-5.28 (m, 3H), 5.13 (d, *J* = 7.2 Hz, 1H), 4.64 (d, *J* = 5.2 Hz, 2H), 4.18-4.16 (m, 1H), 3.73 (s, 3H), 2.12-2.04 (m, 9H).

Preparation of compound Int-TG4

To a solution of compound Int-TG4-2 (500 mg, 1.14 mmol) in DMF (7 mL) under a nitrogen atmosphere at room temperature was treated with Bis(PNP) (517 mg, 1.70 mmol), DIPEA (0.395 mL, 2.27 mmol) and stirred for 2 hours. The reaction mixture was extracted with H₂O and DCM. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG4 (645 mg, 95%) as white foam.


¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 9.2 Hz, 2H), 7.38-7.36 (m, 4H), 7.03 (d, *J* = 8.0 Hz, 2H), 5.36-5.28 (m, 3H), 5.24 (s, 2H), 5.17 (d, *J* = 7.6 Hz, 1H), 4.20-4.18 (m, 1H), 3.73 (s, 3H), 2.06-2.04 (m, 9H).

Preparation of compound Int-TG4a

Yield 98%

¹H NMR (400 MHz, CDCl₃) δ 7.54 (dd, *J* = 8.8, 4.8 Hz, 2H), 7.03 (dd, *J* = 4.4, 8.8 Hz, 2H), 5.37-5.26 (m, 5H), 5.18 (d, *J* = 6.8 Hz, 2H), 4.21-4.18 (m, 2H), 3.73 (s, 3H), 2.09 - 2.06 (m, 9H).

Example 10: Preparation of Compound Int-TG5



Compound Int-TG5 was synthesized via a similar method as described in Example 9.

Compound Int-TG5-1

Yield quant

^1H NMR (400 MHz, CDCl_3) δ 9.98 (s, 1H), 8.31 (d, $J = 2.0$ Hz, 1H), 8.07 (dd, $J = 2.0$ Hz, 8.8 Hz, 1H), 7.48 (d, $J = 8.8$ Hz, 1H), 5.59 (dd, $J = 7.6$ Hz, 10.4 Hz, 1H), 5.49 (d, $J = 3.2$ Hz, 1H), 5.20 (d, $J = 7.6$ Hz, 1H), 5.13 (dd, $J = 3.6$ Hz, 10.4 Hz, 1H), 4.28-4.09 (m, 3H), 2.20 (s, 3H), 2.13 (s, 3H), 2.10 (s, 3H), 2.04 (s, 3H).

Compound Int-TG5-2

Yield 96%


^1H NMR (400 MHz, CDCl_3) δ 7.81 (d, $J = 2.0$ Hz, 1H), 7.52 (dd, $J = 2.0$ Hz, 8.8 Hz, 1H), 7.35 (d, $J = 8.8$ Hz, 1H), 5.54 (dd, $J = 8.0$ Hz, 10.4 Hz, 1H), 5.47 (d, $J = 3.2$ Hz, 1H), 5.10 (dd, $J = 3.6$ Hz, 10.4 Hz, 1H), 5.05 (d, $J = 8.0$ Hz, 1H), 4.73 (d, $J = 6.0$ Hz, 2H), 4.28-4.04 (m, 3H), 2.19 (s, 3H), 2.13 (s, 3H), 2.10 (s, 3H), 2.02 (s, 3H).

Compound Int-TG5

Yield 84%

^1H NMR (400 MHz, CDCl_3) δ 7.89 (d, $J = 2.4$ Hz, 1H), 7.60 (dd, $J = 2.0$ Hz, 8.4 Hz, 1H), 7.41 (d, $J = 8.4$ Hz, 1H), 5.56 (dd, $J = 8.0$ Hz, 10.4 Hz, 1H), 5.48 (d, $J = 2.4$ Hz, 1H), 5.32 (s, 2H), 5.13-5.09 (m, 2H), 4.28-4.07 (m, 3H), 2.19 (s, 3H), 2.13 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H).

Example 11: Preparation of Compound Int-TG6 and Int-TG7



Preparation of compound Int-TG6-1

To a solution of 3-formyl-4-hydroxybenzoic acid (5 g, 43.06 mmol) in DMF (100 mL) at room temperature under N₂ atmosphere was treated with benzyl bromide (5.1 mL, 43.06 mmol) and NaHCO₃ (2.53 g, 43.06 mmol) and stirred overnight. The reaction mixture was extracted with EA (200 mL × 2) and distilled water (100 mL). The obtained organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG6-1 (2.56 g, 39 %).

¹H NMR (400 Hz, CDCl₃) δ 11.41 (s, 1H), 9.95 (s, 1H), 8.34 (d, *J* = 2.0 Hz, 1H), 8.23 (dd, *J* = 6.4 Hz, 2.4 Hz, 1H), 7.46 - 7.35 (m, 5H), 7.04 (d, *J* = 9.2 Hz, 1H), 5.37 (s, 2H).

Preparation of compound Int-TG6-2

To a solution of compound Int-TG6-1 (1.0 g, 3.90 mmol), compound Int-TG1 (1.6 g, 3.90 mmol) in anhydrous ACN (30mL) at room temperature under N₂ atmosphere was treated with molecular sieve (8 g), Ag₂O (3.62 g, 15.61 mmol) and stirred for 1 hour. The reaction mixture was filtered through CELITE® and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG6-2 (2.1 g, 92 %).

¹H NMR (400 Hz, CDCl₃) δ 10.34 (s, 1H), 8.55 (d, *J* = 2.0 Hz, 1H), 8.26 (dd, *J* = 6.8, 2.0 Hz, 1H), 7.45 - 7.35 (m, 5H), 7.17 (d, *J* = 8.8 Hz, 1H), 5.63 - 5.60 (m, 1H), 5.50 (d, *J* = 3.6 Hz, 1H), 5.37 (s, 2H), 5.23 (d, *J* = 8.0 Hz, 1H), 5.16 (dd, *J* = 7.2, 3.6 Hz, 1H) 4.24 - 4.10 (m, 4H), 2.20 (s, 3H), 2.10 - 2.03 (m, 9H).

Preparation of compound Int-TG6-3

To a solution of compound Int-TG6-2 (2.1 g, 3.58 mmol) in DCM (30 mL) at 0 °C under N₂ atmosphere was treated m-CPBA (2.65 g, 10.74 mmol) and stirred for 7 hours. The reaction mixture was quenched by addition of saturated sodium bicarbonate (40 mL × 2). The mixture was separated and the organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was dissolved in chloroform (5 mL) at 0 °C under N₂ atmosphere and treated with hydrazine-hydrate (261 μL, 5.37 mmol). After stirring for 1 hour. The reaction mixture was extracted with EA (30 mL × 2) and 1M HCl aqueous solution (10 mL) were added. The obtained organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to obtain compound Int-TG6-3 (1.1 g, 55%).

EI-MS m/z : 574 ($M^+ + Na$)

Preparation of compound Int-TG6-4

To a solution of compound Int-TG6-3 (280 mg, 0.49 mmol) in DCM (5 mL) was at 0 °C under N₂ atmosphere was treated with TBDMS-OTf (224 μ L, 0.97 mmol), Et₃N (207 μ L, 1.46 mmol) and stirred for 1.5 hours. The reaction mixture was quenched by addition of citric acid (20 mL). The organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG6-4 (246.3 mg, 68 %).

¹H NMR (400 Hz, CDCl₃) δ 7.67 (d, J = 8.4 Hz, 1H), 7.57 (s, 1H), 7.44 - 7.34 (m, 5H), 7.02 (d, J = 8.4 Hz, 1H), 5.49 - 5.44 (m, 2H), 5.30 (s, 2H), 5.19 (d, J = 7.6 Hz, 1H), 5.10 (dd, J = 6.8, 3.2 Hz, 1H), 4.20 - 4.11 (m, 2H), 4.05 (t, J = 6.8 Hz, 2H), 2.19 (s, 3H), 2.04 (s, 3H), 2.01 (d, J = 6.0 Hz, 6H), 1.02 (s, 9H), 0.20 (d, J = 15.6 Hz, 6H).

Preparation of compound Int-TG6-5

To a solution of compound Int-TG6-4 (283.2 mg, 0.41 mmol) in EA (5 mL) was added Pd/C (5%, 87.5 mg, 0.04 mmol) at room temperature under H₂. The mixture was stirred for 1 hours and filtered through CELITE®, and then concentrated under reduced pressure. The compound Int-TG6-5 was used directly in the next step without further purification (246 mg, quant).

¹H NMR (400 Hz, CDCl₃) δ 7.67 (d, J = 8.8 Hz, 1H), 7.57 (s, 1H), 7.05 (d, J = 8.4 Hz, 1H), 5.49 - 5.45 (m, 2H), 5.22 (d, J = 7.6 Hz, 1H), 5.12 (dd, J = 7.2, 3.6 Hz, 1H), 4.20 - 4.06 (m, 4H), 2.19 (s, 3H), 2.05 (s, 3H), 2.02 (d, J = 7.6 Hz, 6H), 1.01 (s, 9H), 0.21 (d, J = 15.2 Hz, 6H).

Preparation of compound Int-TG6

To a solution of compound Int-TG6-5 (243.2 mg, 0.41 mmol) and 11-azido-3,6,9-trioxaundecan-1-amine (Aldrich, CAS 134179-38-7, 89.5 mg, 0.41 mmol) in DMF (5 mL) at room temperature under N₂ atmosphere was treated PyBOP (275 mg, 0.53 mmol), DIPEA (176 μ L, 1.02 mmol) and stirred for 2 hours. The reaction was extracted with EA (30 mL $\times$ 2) and distilled water (10 mL). The obtained organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG6 (272.8 mg, 84 %).

^1H NMR (400 Hz, CDCl_3) δ 7.34(s, 1H), 7.31 (d, $J = 9.2$ Hz, 1H), 7.02 (d, $J = 8.0$ Hz, 1H), 6.73(s, 1H), 5.48 - 5.44 (m, 2H), 5.19 (d, $J = 7.6$ Hz, 1H), 5.10 (dd, $J = 6.4, 3.6$ Hz, 1H), 4.20 - 4.10 (m, 2H), 4.06 (t, $J = 6.4$ Hz, 2H), 3.66 (s, 14H), 3.38 (t, $J = 4.4$ Hz, 2H), 2.19 (s, 3H), 2.02 (t, $J = 8.4$ Hz, 9H), 1.00 (s, 9H), 0.20 (d, $J = 14.4$ Hz, 6H).


5 EI-MS m/z : 799 ($\text{M}^+ + 1$).

Preparation of compound Int-TG7

To a solution of compound Int-TG1-6 (1.05 g, 1.75 mmol), L-12 (565 mg, 2.1 mmol) in DMF (10 mL) at 0°C under N_2 atmosphere was treated with DIPEA (0.77 mL, 4.38 mmol), PyBOP (1.09 g, 2.1 mmol) and stirred at room temperature for 2 hours. The reaction was added H_2O (250 mL) and extracted with EA (250 mL X 3). The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain a compound Int-TG7 (1.17 g, 83%).

^1H NMR (400 MHz, CDCl_3) δ 7.00 – 6.96 (m, 2H), 6.90 (s, 1H), 5.48 – 5.43 (m, 2H), 5.16 (d, $J = 8.0$ Hz, 1H), 5.10 (dd, $J = 3.2, 10.4$ Hz, 1H), 4.20 – 4.11 (m, 2H), 4.05 (t, $J = 7.2$ Hz, 1H), 3.76 – 3.49 (m, 14H), 3.46 – 3.39 (m, 2H), 3.10 – 3.04 (m, 3H), 2.19 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.01 (s, 3H), 0.99 (s, 9H), 0.21 (s, 3H), 0.17 (s, 3H); EI-MS m/z : 813 ($\text{M}^+ + 1$).

20 Example 12: Preparation of Compound Int-TG8 and int-TG8a



Compound Int-TG8 was synthesized via a similar method as described in Example 11.

Compound Int-TG8-1

25 Yield 65%

^1H NMR (400 MHz, CDCl_3) δ 10.32 (s, 1H), 8.54 (d, $J = 2.4$ Hz, 1H), 8.28 (dd, $J = 8.8$ Hz, 1H), 7.45 – 7.35 (m, 5H), 7.16 (d, $J = 8.8$ Hz, 1H), 5.39 – 5.34 (m, 6H), 4.28 – 4.26 (m, 1H), 3.72 (s, 3H), 2.11 – 2.06 (m, 9H).

5 Compound Int-TG8-2

Yield 63%

^1H NMR (400 MHz, CDCl_3) δ 7.66 (d, $J = 2$ Hz, 1H), 7.60 (dd, $J = 8.4$ Hz, 1H), 7.43 – 7.31 (m, 5H), 7.00 (d, $J = 8.4$ Hz, 1H), 6.13 (s, 1H), 5.41 – 5.28 (m, 5H), 5.12 (d, $J = 7.2$ Hz, 1H), 4.23 (d, $J = 9.2$ Hz, 1H), 3.76 (s, 3H), 2.09 (s, 3H), 2.06 (d, $J = 3.6$ Hz, 6H).

10

Compound Int-TG8-3

Yield 70%

^1H NMR (400 MHz, CDCl_3) δ 7.60 (dd, $J = 2.0, 2.0$ Hz, 1H), 7.43 (d, $J = 0.8$ Hz, 1H), 7.48 – 7.32 (m, 5H), 7.01 (d, $J = 8.4$ Hz, 1H), 5.40 – 5.26 (m, 6H), 4.18 (d, $J = 9.2$ Hz, 1H), 3.72 (s, 3H), 2.09 – 2.04 (m, 9H), 0.99 (s, 9H), 0.18 (d, $J = 12.8$ Hz, 1H).

15

Compound Int-TG8-4

Yield quant

EI-MS m/z : 607 ($\text{M}^+ + \text{Na}$)

20

Compound Int-TG8-5

Yield 96%

^1H NMR (400 Hz, $\text{DMSO}-d_6$) δ 9.73 (brs, 1H), 7.44 (d, $J = 2.0$ Hz, 1H), 7.37 (dd, $J = 2.4, 6.4$ Hz, 1H), 7.08 (d, $J = 8.4$ Hz, 1H), 5.61 (d, $J = 7.6$ Hz, 2H), 5.45 (t, $J = 9.6$ Hz, 1H), 5.15 – 5.02 (m, 2H), 4.67 (d, $J = 10$ Hz, 1H), 3.63 (s, 3H), 2.04 – 1.98 (m, 9H).

25

EI-MS m/z : 785 ($\text{M}^+ + 1$)

Compound Int-TG8-6

Yield 78%

EI-MS m/z : 1097 ($\text{M}^+ + 1$)

30

Compound Int-TG8

Yield 85%


EI-MS m/z : 785 ($\text{M}^+ + 1$)

Compound Int-TG8a

Yield 70%


EI-MS m/z: 971 ($M^{+}+1$)

5

Example 13: Preparation of Compound Int-TG9

Preparation of compound Int-TG9

- 10 To a solution of 4-hydroxybenzaldehyde (1 g, 8.19 mmol) in DCM (3 mL) was added Et_3N (2.28 mL, 16.38 mmol) at room temperature under N_2 atmosphere. SO_2F_2 gas was introduced via a balloon, and the mixture was stirred at room temperature for 2 hours. Then the mixture was washed with DCM ($30 \text{ mL} \times 3$) and brine (30 mL), and the organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was
- 15 purified by column chromatography to obtain compound Int-TG9 (790 mg, 63 %).
- ^1H NMR (400 Hz, CDCl_3) δ 10.06 (s, 1H), 8.05 (d, $J = 8.0$ Hz, 2H), 7.55 (d, $J = 8.8$ Hz, 2H).

Example 14: Preparation of Compound Int-TG10 and Int-TG11

- 20 Preparation of compound Int-TG10-1

To a solution of compound Int-TG6 (2.0 g, 2.5 mmol), Int-TG9 (560 mg, 2.75 mmol), in anhydrous ACN (25 mL) at room temperature under N_2 atmosphere was treated with BEMP

(292 μ L, 1.0 mmol) and stirred for 4 hours. The reaction was quenched with water (20 mL) and extracted with EA (30 mL $\times$ 2). The organic layer was dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG10-1 (1.7 g, 81 %) as white foam solid.

5 EI-MS m/z: 869 ($\text{M}^+ + 1$).

Preparation of compound Int-TG10-2

To a solution of compound Int-TG10-1 (1.7 g, 1.96 mmol) in anhydrous THF (45 mL) at 0 $^\circ\text{C}$ under N_2 atmosphere was treated with NaBH_4 (150 mg, 3.91 mmol) and the stirred for 2
10 hours. The reaction was quenched with water (30 mL) and extracted with EA (50 mL $\times$ 2). The organic layer was dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG10-2 (1.17 g, 69 %) as white foam solid.

EI-MS m/z: 871 ($\text{M}^+ + 1$).

15

Preparation of compound Int-TG10-3

To a solution of compound Int-TG10-2 (1.17 g, 1.34 mmol) in anhydrous THF (40 mL) at 0 $^\circ\text{C}$ under N_2 atmosphere was treated with methane sulfonyl chloride (312 μ L, 4.0 mmol), TEA (940 μ L, 6.72 mmol) and stirred overnight. The reaction was quenched with water (20
20 mL) and extracted with DCM (60 mL $\times$ 2). The organic layer was dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG10-3 (1.25 g, 98 %) as white foam solid. EI-MS m/z: 949 ($\text{M}^+ + 1$).

25 Preparation of compound Int-TG10

To a solution of compound Int-TG10-3 (1.25 g, 1.32 mmol) in anhydrous THF (40 mL) at room temperature under N_2 atmosphere was treated with LiBr (570 mg, 6.58 mmol) and stirred for 3 hours. The reaction was diluted with water (30 mL) and extracted with DCM (50
30 mL $\times$ 3). The organic layer was dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG10 (1.2 g, 98 %) as white foam solid. EI-MS m/z: 933 (M^+), 935 ($\text{M}^+ + 2$).

Compound Int-TG11 was synthesized via a similar synthetic route of preparing compound Int-TG10.

Preparation of compound Int-TG11-1

Yield 80%

- 5 ^1H NMR (400 MHz, CDCl_3) δ 10.04 (s, 1H), 8.00 (d, $J = 8.8$ Hz, 2H), 7.57 (d, $J = 8.4$ Hz, 2H), 7.44 – 7.27 (m, 3H), 5.57 – 5.51 (m, 1H), 5.47 (d, $J = 3.2$ Hz, 1H), 5.14 – 5.10 (m, 2H), 4.27 – 4.09 (m, 3H), 3.76 – 3.53 (m, 14H), 3.42 – 3.36 (m, 2H), 3.12 – 3.04 (m, 3H), 2.19 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H); EI-MS m/z : 883 ($\text{M}^+ + 1$).

10 Preparation of compound Int-TG11-2

Yield 81%

- ^1H NMR (400 MHz, CDCl_3) δ 7.47 – 7.42 (m, 2H), 7.40 – 7.31 (m, 3H), 7.24 – 7.21 (m, 2H), 5.54 – 5.45 (m, 2H), 5.11 – 5.07 (m, 2H), 4.74 – 4.70 (m, 2H), 4.25 – 4.21 (m, 1H), 4.17 – 4.12 (m, 1H), 4.06 (t, $J = 7.2$ Hz, 1H), 3.74 – 3.44 (m, 12H), 3.37 (t, $J = 4.8$ Hz, 2H), 3.07 – 3.04 (s, 3H), 2.20 (s, 3H), 2.06 (s, 6H), 2.02 (s, 3H).
- 15

Preparation of compound Int-TG11-3

Yield 98%


EI-MS m/z : 963 ($\text{M}^+ + 1$).

20

Preparation of compound Int-TG11


Yield 90%

- ^1H NMR (400 MHz, CDCl_3) δ 7.53 – 7.41 (m, 4H), 7.37 – 7.33 (m, 2H), 7.29 – 7.28 (m, 1H), 5.59 – 5.55 (m, 1H), 5.47 (d, $J = 3.2$ Hz, 1H), 5.13 – 5.09 (m, 2H), 4.26 – 4.22 (m, 1H), 4.18 – 4.08 (m, 2H), 3.80 – 3.48 (m, 12H), 3.37 (t, $J = 5.2$ Hz, 2H), 3.12 – 3.06 (s, 3H), 2.19 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H); EI-MS m/z : 948 ($\text{M}^+ + 1$).
- 25

Example 15: Preparation of Compound Int-TG12**Preparation of compound Int-TG12-1**

To a solution of compound Int-TG8 (100 mg, 0.13 mmol) and compound Int-TG9 (31.8 mg, 0.16 mmol) in anhydrous ACN (2.5 mL) at room temperature N₂ atmosphere was treated with DBU (7.6 μ L, 0.052 mmol) and stirred for 5 hours. The reaction mixture was extracted H₂O (10 mL) and EA (15 mL $\times$ 2). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG12-1 (54.5 mg, 50 %).

10 EI-MS m/z: 855 (M⁺+1).

Preparation of compound Int-TG12a

Compound Int-TG11a was synthesized via a similar synthetic route of preparing compound Int-TG12.

15 Compound Int-TG12 was synthesized via a similar synthetic route as described in Example 14.

Compound Int-TG12-2

Yield 77%


EI-MS m/z: 857 (M⁺+1).

Compound Int-TG12-3

Yield 98%

EI-MS m/z: 935 ($M^{+}+1$).5 Compound Int-T12

Yield 81%

EI-MS m/z: 920 ($M^{+}+1$).**Example 16: Preparation of Compound Int-TG13**

Compound Int-TG13 was synthesized via a similar synthetic method as described in Example 11 and Example 14.

Preparation of compound Int-TG13-1

Yield 72%, colorless oil

EI-MS m/z: 1226 ($M^{+}+1$).Preparation of compound Int-TG13-2

Yield 82%, colorless oil

EI-MS m/z: 1296 ($M^{+}+1$).Preparation of compound Int-TG13-3

Yield 75%, colorless oil

EI-MS m/z: 1298 ($M^{+}+1$).Preparation of compound Int-TG13-4

Yield 82%, colorless oil


EI-MS m/z: 1376 ($M^{+}+1$).

Preparation of compound Int-TG13

Yield 82%, colorless oil

5 EI-MS m/z: 1361 ($M^{+}+1$).

Example 17: Preparation of Compound Int-TG14 and Int-TG15



Preparation of compound Int-TG14-1

10 Compound Int-TG14-1 was synthesized via a similar method of preparing Int-TG6-5 in Example 11.

Yield 99%

¹H NMR (400 Hz, CDCl₃) δ 7.67 (s, 1H), 7.62 (dd, *J* = 6.4, 2.0 Hz, 1H), 7.02 (d, *J* = 8.4 Hz, 1H), 5.51 - 5.45 (m, 2H), 5.16 (dd, *J* = 7.2, 3.6 Hz, 1H), 5.04 (d, *J* = 8.0 Hz, 1H), 4.21 - 4.09 (m, 4H), 2.20 (s, 3H), 2.12 (s, 3H), 2.01 (d, *J* = 7.6 Hz, 8.4H).

Preparation of compound Int-TG14-2

To a solution of compound Int-TG14-1 (578 mg, 1.19 mmol) and compound L-2 (384.8 mg, 1.43 mmol) in DMF (12 mL) at room temperature under N₂ atmosphere was treated PyBOP (807.2 mg, 1.55 mmol), DIPEA (520 μ L, 2.98 mmol) and stirred for 1 hour. The reaction was extracted with EA (40 mL $\times$ 2) and distilled water (25 mL). The obtained organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG14-2 (660 mg, 80%). EI-MS m/z: 699(M⁺+1).

Preparation of compound Int-TG15-1

Compound Int-TG14-1 was synthesized via a similar method of preparing compound Int-TG14-2.

Yield 76%

30 ¹H NMR (400 MHz, CDCl₃) δ 7.36 – 7.31 (m, 2H), 7.01 (d, J = 8.0 Hz, 1H), 6.64 – 6.58 (m, 1H), 6.06 (brs, 1H), 5.50 – 5.46 (m, 2H), 5.14(dd, J = 7.6, 3.2 Hz, 1H), 4.99 (d, J = 8.0 Hz,

¹H), 4.28 – 4.08 (m, 3H), 3.70 – 3.64 (m, 14H), 3.46 (t, J = 5.2 Hz, 2H), 2.18 (s, 3H), 2.12 (s, 3H), 2.09 (s, 3H), 2.04 (s, 3H)

EI-MS m/z: 685 (M⁺+1).

5 Preparation of compound Int-TG14

To a solution of compound Int-TG14-2 (480 mg, 0.69 mmol) in DCM (10 mL) was added Et₃N (335 uL, 2.4 mmol) at room temperature under N₂ atmosphere. SO₂F₂ gas was introduced via a balloon, and the mixture was stirred at room temperature for 3 hours. Then the mixture was washed with DCM (30 mL × 3) and brine (30 mL), and the organic layer was

10 dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG14 (430 mg, 80 %).

EI-MS m/z: 781 (M⁺+1).

Preparation of compound Int-TG15


15 Compound Int-TG15 was synthesized via a similar method of preparing compound Int-TG14. Yield 86%

¹H NMR (400 MHz, CDCl₃) δ 7.86 (s, 1H), 7.83 (dd, J = 6.4, 2.0 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 6.89 – 6.83 (m, 1H), 5.61 – 5.56 (m, 1H), 5.50 – 5.48 (m, 1H), 5.18 (d, J = 8.0 Hz, 1H), 5.13 (dd, J = 7.2, 3.2 Hz, 1H), 4.27 – 4.10 (m, 4H), 3.70 – 3.62 (m, 14H), 3.37 (t, J = 5.2 Hz, 2H), 2.20 (s, 3H), 2.08 (s, 6H), 2.02 (s, 3H)

20

EI-MS m/z: 767 (M⁺+1).

Example 18: Preparation of Compound Mono-1



25 Mono-1 was obtained by performing a reaction in a similar method as described in document WO 2020/089687

Preparation of compound Mono-1-1

Yield 77%

¹H NMR (400 MHz, DMSO-d₆) δ 9.95 (brs, 1H), 7.48 (d, J = 5.2 Hz, 1H), 6.94 (d, J = 5.2 Hz, 1H), 4.48-4.44 (m, 1H), 4.28 (d, J = 15.6 Hz, 1H), 4.18 (d, J = 16.0 Hz, 1H), 3.39 (dd, J = 11.6, 5.2 Hz, 1H), 3.17-3.10 (m, 1H). EI-MS m/z : 184 ($M^{+}+1$).

Preparation of compound Mono-1-2

Yield 99%

¹H NMR (400 MHz, DMSO-d₆) δ 10.22 (brs, 2H), 7.49 (d, J = 5.2 Hz, 1H), 6.94 (d, J = 5.2 Hz, 1H), 4.65-4.61 (m, 1H), 4.30 (d, J = 15.6 Hz, 1H), 4.19 (d, J = 15.6 Hz, 1H), 3.80 (s, 3H), 3.60 (dd, J = 11.6, 5.2 Hz, 1H), 3.21-3.14, (m, 1H). EI-MS m/z : 198 ($M^{+}+1$).

Preparation of compound Mono-1-3

Yield 89%

EI-MS m/z : 483 ($M^{+}+1$).

Preparation of compound Mono-1-4

Yield 85%

EI-MS m/z : 453 ($M^{+}+1$).

Preparation of compound Mono-1-5

Yield 85%

¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, J = 5.6 Hz, 1H), 7.47 (m, 5H), 7.22 (d, J = 5.2 Hz, 1H), 6.95 (d, J = 5.2 Hz, 1H), 6.85 (s, 1H), 5.26-5.14 (m, 2H), 4.98 (d, J = 16.4 Hz, 1H), 4.44 (d, J = 16.8 Hz, 1H), 4.08-4.02 (m, 1H), 3.98 (s, 3H), 3.32-3.26 (m, 1H).


EI-MS m/z : 453 ($M^{+}+1$).

Preparation of compound Mono-1

Yield 82%

¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, J = 5.6 Hz, 1H), 7.54 (s, 1H), 7.23 (d, J = 5.2 Hz, 1H), 6.95 (d, J = 5.2 Hz, 1H), 6.89 (s, 1H), 6.06 (s, 1H), 5.30 (s, 1H), 4.99 (d, J = 16.4 Hz, 1H), 4.44 (d, J = 16.4 Hz, 1H), 4.10-4.04 (m, 1H), 3.99 (s, 3H), 3.32-3.26 (m, 1H).

EI-MS m/z : 315 ($M^{+}+1$).

Example 19: Preparation of Compound Mono-2**Preparation of compound Mono-2-1**

To a solution of compound Mono-1-1 (1g, 4.28mmol) in 20ml of dry THF at 0°C under N₂ atmosphere was treated with 1M LAH solution in THF (5.31ml, 5.31 mmol) and stirred for 15 hours. The reaction mixture was quenched with water (5.3 ml), 15% NaOH (5.3 ml), H₂O (16.0 mL) and stirred for 30 minutes. The inorganic solid was filtered and washed with EA. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to obtain compound Mono-2-1 (652mg, 3.85mmol, 90%) as red solid, which was used without further purification.

¹H NMR (400 MHz, CDCl₃) δ 7.08 (d, *J* = 4.8, 1H), 6.73(d, *J* = 5.2 Hz, 1H), 4.01–3.88 (m, 2H), 3.80 (dd, *J* = 11.2 Hz, 1H), 3.55 (dd, *J* = 8.4 Hz, 1H), 3.13 – 3.07 (m, 1H), 2.78 – 2.74 (m, 1H), 2.60 – 2.51 (m, 1H); ET-MS *m/z* : 170.0(M⁺+1).

Preparation of compound Mono-2-2

To a solution of compound Mono-2-1 (700 mg, 4.14 mmol) in anhydrous DCM (20 ml) at 0°C under N₂ atmosphere was treated with imidazole (844 mg, 12.41 mmol), TBDMS-Cl (686 mg, 4.55 mmol) and stirred for 4 hours at room temperature. The reaction mixture was extracted with H₂O (100 mL), DCM (100 mL X 3). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Mono-2-2 (792 mg, 67%).

¹H NMR (400 MHz, CDCl₃) δ 7.07 (d, *J* = 5.2 Hz, 1H), 6.75 (d, *J* = 5.2 Hz, 1H), 4.04 – 3.92 (m, 2H), 3.77 (dd, *J* = 9.6 Hz, 1H), 3.65 (dd, *J* = 9.6 Hz, 1H), 3.05 – 3.00 (m, 1H), 2.75 – 2.71 (m, 1H), 2.65 – 2.59 (m, 1H); ET-MS *m/z* : 284.1(M⁺+1).

Preparation of compound Mono-2-3

To a solution of compound Int-2 (536 mg, 1.96 mmol) and compound Mono-2-2 (666 mg, 2.35 mmol) in anhydrous DMF (1.8 ml) 0°C under N₂ atmosphere was treated with DIPEA (0.85 ml, 4.89 mmol) and stirred for 3 hours at room temperature. The reaction mixture was extracted with EA/H₂O. The organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure. The reaction mixture was purified by column


chromatography (EA/HEX: 1/1) to obtain yellow solid Mono-2-3 (758.5 mg 76%); EI-MS m/z: 521 ($M^{+}+1$).

Preparation of compound Mono-2

- 5 To a solution of compound Mono-2-3 (200 mg, 0.384 mmol) in MeOH (4.5 ml) at 0°C under N₂ atmosphere was treated with K₂CO₃ (63.7 mg, 0.461 mmol) and stirred for 20 minutes. The reaction mixture was extracted with EA/H₂O. The organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure and vacuum dry to obtain a yellow solid Mono-2 (189.8 mg quant); EI-MS m/z: 479 ($M^{+}+1$).

10

Example 20: Preparation of Compound Mono-4



Compound Mono-4 was synthesized via a similar method as described in Example 19.


- 15 Preparation of compound Mono-4

Yield 93%

¹H NMR (400 MHz, CDCl₃) δ 8.04 - 7.98 (m, 1H), 7.26 - 7.19 (m, 3H), 7.00 - 6.75 (m, 2H), 4.41 - 4.22 (m, 2H), 3.92 (s, 3H), 3.86 (s, 1H), 3.76 - 3.66 (m, 1H), 3.51 - 3.42 (m, 1H), 3.23 - 2.68 (m, 2H), 0.89 - 0.73 (m, 9H), 0.05 - -0.08 (m, 6H); EI-MS m/z: 473($M^{+}+1$).

20

Example 21: Preparation of Compound Mono-5



Compound Mono-5 was obtained by performing a reaction in a similar method as described in Journal of Medicinal Chemistry, 2001, Vol. 44, No. 5, 737.

25


Preparation of compound Mono-5

Yield 67%

^1H NMR (400 Hz, CDCl_3) δ 4.95 – 4.90 (m, 2H), 3.69 – 3.54 (m, 4H), 3.35 – 3.27 (m, 1H), 2.46 – 2.44 (m, 1H), 2.27 – 2.25 (m, 1H), 0.89 (s, 9H), 0.05 (s, 6H)

5

Example 22: Preparation of Compound D-1




Preparation of compound D-1

To a solution of compound Mono-1 (100 mg, 0.32 mmol), 1,3,5-tris(bromomethyl)benzene (56.6 mg, 0.16 mmol) in DMF (2.0 mL) at room temperature under N_2 atmosphere was treated with K_2CO_3 (44.2 mg, 0.32 mmol) was stirred for 6 hours. The reaction mixture was treated with dimethyl amine (0.5 mL) and stirred for 30 minutes. The mixture was purified by preparative HPLC to obtain compound D-1 (29 mg, 23 %).

EI-MS m/z : 788($\text{M}^+ + 1$).

15

Example 23: Preparation of Compound D-2**Preparation of compound D-2-1**

To a solution of 1,3,5-tris(bromomethyl)benzene (3.9 g, 11.0 mmol), compound Int-2 (4.96 g, 21.9 mmol, in DMF (10.0 mL) at room temperature under N₂ atmosphere was treated with K₂CO₃ (44.2 mg, 0.32 mmol, 1.0 eq) was stirred for 6 hours. The reaction mixture was treated with dimethyl amine (5.0 mL) and stirred for 30 minutes. The reaction mixture was diluted with distilled water (50 mL) and DCM (100 mL X 2). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound D-2-1 (2.74g g, 41%).

¹H NMR (400 MHz, CDCl₃) δ 7.50 (s, 2H), 7.41 (d, *J* = 12.0 Hz, 3H), 7.08 (s, 2H), 5.20 (s, 4H), 3.97 (s, 6H), 3.91 (s, 6H), 3.47 (s, 2H), 2.25 (s 6H) ; EI-MS *m/z*: 614(M⁺+1).

Preparation of compound D-2-2

To a solution of compound D-2-1 (2.74 g, 4.46 mol) in THF (75 mL) and H₂O (50 mL) was added LiOH (937 mg, 22.33 mol). After stirring for 5 hours. The reaction mixture was concentrated under reduced pressure. The residue was cooled to 0°C and adjusted to have pH 2 by addition of 2N HCl solution, and then solid was filtered and washed with H₂O (30 mL), EA (100 mL) to obtain compound D-2-2 (2.5 g, 96%).

¹H NMR (400 MHz, DMSO-d₆) δ 7.71 (s, 2H), 7.60 (d, J = 17.6 Hz, 3H), 7.32 (s, 2H), 5.30 (s, 4H), 3.91 (s, 6H), 2.67 (s, 6H); EI-MS m/z: 586(M⁺+1).

Preparation of compound D-2-3

To a solution of compound D-2-2 (1.5 g, 2.56 mmol), compound Mono-2 (1.52 g, 5.38 mmol) in DMF (50.0 ml) at room temperature under N₂ atmosphere was treated with PyBop (3.5g, 6.40 mmol), DIPEA (2.2 mL, 12.8 mmol) was stirred for 2 hours. The reaction mixture was diluted with distilled water (100 mL) and EA (100 mL X 2). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound D-2-3 (2.7 g, 94%); EI-MS m/z: 1116(M⁺).

Preparation of compound D-2-4

To a solution of compound D-2-3 (2.7 g, 2.42 mmol) in EA (50.0 ml) was treated with 5% Pd/C (5.1 g, 2.42 mmol) at room temperature under H₂ and stirred for 1 hour. The reaction mixture was filtered through CELITE®, and then concentrated under reduced pressure to obtain compound D-2-4 (1.87 g, 93%); EI-MS m/z: 1056(M⁺).

Preparation of compound D-2-5

To a solution of compound D-2-4 (100 mg, 0.095mmol), Int-TG3 (189 mg, 0.28 mmol) in anhydrous THF (3.0 ml) at room temperature under N₂ atmosphere was treated with HOBT (13.0 mg, 0.095 mmol), DIPEA (36 μ L, 0.208 mmol) was stirred for 44 hours. The reaction mixture was extracted with distilled water (10 mL) and EA (20 mL X 2) and organic layer wash with sat NH₄Cl (50 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound D-2-5 (76 mg, 40%); EI-MS m/z: 2017(M⁺).


Preparation of compound D-2-6

To a solution of compound D-2-5 (116.7 mg, 0.06 mmol) in ACN (2.0 ml), H₂O (800 uL) at 0°C under N₂ atmosphere was treated with TFA/ACN (1.0mL) was stirred for 2 hours. The residue was purified by prep HPLC to obtain compound D-2-6 (83.3 mg, 80%); EI-MS m/z:

5 1788(M⁺).

Preparation of compound D-2

To a solution of compound D-2-6 (83.3 mg, 0.046 mmol) in anhydrous DCM (3.0 ml) at 0°C under N₂ atmosphere was treated with Dess-Martin periodinane (45.4 mg, 0.11 mmol) was stirred for 4 hours. The reaction mixture was diluted with distilled water (10 mL) and EA (30 mL X 2). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by prep HPLC to obtain compound D-2 (59.3 mg, 71%); EI-MS m/z: 1784(M⁺).

15 **Example 24: Preparation of Compound D-3**

Compound D-3 was synthesized via a similar method as described in Example 23.

Compound D-3-1

Yield 9%

20 EI-MS m/z: 1989 (M⁺).

Compound D-3-2

Yield 65%


EI-MS m/z: 1760 (M^+).

Compound D-3

Yield 48%

5 EI-MS m/z: 1756 (M^+).

Example 25: Preparation of Compound D-4



Compound D-4 was synthesized via a similar method as described in Example 23.

10 Compound D-4-1

Yield 56%

EI-MS m/z: 1054.42($M^+/2$), 2107.27(M^+).

Compound D-4-2


15 Yield 77%

EI-MS m/z: 1879.18($M+1$).

Compound D-4

Yield 74%

20 EI-MS m/z: 1874.36(M^+).

Example 26: Preparation of Compound D-5**Preparation of compound D-5-1**

To a solution of compound L-1 (189 mg, 0.48 mmol), compound Int-2 (239.6 mg, 1.05 mmol) in DMF (5.0 mL) at room temperature under N₂ atmosphere was treated with K₂CO₃ (166 mg, 1.20 mmol) was stirred for 6 hours. The reaction mixture was extracted with EA (30 mL X 2), H₂O (15 mL). The organic layer was dry over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound D-5-1 (227.8 mg, 83 %).

¹H NMR (400 MHz, CDCl₃) δ 7.49 (s, 2H), 7.09 (s, 2H), 7.05 (s, 1H), 6.90 (s, 2H), 5.16 (s, 4H), 3.98 (s, 6H), 3.91 (s, 6H).

Preparation of compound D-5-2

To a solution of compound D-5-1 (277.8 mg, 0.4 mol) in THF (6.0 mL), H₂O (4.0 mL) at room temperature was treated with LiOH (83.5 mg, 2.0 mol) and stirred for 3 hours. The reaction mixture was concentrated under reduced pressure. The residue was cooled to 0°C and adjusted to have pH 2 by addition of 2N HCl solution, and then solid was filtered and washed with H₂O (30 mL), Ether (100 mL) to obtain compound D-5-2 (207.6 mg, 96%).

¹H NMR (400 MHz, DMSO-d₆) δ 9.72 (brs, 1H), 7.65 (s, 2H), 7.29 (s, 1H), 6.94 (s, 1H), 6.84 (s, 1H), 5.17 (s, 4H), 3.91 (s, 6H).

Preparation of compound D-5-3




To a solution of compound D-5-2 (60 g, 0.11 mmol), compound Mono-2-2 (68.7 mg, 0.24 mmol) in DMF (5.0 mL) at room temperature under N₂ atmosphere was treated with PyBop (143.4g, 0.28 mmol), DIPEA (96 μ L, 0.55 mmol) was stirred for 1 hour. The reaction mixture was diluted with distilled water (10 mL) and EA (30 mL X 2). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue

was purified by column chromatography to obtain compound D-5-3 (73.1 mg, 62%); EI-MS m/z : 1076(M^+).

Preparation of compound D-5

- 5 To a solution of compound D-5-3 (65 mg, 0.06 mmol) in EA (4.0 ml) was treated with 5% Pd/C (128.6 g, 0.06 mmol) at room temperature under H_2 and stirred for 1 hour. The reaction mixture was filtered through CELITE®, and then concentrated under reduced pressure to obtain compound D-5 (54.6 mg, 89%); EI-MS m/z : 1016(M^+).


10 *Table 1. Compounds synthesized via the synthetic route described in Example 23.*

Compounds	Structure	Analytical Data
D-6		Yield 76% EI-MS m/z : 1773(M^++1)
D-7		Yield 83% EI-MS m/z : 836.98(M^++2), 1673 (M^++1)
D-8		Yield 68% EI-MS m/z : 890.01(M^++2+1), 1779 (M^++1).

¹H NMR (400 MHz, CDCl₃) δ 6.71 (s, 2H), 4.21 (d, *J* = 2.4 Hz, 2H), 3.75 – 3.58 (m, 24H), 2.44 (t, *J* = 2.4 Hz, 1H); EI-MS *m/z*: 400 (*M*⁺+1).

To a solution of compound D-1 (34mg, 0.052 mmol) and compound Int-TG11 (64.2 mg, 0.068 mmol) in DMF (2.0 mL) at room temperature under N₂ atmosphere was treated with DIPEA (18 μ L, 0.104 mmol) and stirred for 3 hours. The mixture was separated and purified by Prep-HPLC to obtain compound T-Int-1-1 (52.8 mg, 74 %); EI-MS m/z: 1656 (M⁺+1).

To a solution of compound T-Int-1-1 (52.8 mg, 0.032 mmol) in MeOH (2.0 mL) at 0°C under N₂ atmosphere was treated with K₂CO₃ (26.4 mg, 0.19 mmol) and stirred for 1 hour. The mixture was separated and purified by Prep-HPLC to obtain compound T-Int-1 (41.1 mg, 86 %); EI-MS m/z: 1488 (M⁺+1).

Example 29: Preparation of Compound T-Int-2

Compound T-Int-2 was synthesized via a similar method as described in Example 26.

Compound T-Int-2-1


5 Yield 73%

EI-MS m/z: 2638 (M^+).

Compound T-Int-2

Yield 68%

10 EI-MS m/z: 2134 (M^+).

Example 30: Preparation of Compound T-Int-3

Compound T-Int-3 was synthesized in a way similar to that as described in Examples 24 and 26.

Compound T-Int3-1

Yield 80%


EI-MS m/z: 2596 (M^+).

Compound T-Int-3

Yield 64%

EI-MS m/z: 2176 (M^+).

5

Example 31: Preparation of Compound T-Int-4

Compound T-Int-4 was synthesized via a similar synthetic route as described in Example 26.


Compound T-Int4-1

10 Yield 68%

EI-MS m/z: 1112.20($M^+/2$).Compound T-Int-4

Yield 63%

15 EI-MS m/z: 1311($M^+/2$), 2623(M^+).

Example 32: Preparation of Compound T-Int-5**Preparation of compound T-Int-5-1**

To a solution of compound D-5 (100mg, 0.0934mmol), compound Int-TG14 (84.5mg, 0.1083 mmol) in dry ACN (1.5 ml) at room temperature under N₂ atmosphere was treated with BEMP (11.5 ul, 0.0394 mmol) and stirred for 6 hours. The reaction mixture was extracted with EA (10 mL X 2), H₂O (5 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure. The reaction mixture was purified by prep HPLC obtain compound T-Int-5-1 (68.3 mg, 46%); EI-MS m/z: 888(M⁺/2), 1776 (M⁺).

Preparation of compound T-Int-5-2

To a solution of compound T-Int-5-1 (30 mg, 0.0169 mmol), compound Int-TG3 (33.6 mg, 0.0507 mmol X 2) in anhydrous THF (1.5 mL) at room temperature under N₂ atmosphere was treated with DIPEA (6.4 ul, 0.0372 mmol), HOBt (2.3 mg, 0.0169 mmol X 4) and stirred for 44 hours. The reaction mixture was extracted with EA/H₂O. The organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure. The reaction mixture was purified by prep TLC to obtain compound T-Int-5-2 (35.7 mg, 78%); EI-MS m/z: 1369(M⁺/2), 2737 (M⁺).

Preparation of compound T-Int-5-3

To a solution of compound T-Int-5-2 (35.7 mg, 0.013mmol) in ACN (0.6 ml) at 0°C under N₂ atmosphere was dropwised with TFA/ACN solution (0.3 ml, 1:1) and stirred for 2.5 hours.

The reaction mixture was purified by prep HPLC to obtain compound T-Int-5-3 (22 mg, 67%); EI-MS m/z: 1255($M^+/2$), 2509 (M^++1).


Preparation of compound T-Int-5-4

- 5 To a solution of compound T-Int-5-3 (22 mg, 0.001 mmol) in dry DCM (2.0 ml) at 0°C under N_2 atmosphere was treated with Dess Martin periodinane (8.6 mg, 0.02 mmol) and stirred overnight at room temperature. The reaction mixture was extracted with EA (10 mL X 2), H_2O (3 mL). The organic layer was dried over anhydrous Na_2SO_4 , filtered, concentrated under reduced pressure. The reaction mixture was purified by prep HPLC to to obtain
- 10 compound T-Int-5-4 (19.6mg, 89%).
EI-MS m/z: 1252($M^+/2$), 2504 (M^++1).

Preparation of compound T-Int-5


- To a solution of compound T-Int-5-4 (19.6 mg, 0.008 mmol) in MeOH/ACN (1.0 ml/1.0 ml)
- 15 at 0°C was treated with K_2CO_3 (9.5 mg, 0.047 mmol) and stirred for 2.5 hours. The reaction mixture was purified by prep HPLC to obtain compound T-Int-5 (10.3 mg, 66%); EI-MS m/z: 1000($M^+/2$), 2000 (M^+).

Example 33: Preparation of Compound T-1




T-1


- 20 To a solution of compound T-Int-1 (10 mg, 0.007 mmol), Mal-1 (4.0 mg, 0.010 mmol) in EtOH (3.2 mL), H_2O (0.8 mL) at room temperature under N_2 nitrogen atmosphere was treated with 1 M sodium ascorbate (13 μL , 0.013 mmol) and 0.1 M $CuSO_4$ (26 μL , 0.0026 mmol) and stirred for 40 minutes. The reaction mixture was purified by Prep-HPLC to obtain
- 25 compound T-1 (6.6 mg, 51%); EI-MS m/z: 1888(M^+).

Example 34: Preparation of Compound T-2

To a solution of compound T-1 (2.4 mg, 0.0013 mmol) in 0.1% formic acid in H₂O (1.0 mL) at room temperature was treated with NaHSO₃ and stirred for 6 hours. The reaction mixture was freeze dry to obtain compound T-2 (2.7 mg, quant).

Example 35: Preparation of Compound T-3

To a solution of compound T-Int-2 (2.5 mg, 0.0012 mmol), Mal-2 (1.4 mg, 0.0035 mmol) in DMSO (200 μ L), H₂O (200 μ L) at room temperature under N₂ atmosphere was treated with CuBr (0.5 mg, 0.0035 mmol) stirred for 1 hour. The reaction mixture was purified by prep-HPLC (0.1% formic acid in water/0.1% formic acid in ACN) to obtain compound T-23 (1.8 mg, 61%); EI-MS m/z: 1267 (M⁺/2), 2534 (M⁺+1).

Example 36: Preparation of Compound T-7

T-7 was synthesized via a similar synthetic route as described in document WO2020/089687.





Yield 92%:





- 5 ESI-MS m/z: 2580(M^{+1}).

Example 37: Preparation of Additional Compounds

Table 2: Compounds synthesized via a similar synthetic route as described in Example 33.

Compounds	Structure	Analytical Data
T-4		Yield 58% EI-MS m/z: 1288 ($M^{+}/2$), 2576 (M^{+1}).
T-5		Yield 63% ESI-MS m/z: 1312($M^{+}/2$), 2623(M^{+}).

T-6	 T-6	Yield 63% ESI-MS m/z: 1200(M ⁺ /2), 2399(M ⁺).
<i>T-9</i>		Yield 60% ESI-MS m/z: 1305 (M ⁺ /2).
<i>T-10</i>		Yield 54% ESI-MS m/z: 1281(M/2) ⁺¹ , 2562(M ⁺ +1)
<i>T-11</i>		Yield 74% EI-MS m/z: 1260 (M ⁺ /2+1), 2519 (M ⁺).

T-12		Yield 63% EI-MS m/z: 1210 (M ⁺ /2).
T-13		Yield 70% EI-MS m/z: 1263 (M ⁺ /2).
T-14		Yield 54% ESI-MS m/z: 1281(M/2) ⁺¹ , 2562(M ⁺ +1)
T-15	 T-15	Yield 68% ESI-MS m/z: 1273 (M ⁺ /2)





T-16	 T-16	Yield 75% ESI-MS m/z: 1218.33 ($M^{+}/2$)
T-17	 T-17	Yield 78% ESI-MS m/z: 1231.87 ($M^{+}/2$), 2464.14 ($M^{+}+1$).

Table 3: Compounds synthesized via a similar synthetic route as described in Example 30.

Compounds	Structure	Analytical Data
T-8	 T-8	Yield 47% EI-MS m/z: 1253 ($M^{+}/2$)

Example 38: Preparation of Compound DA-1**Preparation of compound DA-1a**

To a solution of dimethyl succinate (9.58 mL, 73.4 mmol) was added NaOMe 0.5 M solution
 5 in MeOH (220 mL, 110 mmol) and *m*-anisaldehyde (10 g, 73.4 mmol) at room temperature under N₂ atmosphere. The reaction mixture was stirred at 80 °C for 1 hour. The reaction mixture was cooled at room temperature and concentrated under reduced pressure. And then neutralized with 2 M hydrochloric acid, and diluted with water. The product was extracted with EA. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. Producing compound DA-1a (18.3 g, quant.) as orange oil, which
 10 was used without further purification.

Preparation of compound DA-1b

To a solution compound DA-1a (18.3 g, 73.4 mmol) in dried THF (40 mL) was added TFAA
 15 (11.2 mL, 80.74 mmol) at room temperature under N₂ atmosphere. The reaction mixture was stirred at 80 °C for 1 h. The reaction mixture was neutralized with an aqueous K₂CO₃ solution. The product was extracted with EtOAc. The organic layer was dried with NaSO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DA-1b (8.3 g, 48%).

^1H NMR (400 Hz, CDCl_3) δ 8.14-8.11 (m, 2H), 8.28 (s, 1H), 7.24-7.20 (m, 3H), 3.96 (s, 3H), 3.94 (s, 3H)

EI-MS m/z : 233 (M^++1).

5 Preparation of Compound DA-1c

To a solution of compound DA-1b (6.1 g, 26.2 mmol) in anhydrous DMF (25 mL) at 0 °C were added K_2CO_3 (5.43 g, 39.3 mmol) and Benzyl bromide (3.4 mL, 28.8 mmol) under N_2 atmosphere. The reaction mixture was stirred at 80 °C for 3 hours. The reaction mixture was cooled at room temperature. And then neutralized with 2 M hydrochloric acid, and diluted
10 with water. The product was extracted with EA. The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DA-1c (5.2 g, 61%).

^1H NMR (400 Hz, CDCl_3) δ 8.25 (d, $J = 8.8$ Hz, 1H), 8.21 (s, 1H), 7.55 (d, $J = 6.8$ Hz, 1H), 7.45-7.42 (m, 2H), 7.38-7.35 (m, 2H) 7.24-7.17 (m, 2H), 5.29 (s, 2H), 3.97 (s, 3H), 3.93 (s,
15 3H)

EI-MS m/z : 323 (M^++1).

Preparation of Compound DA-1d

To solution of compound DA-1c (5.2 g, 16.1 mmol) in Toluene (30 mL) and MeOH (50 mL)
20 was added 4 M NaOH (32.2 mL, 129 mmol) under N_2 atmosphere. After stirring for 4 hours, concentrated up to 1/3 volume and then acidified with 4 M HCl. The product was extracted with EA. The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. Producing compound DA-1d (4.55 g, 92%) as orange oil, which was used without further purification.

^1H NMR (400 Hz, CDCl_3) δ 8.28 (d, $J = 8.8$ Hz, 1H), 8.22 (s, 1H), 7.57-7.52 (m, 2H), 7.47-7.36 (m, 4H) 7.25-7.23 (m, 2H), 5.30 (s, 2H), 3.99 (s, 3H)

EI-MS m/z : 309 (M^++1).

Preparation of Compound DA-1e

To solution of compound DA-1d (4.20 g, 13.6 mmol) in Toluene (25.0 mL) was added TEA (2.08 mL, 14.96 mmol), DPPA (3.20 mL, 14.96 mmol) and t-BuOH (3.40 mL, 35.36 mmol) under N₂ atmosphere. The reaction mixture was stirred at 80 °C for 1.5 hours. After the mixture was cooled at room temperature, EtOAc and an aqueous Na₂CO₃ solution were added, and the layers were separated. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DA-1e (4.49 g, 87%).

¹H NMR (400 Hz, CDCl₃) δ 8.11 (d, *J* = 9.2 Hz, 1H), 7.51 (d, *J* = 7.6 Hz, 2H), 7.44-7.40 (m, 2H), 7.37-7.34 (m, 2H) 7.01-6.97 (m, 2H), 6.87 (d, *J* = 1.6 Hz, 1H), 6.58 (s, 1H), 5.21 (s, 2H), 3.88 (s, 3H), 1.55 (s, 9H)

EI-MS *m/z*: 379 (M⁺).

Preparation of Compound DA-1f

To solution of compound DA-1e (8.70 g, 22.9 mmol) in DMSO (115 mL) was added NIS (5.40 g, 24.0 mmol) at room temperature under N₂ atmosphere. After stirring for 1 hour, the reaction mixture was extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DA-1f (10.5 g, 91%).

¹H NMR (400 Hz, CDCl₃) δ 8.15 (d, *J* = 8.8 Hz, 1H), 7.92 (s, 1H) 7.56-7.52 (m, 2H), 7.45-7.41 (m, 2H), 7.38-7.36 (m, 2H), 7.02 (dd, *J* = 8.8, 2.4 Hz, 1H), 5.26 (s, 2H), 3.97 (s, 3H), 1.58 (s, 9H)

EI-MS *m/z*: 506 (M⁺+1).

Preparation of Compound DA-1g

Compound DA-1f (1.0 g, 1.98 mmol) was dissolved in DMF (7.30 mL), deprotonated with 60% NaH (119 mg, 2.97 mmol) at 0 °C, and alkylated with (S)-glycidyl 3-Nitrobenzenesulfonate (617 mg, 2.38 mmol) at room temperature for 1.5 h. The reaction was quenched by addition of an aqueous NH₄Cl solution, and the mixture was extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under

reduced pressure. The residue was purified by column chromatography to obtain compound DA-1g (1.04 g, 94%).

^1H NMR (400 Hz, CDCl_3) δ 8.25-8.17 (m, 1H), 7.92 (s, 1H), 7.54-7.49 (m, 2H), 7.43-7.34 (m, 3H), 7.17-7.13 (m, 1H), 6.91-6.69 (m, 1H), 5.32-5.17 (m, 2H), 3.99 (s, 3H), 3.48-3.41 (m, 1H), 3.17-3.14 (m, 1H), 2.43-2.41 (m, 1H), 1.59 (d, $J = 6.8$ Hz, 2H), 1.56 (s, 9H)

EI-MS m/z : 583 ($\text{M}^+ + \text{Na}$).

Preparation of Compound DA-1h

To solution of compound DA-1g (2.0 g, 3.56 mmol) in dried THF (23.0 mL) was added Turbo grignard 1.3 M solution in THF (22.0 mL, 28.5 mmol) at -40°C under N_2 atmosphere. After stirring for 20 min, and the temperature slowly being increased to room temperature. The mixture was stirred for an additional 3 hours and then quenched with a saturated aqueous NH_4Cl solution. The mixture was extracted with EtOAc. The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DA-1h (1.30 g, 85%).

^1H NMR (400 Hz, CDCl_3) δ 8.21 (dd, $J = 8.0, 2.0$ Hz, 1H), 7.54 (d, $J = 1.2$ Hz, 1H), 7.52-7.41 (m, 3H), 7.13 (s, 1H), 7.10-7.07 (m, 2H), 5.21 (s, 2H), 3.92 (s, 3H), 1.54 (s, 9H)

EI-MS m/z : 436 ($\text{M}^+ + 1$).

Preparation of Compound DA-1i

To a solution of compound DA-1h (1.0 g, 2.30 mmol) in THF (55 mL) and Methanol (37 mL) was added Ammonium formate (2.18 g, 34.5 mmol) and 5% Pd/C (1.47 g, 0.690 mmol) under H_2 atmosphere. The reaction mixture was stirred for 1 hour at room temperature. The reaction mixture was filtered through CELITE® and concentrated under reduced pressure. The compound DA-1i was used directly in the next step without further purification (810 mg, quant).

^1H NMR (400 Hz, CDCl_3) δ 8.06 (d, $J = 8.8$ Hz, 1H), 7.11-7.07 (m, 2H), 7.03 (d, $J = 2.4$ Hz, 1H), 4.44-4.38 (m, 1H), 3.92 (s, 3H), 3.86-3.82 (m, 2H), 3.31 (dd, $J = 16.8, 6.0$ Hz, 1H), 2.95 (dd, $J = 16.8, 5.2$ Hz, 1H), 1.96 (d, $J = 5.6$ Hz, 1H), 1.55 (s, 9H)

EI-MS m/z : 345 (M^+).

Preparation of Compound DA-1j

To a solution of compound DA-1i (810 mg, 2.35 mmol) in Toluene (78.0 mL) was added ADDP (2.98 g, 11.8 mmol) and Bu₃P (2.95 g, 11.8 mmol) under H₂ atmosphere. The reaction mixture was stirred for 1 hour at room temperature. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DA-1j (570 mg, 74%)

¹H NMR (400 Hz, CDCl₃) δ 8.17 (d, *J* = 8.4 Hz, 1H), 6.92 (dd, *J* = 8.8, 2.4 Hz, 1H), 6.731 (s, 1H), 6.29 (d, *J* = 2.4 Hz, 1H), 4.02-3.94 (m, 2H), 3.85 (s, 3H), 2.72-2.68 (m, 1H), 1.59-1.58 (m, 1H), 1.56 (s, 9H), 1.46 (t, *J* = 4.8 Hz, 1H),


EI-MS *m/z*: 328 (M⁺+1).

Preparation of Compound DA-1

Compound DA-1j (570 mg, 1.74 mmol) was dissolved in EA (29.0 mL). HCl 4 M in 1,4-Dioxane (2.50 mL) was added at -78 °C under H₂ atmosphere. After stirring for 20 min, the reaction mixture was concentrated under reduced pressure. The compound DA-1 was used directly in the next step without further purification (640 mg, 99%).

¹H NMR (400 Hz, CDCl₃) δ 8.08 (d, *J* = 9.2 Hz, 1H), 7.54-7.52 (m, 1H), 6.99 (dd, *J* = 9.2, 2.4 Hz, 1H), 6.86 (d, *J* = 2.4 Hz, 1H), 4.24-4.22 (m, 1H), 4.15-4.09 (m, 2H), 3.92-3.87 (m, 1H), 3.92 (s, 3H), 3.42 (t, *J* = 12.0 Hz, 1H), 1.60 (s, 9H)

EI-MS *m/z*: 364 (M⁺+1).

Example 39: Preparation of Compound Int-TG101

Preparation of Compound Int-TG101-1


To a solution of compound Int-TG6-4 (5.4 g, 9.40 mmol) in EA (470 mL) was added Pd/C (5%, 500 mg, 0.235 mmol) at room temperature under H₂. The mixture was stirred for 4.5 hour and filtered through CELITE®, and then concentrated under reduced pressure. The compound Int-TG101-1 was used directly in the next step without further purification (4.97 g, quant.).

¹H NMR (400 MHz, CDCl₃) δ 7.67 (s, 1H), 7.62 (dd, J = 6.4, 2.0 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 5.51 - 5.45 (m, 2H), 5.16 (dd, J = 7.2, 3.6 Hz, 1H), 5.04 (d, J = 8.0 Hz, 1H), 4.21 - 4.09 (m, 4H), 2.20 (s, 3H), 2.12 (s, 3H), 2.01 (d, J = 7.6 Hz, 8.4H).

Preparation of Compound Int-TG101

To a solution of compound Int-TG101-1 (1.07 g, 2.21 mmol) in DMF (11.0 mL) was added compound L-2 (730 mg, 2.72 mmol), PyBOP (1.38 g, 2.65 mmol) and DIPEA (0.96 mL, 5.53 mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 1 h. The reaction was quenched with water and extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG101 (1.17 g, 76%).

EI-MS m/z: 699 (M⁺).

Example 40: Preparation of Compound T-Int101

Preparation of Compound T-Int101-1

To a solution of compound DA-1 (330 mg, 0.907 mmol) in DCM (15.0 mL) was added Et₃N (0.510 mL, 3.63 mmol) at room temperature under N₂ atmosphere. SO₂F₂ gas was introduced via a balloon, and the mixture was stirred at room temperature for 45 min. The mixture was

extracted with DCM. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound T-Int101-1 (306 mg, 76 %).

¹H NMR (400 Hz, CDCl₃) δ 8.20-7.82 (m, 1H), 7.93 (d, J = 9.6 Hz, 1H), 7.16 (dd, J = 9.2, 2.4 Hz, 1H), 6.94 (d, J = 2.0 Hz, 1H), 4.31 (brs, 1H), 4.18-4.11 (m, 1H), 4.01-3.89 (m, 2H), 3.95 (s, 3H), 3.50 (t, J = 11.2 Hz, 1H), 1.60 (s, 9H)

EI-MS m/z : 468 (M^+ +Na).

Preparation of Compound T-Int101-2

To a solution of compound T-Int101-1 (150 mg, 0.336 mmol) in DMF (1.50 mL) was added Int-TG101 (247 mg, 0.353 mmol) and BEMP (84 μ L, 0.302 mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 40 min. The reaction was quenched with water and extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound T-Int101-2 (344 mg, 91%).


EI-MS m/z : 1124 (M^+).

Preparation of Compound T-Int101

To a solution of compound T-Int101-2 (140 mg, 0.124 mmol) in DCM (6.0 mL) was added Hydrogen chloride 4.0 M solution in 1,4-Dioxane (2.0 mL) at room temperature under N₂ atmosphere. After stirring for 1.5 hours, the reaction mixture was diluted with DCM and concentrated under reduced pressure. The compound T-Int101 was used in the next step without further purification. (128 mg, 97%)

EI-MS m/z : 1024 (M^+).

Example 41: Preparation of Compound DB-1



Preparation of Compound DB-1-1

To a solution of sodium methoxide 0.5 M solution in methanol (52.8 mL, 26.4 mmol) was added a solution of 3,4,5-trimethoxybenzaldehyde (650 mg, 3.31 mmol) and methyl azidoacetate (3.81 g, 33.1 mmol, CAS No. 1816-92-8) in MeOH (5.30 mL) at -20 °C under N₂ atmosphere. The reaction mixture was stirred at 0 °C for 6 hours. After addition of cold water, the resulting precipitate was collected by filtration. The solid was washed with water and dried in vacuo to obtain compound DB-1-1 (640 mg, 66%) as yellow solid.

¹H NMR (400 Hz, CDCl₃) δ 7.10 (s, 2H), 6.85 (s, 1H), 3.92 (s, 3H), 3.90 (s, 6H), 3.89 (s, 3H)

10 Preparation of Compound DB-1-2

To a solution of compound DB-1-1 (100 mg, 0.341 mmol) in p-xylene (3.40 mL) at room temperature under N₂ atmosphere. The reaction mixture was stirred at 180 °C for 30 min. The reaction mixture was cooled at room temperature and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DB-1-2 (92.0 mg, quant.).

¹H NMR (400 Hz, CDCl₃) δ 7.10 (d, J = 2.4 Hz, 1H), 6.82 (s, 1H), 4.08 (s, 3H), 3.93 (d, J = 1.2 Hz, 6H), 3.90 (s, 3H)


EI-MS m/z : 266 (M⁺+1).

20 Preparation of Compound DB-1

To a solution of compound DB-1-2 (1.0 g, 3.77 mmol) in Methanol/H₂O/1,4-Dioxane (10.0 mL/ 5.00 mL/ 10.0 mL) was added lithium hydroxide monohydrate (316 mg, 7.54 mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 5 hrs. After the reaction was quenched with HCl, the resulting precipitate was collected by filtration. The solid washed with water and dried in vacuo to obtain compound DB-1 (830 mg, 88%) as white solid.

¹H NMR (400 Hz, CDCl₃) δ 7.24 (d, J = 2.4 Hz, 1H), 6.84 (s, 1H), 4.09 (s, 3H), 3.94 (s, 3H), 3.91 (s, 3H)

EI-MS m/z : 252 (M⁺+1).

Example 42: Preparation of Compound DB-2**Preparation of Compound DB-2-1**

To a solution of isovanillin (5.0 g, 32.9 mmol) in 1.6 N NaOH solution (41.1 mL) was added 1,2-dibromoethane (17.1 mL, 197 mmol) under N₂ atmosphere. The mixture was refluxed overnight. After the reaction was completed the mixture was cooled at room temperature. The reaction mixture was extracted with MC. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DB-2-1 (5.60 g, 66%).

¹H NMR (400 Hz, CDCl₃) δ 9.85 (s, 1H), 7.53-7.50 (m, 1H), 7.42 (d, J = 1.6 Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 4.40 (t, J = 6.4 Hz, 2H), 3.97 (s, 3H), 3.70 (t, J = 6.8 Hz, 2H)

EI-MS m/z : 260 ($M^{+}+1$).

Compound DB-2-2 and DB-2-3 were synthesized in a way similar to the preparation method of compound DB-1-2 in Example 41.

Compound DB-2-2**Yield 18%**

¹H NMR (400 Hz, CDCl₃) δ 7.56 (d, J = 2.0 Hz, 1H), 7.39 (dd, J = 8.4, 2.0 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 6.86 (s, 1H), 4.38 (t, J = 7.2 Hz, 2H), 3.91 (s, 3H), 3.90 (s, 3H), 3.69 (t, J = 6.8 Hz, 2H)

Compound DB-2-3

Yield 73%

¹H NMR (400 Hz, CDCl₃) δ 7.14 (s, 1H), 7.11-7.10 (m, 1H), 6.86 (s, 1H), 4.35 (t, J = 6.8 Hz, 2H), 3.93 (s, 3H), 3.92 (s, 3H), 3.69 (t, J = 6.8 Hz, 2H)

EI-MS m/z : 329 ($M^{+}+1$).

Preparation of Compound DB-2-4

To a solution of compound DB-2-3 (100 mg, 0.305 mmol) in DMF (2.50 mL) was added dimethylamine (0.77 mL, 1.53 mmol) and potassium carbonate (42.2 mg, 0.305 mmol) under N₂ atmosphere. The reaction mixture was stirred at room temperature for 1 hr. The reaction was quenched with water and extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DB-2-4 (90.0 mg, quant.).


EI-MS m/z: 293 (M⁺+1).

Preparation of Compound DB-2

To a solution of compound DB-2-4 (45.0 mg, 0.154 mmol) in methanol (1.0 mL) at 0 °C under N₂ atmosphere was treated with 2 N NaOH solution (0.92 mL, 1.85 mmol) was stirred overnight. The mixture was purified by preparative HPLC to obtain compound DB-2 (53 mg, quant.).

¹H NMR (400 Hz, CDCl₃) δ 11.6 (s, 1H), 7.24 (s, 1H), 6.97 (d, *J* = 2.0 Hz, 1H), 6.92 (s, 1H), 4.24 (t, *J* = 4.8 Hz, 2H), 3.82 (s, 3H), 3.48-3.44 (m, 2H), 2.86 (s, 6H)

EI-MS m/z: 279 (M⁺+1).

Example 43: Preparation of Compound DB-3

Preparation of Compound DB-3-1

To a solution of 2,3-dihydroxybenzaldehyde (5.0 g, 36.2 mmol) in DMF (100 mL) was added potassium carbonate (15.1 g, 109 mmol) at 0 °C. After the reaction mixture was stirred for 1 hr, dibromomethane (7.55 mL, 109 mmol) was added. The reaction mixture was stirred at 75 °C for 4 hrs. The reaction was quenched with 2 N HCl and extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced

pressure. The residue was purified by column chromatography to obtain compound DB-3-1 (4.08 g, 75%).

^1H NMR (400 Hz, CDCl_3) δ 10.1 (s, 1H), 7.29 (d, $J = 8.0$ Hz, 1H), 7.03 (d, $J = 7.2$ Hz, 1H), 6.94 (t, $J = 8.0$ Hz, 1H), 6.14 (s, 2H)

5 EI-MS m/z : 151 ($\text{M}^+ + 1$).

Compound DB-3 was synthesized in a way similar to the preparation method of compound DB-1 of Example 41.

Compound DB-3-2

10 Yield 79%

^1H NMR (400 Hz, CDCl_3) δ 7.75-7.72 (m, 1H), 7.03 (s, 1H), 6.86 (t, $J = 8.0$ Hz, 1H), 6.80 (dd, $J = 8.0, 1.6$ Hz, 1H), 6.00 (s, 2H), 3.91 (s, 3H)

Compound DB-3-3

15 Yield 31%


^1H NMR (400 Hz, CDCl_3) δ 7.13-7.11 (m, 1H), 6.99 (d, $J = 8.4$ Hz, 1H), 6.90 (dd, $J = 8.4, 0.8$ Hz, 1H), 6.05 (s, 2H), 3.94 (s, 3H); EI-MS m/z : 438 (2M).

Compound DB-3

Yield 27%

20 ^1H NMR (400 Hz, Methanol- D_4) δ 6.91-6.81 (m, 3H), 5.94 (s, 2H); EI-MS m/z : 206 ($\text{M}^+ + 1$).

Example 44: Preparation of Compound DB-4



Compound DB-4 was synthesized via a similar method as described in Example 43.

25 Compound DB-4-1

Yield 92%

^1H NMR (400 Hz, CDCl_3) δ 10.36 (s, 1H), 7.39 (dd, $J = 7.6, 2.0$ Hz, 1H), 7.10 (dd, $J = 8.0, 1.6$ Hz, 1H), 6.93-6.89 (m, 1H), 4.40-4.37 (m, 2H), 4.34-4.31 (m, 2H).

Compound DB-4-2

Yield 75%

5 ^1H NMR (400 Hz, CDCl_3) δ 7.80-7.76 (m, 1H), 7.29 (s, 1H), 6.88 (s, 1H), 6.86 (s, 1H), 4.34-4.31 (m, 2H), 4.27-4.25 (m, 2H), 3.91 (s, 3H).

Compound DB-4-3

Yield 65%

10 ^1H NMR (400 Hz, CDCl_3) δ 7.22-7.21 (m, 1H), 6.93-6.87 (m, 2H), 4.41-4.39 (m, 2H), 4.32-4.30 (m, 2H), 3.93 (s, 3H); EI-MS m/z : 467 (2M).


Compound DB-4

Yield 71%

^1H NMR (400 Hz, CDCl_3) δ 7.06 (s, 1H), 6.89 (d, $J = 8.8$ Hz, 1H), 6.80 (d, $J = 8.4$ Hz, 1H), 4.36-4.34 (m, 2H), 4.26-4.25 (m, 2H)

15


Example 45: Preparation of Compound DB-5



Compound DB-5 was synthesized in a way similar to the preparation method of compound DB-4 of Example 44.

20 Yield 99%

^1H NMR (400 Hz, DMSO) δ 12.3 (s, 1H), 8.30 (d, $J = 1.6$ Hz, 1H), 7.75 (dd, $J = 9.2, 2.0$ Hz, 1H), 7.64 (d, $J = 8.8$ Hz, 1H), 7.32 (d, $J = 1.2$ Hz, 1H), 3.18 (s, 3H); EI-MS m/z : 239 (M^+).

Example 46: Preparation of Compound DB-6, DB-7 and DB-8**Preparation of compound DB-6-1**

To a solution of methyl 6-methoxy-1H-indole-2-carboxylate (2 g, 9.74 mmol) in dry DCM (97 mL) was added boron tribromide (39 mL, 37.96 mmol, 1M in DCM) dropwise at -40 °C under N₂ atmosphere. After stirring at 0 °C for 5 hours, the reaction was quenched by addition of NaHCO₃ solution (50 mL) and extracted with DCM (250 mL x 3), H₂O (200 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DB-6-1 (1.5 g, 80%).

¹H NMR (400 MHz, CDCl₃) δ 8.69 (brs, 1H), 7.54 (d, *J* = 8.8 Hz, 1H), 7.46 (dd, *J* = 2.0, 1.2 Hz, 1H), 6.83 - 6.82 (m, 1), 6.74 (dd, *J* = 8.8, 2.4 Hz, 1H), 4.88 (s, 1H), 3.92 (s, 3H).

EI-MS *m/z*: 191 (M⁺).

Preparation of compound DB-6-2

To a solution of compound DB-6-1 (700 mg, 3.66 mmol) in dry DCM (25 mL) was added acetic anhydride (0.38 mL, 4.03 mmol) and TEA (1.02 mL, 7.32 mmol) under N₂ atmosphere. After stirring at room temperature for 2 hours, the mixture was extracted with EA (250 mL x 3), H₂O (200 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DB-6-2 (800 mg, 94%).

¹H NMR (400 MHz, CDCl₃) δ 8.88 (brs, 1H), 7.67 (d, *J* = 8.8 Hz, 1H), 7.21 - 7.17 (m, 2H), 6.91 - 6.88 (m, 1H), 3.95 (s, 3H), 2.34 (s, 3H).

EI-MS *m/z*: 234 (M⁺⁺¹).

Preparation of Compound DB-6-3a and DB-6-3b

Compound DB-6-2 (10 mg, 0.043 mmol) was added boron trifluoride diethyl etherate (0.005 ml, 0.043 mmol) and acetic acid (0.005 ml, 0.086 mmol) at room temperature under N₂ atmosphere. After stirring at 110 °C for 1 hour, the reaction was quenched by addition of NaHCO₃ solution (0.5 mL) and extracted with EA (15 ml x 3), H₂O (10 ml). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DB-6-3a (4.6 mg, 46%).

¹H NMR (400 MHz, CDCl₃) δ 12.28 (s, 1H), 8.81 (s, 1H), 8.18 (s, 1H), 7.23 – 7.21 (m, 1H), 6.87 (s, 1H), 3.95 (s, 3H), 2.72 (s, 3H).

EI-MS m/z: 234 (M⁺+1).

Compound DB-6-3b

Yield 48%

¹H NMR (400 Hz, CDCl₃) δ 9.06 (s, 1H), 7.78 (d, *J* = 8.8 Hz, 1H), 7.22 (d, *J* = 2.0 Hz, 1H), 6.84 (d, *J* = 8.8 Hz, 1H), 3.95 (s, 3H), 2.86 (s, 3H); EI-MS m/z: 234 (M⁺+1).

Preparation of compound DB-6 and DB-7

To a solution of compound DB-6-3a (14 mg, 0.06 mmol) in MeOH (1 mL) and H₂O (0.5 mL) was added lithium hydroxide monohydrate (7.6 mg, 0.18 mmol) under N₂ atmosphere. After stirring at 60 °C for 3 hours, the reaction was quenched by addition of 2N HCl solution (1 mL) and extracted with EA (15 ml x 3), H₂O (10 ml). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. Producing compound DB-6 (13 mg, 100%), which was used without further purification.

¹H NMR (400 MHz, MeOH-d₄) δ 8.34 (s, 1H), 7.18 (d, *J* = 0.8 Hz, 1H), 6.80 (s, 1H), 2.70 (s, 3H).

EI-MS m/z: 220 (M⁺+1).

Compound DB-6-7

Yield 99%

^1H NMR (400 MHz, MeOH- d_4) δ 7.68 (d, J = 8.4 Hz, 1H), 6.97 (s, 1H), 6.72 (d, J = 8.8 Hz, 1H), 2.76 (s, 3H); EI-MS m/z : 220 (M^+ +1).

Preparation of compound DB-8


- 5 Compound DB-8 was synthesized in a way similar to the preparation method of compound DB-6 of Example 46.

Yield 99%

^1H NMR (400 MHz, DMSO- d_6) δ 11.32 (s, 1H), 9.32 (s, 1H), 7.41 (dd, J = 8.8, 2.8 Hz, 1H), 6.96 (s, 1H), 6.77 (s, 1H), 6.61 – 6.58 (m, 1H); EI-MS m/z : 178 (M^+ +1).

10

Example 47: Preparation of Compound DB-9



Preparation of compound DB-9-1

- To a solution of compound DB-7 (90 mg, 0.411 mmol) in DMF (2 mL) was added DIPEA (0.193 mL, 1.13 mmol) and benzyl bromide (0.079 mL, 0.658 mmol) at room temperature under N_2 atmosphere. The reaction was stirred at room temperature for 4 hours under N_2 atmosphere. After the reaction was completed, the reaction mixture was extracted with EA (50 mL $\times$ 3), H_2O (50 mL). The organic layer was dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DB9-1 (99 mg, 78 %).
- 15
- 20

^1H NMR (400 Hz, CDCl_3) δ 9.06 (s, 1H), 7.77 (d, J = 8.8 Hz, 1H), 7.47 – 7.36 (m, 5H), 7.27 (s, 1H), 6.84 (d, J = 8.8 Hz, 1H), 5.40 (s, 2H), 2.82 (s, 3H).

EI-MS m/z : 310 (M^+ +1).

Preparation of Compound DB-9-2

To a solution of compound DB-9-1 (5 mg, 0.411 mmol) in anhydrous DMF (2 mL) was added Int-TG1 (66.5 mg, 0.162 mmol), silver oxide (56.3 mg, 0.243 mmol) and molecular sieve (200 mg) at room temperature under N₂ atmosphere. After stirring at same temperature for 18 hours, the reaction was filtered through CELITE®, and then concentrated under reduced pressure. The reaction mixture was purified by prep HPLC to obtain compound DB-9-2 (3.2 mg, 31%).


¹H NMR (400 MHz, CDCl₃) δ 10.95 (s, 1H), 7.81 (d, *J* = 8.8 Hz, 1H), 7.47 – 7.33 (m, 5H), 7.24 (d, *J* = 2.4 Hz, 1H), 6.94 (d, *J* = 8.8 Hz, 1H), 5.61 (dd, *J* = 10.4, 8.0 Hz, 1H), 5.49 (d, *J* = 3.2 Hz, 1H), 5.39 (s, 2H), 5.34 (d, *J* = 8.0 Hz, 1H), 5.17 (dd, *J* = 10.4, 3.6 Hz, 1H), 4.31 – 4.05 (m, 3H), 2.71 (s, 3H), 2.22 (s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H).

EI-MS *m/z*: 662 (M⁺+Na).

Preparation of Compound DB-9

To a solution of compound DB-9-2 (3.2 mg, 0.005 mmol) in MeOH (1 mL) was added Pd/C (5%, 1 mg, 0.0005 mmol) at room temperature under H₂. The mixture was stirred for 1 hour and filtered through CELITE®, and then concentrated under reduced pressure. The compound DB-9 was used directly in the next step without further purification (2.7 mg, 100%).

EI-MS *m/z*: 572 (M⁺+Na).

Example 48: Preparation of Compound Int-TG102

Preparation of Compound Int-TG102-1

To a solution of beta-D-galactose pentaacetate (1 g, 2.56 mmol) in THF (10 mL) was added 3-(dimethylamino)1-propylamine (1.61 mL, 12.8 mmol) at room temperature under N₂ atmosphere. After stirring at same temperature for 3 hours, the reaction was extracted with EA (250 ml x 3), H₂O (200 ml). The organic layer was dried over anhydrous Na₂SO₄,
 5 filtered and concentrated under reduced pressure. Producing compound Int-TG102-1 (891 mg, 100%), which was used without further purification.

EI-MS m/z: 371 (M⁺⁺Na).

Preparation of Compound Int-TG102


10 To a solution of compound Int-TG102-1 (891 mg, 2.56 mmol) in DCM (10 mL) was added trichloroacetonitrile (2.57 mL, 25.6 mmol) and DBU (0.3 mL, 2.05 mmol) at 0 °C under N₂ atmosphere. After stirring at room temperature for 30 minutes, the reaction was extracted with DCM (250 ml x 3), H₂O (200 ml). The organic layer was dried over anhydrous Na₂SO₄,
 15 filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain a compound Int-TG102 (880 mg, 70%).

¹H NMR (400 MHz, CDCl₃) δ 8.70 (s, 1H), 6.61 (d, J = 3.6 Hz, 1H), 5.57 (dd, J = 2.8, 0.8 Hz, 1H), 5.55 - 5.35 (m, 2H), 4.44 (t, J = 7.6 Hz, 1H), 4.19 - 4.06 (m, 2H), 2.17 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H).

EI-MS m/z: 515 (M⁺+Na).

20

Example 49: Preparation of Compound DB-10



Preparation of compound DB-10-1

To a solution of compound DB-8 (100 mg, 0.564 mmol) in DMF (10 mL) was added DIPEA (0.275 mL, 1.579 mmol) and benzyl bromide (0.1 mL, 0.846 mmol) at room temperature
 25 under N₂ atmosphere. After stirring for 5 hours at same temperature, the reaction mixture was extracted with EA (100 ml x 3), H₂O (100 ml). The organic layer was dried over anhydrous

Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain a compound DB-10-1 (109 mg, 73%).

¹H NMR (400 MHz, CDCl₃) δ 8.70 (s, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.47 – 7.36 (m, 5H), 7.22 (dd, J = 2.4, 1.2 Hz, 1H), 6.81 – 6.80 (m, 1H), 6.73 (dd, J = 8.8, 2.4 Hz, 1H), 5.37 (s, 2H), 4.88 (s, 1H).

EI-MS m/z : 268 ($M^{+}+1$).

Preparation of compound DB-10-2


To a solution of compound DB-10-1 (50 mg, 0.187 mmol) in dry DCM (4.5 mL) was added compound Int-TG101 (184 mg, 0.374 mmol) and boron trifluoride diethyl etherate (0.023 mL, 0.187 mmol) at -10 °C under N₂ atmosphere. After stirring for 30 minutes at same temperature, the reaction mixture was extracted with EA (50 ml x 3), H₂O (30 ml). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain a compound DB-10-2 (50 mg, 45%).

¹H NMR (400 MHz, CDCl₃) δ 8.80 (s, 1H), 7.58 (d, J = 8.8 Hz, 1H), 7.47 – 7.38 (m, 5H), 7.24 – 7.23 (m, 1H), 7.03 (d, J = 2.0 Hz, 1H), 6.88 (dd, J = 8.8, 2.0 Hz, 1H), 5.55 – 5.47 (m, 2H), 5.38 (s, 2H), 5.14 – 5.07 (m, 2H), 4.27 (dd, J = 11.2, 6.4 Hz, 1H), 4.19 – 4.07 (m, 2H), 2.20 (s, 3H), 2.11 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H).

Preparation of compound DB-10

To a solution of compound DB-10-2 (40 mg, 0.187 mmol) in MeOH (3 mL) was added Pd/C (5%, 8 mg, 0.004 mmol) at room temperature under H₂. The mixture was stirred for 1 hour and filtered through CELITE®, and then concentrated under reduced pressure. The compound DB-10 was used directly in the next step without further purification (34 mg, 100%).

EI-MS m/z : 508 ($M^{+}+1$).

Example 50: Preparation of Compound DB-11

Compound DB-11 was synthesized via a similar method as described in Example 49.

Compound DB-11-1

5 Yield 43%

^1H NMR (400 MHz, CDCl_3) δ 8.76 (s, 1H), 7.46 – 7.38 (m, 5H), 7.29 (d, $J = 8.8$ Hz, 1H), 7.15 (dd, $J = 2.0, 1.2$ Hz, 1H), 7.05 (d, $J = 2.8$ Hz, 2H), 6.93 (dd, $J = 8.8, 2.4$ Hz, 1H), 5.38 (s, 2H), 4.61 (s, 1H); EI-MS m/z : 268 ($\text{M}^+ + 1$). b

Compound DB-11-2


10 Yield 96%

^1H NMR (400 MHz, CDCl_3) δ 8.84 (s, 1H), 7.45 – 7.28 (m, 7H), 7.20 (dd, $J = 2.4, 1.2$, 1H), 7.06 (dd, $J = 8.8, 2.4$ Hz, 1H), 5.53 – 5.46 (m, 2H), 5.39 (s, 2H), 5.11 (dd, $J = 10.4, 3.6$ Hz, 1H), 5.02 (d, $J = 8.0$ Hz, 1H), 4.26 (dd, $J = 11.2, 6.8$ Hz, 1H) 4.18 (dd, $J = 11.2, 6.4$ Hz, 1H), 4.08 – 4.04 (m, 1H), 2.20 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 2.01 (s, 3H); EI-MS m/z : 598 ($\text{M}^+ + 1$). 15

Compound DB-11

Yield 100%

EI-MS m/z : 507(M^+).

20 **Example 51: Preparation of Compound D-101**

Preparation of compound D-101-1

To a solution of compound DA-1 (100 mg, 0.274 mmol) in dry DCM (5.5 mL) was added hydrogen chloride solution (3 mL, 4.0 M in dioxane) at 0 °C under N₂ atmosphere. After stirring for 3 hours at room temperature, the reaction mixture was concentrated under reduced pressure. Producing compound D-101-1 (82 mg, 100%), which was used without further purification.

EI-MS m/z : 264 (M⁺+1).

Preparation of compound D-101




To a solution of compound D-101-1 (7.0 mg, 0.023 mmol) in DMF (1 mL) was added compound DB-1 (8.6 mg, 0.035 mmol) and EDCI (13.2 mg, 0.069 mmol) at room temperature under N₂ atmosphere. After stirring for 2 hours at same temperature, the reaction mixture was purified by prep HPLC to obtain compound D-101 (6.5 mg, 58%).



¹H NMR (400 MHz, MeOH-d₄) δ 8.09 (d, *J* = 9.2 Hz, 1H), 7.60 (brs, 1H), 7.06 – 6.98 (m, 4H), 4.65 (d, *J* = 4.8 Hz, 2H), 4.10 – 4.07 (m, 1H), 4.05 (s, 3H), 3.97 (dd, *J* = 11.2, 3.2 Hz, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 3.88 (s, 3H), 3.64 (dd, *J* = 11.2, 9.2 Hz, 1H).


EI-MS m/z: 496 (M⁺).

Table 4: compounds synthesized via a similar synthetic route as described in Example 51.

Compound	Structure	Characterization Data
D-102		Yield 68% ¹H NMR (400 MHz, DMSO-d₆) δ 11.57 (s, 1H), 10.33 (s, 1H), 9.63 (brs, 1H), 8.01 (d, <i>J</i> = 9.2 Hz, 1H), 7.82 (s, 1H), 7.32 (s, 1H), 7.11 – 7.09 (m, 2H), 7.03 (s, 1H), 6.98 (dd, <i>J</i> = 9.2, 2.4 Hz, 1H), 4.75 (t, <i>J</i> = 10.4 Hz, 1H), 4.53 (d, <i>J</i> = 10.4 Hz, 1H), 4.29 (t, <i>J</i> = 4.4 Hz, 2H), 4.19 (t, <i>J</i> = 8.4 Hz, 1H), 4.05 (dd, <i>J</i> = 11.2, 3.2 Hz, 1H), 3.91 (s, 3H), 3.85 (s, 3H), 3.82 – 3.81 (m, 1H), 3.54 – 3.51 (m,

		2H), 2.94 (s, 3H), 2.93 (s, 3H); EI-MS m/z : 524 (M ⁺).
D-103		Yield 60% ¹H NMR (400 MHz, DMSO-d₆) δ 11.76 (s, 1H), 10.34 (s, 1H), 8.02 (d, <i>J</i> = 9.2 Hz, 1H), 7.80 (s, 1H), 7.12 (d, <i>J</i> = 2.8 Hz, 1H), 7.05 (d, <i>J</i> = 1.6 Hz, 1H), 7.01 – 6.97 (m, 3H), 6.07 (s, 2H), 4.80 (t, <i>J</i> = 10.4 Hz, 1H), 4.53 (d, <i>J</i> = 9.6 Hz, 1H), 4.19 (t, <i>J</i> = 2.0 Hz, 1H), 4.05 (dd, <i>J</i> = 11.2, 3.2 Hz, 1H), 3.91 (s, 3H), 3.87 (dd, <i>J</i> = 11.2, 7.2 Hz, 1H); EI-MS m/z : 451 (M⁺+1).
D-104		Yield 62%) ¹H NMR (400 MHz, DMSO-d₆) δ δ 8.09 (d, <i>J</i> = 9.2 Hz, 1H), 7.64 (s, 1H), 7.09 – 6.95 (m, 4H), 6.84 (d, <i>J</i> = 8.8 Hz, 1H), 5.34 (t, <i>J</i> = 4.8 Hz, 1H), 4.70 (d, <i>J</i> = 4.4 Hz, 1H), 4.60 (s, 1H), 4.39 – 4.37 (m, 2H), 4.29 – 4.27 (m, 2H), 4.14 – 4.06 (m, 1H), 4.01 – 3.97 (m, 1H), 3.94 (s, 3H); EI-MS m/z: 465 (M⁺+1).
D-105		Yield 60% ¹H NMR (400 MHz, DMSO-d₆) δ 12.31 (s, 1H), 10.37 (s, 1H), 8.33 (s, 1H), 8.03 (d, <i>J</i> = 9.2 Hz, 1H), 7.81 (s, 1H), 7.77 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 7.70 (d, <i>J</i> = 8.8 Hz, 1H), 7.44 (s, 1H), 7.13 (d, <i>J</i> = 2.8 Hz, 1H), 7.05 (dd, <i>J</i> = 9.2, 2.4 Hz, 1H), 4.80 (t, <i>J</i> = 10.0 Hz, 1H), 4.55 (d, <i>J</i> = 10.8 Hz, 1H), 4.23 (t, <i>J</i> = 8.0 Hz, 1H), 4.05 (dd, <i>J</i> = 11.2, 3.2 Hz, 1H), 3.92 (s, 3H), 3.87 (dd, <i>J</i> = 11.2, 7.6 Hz, 1H), 3.20 (s, 3H); EI-MS m/z : 485 (M⁺+1).

D-106		Yield 59% ¹H NMR (400 MHz, DMSO-d₆) δ 12.11 (s, 1H), 11.77 (s, 1H), 10.35 (s, 1H), 8.44 (s, 1H), 8.02 (d, <i>J</i> = 9.2 Hz, 1H), 7.82 (s, 1H), 7.28 (s, 1H), 7.12 (d, <i>J</i> = 2.0 Hz, 1H), 7.00 (dd, <i>J</i> = 9.2, 2.4 Hz, 1H), 6.85 (s, 1H), 4.78 (t, <i>J</i> = 9.2 Hz, 1H), 4.54 (dd, <i>J</i> = 10.8, 1.6 Hz, 1H), 4.22 (t, <i>J</i> = 2.0 Hz, 1H), 4.05 (dd, <i>J</i> = 11.2, 3.2 Hz, 1H), 3.92 (s, 3H), 3.85 (dd, <i>J</i> = 10.8, 7.6 Hz, 1H), 2.72 (s, 3H); EI-MS <i>m/z</i> : 465 (<i>M</i>⁺+1).
D-107		Yield 58% ¹H NMR (400 MHz, DMSO-d₆) δ 11.08 (s, 1H), 10.35 (s, 1H), 8.01 (d, <i>J</i> = 9.2 Hz, 1H), 7.85 (s, 1H), 7.84 (d, <i>J</i> = 8.8 Hz, 1H), 7.25 (d, <i>J</i> = 2.0 Hz, 1H), 7.11 (d, <i>J</i> = 2.0 Hz, 1H), 6.99 (dd, <i>J</i> = 9.2, 2.8 Hz, 1H), 6.89 (d, <i>J</i> = 8.4 Hz, 1H), 6.54 (s, 1H), 4.75 (t, <i>J</i> = 10.8 Hz, 1H), 4.55 (dd, <i>J</i> = 10.8, 1.6 Hz, 1H), 4.23 (t, <i>J</i> = 9.2 Hz, 1H), 4.05 (dd, <i>J</i> = 10.8, 2.8 Hz, 1H), 3.92 (s, 3H), 3.87 (dd, <i>J</i> = 11.2, 7.6 Hz, 1H), 2.71 (s, 3H). EI-MS <i>m/z</i>: 465 (<i>M</i>⁺⁺+1).

Example 52: Preparation of Compound T-101**Preparation of compound T-101a**

- 5 To a solution of compound T-int-101 (35 mg, 0.033 mmol) in DMF (0.3 mL) was added compound DB-6 (8.7 mg, 0.04 mmol) and EDCI (19 mg, 0.099 mmol) at room temperature under N₂ atmosphere. After stirring for 1 hour at same temperature, the reaction mixture was purified by prep HPLC to obtain compound T-101a (29 mg, 69%).

EI-MS m/z: 1225 (M⁺).

10 Preparation of compound T-101b

To a solution of compound T-101a (4 mg, 0.0032 mmol) in MeOH (0.5 mL) was added potassium carbonate (4.5 mg, 0.032 mmol) at 0 °C under N₂ atmosphere. After stirring for 1 hour at same temperature, the reaction mixture was purified by prep HPLC to obtain compound T-101b (2.8 mg, 82%).

- 15 EI-MS m/z: 1057 (M⁺).


Preparation of compound T-101

To a solution of compound T-101b (6.3 mg, 0.006 mmol), Mal-1 (4.8 mg, 0.012 mmol) in DMSO (2 mL) at room temperature under N₂ nitrogen atmosphere was treated with CuBr

(5.1 mg, 0.036 mmol) and stirred for 1 hour. The reaction mixture was purified by Prep-HPLC to obtain compound T-101 (5.3 mg, 61%).

EI-MS m/z : 1456 (M^+).

5 Example 53: Preparation of Compound T-102



Preparation of Compound T-102a

To a solution of compound T-101a (10 mg, 0.008 mmol) in anhydrous DMF (0.3 mL) was added BGal-Br (67 mg, 0.16 mmol), silver oxide (55 mg, 0.24 mmol) and molecular sieve (20 mg) at room temperature under N_2 atmosphere. After stirring at same temperature for 5 hours, the reaction was filtered through CELITE®, and then concentrated under reduced pressure. The reaction mixture was purified by prep HPLC to obtain compound T-102a (2.7 mg, 22%).

EI-MS m/z : 1555 (M^+).

Preparation of compound T-102b

To a solution of compound T-102a (2.7 mg, 0.0017 mmol) in MeOH (0.4 mL) and DCM (0.1 mL) was added potassium carbonate (2.4 mg, 0.017 mmol) at 0 °C under N_2 atmosphere. After stirring for 1 hour at same temperature, the reaction mixture was purified by prep HPLC to obtain compound T-102b (1.7 mg, 80%).


EI-MS m/z : 1219 (M^+).

Preparation of compound T-102

To a solution of compound T-102b (2.2 mg, 0.0018 mmol), Mal-1 (1.4 mg, 0.036 mmol) in DMSO (2 mL) at room temperature under N_2 nitrogen atmosphere was treated with CuBr (1.5 mg, 0.011 mmol) and stirred for 1 hour. The reaction mixture was purified by Prep-HPLC to obtain compound T-102 (1.8 mg, 62%).

EI-MS m/z : 1619 (M^+)

Example 54: Preparation of Compound Int-TG103



Preparation of Compound Int-TG103-1

To a solution of 4-hydroxybenzoic acid (5.0 g, 36.2 mmol) in Methanol (150 mL) was added Thionyl chloride (26.3 mL, 362 mmol) at 0 °C under N_2 atmosphere. The reaction mixture was stirred at room temperature for 4 h. The reaction was quenched with aqueous $NaHCO_3$ and extracted with EtOAc. The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG103-1 (4.87 g, 89%).

^1H NMR (400 Hz, $CDCl_3$) δ 7.87 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 9.2 Hz, 2H), 3.85 (s, 3H)

EI-MS m/z : 153 (M^++1).

Preparation of Compound Int-TG103-2

To a solution of compound Int-TG103-1 (1.0 g, 6.57 mmol) in MC (22.0 mL) was added DIPEA (2.3 mL, 13.4 mmol) and MOM-Cl (0.55 mL, 7.23 mmol) at 0 °C under N_2 atmosphere. The reaction mixture was stirred at room temperature for 6 h. The reaction was quenched with water and extracted with EtOAc. The organic layer was dried over anhydrous

Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG103-2 (1.14 g, 88%).

¹H NMR (400 Hz, CDCl₃) δ 8.01-7.97 (m, 2H), 7.07-7.04 (m, 2H), 5.23 (s, 2H), 3.89 (s, 3H), 3.48 (s, 3H)

5

Preparation of Compound Int-TG103


To a solution of compound Int-TG103-2 (1.14 g, 5.81 mmol) in Methanol/H₂O/1,4-Dioxane (16.0 mL/ 8.0 mL/ 16.0 mL) was added Lithium hydroxide monohydrate (975 mg, 23.2 mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 5 h. The reaction was quenched with 2N HCl and extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The compound Int-TG103 was used in the next step without further purification. (995 mg, 94%)

10

¹H NMR (400 Hz, MeOH-*D*₄) δ 7.96 (d, *J* = 8.8 Hz, 2H), 7.08 (d, *J* = 8.8 Hz, 2H), 5.25 (s, 2H), 3.55 (s, 3H)

15

Example 55: Preparation of Compound DB-12



20

Preparation of Compound DB-12-1

To a solution of 2-amino-5-nitropyridine (5.0 g, 35.9 mmol) in ethanol (72.0 mL) was added ethyl bromopyruvate (6.31 mL, 50.3 mmol) under N₂ atmosphere. The mixture was refluxed overnight. After the reaction was completed the mixture was cooled at room temperature. After addition of cold water, the resulting precipitate was collected by filtration. The solid was washed with water and dried in vacuo to obtain compound DB-12-1 (6.28 g, 74%) as brown solid.

25

¹H NMR (400 Hz, CDCl₃) δ 9.30-9.29 (m, 1H), 8.38 (s, 1H), 8.05 (dd, *J* = 10, 2.4 Hz, 1H), 7.81 (d, *J* = 10 Hz, 1H), 4.53-4.47 (m, 2H), 1.44 (t, *J* = 7.2 Hz, 3H)

EI-MS m/z : 236 ($M^{+}+1$).

Preparation of Compound DB-12-2

A suspension of compound DB-12-1 (2.0 g, 8.50 mmol) in methanol (20.0 mL) was cooled to
5 0 °C, and hydrochloric acid (6.4 mL) was added drop by drop, followed by addition of zinc
(2.22 g, 34.0 mmol) in small portions. The reaction mixture was stirred for 30 min. Next,
methanol (14 mL) was added, and the reaction was quenched with concentrated ammonia.
The suspension was filtered and the residue washed with methanol. The combined filtrate
10 mL), and concentrated ammonia (30 mL, 30% solution). The mixture was stirred until it
became clear. Layers were separated, and the water layer was extracted once with
chloroform. The combined organic layers were washed with saturated aqueous NaCl, dried
with MgSO₄, filtered, and concentrated under reduced pressure. The compound DB-12-2 was
used in the next step without further purification. (1.12 g, 64%)
15 ¹H NMR (400 Hz, CDCl₃) δ 8.01 (s, 1H), 7.54-7.51 (m, 2H), 6.86 (dd, J = 9.6, 2.4 Hz, 1H),
4.45 (m, 2H), 3.53 (s, 2H), 1.47 (t, J = 6.8 Hz, 3H)

Preparation of Compound DB-12-3

To a solution of compound DB-12-2 (1.12 g, 5.46 mmol) in DMA (18 mL) were added
20 compound Int-TG102 (995 mg, 5.46 mmol) and EDC·HCl (1.26 g, 6.55 mmol). The resulting
mixture was stirred for overnight at room temperature. Subsequently, the reaction mixture
was concentrated. The residue was dissolved in water and CH₂Cl₂, and the layers were
separated. The organic layer was washed with water, dried with Na₂SO₄, and concentrated.
The residue was purified by column chromatography to obtain compound DB-12-3 (927 mg,
25 46%).


¹H NMR (400 Hz, CDCl₃) δ 9.33-9.32 (m, 1H), 8.45 (d, J = 0.8 Hz, 1H), 7.97-7.93 (m, 2H),
7.61-7.52 (m, 2H), 7.18-7.15 (m, 2H), 5.28 (s, 1H), 4.62 (s, 1H), 4.44-4.38 (m, 2H), 3.48 (s,
3H), 1.41 (t, J = 6.8 Hz, 3H)

Preparation of Compound DB-12

To a solution of compound DB-12-3 (300 mg, 0.812 mmol) in 1,4-Dioxane/H₂O (1.5 mL/1.5 mL) were added 2N NaOH (3.0 mL). The resulting mixture was stirred for 1 h at 70°C. The mixture was stirred at 70 °C for 1 h. Next, the mixture was cooled to room temperature, water was added, and the mixture was acidified with a 4 M hydrochloric acid solution. The resulting suspension was filtered, and the residue was dried to give compound DB-12 (242 mg, 87%) as a yellow-brown solid.

¹H NMR (400 Hz, DMSO) δ 10.37 (s, 1H), 9.47 (s, 1H), 7.99 (d, J = 8.4 Hz, 2H), 7.67 (t, J = 14 Hz, 2H), 7.17 (d, J = 8.4 Hz, 2H), 5.26 (s, 2H), 3.38 (s, 3H)


EI-MS m/z : 342 ($M^{+}+1$).

Example 56: Preparation of Compound D-108

Compound D-108 was synthesized via a similar method as described in Example 51.

Yield 23%

EI-MS m/z : 588 ($M^{+}+1$).

Example 57: Preparation of Compound T-103**Preparation of Compound T-103-1**

- 5 To a solution of compound T-Int-101 (70 mg, 0.0660 mmol) in DMF (1.2 mL) was added compound DB-12 (22.5 mg, 0.0660 mmol) and EDCI (37.9 mg, 0.198 mmol) at room temperature under N₂ atmosphere. After stirring for 1 hour at same temperature, the reaction mixture was purified by prep HPLC to obtain compound T-103-1 (48.3 mg, 54%).

EI-MS m/z: 1347 (M⁺)

10

Preparation of Compound T-103-2

- To a solution of compound T-103-1 (48.3 mg, 0.0358 mmol) in MC (2.0 mL) was added HCl in 4N 1,4-Dioxane (0.7 mL) at 0 °C under N₂ atmosphere. After stirring for 1 hour at same temperature, the reaction mixture was purified by prep HPLC to obtain compound T-103-2 (43.5 mg, 93%).
- 15

EI-MS m/z: 1303 (M⁺).

Preparation of Compound T-103-3

- To a solution of compound T-103-2 (43.5 mg, 0.0334 mmol) in anhydrous ACN (1.0 mL) was added βGal-Br (192 mg, 0.468 mmol), silver oxide (171 mg, 0.73 mmol) and molecular sieve (90 mg) at room temperature under N₂ atmosphere. After stirring at same temperature
- 20

for overnight, the reaction was filtered through CELITE®, and then concentrated under reduced pressure. The reaction mixture was purified by prep HPLC to obtain compound T-103-3 (33.1 mg, 61%).

EI-MS m/z: 1635 ($M^{+}+1$).

5

Preparation of Compound T-103-4

To a solution of compound T-103-3 (33.1 mg, 0.0203 mmol) in Methanol (2.0 mL) was added Potassium carbonate (28.1 mg, 0.203 mmol) at 0 °C under N₂ atmosphere. After stirring for 1 hour at same temperature, the reaction mixture was purified by prep HPLC to obtain compound T-103-4 (21.2 mg, 81%).

10

EI-MS m/z: 1297 (M^{+}).


Preparation of compound T-103

To a solution of compound T-103-4 (5.0 mg, 0.00385 mmol), Mal-1 (3.08 mg, 0.00771 mmol) in DMSO (2 mL) at room temperature under N₂ nitrogen atmosphere was treated with CuBr (3.3 mg, 0.0231 mmol) and stirred for 1 hour. The reaction mixture was purified by Prep-HPLC to obtain compound T-103 (5.4 mg, 82%).

15

EI-MS m/z: 1697 (M^{+}).

20 Example 58: Preparation of Compound T-104



Compound T-104 was synthesized via a similar method as described in Example 52.

Preparation of compound T-104-1





Yield 97%; EI-MS m/z: 1135 (M^+).






Preparation of compound T-104






Yield 64%; EI-MS m/z: 1535 (M^+).





5

Table 5: Compounds synthesized via a similar synthetic route as described in Example 52 and 57.

Compound	Structure	Analytical Data
T-105		Yield 43% EI-MS m/z: 1488 (M^+).
T-106		Yield 64% EI-MS m/z: 1516 (M^+).
T-107		Yield 32% EI-MS m/z: 1442 (M^+).
T-108		Yield 32% EI-MS m/z: 1456 (M^+).


T-109		Yield 70% EI-MS m/z: 1476 (M⁺).
T-110		Yield 66% EI-MS m/z: 1456 (M⁺).
T-111		Yield 67% EI-MS m/z: 1619 (M⁺).
T-112		Yield 84% EI-MS m/z: 1414 (M⁺).
T-113		Yield 83% EI-MS m/z: 1577 (M⁺).

T-114		Yield 68% EI-MS m/z: 1414 (M^+).
T-115		Yield 84% EI-MS m/z: 1577 (M^+).
T-116		Yield 97% EI-MS m/z: 1709 (M^+).
T-117		In progress Yield 30% EI-MS m/z: 1725 (M^+).
T-118		Yield 80% EI-MS m/z: 1455 (M^+).

T-119		Yield 45% EI-MS m/z: 1618 (M ⁺).
T-120		Yield 60% ESI-MS m/z: 1458 (M ⁺).
T-121		Yield 60% ESI-MS m/z: 1621 (M ⁺).
T-138		Yield 71% ESI-MS m/z: 863(M ⁺ /2)

T-139		Yield 69% ESI-MS m/z: 731.16(M+/2 +1), 1460.38(M+)
T-140		Yield 18% ESI-MS m/z: 726.67 (M+/2 +1), 1451.46 (M+)
T-141		ESI-MS m/z: 1668.86 (M+)

Example 59: *Preparation of Compound Int-TG16*



Preparation of compound Int-TG16-1

To a solution of compound 1,2,3,4-Tetra-O-acetyl-beta-D-glucuronic acid methyl ester (10.0 g, 26.6 mmol) in anhydrous DMF (133 mL) was added Benzylamine (3.48 mL, 319 mmol) under N₂ atmosphere. The reaction mixture was stirred at room temperature for 3 hours.


- 5 When the reaction was completed, the mixture was diluted with EA and H₂O. The aqueous layer was washed further EA. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG16-1 (7.03 g, 79%).

¹H NMR (400 Hz, CDCl₃) δ 5.31-5.30 (m, 1H), 4.94-4.91 (m, 1H), 4.61-4.60 (m, 1H), 4.44
10 (d, J = 5.2 Hz, 2H), 3.75 (s, 3H), 2.04-2.03 (m, 9H)

Preparation of compound Int-TG16

To a solution of compound Int-TG16-1 (7.03 g, 21.0 mmol) in dried MC (210 mL) was added CCl₃CN (31.6 mL, 315 mmol) and DBU (1.57 mL, 10.5 mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 2 hours. When the reaction was
15 completed, the mixture was diluted with MC and H₂O. The aqueous layer was washed further EA. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG16 (7.98 g, 79%).

¹H NMR (400 Hz, CDCl₃) δ 8.73 (s, 1H), 7.27-7.23 (m, 1H), 5.66-5.60 (m, 1H), 5.30-2.25
20 (m, 1H), 5.17-5.14 (m, 1H), 4.52-4.49 (m, 1H), 3.75 (s, 3H), 2.10-1.99 (m, 9H)

Example 60: *Preparation of Compound Int-TG17*

Preparation of compound Int-TG-17-1

To a solution of compound Int-TG2 (11.69 g, 29.42 mmol), N-hydroxyphthalimide (4 g, 24.52 mmol) in dried DCM (163 mL) was added Tetrabutylammonium hydrogensulfate (1.66 g, 4.9 mmol) and 1M Na₂CO₃ (49.04 mL, 49.04 mmol) at room temperature under N₂ atmosphere. The reaction mixture was stirred at same temperature for 2 hours. When the reaction was completed, the mixture was diluted with DCM and H₂O. The aqueous layer was washed further DCM. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG17-1 (7.4 g, 63%).

¹H NMR (400 Hz, CDCl₃) δ 7.88-7.86 (m, 2H), 7.79-7.77 (m, 2H), 5.39-5.31 (m, 3H), 5.15 (d, J = 7.6 Hz, 1H), 4.13-4.06 (m, 1H), 3.77 (s, 3H), 2.20 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H)

ESI-MS m/z : 480 (M⁺+1).

Preparation of compound Int-TG17-2

To a solution compound Int-TG17-1 (4.4 g, 9.18 mmol) in MeOH (46 mL) was added hydrazine monohydrate (0.468 mL, 9.64 mmol) at room temperature under N₂ atmosphere. The reaction mixture was stirred at same temperature for 30 minutes. When the reaction was completed, saturated NaHCO₃ (5 mL) was added and extracted with MC. The organic layer was dried with NaSO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG17-2 (3.1 g, 97%).

¹H NMR (400 Hz, CDCl₃) δ 5.91 (s, 2H), 5.31-5.19 (m, 2H), 5.11-5.07 (m, 1H), 4.78 (d, J = 8.0 Hz, 1H), 4.11 (d, J = 9.2 Hz, 1H), 3.77 (s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H).

Preparation of compound Int-TG17-3

To a solution of compound Int-TG17-2 (1 g, 2.86 mmol) in anhydrous THF (19 mL) was added Boc₂O (3.12 g, 14.3mmol) and TEA (0.798 mL, 5.72 mmol) at room temperature under N₂ atmosphere. The reaction mixture was stirred at same temperature for 15 hours. When the reaction was completed, the mixture was extracted with EA and H₂O. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG17-3 (620 mg, 48%).

^1H NMR (400 Hz, CDCl_3) δ 7.71 (s, 1H), 5.32-5.23 (m, 2H), 5.17-5.13 (m, 1H), 4.90 (d, J = 6.8 Hz, 1H), 4.14 (d, J = 8.8 Hz, 1H), 3.76 (s, 3H), 2.13 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.47 (s, 9H)

ESI-MS m/z : 472 ($\text{M}^+ + \text{Na}$).

5 Preparation of compound Int-TG17-4

To a solution of compound Int-TG17-3 (20 mg, 0.044 mmol) in MeOH (1.5 mL) at -10°C was added NaOMe (0.5M in MeOH, 0.267 mL, 0.133 mmol) under N_2 atmosphere. After stirring for 10 minutes, the mixture was warmed up to 0°C and stirred further 1 hour 30 minutes at same temperature. When the reaction was completed, the mixture was acidified with 2 M HCl. The reaction mixture was extracted with EA and H_2O . The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. Producing compound Int-TG17-4 (13 mg, 90%), which was used without further purification.

^1H NMR (400 Hz, MeOH-d_4) δ 4.44 (d, J = 7.6 Hz, 1H), 3.77 (d, J = 9.6 Hz, 1H), 3.66 (s, 3H), 3.41 (t, J = 8.8 Hz, 4H), 3.32 (t, J = 8.8 Hz, 2H), 3.23 (t, J = 8.0 Hz, 1H), 1.36 (s, 9H)

15 ESI-MS m/z : 346 ($\text{M}^+ + \text{Na}$).

Preparation of compound Int-TG17-5

To a solution of compound Int-TG17-4 (70 mg, 0.21 mmol), C-2 (201 mg, 0.42 mmol) in dried MC (3.5 mL) was added $\text{BF}_3 \cdot \text{OEt}_2$ (0.013 mL, 0.11 mmol) at -10°C under N_2 atmosphere. The reaction mixture was stirred at -10°C for 45 minutes. After the reaction was completed, the mixture was diluted with DCM and H_2O . The aqueous layer was washed further DCM. The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG17-5 (37.5 mg, 27%).

^1H NMR (400 Hz, CDCl_3) δ 7.46 (s, 1H), 5.30 (t, J = 4.8 Hz, 2H), 5.20 (t, J = 9.6 Hz, 1H), 5.09-5.04 (m, 1H), 4.78 (d, J = 7.6 Hz, 1H), 4.60 (d, J = 8.4 Hz, 1H), 4.15-4.07 (m, 2H), 3.91 (d, J = 9.6 Hz, 1H), 3.82 (s, 3H), 3.81-3.76 (m, 1H), 3.74 (s, 3H), 3.64 (d, J = 8.8 Hz, 1H), 3.57-3.52 (m, 1H), 2.06 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.48 (s, 9H)

Preparation of compound Int-TG17


To a solution of compound Int-TG17-5 (18 mg, 0.028 mmol) in dried DCM (1 mL) was added trifluoroacetic acid (0.2 mL) at 0°C under N_2 atmosphere. After stirring for 10 minutes, the reaction mixture was warmed up to room temperature and stirred further 1 hour.

When the reaction was completed, the mixture was diluted with DCM and concentrated under reduced pressure. The compound Int-TG17 was used directly in the next step without further purification (15.2 mg, 100%).

ESI-MS m/z: 539 (M^+)

5

Example 61: *Preparation of Compound Int-TG18*



Preparation of compound Int-TG18-1

To a solution of 1,2,3,4,6-Penta-O-acetyl- β -D-galactopyranose (2.0 g, 5.12 mmol) in MeOH (51 mL), H₂O (15 mL) was added TEA (5.7 mL, 41 mmol) at room temperature under N₂ atmosphere. The reaction mixture was stirred at same temperature for 4 hours. When the reaction was completed, the mixture was diluted toluene (250 mL) and concentrated with under reduced pressure for 3 hours. The compound Int-TG18-1 was used directly in the next step without further purification (923 mg, 100%).

¹H NMR (400 Hz, D₂O) δ 5.23 (d, *J* = 3.6 Hz, 1H), 4.55 (d, *J* = 8.0 Hz, 1H), 4.06 (t, *J* = 6.4 Hz, 1H), 3.95 (d, *J* = 2.8 Hz, 1H), 3.90 (d, *J* = 3.2 Hz, 1H), 3.82-3.59 (m, 6H), 3.46 (t, *J* = 8.4 Hz, 1H)

Preparation of compound Int-TG18-2

To a suspension of compound Int-TG18-1 (500 mg, 2.77 mmol) in pyridine (9.2 mL) was added TBDMS-Cl (438 mg, 2.90 mmol) at room temperature under N₂ atmosphere. After 3 hours, acetic anhydride (2.62 mL, 27.7 mmol) was added to reaction mixture. The reaction mixture was stirred at same temperature further 18 hours. When the reaction was completed, 2N-HCl (5 mL) was added to the reaction mixture and the mixture was diluted with EA and H₂O. The aqueous layer was washed further EA. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG18-2 (830 mg, 65%).

¹H NMR (400 Hz, CDCl₃) δ 5.69 (d, *J* = 8.4 Hz, 1H), 5.53 (dd, *J* = 3.6, 1.2 Hz, 1H), 5.36-5.30 (m, 1H), 5.10 (dd, *J* = 10.8, 3.6 Hz, 1H), 3.89-3.85 (m, 1H), 3.76-3.71 (m, 2H), 3.60 (dd,

$J = 9.6, 8.4$ Hz, 1H), 2.15 (s, 3H), 2.11 (s, 3H), 2.04 (s, 3H), 1.99 (s, 3H), 0.85 (s, 9H), 0.01 (s, 6H)

ESI-MS m/z : 485 ($M^+ + Na$).


Preparation of compound Int-TG18

- 5 To a solution of compound Int-TG18-2 (530 mg, 1.14 mmol) in dried THF (3.5 mL), pyridine (3.5 mL) was added HF pyridine (1.71 mL, 1.71 mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 4 hours. When the reaction was completed, saturated NaHCO₃ (5 mL) was added to the reaction mixture at 0 °C and the mixture was diluted with EA and H₂O. The aqueous layer was washed further EA. The
- 10 organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG18 (290 mg, 73%).

- ¹H NMR (400 Hz, CDCl₃) δ 5.72 (d, $J = 8.4$ Hz, 1H), 5.43 (dd, $J = 3.6, 0.8$ Hz, 1H), 5.37 (dd, $J = 10.4, 5.2$ Hz, 1H), 5.11 (dd, $J = 10.4, 3.2$ Hz, 1H), 4.31-3.82 (m, 1H), 3.91-3.87 (m, 1H),
- 15 3.77-3.71 (m, 1H), 3.56-3.49 (m, 1H), 2.20 (s, 3H), 2.12 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H)

ESI-MS m/z : 371 ($M^+ + Na$)

Example 62: Preparation of Compound Int-TG19



- 20 Preparation of compound Int-TG19-1

- To a solution of compound Int-TG18 (500 mg, 1.43 mmol) and compound Int-TG16 (823 mg, 1.72 mmol) in dried DCM (14.3 mL) and molecular sieve (1 g) was added BF₃ OEt₂ (0.176 mL, 1.43 mmol) at -10 °C under N₂ atmosphere. The reaction mixture was stirred at same temperature for 1 hour. When the reaction was completed, the reaction mixture was
- 25 filtered with DCM and the filtrate was diluted with DCM and H₂O. The aqueous layer was washed further DCM. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG19-1 (650 mg, 68%).

^1H NMR (400 Hz, CDCl_3) δ 5.72-5.66 (m, 1H), 5.47-5.29 (m, 4H), 5.17-5.04 (m, 1H), 4.96-4.92 (m, 1H), 4.61-4.55 (m, 1H), 4.15-4.10 (m, 1H), 4.03-3.98 (m, 1H), 3.89-3.80 (m, 1H), 3.78-3.72 (m, 3H), 2.21-2.12 (m, 6H), 2.05-1.98 (m, 12H), 1.54-1.53 (m, 3H)

Preparation of compound Int-TG19-2

- 5 To a solution of compound Int-TG19-1 (50 mg, 0.075 mmol) in dried DMF (0.2 mL) was added Benzylamine (0.01 mL, 0.09 mmol) at room temperature under N_2 atmosphere. The reaction mixture was stirred at same temperature for 6 hours. When the reaction was completed, the mixture was diluted with EA and H_2O . The aqueous layer was washed further EA. The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under
10 reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG19-2 (35 mg, 75%).


^1H NMR (400 Hz, CDCl_3) δ 5.51 (d, $J = 3.2$ Hz, 1H), 5.41-5.39 (m, 2H), 5.27-2.23 (m, 2H), 4.97-4.93 (m, 1H), 4.70 (d, $J = 6.8$ Hz, 1H), 4.51-4.49 (m, 1H), 4.44 (d, $J = 5.6$ Hz, 2H), 4.09-4.04 (m, 1H), 3.94-3.92 (m, 1H), 3.8 (s, 3H), 2.22-1.98 (m, 18H)

15 Preparation of compound Int-TG19

- To a solution of compound Int-TG19-2 (15 mg, 0.024 mmol) in dried DCM (0.2 mL) was added CCl_3CN (0.029 mL, 0.36 mmol) and DBU (0.002 mL, 0.012 mmol) at 0°C under N_2 atmosphere. The reaction mixture was stirred at room temperature for 3 hours. When the reaction was completed, the mixture was diluted with DCM and H_2O . The aqueous layer was
20 washed further DCM. The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG19 (8 mg, 44%).

- ^1H NMR (400 Hz, CDCl_3) δ 8.67 (s, 1H), 6.56 (d, $J = 3.6$ Hz, 1H), 5.53 (s, 1H), 5.42-5.30 (m, 3H), 5.21-5.17 (m, 3H), 4.95-4.93 (m, 1H), 4.62 (d, $J = 7.6$ Hz, 1H), 4.39-4.38 (m, 1H),
25 4.03-4.01 (m, 1H), 3.76 (s, 3H), 2.16 (s, 3H), 2.03-2.00 (m, 15H)

Example 63: *Preparation of Compound Int-TG20*



Preparation of Compound Int-TG20-1

Int-TG20-1 was synthesized in a way similar to the preparation method of compound L-1-2 of Example 1.

Yield 70%

¹H NMR (400 Hz, CDCl₃) δ 6.69 (d, *J* = 4 Hz, 1H), 5.53-5.46 (m, 2H), 5.42-5.38 (m, 1H), 5.30 (s, 1H), 5.18-5.13 (m, 1H), 5.05-5.00 (m, 2H), 4.99-4.86 (m, 1H), 4.49-4.48 (m, 1H), 4.34-4.31 (m, 1H), 3.79 (s, 3H), 2.18-2.00 (m, 18H)

Preparation of Compound Int-TG20-2

To a solution of compound Int-TG20-1 (50 mg, 0.0729 mmol) in dried MC (0.5 mL) were added N-Hydroxyphthalimide (11.9 mg, 0.0729 mmol), Tetrabutyl ammonium hydrogensulfate (5 mg, 0.0146 mmol) and 1 M Na₂CO₃ (146 uL, 0.146 mmol) under N₂ atmosphere. The reaction mixture was stirred at room temperature for 2 hours. The product was extracted with MC. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica column chromatography to obtain Int-TG20-2 (34 mg, 61%).


¹H NMR (400 Hz, CDCl₃) δ 8.10-7.98(m, 1H), 7.89-7.87 (m, 2H), 7.82-7.78 (m, 2H), 5.52-5.39 (m, 4H), 5.14-5.06 (m, 2H), 4.99-4.97 (m, 2H), 4.90-4.85 (m, 2H), 4.30-4.27 (m, 1H), 3.75 (s, 3H), 2.25 (s, 3H), 2.19 (s, 3H), 2.07 (s, 3H), 2.02-2.00 (m, 9H)

Preparation of Compound Int-TG20

Int-TG20 was synthesized in a way similar to the preparation method of compound Int-TG17-2 of Example 60.

ESI-MS m/z : 638 ($M^{+}+1$)

5

Example 64: *Preparation of Compound Int-TG21*

Preparation of compound Int-TG21-1

To a solution of 2,4-Dihydroxybenzoic acid (3.0 g, 19.5 mmol) in anhydrous DMF (27.8 mL, 0.7 M) was added Potassium carbonate (2.34 g, 23.4 mmol) at room temperature under N₂ atmosphere. After stirring for 30 min, the mixture was treated with Benzyl bromide (3.47 mL, 29.3 mmol). The mixture was stirred at 50 °C for 16 hours and then quenched with a saturated aqueous NaH₃CO₃ solution. The product was extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG21-1 (4.47 g, 94%).

¹H NMR (400 Hz, CDCl₃) δ 10.95 (s, 1H). 7.90 (dd, J = 8.8, 4.4 Hz, 1H). 7.42-7.38 (m, 5H), 6.40 (s, 1H), 6.35 (d, J = 2.8 Hz, 1H), 5.37 (s, 2H), 6.16 (s, 1H)

Preparation of compound Int-TG21-2

To a solution of compound Int-TG21-1 (50 mg, 0.205 mmol) in anhydrous ACN (1.0 mL, 0.2 M) were added Acetobromo- α -D-glucuronic acid methyl ester (325 mg, 0.819 mmol) and Silver oxide (285 mg, 1.23 mmol) under N₂ atmosphere. The reaction mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was filtered through CELITE® and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG21-2 (50.6 mg, 28%).

¹H NMR (400 Hz, CDCl₃) δ 7.80 (d, J = 8.8 Hz, 1H), 7.40-7.35 (m, 5H), 6.91 (s, 1H), 6.71 (dd, J = 8.8, 2.4 Hz, 1H), 5.35-5.20 (m, 10H), 4.28-4.22 (m, 2H), 3.78-3.71 (m, 6H), 2.0-2.02 (m, 18H)

ESI-MS m/z : 876 (M⁺).

Preparation of Compound Int-TG21-3


To a solution of compound Int-TG21-2 (50.6 mg, 0.0577 mmol) in MeOH (3 mL), THF (1 mL) was added Palladium 5% on Carbon (wetted with ca. 55% water, 12.3 mg, 0.00577 mmol) at room temperature under H₂ atmosphere. The mixture was stirred for 2 hours and filtered through CELITE®, and then concentrated under reduced pressure. The compound Int-TG21-3 was used directly in the next step without further purification (45.4 mg, 100%).

ESI-MS m/z : 787 (M⁺⁺¹)

Preparation of Compound Int-TG21

To a solution of compound Int-TG21-3 (45.4 mg, 0.0577 mmol) in anhydrous ACN (1.2 mL, 0.05 M) were added DMF (Cat.) and Oxalyl chloride (14.8 μ L, 0.173 mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 30 min. After the reaction was completed, the mixture was concentrated under reduced pressure. The crude compound Int-TG21 was used directly in the next step without further purification (46.5 mg, 100%).

Example 65: *Preparation of Compound Int-TG22*



Int-TG-22 was synthesized in a way similar method of Example 64.

Compound Int-TG22-1

5 Yield 44%

¹H NMR (400 Hz, CDCl₃) δ 8.02-7.98 (m, 2H). 7.45-7.34 (m, 5H). 6.87-6.84 (m, 2H), 5.34 (s, 2H)

Compound Int-TG-22-2

Yield 87%


10 ¹H NMR (400 Hz, CDCl₃) δ 8.05-8.03 (m, 2H), 7.45-7.34 (m, 5H), 7.02-7.00 (m, 2H), 5.48-5.29 (m, 6H), 4.25-4.21 (m, 1H), 3.72 (s, 3H), 2.05-2.04 (m, 9H)

Compound Int-TG22

Yield 97%

¹H NMR (400 Hz, CDCl₃) δ 8.07-8.04 (m, 2H), 7.06-7.00 (m, 2H), 5.41-5.26 (m, 4H), 4.25-4.23 (m, 1H), 3.75 (s, 3H), 2.07-2.04 (m, 9H)

Example 66: *Preparation of Compound Int-TG23a*



Preparation of compound Int-TG-23a-1

In a round-bottomed flask under an N₂ atmosphere, dry DCM (190 mL) was added. The solvent was degassed with Ar, and MgSO₄ (23.1 g, 0.912 mol), H₂SO₄ (2.57 mL, 0.0479 mol) were added the reaction flask and vigorously stirred at room temperature for 10 minutes.

- 5 Bromopyruvic acid (8.00 g, 0.0479 mol), t-BuOH (22.7 mL, 0.240 mol) were added to the reaction mixture at room temperature under N₂ atmosphere and the flask was tightly sealed. The reaction mixture was stirred at room temperature for 5 days. The reaction mixture was quenched by the addition of water (95 mL), saturated aqueous NaHCO₃ until no further evolution of gas observed, keeping the temperature below 30 °C. The phases were separated
10 and the aqueous phase extracted with DCM. The combined organic layer was washed with saturated NaCl solution, dried over anhydrous MgSO₄, and filter. The solvent was carefully removed under reduced pressure to obtain compound Int-TG-23a-1 as colorless oil (9.25 g, 86%).

¹H-NMR (400 MHz, CDCl₃) δ 4.27 (s, 2H), 1.57 (s, 9H).

15 Preparation of compound Int-TG-23a-2

To a solution of 2-amino-5-nitropyridine (14.7 g, 0.106 mol) in tert-butanol/ethanol(3:1) (530 mL) was added compound Int-TG-23a-1 (33.0 mL, 0.148 mol) under N₂ atmosphere. The mixture was refluxed overnight. After the reaction was completed, the mixture was concentrated under reduced pressure. The residue was extracted with DCM (500 mL). The
20 organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG-23a-2 (24.4 mg, 87%) as yellow solid.

¹H-NMR (400 MHz, CDCl₃) δ 9.27 (dd, J = 2, 0.8 Hz, 1H), 8.29 (s, 1H), 8.01 (dd, J = 10, 2.4 Hz, 1H), 6.92 (dd, J = 10, 0.8 Hz, 1H), 1.59 (s, 9H);

- 25 ESI-MS m/z: 264 (M⁺+1).


Preparation of compound Int-TG-23a

To a solution of compound Int-TG-23a-2 (50 mg, 0.190 mmol) in THF/H₂O (4:1) (3.8 mL) was treated with Zn (124 mg, 19.0 mmol), NH₄Cl (203 mg, 3.80 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was filtered through
30 CELITE®, and the filtrate was extracted with EtOAc (100 mL). The combined organic layer was dried over anhydrous Na₂SO₄, filter, and concentrated under reduced pressure to obtain compound Int-TG-23a (42 g, 100%).

^1H -NMR (400 MHz, DMSO- d_6) δ 8.21 (s, 1H), 7.65 (s, 1H), 7.36 (d, J = 9.2 Hz, 1H), 6.92 (d, J = 8.0 Hz, 1H), 5.09 (s, 2H), 1.50 (s, 9H);

ESI-MS m/z : 234 (M^+ +1).

5 Example 67: *Preparation of Compound Int-TG23*



Preparation of Compound Int-TG23-1

To solution of compound Int-TG23a (12.0 mg, 0.0514 mmol) in dried THF (0.5 mL) was added Int-TG21 (45.5 mg, 0.0566 mmol) and DIPEA (13.4 μL , 0.0771 mmol) at room temperature under N_2 atmosphere. The reaction mixture was stirred at same temperature for 1.5 hours. The reaction was quenched by addition of an aqueous 2 N HCl solution, and the mixture was extracted with EtOAc. The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-TG23-1 (22.9 mg, 44%).


^1H NMR (400 Hz, CDCl_3) δ 9.32 (s, 1H), 9.09 (s, 1H), 8.18 (d, J = 9.2 Hz, 1H), 8.12 (s, 1H), 7.68 (d, J = 9.2 Hz, 1H), 7.34 (d, J = 1.6 Hz, 1H), 6.73 (dd, J = 8.8, 2.0 Hz, 1H), 6.81 (s, 1H), 5.49-5.29 (m, 8H), 4.32-4.26 (m, 2H), 3.76 (s, 3H), 3.75 (s, 3H), 2.18-2.07 (m, 18H), 1.65 (s, 9H)

ESI-MS m/z : 1002 (M^+ +1).

Preparation of Compound Int-TG23

To solution of compound Int-TG23-1 (8.6 mg, 0.00858 mmol) in 1,4-Dioxane (43 μL) was added 4 M HCl in dioxane (500 μL) at room temperature under N_2 atmosphere. After stirring for 1 hour at 50 $^\circ\text{C}$, the mixture was concentrated under reduced pressure. The crude compound Int-TG23 was used directly in the next step without further purification (8.4 mg, 100%).

ESI-MS m/z : 946 (M^+ +1).

Example 68: Preparation of Compound Int-TG24**Preparation of compound Int-TG24-1~Int-TG24-3**

- 5 Int-TG24-1, Int-TG24-2, and Int-TG24-3 were synthesized in a way similar method of Example 64.

Compound Int-TG24-1

Yield 86%

- 10 ^1H NMR (400 Hz, CDCl_3) δ 8.08 (d, $J = 8.8$ Hz, 2H), 7.46-7.36 (m, 5H), 7.02 (d, $J = 8.8$ Hz, 2H), 5.51-5.44 (m, 2H), 5.36 (s, 3H), 5.22-5.20 (m, 2H), 5.12-5.10 (m, 2H), 5.03-4.98 (m, 1H), 4.58 (d, $J = 7.6$ Hz, 1H), 4.11-4.08 (m, 2H), 4.01-3.98 (m, 2H), 3.93-3.89 (m, 2H), 3.75 (s, 3H), 2.17 (s, 3H), 2.05 (s, 3H), 2.02-2.00 (m, 9H), 1.84 (s, 3H)

Compound Int-TG24-2

Yield 96%

- 15 ^1H NMR (400 Hz, CDCl_3) δ 8.08 (d, $J = 8.4$ Hz, 2H), 7.04 (d, $J = 8.0$ Hz, 2H), 5.50-5.44 (m, 2H), 5.21-5.10 (m, 4H), 5.03-4.99 (m, 1H), 4.59 (d, $J = 7.6$ Hz, 1H), 4.13-4.10 (m, 1H), 3.97-3.89 (m, 2H), 3.78-3.75 (m, 4H), 2.18 (s, 3H), 2.06 (s, 3H), 2.01-2.00 (m, 9H), 1.85 (s, 3H),

Compound Int-TG24-3

Yield 100%

- 20 Preparation of compound Int-TG24-4

Int-TG24-4 was synthesized in a way similar to the preparation method of compound Int-TG23-1 of Example 67.

Yield 71%

ESI-MS m/z : 958 ($M^+ + 1$)

Preparation of compound Int-TG24-5

To solution of compound Int-TG24-4 (52 mg, 0.054 mmol) in dried MC (1.0 mL) was added TFA (0.3 mL) at room temperature under N_2 atmosphere. After stirring for 17 hours at room temperature, the mixture was concentrated under reduced pressure. The crude compound Int-TG24-5 was used directly in the next step without further purification (49 mg, 100%).


ESI-MS m/z : 902 ($M^+ + 1$)

Preparation of compound Int-TG24

Int-TG24 was synthesized in a way similar method of compound Int-TG21 of Example 64.

Yield 100%

Example 69: Preparation of Compound Int-TG25



Preparation of compound Int-TG25-1

To a solution of Acetobromo- α -D-glucuronic acid methyl ester (3.0 g, 7.97 mmol) in Hydrogen bromide solution 33wt.% in AcOH at 0 °C under N_2 atmosphere. The reaction mixture was stirred at room temperature for 3 hours and then concentrated under reduced pressure. The residue was purified by column chromatography to produce compound Int-TG25-1 (2.50 g, 79%).

^1H NMR (400 Hz, $CDCl_3$) δ 6.65 (d, J = 4 Hz, 1H), 5.62 (t, J = 9.6 Hz, 1H), 5.25 (t, J = 9.6 Hz, 1H), 4.86 (d, J = 4 Hz, 1H), 4.58 (d, J = 10.4 Hz, 1H), 3.75 (s, 3H), 2.07-2.05 (m, 9H)

Preparation of compound Int-TG25-2

To a solution of compound Int-TG25-1 (2.07 g, 5.21 mmol) in anhydrous DCM (30 mL) was added N-Hydroxyphthalimide (850 mg, 5.21 mmol) and Tetrabutylammonium hydrogen sulfate (354 mg, 1.04 mmol) and 1M Sodium carbonate solution (10.4 mL, 10.42 mmol) at -

10 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 8 hours. The reaction mixture diluted with H₂O (100 mL). The resulting mixture was extracted with DCM (2 × 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography to produce the compound Int-TG25-2 (1.66 g, 66 %).


¹H NMR (400 Hz, CDCl₃) δ 7.88-7.85 (m, 2H), 7.78-7.76 (m, 2H), 5.38-5.29 (m, 3H), 5.14 (d, J = 7.6 Hz, 1H), 4.11-4.07 (m, 1H), 3.76 (s, 3H), 2.19 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H)

Preparation of compound Int-TG25

To a solution of compound Int-TG25 (1.07 g, 2.23 mmol) in anhydrous MeOH (20 mL) was added Hydrazine monohydrate (114 μl, 2.34 mmol) at room temperature under N₂ atmosphere. The reaction mixture was stirred at room temperature for 20 min. The reaction mixture diluted with sat. Sodium bicarbonate solution (40 mL). The resulting mixture was extracted with DCM (2 × 50 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography to produce the compound Int-TG25 (1.07 g, 96 %).

¹H NMR (400 Hz, CDCl₃) δ 5.90 (s, 1H), 5.27-5.21 (m, 2H), 5.08 (m, 1H), 4.77 (d, J = 8 Hz, 1H), 4.12-4.09 (m, 1H), 3.74 (s, 3H), 2.06 (s, 3H), 2.04-2.02 (m, 6H)

Example 70: *Preparation of Compound Int-TG26*



Preparation of compound Int-TG26-1

To a solution of Methyl 1,2,3,4-Tetra-O-acetyl-β-D-glucuronate (3.0 g, 7.97 mmol) in anhydrous DMF (25 mL) was added Benzyl amine (1.05 ml, 9.56 mmol) under N₂ atmosphere. The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture diluted with H₂O (30 mL). The resulting mixture was extracted with EA (2 × 30 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and

concentrated. The residue was purified by column chromatography to produce the compound Int-TG26-1 (2.04 g, 77 %).


^1H NMR (400 Hz, CDCl_3) δ 5.61-5.56 (m, 2H), 5.20 (t, J = 9.2 Hz, 1H), 4.94-4.92 (m, 1H), 4.59 (d, J = 10 Hz, 1H), 3.75 (s, 3H) 2.09 (s, 3H), 2.06-2.03 (m, 6H)

5 Preparation of compound Int-TG26

To a solution of compound Int-TG26-1 (434 mg, 1.30 mmol) in anhydrous DCM (5 mL) was added Trichloroacetonitrile (1.3 mL, 13.0 mmol) and DBU (97 μL , 0.65 mmol) at 0 °C under N_2 atmosphere. The reaction mixture was stirred at 0 °C for 5 hours. The reaction was concentrated in vacuo. The residue was purified by flash chromatography to give the titled compound Int-TG26 (437 mg, 71 %).

^1H NMR (400 Hz, CDCl_3) δ 8.73 (s, 1H), 6.64 (d, J = 3.6 Hz, 1H), 5.63 (t, J = 10 Hz, 1H), 5.27 (t, J = 10 Hz, 1H), 5.15 (dd, J = 6.8, 3.6 Hz, 1H), 4.50 (d, J = 10 Hz, 1H), 3.76 (s, 3H), 2.07-2.04 (m, 6H), 2.02 (s, 3H)

15 **Example 71: Preparation of Compound DB-13**



Preparation of compound DB-13-1

To a solution of Aluminium chloride (1.41 g, 10.58 mmol) in Dichloroethane (15 mL) was added Chloroacetyl chloride (841 μL , 10.58 mmol) at 0 °C under N_2 atmosphere. The reaction mixture was slowly dropwised a solution of Ethyl indole-2-carboxylate (1 g, 5.29 mmol) in Dichloroethane (15 mL). The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture diluted with ice water (70 mL) and extracted with EA (2×100 mL) and washed sat. Sodium bicarbonate solution (150 mL). The combined organic layers were dried over anhydrous Na_2SO_4 , filtered and concentrated. The compound DB-13-1 was used directly in the next step without further purification (1.4 g, 100%).

^1H NMR (400 Hz, CDCl_3) δ 9.21 (s, 1H), 8.38 (s, 1H), 7.98 (m, 1H), 7.50 (d, J = 8.8 Hz, 1H), 7.34 (s, 1H), 4.79 (s, 2H), 4.44 (q, J = 7.2 Hz, 2H), 1.43 (t, J = 7.2 Hz, 3H)

Preparation of compound DB-13-2


To a solution of compound DB-13-1 (1.4 g, 5.27 mmol) in anhydrous THF (32 mL) was added Zinc powder (965 mg, 14.75 mmol) and AcOH (8 mL) at room temperature under N₂ atmosphere. The reaction mixture was stirred at room temperature for 2 hours and filtered and concentrated in vacuo. The resulting mixture diluted with H₂O (70 mL) and extracted with EA (2 × 80 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography to produce the compound DB-13-2 (1.03 g, 84 %).

¹H NMR (400 Hz, CDCl₃) δ 9.19 (s, 1H), 8.37 (s, 1H), 7.99 (d, J = 7.2 Hz, 1H), 7.46 (d, J = 7.2 Hz, 1H), 7.33 (s, 1H), 4.44 (q, J = 7.2 Hz, 2H), 2.68 (s, 3H), 1.44 (t, J = 7.2 Hz, 3H)

Preparation of compound DB-13

To a solution of DB-13-2 (535 mg, 2.31 mmol) in MeOH/H₂O/1,4-Dioxane (4 mL/ 4 mL/ 4 mL) was added lithium hydroxide monohydrate (41 mg, 23.1 mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 2 hours. After the reaction was quenched with HCl, the reaction mixture diluted with H₂O (10 mL) and extracted with EA (2 × 20 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated. The compound DB-13 was used in the next step without further purification (444 mg, 95%).

¹H NMR (400 Hz, DMSO-d₆) δ 12.14 (s, 1H), 8.41 (s, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.48 (d, J = 8.8 Hz, 1H), 7.26 (s, 1H), 2.60 (s, 3H)

Example 72: Preparation of Compound DB-14**Preparation of compound DB-14-1**

To a solution of 3-Ethoxy-4-hydroxybenzaldehyde (6.11 g, 36.8 mmol) in anhydrous DCM (100 mL) was added Chloromethyl methyl ether (3.07 mL, 40.4 mmol) and DIPEA (12.8 ml, 73.6 mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 2.5 hours. The reaction mixture diluted with H₂O (200 mL). The resulting mixture was extracted with DCM (2 × 200 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography to produce the compound DB-14-1 (1.03 g, 82 %).

¹H NMR (400 Hz, CDCl₃) δ 9.86 (s, 1H), 7.41 (s, 1H), 7.41-7.40 (m, 1H), 7.27-7.25 (m, 1H), 5.32 (s, 2H), 4.18 (q, *J* = 6.8 Hz, 2H), 3.53 (s, 3H), 1.48 (t, *J* = 6.8 Hz, 3H)

Preparation of compound DB-14-2

To a solution of compound DB-14-1 (6.3 g, 29.97 mmol) in anhydrous MeOH (25 mL) was added solution of Methyl azidoacetate (13.8 g, 0.12 mol) in MeOH (75 mL) and Sodium methoxide 5M solution (24 mL, 0.12 mol) at -10 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 18 hours. The reaction mixture diluted with H₂O (150 mL). The resulting mixture was extracted with EA (2 × 200 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography to produce the compound DB-14-2 (4.54 g, 49 %).

^1H NMR (400 Hz, CDCl_3) δ 7.53 (s, 1H), 7.30-7.26 (m, 1H), 7.25-7.14 (m, 1H), 6.86 (s, 1H), 5.26 (s, 2H), 4.37-4.35 (m, 2H), 4.16-4.14 (m, 2H), 3.52 (s, 3H), 1.49 (t, $J = 6.8$ Hz, 3H), 1.40 (t, $J = 6.8$ Hz, 3H)

Preparation of compound DB-14-3

5 To a solution of compound DB-14-2 (4.5 g, 14.64 mmol) in *p*-xylene (3.40 mL) at room temperature under N_2 atmosphere. The reaction mixture was stirred at 180 °C for 30 min. The reaction mixture was cooled at room temperature and concentrated under reduced pressure. The residue was purified by column chromatography to produce compound DB-14-3 (2.68 g, 66%).

10 ^1H NMR (400 Hz, CDCl_3) δ 8.72 (s, 1H), 7.19 (s, 1H), 7.10-7.09 (m, 2H), 5.28 (s, 2H), 4.13 (q, $J = 7.2$ Hz, 2H), 3.92 (s, 3H), 3.55 (s, 3H), 1.49 (t, $J = 7.2$ Hz, 3H), 1.40 (t, $J = 6.8$ Hz, 3H)

Preparation of compound DB-14-4

To a solution of compound DB-14-3 (1 g, 3.58 mmol) in anhydrous DCM (15 mL) was added
15 Hydrogen chloride 4.0 M solution in 1,4-Dioxane (4.0 mL) at room temperature under N_2 atmosphere. After stirring for 1.5 hours, the reaction mixture was diluted with DCM and concentrated under reduced pressure. The compound DB-14-4 was used in the next step without further purification (842 mg, 100%).

^1H NMR (400 Hz, CDCl_3) δ 8.65 (s, 1H), 7.09 (m, 1H), 7.02 (s, 1H), 6.93 (s, 1H), 5.98 (s,
20 1H), 4.13 (q, $J = 7.2$ Hz, 2H), 3.96 (s, 3H), 1.49 (t, $J = 7.2$ Hz, 3H)

Preparation of compound DB-14-5

To a solution of compound DB-14-4 (842 mg, 3.58 mmol) in MeOH/ H_2O /1,4-Dioxane (10.0 mL/
5.00 mL/ 10.0 mL) was added lithium hydroxide monohydrate (751 mg, 17.9 mmol) at 0
°C under N_2 atmosphere. The reaction mixture was stirred at 50 °C for 6 hours. After the
25 reaction was quenched with HCl, the resulting precipitate was collected by filtration. The solid washed with water and dried in vacuo to obtain compound DB-14-5 (792 mg, 100%) as white solid.

ESI-MS m/z : 222 ($\text{M}^+ + 1$).

Preparation of compound DB-14-6

30 To a solution of compound DB-14-5 (790 mg, 3.57 mmol) in anhydrous DMF (10 mL) was added DIPEA (933 μL , 5.34 mmol) and Benzyl bromide (510 μL , 4.28 mmol) under N_2

atmosphere. The reaction mixture was stirred at 60 °C for 3 hours. The reaction mixture was cooled at room temperature. The reaction mixture diluted with H₂O (30 mL). The resulting mixture was extracted with EA (2 × 30 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column

5 chromatography to produce the compound DB-14-6 (940 mg, 85 %).

¹H NMR (400 Hz, CDCl₃) δ 8.65 (s, 1H), 7.47-7.38 (m, 5H), 7.15 (s, 1H), 7.00 (s, 1H), 6.91 (s, 1H), 5.99 (s, 1H), 5.38 (s, 2H), 4.15 (q, *J* = 7.2 Hz, 2H), 1.48 (t, *J* = 7.2 Hz, 3H)

Preparation of compound DB-14-7


To a solution of compound DB-14-6 (95 mg, 0.305 mmol) in anhydrous DCM (5 mL) was
10 added compound Int-TG25-1 (220 mg, 0.458 mmol) and boron trifluoride diethyl etherate (57
μℓ, 0.458 mmol) at -10 °C under N₂ atmosphere. After stirring for 30 minutes at same
temperature, the reaction mixture was extracted with DCM (30 ml × 3), H₂O (30 ml). The
organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced
pressure. The residue was purified by column chromatography to produce the compound DB-
15 14-7 (184 mg, 95%).

ESI-MS *m/z*: 628 (M⁺+1).

Preparation of compound DB-14

To a solution of compound DB-14-7 (184 mg, 0.298 mmol) in anhydrous MeOH (4 mL) was
added Pd/C (5%, 63 mg, 0.029 mmol) at room temperature under H₂. The mixture was stirred
20 for 1 hour and filtered through CELITE®, and then concentrated under reduced pressure. The
compound DB-14 was used directly in the next step without further purification (149 mg,
95%).

ESI-MS *m/z*: 538 (M⁺+1).

Example 73: Preparation of Compound T-122**Preparation of compound T-122-1**

To a solution of compound T-Int-101 (100 mg, 94.3 μmol) in anhydrous DMF (3 mL) was added compound DB-13 (39.0 mg, 0.19 mmol) and EDCI (59 mg, 0.283 mmol) at room temperature under N_2 atmosphere. After stirring for 1 hour at same temperature, the reaction mixture was purified by prep HPLC to produce compound T-122-1 (68 mg, 60%).

ESI-MS m/z : 1210 (M^+).

Preparation of compound T-122-2

To a solution of compound T-122-1 (16 mg, 13.2 μmol) in anhydrous MeOH (1.2 mL) was added compound Int1 (46 mg 0.132 mmol) at room temperature under N_2 atmosphere. The reaction mixture was stirred at room temperature for 3.5 hours. The reaction mixture concentrated. The residue was purified by prep HPLC to produce compound T-122-2 (19.8 mg, 97%).

ESI-MS m/z : 1541 (M^+).

Preparation of compound T-122-3

To a solution of T-122-2 (19.8 mg, 12.85 μmol) in MeOH/ H_2O /1,4-Dioxane (0.7 mL/ 0.7 mL/ 0.7 mL) was added lithium hydroxide monohydrate (4.3 mg, 0.102 mmol) at 0 $^\circ\text{C}$ under N_2 atmosphere. The reaction mixture was stirred at -20 $^\circ\text{C}$ for 2 hours. After the reaction was

quenched with 2N HCl, the reaction mixture was purified by prep HPLC to produce compound Int2-3 (12.9 mg, 82%).

ESI-MS m/z : 1233 (M^+).


Preparation of compound T-122

- 5 To a solution of compound T-122-3 (5.3 mg, 4.3 μmol), Mal-1 (3.43 mg, 8.60 μmol) in DMSO (800 μL) at room temperature under N_2 nitrogen atmosphere was treated with CuBr (3.7 mg, 25.8 μmol) and stirred for 1 hour. The reaction mixture was purified by Prep-HPLC to produce compound Int2 (5.4 mg, 77%).

ESI-MS m/z : 1632 (M^+).

10

Example 74: *Preparation of Compound T-123*



Preparation of compound T-123-1

- 15 To a solution of compound T-Int-101 (10 mg, 9.42 μmol) in anhydrous DMF (0.6 mL) was added compound DB-14 (6.07 mg, 11.31 μmol) and EDCI (2.7 mg, 14.13 μmol) at room temperature under N_2 atmosphere. After stirring for 1 hour at same temperature, the reaction mixture was purified by prep HPLC to produce compound T-123-1 (4.0 mg, 27%).

ESI-MS m/z : 1544 (M^+).

Preparation of compound T-123-2

To a solution of T-123-1 (4.0 mg, 2.59 μmol) in MeOH/H₂O/1,4-Dioxane (0.3 mL/ 0.3 mL/ 0.3 mL) was added lithium hydroxide monohydrate (0.87 mg, 20.72 μmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at -20 °C for 2 hours. After the reaction was quenched with 2N HCl, the reaction mixture was purified by prep HPLC to produce compound T-123-2 (2.6 mg, 81%).


ESI-MS m/z : 1236 (M^+).

Preparation of compound T-123

To a solution of compound T-123-2 (2.6 mg, 2.1 μmol), Mal-1 (1.68 mg, 4.21 μmol) in DMSO (600 μL) at room temperature under N₂ nitrogen atmosphere was treated with CuBr (1.81 mg, 12.6 μmol) and stirred for 1 hour. The reaction mixture was purified by Prep-HPLC to produce compound T-123 (2.1 mg, 61%).

ESI-MS m/z : 1635 (M^+).

Example 75: *Preparation of Compound T-124*



Compound T-124 was synthesized via a similar synthetic route as described in Example 73 (77.8 mg, 74%).

Compound T-124-1

Yield 74%

ESI-MS m/z: 1195 (M^+).

Compound T-124-2

5 Yield 87%

ESI-MS m/z: 1526 (M^+).


Compound T-124-3

Yield 84%

ESI-MS m/z: 1246 (M^+).

10 Compound T-124

Yield 86%

ESI-MS m/z: 1646 (M^+).**Example 76: *Preparation of Compound T-125***

Compound T-125 was synthesized via a similar synthetic route as described in Example 74.

Compound T-125-1

Yield 82%

ESI-MS m/z : 1529 (M^+).

5 Compound T-125-2

Yield 61%


ESI-MS m/z : 1249 (M^+).

Compound T-125

Yield 95%

10 ESI-MS m/z : 1649 (M^+).

Example 77: *Preparation of Compound Int-TG104*



Preparation of Compound Int-TG104-1 to Int-TG104-4

15 Int-TG104-1 to Int-TG104-4 were synthesized in a way similar method of Example 11.

Compound Int-TG104-1

Yield 70%

^1H NMR (400 Hz, CDCl_3) δ 10.33 (s, 1H), 8.55 (d, $J = 2.0$ Hz, 1H), 8.28 (dd, $J = 8.8, 2.4$ Hz, 1H), 7.45-7.35 (m, 5H), 7.17 (d, $J = 8.4$ Hz, 1H), 5.39-5.36 (m, 6H), 4.30-4.25 (m, 1H), 3.72 (s, 3H), 2.09-2.05 (m, 9H).

20

ESI-MS m/z : 595 ($M^+ + Na$).

Compound Int-TG104-2

Yield 86%

5 ^1H NMR (400 Hz, $CDCl_3$) δ 7.67 (d, $J = 2.0$ Hz, 1H), 7.61 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.44-7.32 (m, 5H), 7.00 (d, $J = 8.4$ Hz, 1H), 6.05 (s, 1H), 5.41-5.25 (m, 5H), 5.11 (d, $J = 7.2$ Hz, 1H), 4.22 (d, $J = 8.8$ Hz, 1H), 3.77 (s, 3H), 2.11-2.06 (m, 9H).

ESI-MS m/z : 583 ($M^+ + Na$).

Compound Int-TG104-3

Yield 100%

10 ^1H NMR (400 Hz, $CDCl_3$) δ 7.68 (d, $J = 2.0$ Hz, 1H), 7.63 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.03 (d, $J = 8.8$ Hz, 1H), 5.43-5.29 (m, 3H), 5.14 (d, $J = 7.2$ Hz, 1H), 4.24 (d, $J = 8.8$ Hz, 1H), 3.78 (s, 3H), 2.12-2.07 (m, 9H).

ESI-MS m/z : 493 ($M^+ + Na$).

Compound Int-TG104-4

15 Yield 80%


^1H NMR (400 Hz, $CDCl_3$) δ 7.06-6.89 (m, 3H), 6.32-6.23 (m, 1H), 5.40-5.27 (m, 3H), 5.05 (d, $J = 7.6$ Hz, 1H), 4.19 (d, $J = 9.2$ Hz, 1H), 3.84-3.46 (m, 17H), 3.39 (t, $J = 5.6$ Hz, 2H), 3.09-3.04 (m, 3H), 2.12-2.06 (m, 9H).

ESI-MS m/z : 685 ($M^+ + 1$)

20 Preparation of Compound Int-TG104

To a solution of Int-TG104-4 (70.2 mg, 0.103 mmol) in Methanol/MC (2.5 mL/0.5 mL) was added K_2CO_3 (42.7 mg, 0.309 mmol) at 0 °C under N_2 atmosphere. After stirring for 1 hour 30 min at same temperature, the reaction mixture was purified by prep-HPLC to obtain compound Int-TG104 (36.7 mg, 64%).

25 ESI-MS m/z : 559 ($M^+ + 1$)

Example 78: *Preparation of Compound T-Int102***Preparation of Compound T-Int102-1**

T-Int102-1 was synthesized in a way similar method of Example 40.

5 Yield 23%

ESI-MS m/z : 984 (M^+).

Preparation of Compound T-Int102-2

To a solution of T-Int102-1 (8.1 mg, 0.00823 mmol) was dissolved in Pyridine (0.16 mL) was added DMAP (0.10 mg, 0.000823 mmol) and Acetic anhydride (9.34 μ L, 0.0411 mmol) at room temperature under N_2 atmosphere. After stirring for 5 hours 30min at same temperature, the reaction mixture was purified by prep-HPLC to obtain compound T-Int102-2 (9.1 mg, 100%).


ESI-MS m/z : 1110 (M^+).

Preparation of Compound T-Int102

15 T-Int102 was synthesized in a way similar method of Example 40.

Yield 100%

ESI-MS m/z : 1010 (M^+).

Example 79: Preparation of Compound T-126**Preparation of Compound T-126-1**

- 5 To a solution of T-Int102 (8.95 mg, 0.00855 mmol) in anhydrous DMF (0.5 mL) was added Int-TG23 (8.4 mg, 0.00855 mmol) and EDCI (4.92 mg, 0.0257 mmol) at room temperature under N₂ atmosphere. After stirring for 35 min at same temperature, the reaction mixture was purified by prep-HPLC to obtain compound T-126-1 (7.0 mg, 42%).

ESI-MS m/z : 1938 (M⁺)

10 Preparation of Compound T-126- 2

To a solution of T-126-1 (7.0 mg, 0.00361 mmol) in THF (0.2 mL), MeOH (40 uL), H₂O (110 uL) was added Lithium hydroxide monohydrate (5.30 mg, 0.126 mmol) at -30 °C under N₂ atmosphere. After stirring for 1.5 hours at same temperature, the reaction mixture was purified by prep-HPLC to obtain compound T-126-2 (4.6 mg, 84%).


- 15 ESI-MS m/z : 1517 (M⁺).

Preparation of compound T-126

To a solution of compound T-126-2 (4.6 mg, 0.00303 mmol) in degassed DMSO (1.5 mL) was added Mal-1 (2.42 mg, 0.00606 mmol) at room temperature under N₂ atmosphere was treated with CuBr (2.61 mg, 0.0182 mmol) and stirred for 30 min. The reaction mixture was

5 purified by prep-HPLC to obtain compound T-126 (4.82 mg, 83%).

ESI-MS m/z : 1917 (M^+).

Example 80: Preparation of Compound T-127

10 Preparation of Compound T-127-1

To a solution of compound T-124-1 (15.2 mg, 0.0127 mmol) was dissolved in Methanol (0.5 mL) was added compound Int-TG17 (15.2 mg, 0.0281 mmol) at room temperature under N₂ atmosphere. After stirring for 1 day at same temperature, the reaction mixture was purified by silica column chromatography to obtain compound T-127-1 (14 mg, 64%).

15 ESI-MS m/z : 858 ($M^+/2$).

Preparation of Compound T-127-2, and T-127

T-127-2, and T-127 were synthesized in a way similar method of Example 74.

Compound T-127-2

Yield 60%

ESI-MS m/z : 1422 (M^+).


Compound T-127

Yield 87%

ESI-MS m/z : 911 ($M^+/2$).

5

Example 81: Preparation of Compound T-128



Preparation of Compound T-128-1

To a solution of T-Int102 (17 mg, 0.0166 mmol) in dried THF (0.5 mL) was added Int-TG24 (15.3 mg, 0.066 mmol) and DIPEA (5.8 μ L, 0.033 mmol) at room temperature under N_2 atmosphere. After stirring for 1.5 hours at same temperature, the reaction mixture was purified by prep-HPLC to obtain compound T-128-1 (22 mg, 70%).

ESI-MS m/z : 947 ($M^+/2$)

Preparation of Compound T-128-2 and T-128

T-128-2 and T-128 were synthesized in a way similar method of Example 79.


Compound T-128-2

Yield 78%

ESI-MS m/z : 744 ($M^+/2$)

Compound T-128

5 Yield 52%

ESI-MS m/z : 944 ($M^+/2$)**Example 82: *Preparation of Compound T-129*****10 Preparation of Compound T-129-1**

To a solution of T-124-1 (9.1 mg, 0.0076 mmol) was dissolved in DMSO (0.15 mL) was added Int-TG20 (9.2 mg, 0.0144 mmol), Aniline (3.46 μ L, 0.038 mmol) and TFA (1 drop) at room temperature under N_2 atmosphere. After stirring for 3 days at same temperature, the reaction mixture was purified by prep-HPLC to obtain compound T1-1 (3.9 mg, 28%).

15 ESI-MS m/z : 907 ($M^+/2$)

Preparation of Compound T-129-2, and T-129

T4-2 was synthesized in a way similar method of Example 79.


Compound T-129-2

Yield 66%

ESI-MS m/z : 704 ($M^+/2$).

Compound T-129

5 Yield 92%

ESI-MS m/z : 1808 (M^+).**Example 83: Preparation of Compound DB-15**

10 Preparation of Compound DB-15-1

To a solution of Ethyl bromoacetate (10 g, 59.9 mmol) in Acetone (62.5 mL) was added Sodium azide (9.73 g, 150 mmol) in Water (50 mL) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 1 hour. The product was extracted with MC. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The compound DB-15-1 was used in the next step without further purification. (6.17 g, 80%)

¹H NMR (400 Hz, CDCl₃) δ 4.28-4.22 (m, 2H), 3.85 (s, 2H), 1.30 (t, J = 7.2 Hz, 3H)

Preparation of Compound DB-15-2

DB-15-2 was synthesized in a way similar method of Example 54.

Yield 100%

¹H NMR (400 Hz, CDCl₃) δ 9.87 (s, 1H), 7.43 (s, 1H), 7.41 (d, J = 2.0 Hz, 1H), 7.27 (d, J = 7.6 Hz, 1H), 5.32 (s, 2H), 4.21-4.16 (m, 2H), 3.53 (s, 3H), 1.49 (t, J = 7.2 Hz, 3H)

Preparation of Compound DB-15-3

To a solution of Sodium ethoxide (3.50 mL, 3.50 mmol) in Ethanol (32.0 mL) was added DB-15-2 (1.0 g, 4.76 mmol), DB-15-1 (1.84 g, 14.3 mmol) and ETFA (1.70 mL, 14.3 mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 3 hours. The reaction was quenched by addition of an aqueous NH₄Cl solution, and the mixture was extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The compound Int5-1 was used in the next step without further purification. (1.16 g, 76%)

¹H NMR (400 Hz, CDCl₃) δ 7.54 (d, J = 7.6 Hz, 1H), 7.29 (dd, J = 8.8, 2.0 Hz, 1H), 7.13 (d, J = 8.4 Hz, 1H), 6.86 (s, 1H), 5.26 (s, 2H), 4.39-4.34 (m, 2H), 4.18-4.13 (m, 2H), 3.52 (s, 3H), 1.48 (t, J = 6.8 Hz, 3H), 1.38 (t, J = 7.2 Hz, 3H)

Preparation of Compound DB-15-4

DB-15-4 was synthesized in a way similar method of Example 42.

Yield 65%

¹H NMR (400 Hz, CDCl₃) δ 7.19 (s, 1H), 7.11-7.10 (m, 1H), 7.08 (s, 1H), 5.28 (s, 2H), 4.41-4.35 (m, 2H), 4.16-4.10 (m, 2H), 3.55 (s, 3H), 1.48 (t, J = 7.2 Hz, 3H), 1.40 (t, J = 7.2 Hz, 3H)

Preparation of Compound DB-15-5

DB-15-5 was synthesized in a way similar method of compound Example 57.

Yield 100%

¹H NMR (400 Hz, DMSO) δ 11.34 (s, 1H), 9.05 (s, 1H), 6.98 (d, J = 30.8 Hz, 1H), 6.82 (s, 2H), 4.28-4.27 (m, 2H), 3.99-3.98 (m, 2H), 3.57 (s, 1H), 1.34-1.31 (m, 6H)

Preparation of Compound DB-15-6

To a solution of DB-15-5 (139 mg, 0.558 mmol) in THF/H₂O(2.7 / 1.0 mL) was added Lithium hydroxide monohydrate (117 mg, 2.79 mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at 50 °C for 7 hours. The reaction was quenched by addition of 2 M HCl solution, and the mixture was extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The compound DB-15-6 was used in the next step without further purification. (123 mg, 100%)

¹H NMR (400 Hz, DMSO) δ 11.22 (s, 1H), 8.98 (s, 1H), 7.02 (s, 1H), 6.89 (s, 1H), 6.81 (s, 1H), 4.04-3.98 (m, 2H), 1.35 (t, J = 6.4 Hz, 3H)

Preparation of Compound DB-15-7

DB-15-7 was synthesized in a way similar method of Example 47.

Yield 75%

¹H NMR (400 Hz, CDCl₃) δ 8.64 (s, 1H), 7.44-7.40 (m, 5H), 7.14 (s, 1H), 6.99 (s, 1H), 6.90 (s, 1H), 5.97 (s, 1H), 5.29 (s, 1H), 4.16-4.11 (m, 2H), 1.25 (t, J = 3.6 Hz, 3H)

Preparation of Compound DB-15-8

DB-15-8 was synthesized in a way similar to the preparation method of Example 60.

Yield 77%


¹H NMR (400 Hz, CDCl₃) δ 7.45-7.34 (m, 5H), 7.21 (s, 1H), 7.14 (s, 1H), 7.07 (s, 1H), 5.61-5.56 (m, 1H), 5.42-5.19 (m, 6H), 5.07-5.03 (m, 1H), 4.92 (d, J = 7.6 Hz, 1H), 4.54 (d, J = 7.6 Hz, 1H), 4.11-4.09 (m, 1H), 3.96-3.94 (m, 1H), 3.78 (s, 3H), 3.75 (s, 1H), 2.17 (s, 3H), 2.09 (s, 3H), 2.03-2.01 (m, 9H), 1.83 (s, 3H), 1.41 (t, J = 7.2 Hz, 3H)

Preparation of Compound DB-15

DB-15 was synthesized in a way similar method of Example 47.

Yield 100%

ESI-MS m/z : 826 (M^+ +1)

Example 84: Preparation of Compound T-130

T-130 was synthesized in a way similar method of Example 79.

Compound T-130-1

5 Yield 28%

ESI-MS m/z : 1818 (M^+)

Compound T-130-2


Yield 84%

ESI-MS m/z : 1411 (M^+).

10 **Compound T-130**

Yield 81%

ESI-MS m/z : 906 ($M^+/2$)

Example 85: Preparation of Compound DB-16**Preparation of Compound DB-16-1**

To a solution of 2-Amino-5-nitropyridine (5.0 g, 35.9 mmol) in Ethanol (72 mL) was added Ethyl bromopyruvate (6.31 mL, 50.3 mmol) under N₂ atmosphere. The reaction mixture was refluxed for 17 hours. After the reaction was completed, the mixture was concentrated under reduced pressure. The residue was filtered and washed with Diethyl ether. The compound DB-16-1 was used in the next step without further purification. (6.28 g, 74%)

¹H NMR (400 Hz, CDCl₃) δ 9.30-9.29 (m, 1H), 8.38 (s, 1H), 8.05 (dd, *J* = 10, 2.4 Hz, 1H), 7.81 (d, *J* = 10 Hz, 1H), 4.53-4.47 (m, 2H), 1.44 (t, *J* = 7.2 Hz, 3H)

EI-MS *m/z* : 236 (*M*⁺+1).

Preparation of Compound DB-16-2

DB-16-2 was synthesized in a way similar to the preparation method of Example 83.

Yield 71%

¹H NMR (400 Hz, CDCl₃) δ 9.76-9.75 (m, 1H), 8.62 (s, 1H), 8.15-8.12 (m, 1H), 7.74 (d, *J* = 10 Hz, 1H)

Preparation of Compound DB-16-3

DB-16-3 was synthesized in a way similar method of Example 64.

Yield 56%

¹H NMR (400 Hz, CDCl₃) δ 9.28-9.27 (m, 1H), 8.37 (s, 1H), 8.05-8.02 (m, 1H), 7.80-7.78 (m, 1H), 7.50-7.48 (m, 2H), 7.39-7.37 (m, 3H), 5.46 (s, 2H)

Preparation of Compound DB-16-4

To a solution of DB-16-3 (100 mg, 0.336 mmol) in anhydrous THF (0.67 mL) was added Tin chloride dihydrate (341 mg, 1.51 mmol) under N₂ atmosphere. The reaction mixture was stirred at 45 °C for 4 hours. The reaction was quenched by addition of 2 N NaOH solution, and the mixture was extracted with EtOAc. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound DB-16-4 (82.3 g, 92%).

ESI-MS m/z : 268 ($M^+ + 1$)

Preparation of Compound DB-16-5

DB-16-5 was synthesized in a way similar method of Example 79.

Yield 33%


ESI-MS m/z : 704 ($M^+ + 1$)

Preparation of Compound DB-16

DB-16 was synthesized in a way similar method of Example 47.

Yield 57%

ESI-MS m/z : 614 ($M^+ + 1$)

Example 86: *Preparation of Compound Int-TG27*

Preparation of Compound Int-TG27-1 to Int-TG27-4

Int-TG27-1 to Int-TG27-4 were synthesized in a way similar method of Example 11.

Compound Int-TG27-1

Yield 70%

- 5 ^1H NMR (400 Hz, CDCl_3) δ 10.33 (s, 1H), 8.55 (d, $J = 2.0$ Hz, 1H), 8.28 (dd, $J = 8.8, 2.4$ Hz, 1H), 7.45-7.35 (m, 5H), 7.17 (d, $J = 8.4$ Hz, 1H), 5.39-5.36 (m, 6H), 4.30-4.25 (m, 1H), 3.72 (s, 3H), 2.09-2.05 (m, 9H).

ESI-MS m/z : 595 ($\text{M}^+ + \text{Na}$).

Compound Int-TG27-2

- 10 Yield 86%

^1H NMR (400 Hz, CDCl_3) δ 7.67 (d, $J = 2.0$ Hz, 1H), 7.61 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.44-7.32 (m, 5H), 7.00 (d, $J = 8.4$ Hz, 1H), 6.05 (s, 1H), 5.41-5.25 (m, 5H), 5.11 (d, $J = 7.2$ Hz, 1H), 4.22 (d, $J = 8.8$ Hz, 1H), 3.77 (s, 3H), 2.11-2.06 (m, 9H).

ESI-MS m/z : 583 ($\text{M}^+ + \text{Na}$).

- 15 Compound Int-TG27-3

Yield 100%

^1H NMR (400 Hz, CDCl_3) δ 7.68 (d, $J = 2.0$ Hz, 1H), 7.63 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.03 (d, $J = 8.8$ Hz, 1H), 5.43-5.29 (m, 3H), 5.14 (d, $J = 7.2$ Hz, 1H), 4.24 (d, $J = 8.8$ Hz, 1H), 3.78 (s, 3H), 2.12-2.07 (m, 9H).

- 20 ESI-MS m/z : 493 ($\text{M}^+ + \text{Na}$).

Compound Int-TG27-4

Yield 80%

- 25 ^1H NMR (400 Hz, CDCl_3) δ 7.06-6.89 (m, 3H), 6.32-6.23 (m, 1H), 5.40-5.27 (m, 3H), 5.05 (d, $J = 7.6$ Hz, 1H), 4.19 (d, $J = 9.2$ Hz, 1H), 3.84-3.46 (m, 17H), 3.39 (t, $J = 5.6$ Hz, 2H), 3.09-3.04 (m, 3H), 2.12-2.06 (m, 9H).

ESI-MS m/z : 685 ($\text{M}^+ + 1$)


Preparation of Compound Int-TG27

To a solution of Int-TG27-4 (70.2 mg, 0.103 mmol) in Methanol/MC (2.5 mL/0.5 mL) was added K_2CO_3 (42.7 mg, 0.309 mmol) at 0 °C under N_2 atmosphere. After stirring for 1.5

hours at same temperature, the reaction mixture was purified by prep-HPLC to obtain compound Int8 (36.7 mg, 64%).

ESI-MS m/z : 559 ($M^+ + 1$)

5 Example 87: *Preparation of Compound T-131*



T-131 was synthesized in a way similar method of Example 84.

Compound T-131-1

Yield 84%

10 ESI-MS m/z : 803 ($M^+ / 2$)

Compound T-131-2

Yield 90%

ESI-MS m/z : 1325 (M^+)


Compound T-131-3

Yield 86%

ESI-MS m/z : 863 ($M^+/2$)

Preparation of compound T-131

- 5 To a solution of compound T-131-3 (5.3 mg, 0.00400 mmol) was dissolved in DMSO (2.0 mL) was added 2-chloro-N-prop-2-ynylacetamide 10 mM in DMSO (0.80 mL, 0.000800 mmol) and CuBr (1.72 mL, 0.012 mmol) at room temperature under N_2 atmosphere. After stirring for 2.5 hours at same temperature, the reaction mixture was purified by prep-HPLC to obtain compound T-131 (5.32 mg, 91%).
- 10 ESI-MS m/z : 1457.22 (M^+)

Example 88: Preparation of Compound L-5

Preparation of compound L-5-1

- 15 A solution of diethylene glycol (10 g, 94.2 mmol) in anhydrous DCM (190 mL) was treated with KOH (42.3 mg, 75.4 mmol), p-TsCl (39.5 g, 0.207 mol) at 0 °C under N_2 atmosphere. The reaction mixture was stirred for 1.5 hours at room temperature. The reaction mixture was extracted with H_2O (100 mL)/ DCM (400 mL). The combined organic layer was dried over anhydrous Na_2SO_4 , filter, and concentrated under reduced pressure to obtain compound L-5-1
- 20 (39 g, 100%).

^1H NMR (400 Hz, $CDCl_3$) δ 7.78 (d, J = 6.8 Hz, 4H), 7.35 (d, J = 8.0 Hz, 4H), 4.10-4.08 (m, 4H), 3.62-3.60 (m, 4H), 2.45 (s, 6H).

Preparation of compound L-5-2

- A solution of compound L-5-1 (39 g, 94.2 mmol) in anhydrous DMF (190 mL) was treated
- 25 with NaN_3 (18.4 g, 0.283 mol) and stirred at 60 °C for overnight. The reaction mixture was extracted with H_2O (250 mL)/ EtOAc (800 mL). The combined organic layer was dried over

anhydrous Na₂SO₄, filter, and concentrated under reduced pressure to obtain compound L-5-2 (13.7 g, 93%).

¹H NMR (400 Hz, CDCl₃) δ 3.72-3.67 (m, 4H), 3.43-3.40 (m, 4H).

Preparation of compound L-5-3

- 5 To a solution of compound L-5-2 (14.7 g, 94.1 mmol) in THF/Et₂O/H₂O (5:1:5) (150 mL) was added dropwise a solution of triphenylphosphine (25.4 g, 96.8 mmol) for 30 minutes at 0 °C. The reaction mixture was stirred at room temperature for overnight. The reaction mixture was concentrated under reduced pressure. The residue was extracted with H₂O/DCM. The combined organic layer was concentrated under reduced pressure and the residue was
- 10 extracted with H₂O/ether. The combined aqueous layer was concentrated under reduced pressure to obtain compound L-5-3 (6.03 g, 53%).

ESI-MS m/z: 131 (M⁺+1).

Preparation of compound L-5-4

- A solution of compound L-5-3 (6.03 g, 46.3 mmol) in 1,4-dioxane/H₂O (4:1) (230 mL) was
- 15 treated with Boc₂O (12.1 g, 55.6 mmol), NaHCO₃ (7.80 g, 92.8 mmol) and stirred at room temperature for 3 hours. The reaction mixture was extracted with H₂O/EtOAc. The combined organic layer was dried over anhydrous Na₂SO₄, filter, and concentrated under reduced pressure. The residue was purified by silica column chromatography to obtain compound L-5-4 (6.7 mg, 63%).

- 20 ¹H NMR (400 Hz, CDCl₃) δ 3.65 (t, *J* = 4.8 Hz, 2H), 3.55 (t, *J* = 4.8 Hz, 2H), 3.39-3.32 (m, 4H), 1.45 (s, 9H);

ESI-MS m/z: 253 (M⁺+Na).


Preparation of compound L-5

- To a solution of compound L-5-4 (6.7 g, 29.1 mmol) in THF (50 mL) was added dropwise
- 25 slowly a solution of triphenylphosphine (7.60 g, 29.1 mmol) in THF (20 mL). The reaction mixture was stirred for 1 hour at room temperature. H₂O (120 mL) was added to the reaction mixture at room temperature and stirred for overnight. The reaction mixture was concentrated under reduced pressure. The residue was extracted with H₂O/ether. The combined aqueous layer was concentrated under reduced pressure to obtain compound L-5 (5.1 g, 86%).

- 30 ¹H NMR (400 Hz, CDCl₃) δ 4.95 (s, 1H), 3.52-3.47 (m, 4H), 3.34-3.31 (m, 2H), 2.87 (t, *J* = 5.2 Hz, 2H), 1.45 (s, 9H);

ESI-MS m/z : 205 ($M^+ + 1$).

Example 89: Preparation of Compound L-6



5 Preparation of compound L-6-1

A solution of dimethylene glycol (10.7 g, 10.1 mmol) in anhydrous THF (150 mL) was treated with *t*-BuOK (5.71 mL, 50.8 mmol), propargyl bromide (80% w/w) (7.49 mL, 50.3 mmol) at 0 °C under N₂ atmosphere. The reaction mixture was allowed to warm up to room temperature and stirred for overnight. The reaction mixture was filtered through CELITE®, and the CELITE® plug was washed with DCM (300 mL). The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound L-6-1 (5.38 g, 74%) as yellow oil.

¹H NMR (400 Hz, CDCl₃) δ 4.21 (d, J = 2.4 Hz, 2H), 3.74-3.70 (m, 6H), 3.62-3.60 (m, 2H), 2.45 (t, J = 2.4 Hz, 1H).

15 Preparation of compound L-6-2

The air in the three-necked round-bottom flask was replaced with N₂ 3-4 times. A solution of oxalyl chloride (595 μ L, 6.94 mmol) in anhydrous DCM (3 mL) was added to the three-necked round-bottom flask. A solution of DMSO (985 μ L, 13.9 mmol) in anhydrous DCM (3 mL) was added dropwise slowly to the reaction mixture at -78 °C. After 30 minutes, a solution of compound L-6-1 (500 mg, 3.47 mmol) in anhydrous DCM (12 mL) was added dropwise slowly to the reaction mixture at -78 °C. After 1.5 hours, trimethylamine (2.9 mL, 20.8 mmol) was added dropwise at -78 °C. The reaction mixture was stirred for 15 minutes at -78 °C then slowly allowed to warm to 0 °C, and stirred for 45 minutes. After the reaction was completed, the reaction mixture was extracted with H₂O (30 mL) and washed with saturated NH₄Cl solution (30 mL). The combined organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica column chromatography to obtain compound L-6-2 (191 mg, 39%) as yellow oil.

^1H NMR (400 Hz, CDCl_3) δ 9.74 (d, J = 0.8 Hz, 1H), 4.22 (d, J = 2.4 Hz, 2H), 4.17 (d, J = 0.8 Hz, 2H), 3.79-3.74 (m, 4H), 2.45 (t, J = 2.8 Hz, 1H).

Preparation of compound L-6-3

A solution of compound *bLD-Int1-2* (70 mg, 0.490 mmol), compound L-5 (50 mg, 0.245 mmol) in anhydrous DCM (1.3 mL) was stirred at 0 °C for 10 minutes under N_2 atmosphere. To the reaction mixture was added $\text{NaBH}(\text{OAc})_3$ (104 mg, 0.490 mmol) at 0 °C under N_2 atmosphere. The reaction mixture was stirred at room temperature for 2 hours. After compound L-6-2 was disappeared, the reaction mixture was extracted with H_2O (100 mL)/DCM (100 mL). The combined organic layer was dried over anhydrous Na_2SO_4 , filter, and concentrated under reduced pressure. The residue was purified by silica column chromatography to obtain compound L-6-3 (46 mg, 41%) as yellow oil.

^1H NMR (400 Hz, CDCl_3) δ 5.25 (s, 1H), 4.20 (s, 4H), 3.67-3.49 (m, 16H), 3.29 (s, 2H), 2.81-2.78 (m, 4H), 2.44 (m, 2H), 1.44 (s, 9H);
ESI-MS m/z : 457 ($\text{M}^+ + 1$).

Preparation of compound L-6-4

A compound L-6-3 (45 mg, 0.986 mmol) was dissolved in dry DCM (1 mL) at 0 °C. To the reaction mixture was added 4M HCl in dioxane solution (0.422 mL, 1.69 mmol), and stirred for 30 minutes at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 4 hours. After reaction was completed, the reaction mixture was concentrated under reduced pressure to obtain compound L-6-4 (41 mg, 100%) as yellow oil.

^1H NMR (400 Hz, DMSO) δ 4.18 (d, J = 5.2 Hz, 4H), 4.08-4.00 (m, 6H), 3.67-3.64 (m, 16H), 3.30 (s, 2H), 2.49 (t, J = 2.4 Hz, 2H);
ESI-MS m/z : 357 ($\text{M}^+ + 1$).


Preparation of compound L-6

A compound L-6-4 (38.7 mg, 0.0986 mmol) was dissolved in sat. NaHCO_3 solution (329 μL) at 0 °C and stirred for 30 minutes at 0 °C. To the reaction mixture was added N-methoxycarbonylmaleimide (16.8 mg, 0.108 mmol), and then stirred at 0 °C for 3 hours. After completion of the reaction as indicated by UPLC-MS, the reaction mixture was extracted with EtOAc (10 mL)/ H_2O (10 mL). The combined organic layer was dried over anhydrous Na_2SO_4 and filtered, and concentrated under reduced pressure. The residue was purified by silica column chromatography to obtain compound L-6 (19.4 mg, 45%) as yellow oil.

^1H NMR (400 Hz, CDCl_3) δ 6.71 (s, 2H), 4.19 (d, $J = 4.8$ Hz, 4H), 3.68-3.53 (m, 18H), 2.77-2.74 (m, 6H), 2.44 (t, $J = 2.4$ Hz, 2H);

ESI-MS m/z : 437 ($\text{M}^+ + 1$).

5 **Example 90: Preparation of Compound L-7**



Preparation of compound L-7-1

A solution of tri-ethylene glycol (5.0 g, 33.3 mmol) in anhydrous DCM (150 mL) was treated with KI (553 mg, 3.33 mmol), Ag_2O (9.26 g, 39.9 mmol), p-TsCl (6.35 g, 33.3 mmol) under N_2 atmosphere and stirred overnight at room temperature. The reaction mixture was filtered through CELITE®, and the CELITE® plug was washed with DCM (100mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica column chromatography to obtain compound L-7-1 (7.49 g, 74%) as colorless oil.

^1H NMR (400 Hz, CDCl_3) δ 7.81 (d, $J = 7.6$ Hz, 2H), 7.34 (d, $J = 8.0$ Hz, 2H), 4.17 (m, 2H), 3.72-3.70 (m, 4H), 3.62-3.58 (m, 6H), 2.45 (s, 3H).

Preparation of compound L-7-2

A solution of compound L-7-1 (7.49 g, 24.6 mmol) in water/acetone (1:1) (43 mL) was treated with NaN_3 (2.40 g, 36.9 mmol), NaI (369 mg, 24.6 mmol) at room temperature under N_2 atmosphere and stirred for 23 hours at 60 °C. The reaction mixture was concentrated under reduced pressure. The residue was extracted with EtOAc. The combined organic layer was dried over anhydrous MgSO_4 , filter, and concentrated under reduced pressure to obtain compound L-1-2 (4.31 g, 100%) as yellow oil.

^1H NMR (400 Hz, CDCl_3) δ 3.74-3.60 (m, 10H), 3.40 (m, 2H), 2.21 (br s, 1H).

Preparation of compound L-7-3

A solution of L-7-2 (4.31 g, 24.6 mmol) in EtOH (123 mL) was treated with 5% Pd/C (55% wetted) (5.11 g, 0.984 mmol) under H_2 atmosphere and stirred at room temperature for 3 hours. The mixture was filtered through CELITE® to remove Pd/C, and concentrated under reduced pressure to produce compound L-7-3 (3.67 mg, 100%) as yellow oil.

^1H NMR (400 Hz, CDCl_3) δ 3.74-3.62 (m, 10H), 2.88 (m, 2H)

Preparation of compound L-7-4

To a solution of compound L-7-3 (3.67 g, 24.6 mmol) in ethanol (61 ml) was added the solution of di-*t*-butyl decarbonate (5.37 g, 24.6 mmol) in ethanol (61 ml) at 0 °C. The reaction mixture was stirred at room temperature for overnight. The reaction mixture was concentrated under reduced pressure to obtain compound L-7-4 (4.51 g, 74%) as yellow oil.

¹H NMR (400 MHz, DMSO-*d*₆) δ 5.30 (s, 1H), 3.76-3.56 (m, 10H), 3.38-3.31 (m, 2H), 2.35 (s, 1H), 1.45 (s, 9H)


ESI-MS *m/z*: 272 (M⁺+Na).

Preparation of compound L-7

To a solution of compound L-7-4 (3.5 g, 14.0 mmol), DMAP (171 mg, 1.4 mmol), and TEA (2.5 ml, 18.25 mmol) in DCM (35 ml) was added methanesulfonyl chloride (1.3 ml, 16.85 mmol) at room temperature. The reaction mixture was stirred at room temperature for overnight. The reaction mixture was evaporated. The crude mixture was diluted with NH₄Cl solution and extracted with EA. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to obtain compound L-7 (4.45 g, 99%) as yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 4.94 (s, 1H), 4.46-4.40 (m, 2H), 3.79-3.77 (m, 2H), 3.67-3.63 (m, 4H), 3.54 (t, *J* = 5.2 Hz, 2H), 3.33-3.31 (m, 2H), 3.08 (s, 3H), 1.45 (s, 9H);

ESI-MS *m/z*: 350 (M⁺+Na).

Example 91: Preparation of Compound L-8

Preparation of compound L-8-1

To a solution of tetraethylene glycol (15.28 g, 78.68 mmol) in THF (16 ml) was added 2M NaOH solution (3.9 ml, 7.87 mmol) at 0 °C, and then stirred at 0 °C for 1 hour. The solution of *p*-toluenesulfonyl chloride (1.50 g, 7.87 mmol) in THF (10 ml) was added dropwise to reaction mixture at 0 °C, and then stirred at 0 °C for 3 hours. The reaction mixture was

evaporated. The crude mixture was purified by column chromatography (EtOAc:Hex = 2:1) to obtain compound L-8-1 (2.11 g, 77 %) as colorless oil.

^1H NMR (400 MHz, CDCl_3) δ 7.81 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 7.6 Hz, 2H), 4.17 (t, J = 5.6 Hz, 2H), 3.71-3.61 (m, 14H), 2.45 (s, 3H);

5 ESI-MS m/z : 349 ($\text{M}^+ + 1$).

Preparation of compound L-8-2

To a solution of compound L-8-1 (2.11 g, 6.07 mmol) in DMF (14 mL) was added sodium azide (1.89 g, 29.1 mmol) at room temperature under N_2 atmosphere. The reaction mixture was stirred at 70 °C for 2 hours. The reaction mixture was filtered and washed with EtOAc
10 / H_2O . the filtrate was diluted with H_2O and extracted with EtOAc. The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure to obtain compound L-8-2 (1.35 g, quant) as yellow oil.

^1H NMR (400 MHz, CDCl_3) δ 3.75-3.73 (m, 2H), 3.71-3.66 (m, 10H), 3.63-3.61 (m, 2H), 3.41 (t, J = 5.6 Hz, 2H), 2.47 (brs, 1H);

15 ESI-MS m/z : 220 ($\text{M}^+ + 1$).

Preparation of compound L-8-3

To a solution of sodium hydride (60%, 18.2 mg, 0.46 mmol) in THF (1.2 mL) was added the solution of compound L-8-2 (100 mg, 0.46 mmol) in anhydrous THF (1.0 mL) at 0 °C under N_2 atmosphere and then stirred at 0 °C for 30 min. The solution of compound L-7 (149 mg,
20 0.46 mmol) in anhydrous THF (1.0 mL) was added to reaction mixture at room temperature. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with H_2O and extracted with DCM. The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography (EtOAc) to obtain compound L-8-3 (124 mg, 60%) as colorless oil.

25 ^1H NMR (400 MHz, CDCl_3) δ 5.04 (s, 1H), 3.69-3.53 (m, 24H), 3.39 (t, J = 5.6 Hz, 2H), 3.34-3.30 (m, 2H), 1.44 (s, 9H);

ESI-MS m/z : 451 ($\text{M}^+ + 1$).


Preparation of compound L-8

To a solution of compound L-8-3 (200 mg, 0.44 mmol) in THF/Ether/ H_2O (2:1:1) (1.2 mL) was added TPP (128 mg, 0.49 mmol) and then stirred at room temperature for overnight. 1N
30 HCl solution was added to quench the reaction mixture (pH~3). The crude mixture was diluted with H_2O and extracted with DCM. The aqueous layer was concentrated under reduced pressure to obtain compound L-8 (186 mg, 91%) as colorless oil.

^1H NMR (400 Hz, CDCl_3) δ 8.31 (brs, 1H), 7.94 (brs, 2H), 3.97-3.57 (m, 24H), 3.32 (t, J = 4.8 Hz, 2H), 3.24-3.18 (m, 2H), 1.44 (s, 9H)

ESI-MS m/z : 425 (M^++1).

5 **Example 92: Preparation of Compound L-9**



Compound L-9 was synthesized via a similar method of Example 89.

Compound L-9-1

Yield 38%

10 ^1H NMR (400 MHz, CDCl_3) δ 5.05 (br s, 1H), 4.20 (d, J = 2.4 Hz, 4H), 3.65-3.61 (m, 36H), 3.31 (m, 2H), 2.78 (m, 6H), 2.44 (m, 2H), 1.44 (s, 9H);

ESI-MS m/z : 677 (M^++1).

Compound L-9-2

Yield 100%

15 ^1H NMR (400 MHz, CDCl_3) δ 8.07 (br s, 2H), 4.18 (d, J = 2.4 Hz, 4H), 4.07-3.95 (m, 6H), 3.73-3.63 (m, 34H), 3.18 (s, 2H), 2.48 (s, 2H);


ESI-MS m/z : 577 (M^++1).

Compound L-9

Yield 57%

20 ^1H NMR (400 MHz, CDCl_3) δ 6.69 (s, 2H), 4.18 (d, J = 2.4 Hz, 4H), 3.65-3.58 (m, 38H), 2.77-2.76 (m, 6H), 2.43 (s, 2H);

ESI-MS m/z : 657 (M^++1).

Example 93: Preparation of Compound T-132

A solution of compound T-131-2 (5 mg, 0.03077 mmol), compound L-6 (1.23 mg, 0.00283 mmol) in DMSO (4.0 mL) was treated with CuBr (0.81 mg, 0.00566 mmol) at room temperature under N₂ nitrogen atmosphere and stirred for 30 minutes. The reaction mixture was purified by prep-HPLC to obtain compound *ITC03-423* (2.2 mg, 34%) as white solid.


ESI-MS m/z: 1544(M⁺/2), 1029(M⁺/3).

Table 6: Compounds synthesized via a similar synthetic route as described in Example 93.

Compounds	Structure	Analytical Data
T-133		Yield 59% ESI-MS m/z: 1467(M ⁺ /2), 979(M ⁺ /3)
T-134		Yield 94% ESI-MS m/z: 1465(M ⁺ /2), 977(M ⁺ /3)

T-135		Yield 41% ESI-MS m/z: 1654(M ⁺ /2), 1103(M ⁺ /3).

Example 94: Preparation of Compound T-18



Preparation of Compound T-18-1

- 5 To a solution of compound D-9 (48.7mg, 0.029 mmol) and compound Int-TG12 (29.5 mg, 0.032 mmol) in DMF (1.1 mL) at room temperature under N₂ atmosphere was treated with DIPEA (10.1 μ L, 0.058 mmol) and stirred for 3.5 hours. The mixture was separated and purified by Prep-HPLC to obtain compound T-18-1 (62 mg, 85 %).

ESI-MS m/z: 1256.78 (M⁺/2), 2512.16 (M⁺).

- 10 **Preparation of Compound T-18-2**

To a solution of compound T-18-1 (62 mg, 0.025 mmol) in MeOH/H₂O (1/1, 4.0 mL) at -5 °C under N₂ atmosphere was treated with LiOH H₂O (7.3 mg, 0.17 mmol) and stirred for 2.5 hours. The reaction mixture was adjusted pH 4 using 2N HCl. The mixture was separated and purified by Prep-HPLC to obtain compound T-18-2 (35.8 mg, 72 %).


ESI-MS m/z: 1018.16 ($M^+/2$), 2036.38 (M^+).

Preparation of Compound T-18

To a solution of compound T-18-2 (8.5mg, 0.0041 mmol), IAA PEG3 (2.0 mg, 0.00566 mmol) in DMSO (0.1 mL) at room temperature under nitrogen atmosphere was treated with
 5 CuBr (1.8 mg, 0.013 mmol) and stirred for 1 hour. The reaction mixture was purified by Prep-HPLC to obtain compound T-18 (5.9 mg, 59%).

ESI-MS m/z: 1231.87 ($M^+/2$), 2464.14 (M^++1).

Example 95: Preparation of Compound Mono-6




Mono-6

Compound Mono-6 was obtained by performing a reaction in a similar method as described in Example 19.

Yield 99%

ESI-MS m/z: 423.19 (M^++1)

Example 96: Preparation of Compound Int-TG29



Int-TG29

Compound Int-TG29 was obtained by performing a reaction in a similar method as described in Example 12.


Yield 85.3%

ESI-MS m/z: 745.24 ($M^+ + 1$)

^1H NMR (400 MHz, CDCl_3) δ 5.05 (br s, 1H), 4.20 (d, $J = 2.4$ Hz, 4H), 3.65-3.61 (m, 36H), 3.31 (m, 2H), 2.78 (m, 6H), 2.44 (m, 2H), 1.44 (s, 9H);

ESI-MS m/z : 677 ($M^+ + 1$).

Example 97: *Preparation of Compound T-19*



5 Preparation of Compound T-19-1

To a solution of compound L-1-3 (39 mg, 0.108 mmol), compound Mono-6 (100 mg, 0.237 mmol) in DMF (5.0 mL) at room temperature under N_2 atmosphere was treated with K_2CO_3 (33 mg, 0.237 mmol) was stirred for 2.5 hours. The reaction mixture was extracted with EA (100 mL $\times$ 2), H_2O (100 mL). The organic layer was dry over anhydrous Na_2SO_4 , filtered

10 and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound T-19-1 (99.6 mg, 89 %).

ESI-MS m/z : 1045.13 (M^+), 1068.25 ($M^+ + 23$)

Preparation of Compound T-19-2

To a solution of compound T-19-1 (75 mg, 0.072 mmol), imidazole (236.34 mg, 0.093 mmol) in dry ACN (3.0 mL) at 0 °C under N_2 atmosphere was treated with Cs_2CO_3 (28 mg, 0.086

15

mmol) was stirred for 5.5 hours. The reaction mixture was extracted with EA (100 mL × 2), H₂O (100 mL). The organic layer was dry over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound T-19-2 (60.3 mg, 77 %).

5 ESI-MS m/z: 1093.23 (M⁺), 1116.25 (M⁺+23)

Preparation of Compound T-19-3

To a solution of compound T-19-2 (55 mg, 0.05 mmol), Methyltriflate (7.4 ul, 0.065 mmol) in ether (3.0 mL) at 0 °C under N₂ atmosphere was stirred for 20 min. The solid was filtered and washed with ether and then concentrated under reduced pressure to obtain compound T-19-3 (43.5mg, 98%).

10

ESI-MS m/z: 1108.13 (M⁺).

Preparation of Compound T-19-4

To a solution of compound T-19-3 (43.5 mg, 0.049mmol), Int-TG29 (44.2 mg 0.059 mmol) in dry DCM (0.5 mL) at room temperature under N₂ atmosphere was treated with 2,6-lutidine (11.5 ul, 0.099 mmol) was stirred for 3 hours. The reaction mixture was extracted with EA (100 mL × 2), H₂O (50 mL). The organic layer was dry over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound T-19-4 (58.8 mg, 66 %).

15

ESI-MS m/z: 1770.15 (M⁺+1), 1792.2 (M⁺+23)

20 Preparation of Compound T-19-5

To a solution of compound T-19-4 (24.3 mg, 0.022 mmol) in THF / H₂O (4/1, 0.5 ml) was treated with Zn (29 mg, 0.445 mmol), NH₄Cl (47.5 mg, 0.889 mmol) at room temperature under N₂ atmosphere and stirred for 7 hours. The reaction mixture was filtered through CELITE®, and then concentrated under reduced pressure to obtain compound T-19-5 (22 mg, 94%).

25

ESI-MS m/z: 1710.35 (M⁺), 1732.22 (M⁺+23)

Preparation of Compound T-19-6

To a solution of compound T-19-5 (22 mg, 0.013 mmol), compound Int-TG3 (25.1 mg, 0.039 mmol X1.3) in anhydrous THF (0.2 mL) at room temperature under N₂ atmosphere was treated with HOBt (1.74 mg, 0.013 mmol X2) and stirred for 40 hours. The reaction mixture was extracted with EA/H₂O. The organic layer was dried over anhydrous Na₂SO₄, filtered,

30

concentrated under reduced pressure. The reaction mixture was purified by prep TLC to obtain compound T-19-6 (20.8 mg, 67%).

ESI-MS m/z: 1322.29 ($M^+/2$).

Preparation of Compound T-19-7

- 5 To a solution of compound T-19-6 (20.8 mg, 0.008 mmol) in ACN / H₂O (1/1, 0.8 ml) at 0 °C under N₂ atmosphere was dropwised with TFA (30 ul, 0.394 mmol) and stirred for 1 hour.

The reaction mixture was extracted with EA/H₂O. The organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure. The reaction mixture was purified by prep TLC to obtain compound T-19-7 (16 mg, 84%).

- 10 ESI-MS m/z: 1207.46 ($M^+/2$) 1157.16 ($(M^+-Boc)/2$).

Preparation of Compound T-19-8

To a solution of compound T-19-7 (16 mg, 0.0066 mmol) in dry DCM (0.2 ml) at 0°C under N₂ atmosphere was treated with Dess Martin periodinane (7.0 mg, 0.0166 mmol) and stirred for 2 hours at room temperature. The reaction mixture was extracted with DCM (10 mL × 2),

- 15 H₂O (3 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure to obtain compound T-19-8 (15.8mg, 99%).

ESI-MS m/z: 1206.22 ($M^+/2$), 2433.78 (M^++23), 1156.34 ($(M^+-Boc)/2$).

Preparation of Compound T-19-9

- 20 To a solution of compound T-19-8 (15.8 mg, 0.0065 mmol) in MeOH/H₂O/THF (1/1/1, 1.0 mL) at -5 °C under N₂ atmosphere was treated with LiOH H₂O (4.1 mg, 0.0983 mmol) and stirred for 2.5 hours. The reaction mixture was adjusted pH 4 using 2N HCl. The mixture was separated and purified by Prep-HPLC to obtain compound T-19-9 (4.6 mg, 35 %).

ESI-MS m/z: 995.07 ($M^+/2$), 1990.26 (M^++1).

Preparation of Compound T-19-10

- 25 To a solution of compound T-19-9 (6.6 mg, 0.0033 mmol) in dry DCM (0.3 mL) at 0 °C under N₂ atmosphere was treated with TFA (80 ul) and stirred for 1 hour. The mixture was concentrated under reduced pressure and freeze dried to obtain compound T-19-10 (7.3 mg, quant).

ESI-MS m/z: 945.51 ($M^+/2$), 1889.64 (M^+).



Preparation of Compound T-19


To a solution of compound T-19-10 (7.3 mg, 0.0039 mmol), 3-(Maleimido)propionic acid (1.3 mg, 0.0046 mmol) in dry DMF (0.2 mL) at 0 °C under N₂ atmosphere was treated with DIPEA (1.7 ul, 0.0096 mmol) and stirred for 6.5 hours at room temperature. The mixture was

5 separated and purified by Prep-HPLC to obtain compound T-19 (1.8 mg, 60 %).

ESI-MS m/z: 1021.19 (M⁺/2)

Table 7: Compounds synthesized via a similar synthetic route as described in Example 94.

Compounds	Structure	Analytical Data
T-20		Yield 52% ESI-MS m/z: 1143(M/2)
T-21		Yield 67% ESI-MS m/z: 1110(M2)

Example 98: Preparation of Compound L-10**Preparation of Compound L-10-1 to L-10-4**

Compounds L-10-1 to L-10-4 were synthesized via a similar synthetic route as described in Example 3.

Compound L-10-1

Yield 73%

^1H NMR (400 MHz, CDCl_3) δ 4.21 (d, $J = 2.4$ Hz, 2H), 3.76 - 3.65 (m, 10H), 3.64 - 3.59 (m, 2H), 2.44 (t, $J = 2.4$ Hz, 1H)

Compound L-10-2

^1H NMR (400 MHz, CDCl_3) δ 7.79 (d, $J = 7.2$ Hz, 2H), 7.33 (d, $J = 7.6$ Hz, 2H), 4.20 - 4.12 (m, 4H), 3.68 - 3.58 (m, 10H), 2.44 (s, 3H), 2.42 (t, $J = 2.4$ Hz, 1H)

Compound L-10-3

Yield 73%

^1H NMR (400 MHz, CDCl_3) δ 4.19 (d, $J = 2.0$ Hz, 2H), 3.69 - 3.56 (m, 10H), 3.38 (m, 2H), 2.42 (t, $J = 2.4$ Hz, 1H)

ESI-MS m/z : 236 ($\text{M}^+ + \text{Na}$).

Compound L-10-4

Yield 85%

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 4.14 (d, $J = 1.6$ Hz, 2H), 3.62 - 3.50 (m, 10H), 2.97 - 2.93 (m, 2H), 2.50 (m, 1H)


Preparation of Compound L-10

To a solution of compound L-10-4 (172mg, 0.92mmol) in anhydrous THF (3.0 mL) at room temperature under N_2 atmosphere was treated with DIPEA (240 μL , 1.84mmol), N-Succinimidyl Bromoacetate (260 mg, 1.10 mmol) and stirred for 1 hour. The reaction was extracted with EA (40 mL $\times$ 2), H_2O (20 mL). The organic layer was dried over Na_2SO_4 ,

filtered and concentrated under reduced pressure. The residue was purified by column chromatography (only EA to 5% MeOH/EA) to obtain compound L-10 (228 mg, 80 %) as white solid.

^1H NMR (400 MHz, CDCl_3) δ 6.95 (brs, 1H), 4.21 (d, J = 2.0 Hz, 2H), 3.39(s, 2H), 3.75 – 3.62 (m, 8H), 3.60 (t, J = 5.6 Hz, 2H), 3.50 (t, J = 5.2 Hz, 2H), 2.44 (t, J = 2.4 Hz, 1H)
ESI-MS m/z : 309 ($\text{M}^+ + 1$).


Example 99: Preparation of Compound T-136



To a solution of compound (5.0 mg, 0.0038 mmol) synthesized in a way similar method of Example 57, and L-9 (1.74 mg, 0.056 mmol) in DMSO (1.0 mL) at room temperature under N_2 nitrogen atmosphere was treated with CuBr (1.62 mg, 0.011 mmol) and stirred for 40 minutes. The reaction mixture was purified by Prep-HPLC to obtain compound T-136 (5.76 mg, 94%).


ESI-MS m/z : 1634 ($\text{M}^+ + 1$).

Example 100: Preparation of Compound T-137



Compound T-137 was synthesized via a similar synthetic route as described in Example 99 (11.7mg, 92.6%).

ESI-MS m/z : 1681 ($\text{M}^+ + 1$).

Example 101: *Preparation of Compound Int-3***Preparation of compound Int-3-1**


- 5 To a solution of 3-(2-Thienyl)-L-alanine (150mg, 0.87mmol) in pyridine (0.85ml) at r.t. under N₂ atmosphere was treated with acetic anhydride (0.5ml) and heated to 90 °C and stirred for overnight. When the reaction was completed, the reaction mixture was concentrated under reduced pressure and then diluted with H₂O (6mL) and diethyl ether (10ml) and 1N HCl (4ml). The organic layer was dried over anhydrous Na₂SO₄, filtered and
- 10 concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-3-1 (120m g, 65%).

¹H NMR (400 Hz, CDCl₃) δ 7.15 (d, *J* = 4.8 Hz, 1H), 6.92 (ddd, *J* = 5.6-3.6 Hz, 1H), 6.77 (d, *J* = 3.2 Hz, 1H), 6.27(broad, 1H), 4.82 (ddd, *J* = 6.8-5.6 Hz, 1H), 3.46-3.32 (DDDd, *J* = 30-0.8 Hz, 2H), 2.23 (s, 3H), 2.20 (s, 3H).

15 Preparation of compound Int-3

To a solution of Int-3-1 (80mg, 0.37mmol) in EtOH (8ml) at r.t. under N₂ atmosphere was treated with 6M HCl (8ml) and heated to 90 °C for 3hours. When the reaction was completed, the reaction mixture was concentrated under reduced pressure. Producing compound Int-3 (70mg, 89%) which was used without further purification.

- 20 ¹H NMR (400 Hz, DMSO-d₆) δ 8.39 (broad, 2H), 7.46-7.42 (m, 1H), 7.02-6.99 (m, 2H), 4.37 (broad, 1H), 3.48-3.42(m, 2H), 2.21(s, 3H).

Example 102: Preparation of Compound Int-4**Preparation of compound Int-4-1**

To a solution of L-isoleucine (5.0 g, 38.12 mmol) and NaOH (3.1 g, 76.23 mmol) in H₂O (40 ml) was added benzyl chloroformate (6.5 ml, 45.74 mmol) dropwise at 0 °C. The reaction mixture was stirred at room temperature for 2 hours, the reaction was quenched by addition of 1N HCl solution (pH~3). And then diluted with H₂O (50 ml) and extracted with EA (100 ml × 3). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (EA : Hex = 1 : 5) to obtain compound Int-4-1 (8.1 g, 80%) as brown liquid.

¹H NMR (400 MHz, CDCl₃) δ 7.37 - 7.34 (m, 5H), 5.24 (d, *J* = 8.0 Hz, 1H), 5.12 (s, 2H), 4.41 - 4.38 (m, 1H), 1.96 (brs, 1H), 1.52 - 1.42 (m, 1H), 1.26 - 1.15 (m, 1H), 0.99 - 0.92 (m, 6H).

ESI-MS *m/z*: 266 (*M*⁺+1).

Preparation of compound Int-4-2

To a solution of compound Int-4-1 (1.0 g, 3.77 mmol) in THF (5.4 mL) was added the solution of CDI (672 mg, 4.15 mmol) in THF (3.1 ml) at 0 °C under N₂ atmosphere. Compound Int-2-1 and CDI mixture was stirred at room temperature for 2 hours and then cooled to -78 °C. 2.5 M *n*-butyllithium solution (in Hex, 4.5ml, 11.31 mmol) was added THF (6.7 ml) at -78 °C and then diisopropylamine (1.6 ml, 11.31 mmol) was added dropwise to *n*-butyllithium solution. Lithium diisopropylamide (LDA) solution was stirred at -78 °C for 40 min and then *t*-butyl acetate was added to LDA solution at -78 °C. The LDA and *t*-butyl acetate mixture was stirred at -78 °C for 1 hour and then added compound Int-4-1 and CDI mixture at -78 °C. The reaction mixture was stirred at -78 °C for 3 hours. The reaction mixture was quenched H₂O (20 mL) and extracted with EA (20 mL × 3). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The

residue was purified by column chromatography (EA : Hex = 1 : 10) to obtain compound Int-4-2 (0.90 g, 66%) as brown liquid.

^1H NMR (400 MHz, CDCl_3) δ 7.36 - 7.26 (m, 5H), 5.34 (d, J = 8.4 Hz, 1H), 5.11 (s, 2H), 4.48 - 4.44 (m, 1H), 3.45 (d, J = 3.2 Hz, 2H), 2.02 - 1.95 (m, 1H), 1.46 (s, 9H), 1.36 - 1.26 (m, 1H), 1.12 - 0.88 (m, 7H).

ESI-MS m/z : 386 ($\text{M}^+ + \text{Na}$).

Preparation of compound Int-4-3

To a solution of compound Int-4-2 (3.5 g, 9.60 mmol) in MeOH (19ml) was added NaBH_4 (726 mg, 19.20 mmol) at -78 °C under N_2 atmosphere. The reaction mixture was stirred at -78 °C for 4 hours. The reaction mixture was diluted with H_2O (50ml) and extracted with EA (50ml $\times$ 3). The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography (EA : Hex = 1 : 5) to obtain compound Int-4-3 (3.3 g, 94%) as yellow oil.

^1H NMR (400 MHz, CDCl_3) δ 7.51 - 7.31 (m, 5H), 5.11 (s, 2H), 4.64 (d, J = 10.0 Hz, 1H), 4.00 - 3.94 (m, 1H), 3.65 - 3.60 (m, 1H), 3.33 (d, J = 4.4 Hz, 1H), 2.53 - 2.48 (m, 1H), 2.41 - 2.35 (m, 1H), 1.88 - 1.82 (m, 1H), 1.62 - 1.58 (m, 1H), 1.46 (s, 9H), 1.04 - 0.85 (m, 6H).

ESI-MS m/z : 366 ($\text{M}^+ + 1$).

Preparation of compound Int-4-4

To a solution of compound Int-4-3 (633 mg, 1.73 mmol) in THF (7ml) was added lithium bis(trimethylsilyl)amide solution (1.0M in THF, 4.3 ml, 4.33 mmol) at -78 °C under N_2 atmosphere. The reaction mixture was stirred at -78 °C for 10 min and then hexamethylphosphoramide (0.9 ml, 5.19 mmol) was added to the reaction mixture. The reaction mixture was warm to -20 °C and then methyl trifluoromethanesulfonate (0.76 ml, 6.92 mmol) was added dropwise to the reaction mixture. The reaction mixture was stirred at -20 °C for 1 hour. The reaction mixture was quenched H_2O (10 ml) at 0 °C. The crude mixture was diluted with NaCl solution (10 ml) and extracted with EA (20 ml $\times$ 3). The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography (EA : Hex = 1 : 10) to obtain compound Int-4-4 (555 mg, 82%) as light yellow oil.

^1H NMR (400 MHz, CDCl_3) δ 7.35 - 7.26 (m, 5H), 5.18 - 5.08 (m, 2H), 4.15 - 4.00 (m, 1H), 3.93 - 3.84 (m, 1H), 3.40 - 3.29 (m, 3H), 2.79 - 2.78 (m, 3H), 2.47 - 2.28 (m, 2H), 1.73 (brs, 1H), 1.54 - 1.45 (m, 10H), 1.13 - 1.00 (m, 1H), 0.99 - 0.81 (m, 6H).

ESI-MS m/z : 394 ($\text{M}^+ + 1$).

Preparation of compound Int-4-5

To a solution of compound Int-4-4 (537 mg, 1.37 mmol) in tBuOH/H₂O (10/1, 5.5 ml) was added 4N HCl in dioxane solution (0.34 ml, 1.37 mmol) and 5% Pd/C (290 mg, 0.14 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was filtered through CELITE®, and the CELITE® plug was washed with MeOH (50 ml). The filtrate was concentrated under reduced pressure to obtain compound Int-4-5 (412 mg, quant) as yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 9.48 (brs, 1H), 9.03 (brs, 1H), 4.02 (s, 1H), 3.40 (s, 3H), 3.10 (s, 1H), 2.83 – 2.65 (m, 5H), 2.05 (s, 1H), 1.78 (s, 1H), 1.45 – 1.44 (m, 10H), 1.14 – 0.99 (m, 6H).

ESI-MS m/z: 260 (M⁺+1).

Preparation of compound Int-4-6

To a solution of compound Int-4-5 (408 mg, 1.38 mmol) in ACN (3 ml) was added diisopropylethylamine (0.36 ml, 2.07 mmol) at 0 °C. The reaction mixture was added to a solution of N,N'-dicyclohexylcarbodiimide (341 mg, 1.66 mmol) and N-carbobenzyloxy-L-valine (416 mg, 1.66 mmol) in ACN (4 ml) at 0 °C. The reaction mixture was stirred at 45 °C for 48 hours. The reaction mixture was diluted with NaCl solution and extracted with EA. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (EA : Hex = 1 : 5) to obtain compound Int-4-6 (440 mg, 65%) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ 7.34 - 7.26 (m, 5H), 5.52 (d, *J* = 9.2 Hz, 1H), 5.10 (s, 2H), 4.73 (brs, 1H), 4.54 – 4.50 (m, 1H), 4.00 - 3.88 (m, 1H), 3.34 (s, 3H), 2.96 - 2.76 (m, 3H), 2.47 - 2.27 (m, 2H), 2.03 - 1.95 (m, 1H), 1.46 - 1.43 (m, 10H), 1.39 - 1.34 (m, 1H), 1.08 - 0.81 (m, 13H).

ESI-MS m/z: 493 (M⁺+1).

Preparation of compound Int-4-7

To a solution of compound Int-4-6 (430 mg, 0.87 mmol) in t-BuOH/H₂O (10/1, 11 ml) was added 5% Pd/C (186 mg, 0.09 mmol) at room temperature. The reaction mixture was stirred at room temperature under H₂ atmosphere for 2 hours. The reaction mixture was filtered through CELITE®, and the CELITE® plug was washed with MeOH (30 ml). The filtrate was concentrated under reduced pressure to obtain compound Int-4-7 (317 mg, quant) as colorless oil.

^1H NMR (400 MHz, CDCl_3) δ 4.80 (brs, 2H), 3.99 - 3.85 (m, 1H), 3.74 - 3.69 (m, 1H), 3.49 - 3.39 (m, 1H), 3.38 - 3.36 (m, 3H), 2.93 - 2.76 (m, 3H), 2.48 - 2.43 (m, 1H), 2.36 - 2.28 (m, 1H), 1.92 - 1.88 (m, 1H), 1.62 - 1.57 (m, 1H), 1.46 (s, 9H), 1.10 - 0.86 (m, 14H).

ESI-MS m/z : 359 ($\text{M}^+ + 1$).

5 Preparation of compound Int-4-8

To a solution of compound Int-4-7 (314 mg, 0.87 mmol), N-methyl-N-[(phenylmethoxy)carbonyl]-L-valine (255 mg, 0.96 mmol), and PyBOP (593 mg, 1.14 mmol) in ACN (9 ml) was added diisopropylethylamine (0.38 ml, 2.19 mmol) at 0 °C under N_2 atmosphere. The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with NaCl solution (20ml) and extracted with EA (20ml $\times$ 3). The organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography (EA : Hex = 1 : 5) to obtain compound Int-2-8 (390 mg, 74%) as white solid.

15 ^1H NMR (400 MHz, CDCl_3) δ 7.34 - 7.26 (m, 5H), 6.51 - 6.20 (m, 1H), 5.25 - 5.09 (m, 2H), 4.69 (t, J = 8.8 Hz, 1H), 4.24 - 3.88 (m, 2H), 3.35 (s, 3H), 2.98 - 2.88 (m, 6H), 2.47 - 2.17 (m, 3H), 2.05 - 1.98 (m, 1H), 1.73 - 1.61 (m, 1H), 1.46 (s, 9H), 1.33 - 1.26 (m, 2H), 1.05 - 0.67 (m, 19H).


ESI-MS m/z : 606 ($\text{M}^+ + 1$).

Preparation of compound Int-4

20 To a solution of compound Int-4-8 (387 mg, 0.64 mmol) in DCM (1.3 ml) was added the solution of trifluoroacetic acid (1.3 ml) in DCM (1.3 ml) at 0 °C under N_2 atmosphere. The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was evaporated to obtain compound Int-4 (439 mg, quant) as brown solid.

25 ^1H NMR (400 MHz, CDCl_3) δ 7.41 - 7.28 (m, 5H), 6.94 (brs, 1H), 5.23 - 5.10 (m, 2H), 4.63 (t, J = 8.4 Hz, 1H), 4.18 - 4.05 (m, 1H), 3.89 (brs, H), 3.38 (s, 3H), 3.08 - 2.91 (m, 6H), 2.63 - 2.44 (m, 2H), 2.24 - 2.19 (m, 1H), 2.03 - 1.90 (m, 1H), 1.71 (brs, 1H), 1.33 - 1.26 (m, 2H), 1.09 - 0.71 (m, 19H).

ESI-MS m/z : 550 ($\text{M}^+ + 1$).

Example 103: Preparation of Compound Int-5**Preparation of Compound Int-5-1**


To a solution of N-Boc-L-tyrosine methyl ester (250mg, 0.84 mmol) and Int-TG26 (567mg, 1.18mmol) in anhydrous DCM (10ml) was added molecular sieve (500 mg) at 0 °C under N₂ atmosphere. The reaction mixture was stirred for 10mins and Boron trifluoride diethyl etherate (145μL, 1.18mmol) was dropwise to the reaction mixture at 0 °C and then stirred for 10 mins at same temperature. After the reaction was completed, filtered through CELITE® and washed with MeOH and then concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound Int-5-1 (277mg, 54%).

¹H NMR (400 Hz, CDCl₃) δ 7.04 (d, *J* = 8.4Hz, 2H), 6.91 (d, *J* = 8.4Hz, 2H), 5.35-5.26 (m, 3H), 5.11(d, *J* = 7.6Hz, 1H), 4.95(d, *J* = 8Hz, 1H), 4.55-4.53 (m, 1H), 4.18-4.15 (m, 1H), 3.73 (s, 3H), 3.72 (s, 3H), 3.11-3.00 (m, 2H), 2.06(s,3H), 2.05(s,3H), 2.04(s,3H), 1.41(s,9H). 1.97-1.86 (m, 4H), 1.48-1.43(m, 9H).

Preparation of compound Int-5

To a solution of compound Int-5-1 (140mg, 0.22mmol) in DCM (2 mL) was added 4N HCl in dioxane (1.3ml) at 0 °C under N₂ atmosphere. The reaction was stirred at r.t. for 4 hours under N₂ atmosphere. After the reaction was completed, the reaction mixture concentrated under reduced pressure. Producing compound Int-5 (125mg, quant) as red solid, which was used without further purification.

¹H NMR (400 Hz, CDCl₃) δ 7.23 (d, *J* = 8.4Hz, 2H), 6.97 (d, *J* = 8.4Hz, 2H), 5.35-5.23 (m, 3H), 5.16(d, *J* = 7.6Hz, 1H), 4.30-4.28 (m,1H), 4.23-4.21 (d, *J* = 8.8Hz, 1H), 3.73 (s, 3H), 3.77 (s, 3H), 3.71(s,3H), 3.35-3.33(m, 2H), 2.05-2.03(m, 9H)

Example 104: Preparation of Compound D-201**Preparation of compound D-201-1**

To a solution of N-Boc-L-proline methyl ester (5g, 21.80mmol) in anhydrous Toluene (40ml) was treated with 1M DIBAL-H (43ml) dropwise at -78 °C under N₂ atmosphere. The reaction mixture was stirred at -78 °C for 3 hours. After the reaction was completed, quenched with MeOH(33ml), H₂O(33ml) dropwise at -78 °C and warmed up to r.t. slowly. The mixture was extracted with DCM(100ml). The organic layer was washed with brine and dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound D-201-1 (3.5g, 81%).

¹H NMR (400 Hz, CDCl₃) δ 9.56-9.45 (m, 1H), 4.21-4.03 (m, 1H), 3.55-3.44 (m, 2H), 1.97-1.86 (m, 4H), 1.48-1.43(m, 9H).

Preparation of compound D-201-2

To a solution of n-Butyllithium 2.5M in hexanes (1.6ml, 4.01mmol) in anhydrous THF (9ml) was treated with Diisopropylamine (0.56ml, 4.01mmol) at -78 °C under N₂ atmosphere. The reaction mixture was stirred for 10 mins and solution of benzyl propionate in anhydrous THF (2ml) was dropwise to the reaction mixture at -78 °C. Compound D-201-1 was placed in another round flask dissolved in anhydrous THF (2.5ml) at -78 °C, and then this solution transfer by cannula to the reaction mixture at -78 °C and stirred for 1hr. After the reaction

was completed, NH_4Cl solution (4.6ml) was added at $-78\text{ }^\circ\text{C}$ and then the reaction mixture was extracted with EA($10\text{ml} \times 3$), H_2O (20ml). The organic layer was washed with brine and dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound D-201-2 (547mg, 60%).

5 ESI-MS m/z : 385 ($\text{M}+\text{Na}$).

Preparation of compound D-201-3

To a solution of compound D-201-2 (1.18g, 3.24mmol) in DMF (6.5ml) was treated with Iodomethane (1ml) and Sodium hydride 60% (259mg) dropwise at $0\text{ }^\circ\text{C}$ under N_2 atmosphere. The reaction mixture was stirred at same temperature for 1 hour. After the
10 reaction was completed, quenched with H_2O (became clear) dropwise at 0°C and then the reaction mixture was extracted with EA ($10\text{ml} \times 4$), H_2O (20ml). The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound D-201-3 (379mg, 31%).

ESI-MS m/z : 399 (M^++Na).

15 Preparation of compound D-201-4

To a solution of compound D-201-3 (6.4g, 16.95mmol) in tert-Butanol (108ml) and H_2O (12ml) was treated with 5% Pd/C (1.8g, 0.84mmol) at room temperature under H_2 atmosphere and stirred for 2 hours and filtered through CELITE® and washed with MeOH and then concentrated under reduced pressure. The compound D-201-4 was used directly in
20 the next step without further purification (4.87g, quant).

ESI-MS m/z : 309 (M^++Na).

Preparation of compound D-201-5

To a solution of compound D-201-4 (142mg, 0.49mmol) and compound Int-3 (70mg, 0.34mmol) in anhydrous ACN (1.4ml) was treated with DIPEA (0.29ml, 1.70mmol) and
25 PyBOP (265mg, 0.51mmol) at $0\text{ }^\circ\text{C}$ under N_2 atmosphere. The reaction mixture was stirred at room temperature for 13 hours. After the reaction was completed, quenched with H_2O (1ml) and then the reaction mixture was extracted with DCM ($10\text{ml} \times 2$), H_2O (10ml). The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound D-201-5 (45mg,
30 30%).

ESI-MS m/z : 439(M^+).

Preparation of compound D-201-6

To a solution of compound D-201-5 (548mg, 1.24mmol) in DCM (20 mL) was added 4N HCl in dioxane (10ml) at 0 °C under N₂ atmosphere. The reaction was stirred at r.t. for 3 hours under N₂ atmosphere. After the reaction was completed, the reaction mixture concentrated under reduced pressure. Producing compound D-201-6 (464mg, quant) as red solid, which was used without further purification.

ESI-MS m/z: 339(M⁺).

Preparation of compound D-201-7

To a solution of compound D-201-6 (30mg, 0.08mmol) and compound Int-4 (43.9mg, 0.08mmol) in anhydrous ACN(0.5ml) was treated with DIPEA (0.04ml, 0.24mmol) and PyBOP(62mg, 0.12mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 3 hours. After the reaction was completed, quenched with H₂O (1ml) and then the reaction mixture was extracted with DCM (4ml × 2), H₂O (5ml). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound D-201-7 (63mg, 91%).

ESI-MS m/z: 870(M).

Preparation of compound D-201-8

Under N₂ atmosphere, compound D-201-7(115mg, 0.13mmol) was added to 33wt% HBr in acetic acid (0.6ml) and the reaction mixture was stirred at r.t. for 30mins. Subsequently, the solvent was removed by rotary evaporation and the residue was washed twice with 3ml of methyl t-Butyl ether to give a light brown oil. The resulting oil was mixed with 3ml of isopropanol and evaporated to dryness. The resulting oil was stirred 3ml of E.A. at r.t. for 30mins in the presence of 5 molar excess of TEA. The slurry was carefully filtered to remove the triethylammonium bromide and the filtrate was evaporated to dryness under reduced pressure. Producing compound D-201-8 (97.2mg, quant) as yellow sticky solid, which was used without further purification.

ESI-MS m/z: 736 (M).


Preparation of compound D-201

A solution of compound D-201-8 (97mg, 0.13mmol) and Formaldehyde solution 37 wt. % in H₂O (29μL, 0.39mmol) and AcOH (148μL, 2.6mmol) in DMF (1.8mL) was stirred at room temperature under N₂ atmosphere. After 1hour, Sodium cyanoborohydride (16mg, 0.26mmol) was added at same temperature under N₂ atmosphere. The reaction was stirred at room

temperature for 3 hours under N₂ atmosphere. After the reaction was completed, the reaction mixture extracted with EA (5 mL × 3) and H₂O (5ml). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound D-201 (63mg, 63%).

5 ESI-MS m/z: 772(M⁺+Na).

Example 105: *Preparation of Compound T-201*



Preparation of compound T-201-1

10 To a solution of compound D-201 (57mg, 0.07mmol) and compound Int-TG17-2 (39.8mg, 0.11mmol) in DMSO (0.15 mL) at room temperature under N₂ atmosphere was treated with aniline (16 μL, 0.37mmol) and TFA(0.3 μL, pH.4) stirred for 3 hours. After the reaction was completed, the mixture was diluted with ACN and purified by Prep-HPLC to obtain compound T-201-1 (80mg, 88%).

15 ESI-MS m/z: 1103 (M⁺+Na).

Preparation of compound T-201-2

To a solution of compound T-201-1 (75mg, 0.06mmol) and Compound A-Br (97mg, 0.10mmol) in anhydrous ACN (0.5 mL) at room temperature under N₂ atmosphere was treated with DIPEA (24 μL, 0.13mmol) and stirred for 42 hours. After the reaction was completed, the mixture was diluted with ACN and purified by Prep-HPLC to obtain compound T-201-2 (40mg, 29%).

ESI-MS m/z: 967 (M/2).

Preparation of compound T-201-3

To a solution of compound T-201-2 (20mg, 0.01mmol) in THF (0.68mL) and MeOH (0.68mL) and H₂O (0.34mL) was treated with LiOH (6.5mg, 0.15mmol) at -15 °C and stirred

for 5 hours. After the reaction was completed, the mixture was quenched with 2N HCl (adjust pH.2) and concentrated under reduced pressure to dryness organic solvents. The residue was diluted with H₂O and ACN and purified by Prep-HPLC to obtain compound T-201-3 (11mg, 64%).


5 ESI-MS m/z: 827 (M/2).

Preparation of compound T-201

To a solution of compound T-201-3 (11mg, 0.00664 mmol), Mal-1 (2.92 mg, 0.00731mmol) in anhydrous DMSO (0.66 mL) at room temperature under N₂ nitrogen atmosphere was treated with CuBr (2.8 mg, 0.01994 mmol) and stirred for 1 hour. The reaction mixture was
10 purified by Prep-HPLC to obtain compound T-201 (9.8mg, 72%).

ESI-MS m/z: 1027 (M/2).

Example 106: *Preparation of Compound D-202*



15 Preparation of compound D-202-1

To a solution of compound Int-5 (105mg, 0.19mmol) and compound D-201-4 (65mg, 0.22mmol) in anhydrous ACN(0.65ml) was treated with DIPEA (0.13ml, 0.76mmol) and PyBOP (128mg, 0.24mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 2 hours. After the reaction was completed, quenched with H₂O (1ml)
20 and then the reaction mixture was extracted with DCM (4ml × 2), H₂O (4ml). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound D-202-1 (103mg, 70%).

ESI-MS m/z: 781(M⁺).

Preparation of compound D-202-2

To a solution of compound D-202-1 (242mg, 0.30mmol) in DCM (6 mL) was added 4N HCl in dioxane (2ml) at 0 °C under N₂ atmosphere. The reaction was stirred at r.t. for 3 hours under N₂ atmosphere. After the reaction was completed, the reaction mixture concentrated under reduced pressure. Producing compound D-202-2 (222mg, quant), which was used without further purification.

ESI-MS m/z: 681(M⁺).

Preparation of compound D-202-3

To a solution of compound D-202-2 (222mg, 0.30mmol) and compound Int-4 (179mg, 0.32mmol) in anhydrous ACN(1.5ml) was treated with DIPEA (0.21ml, 1.23mmol) and PyBOP (242mg, 0.46mmol) at 0 °C under N₂ atmosphere. The reaction mixture was stirred at room temperature for 5 hours. After the reaction was completed, quenched with H₂O (1ml) and then the reaction mixture was extracted with DCM (4ml × 2), H₂O (5ml). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound D-202-3 (337mg, 90%).

ESI-MS m/z: 1213(M⁺).

Preparation of compound D-202-4


To a solution of compound D-202-3 (367.1 mg, 0.303 mmol) in t-BuOH/H₂O (91, 3ml) was treated with Pd/C 5% (64.4 mg, 0.0303 mmol) at room temperature under H₂ atmosphere and stirred for 1 hour. The reaction mixture was filtered through CELITE®, and then concentrated under reduced pressure to obtain compound D-202-4 (296 mg, 91%).

ESI-MS m/z: 1078 (M).

Preparation of compound D-202

A solution of compound D-202-4 (45mg, 0.04mmol) and Formaldehyde solution 37 wt. % in H₂O (10μL, 0.12mmol) and AcOH (53μL, 0.82mmol) in DMF (0.5mL) was stirred at room temperature under N₂ atmosphere. After 15 hours, Sodium cyanoborohydride (5.8mg, 0.08mmol) was added at same temperature under N₂ atmosphere. The reaction was stirred at room temperature for 30 mins under N₂ atmosphere. After the reaction was completed, the reaction mixture extracted with EA (10 mL × 3) and H₂O (10ml). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep-HPLC to obtain compound D-202 (35mg, 77%).

ESI-MS m/z: 1092(M).

Example 107: Preparation of Compound T-202**Preparation of compound T-202-1**

- 5 To a solution of compound D-202 (25mg, 0.02mmol) and compound A-Br (64mg, 0.06mmol) in anhydrous ACN (0.22 mL) at room temperature under N₂ atmosphere was treated with DIPEA (16 μ L, 0.08mmol) and stirred for 52 hours. After the reaction was completed, the mixture was diluted with ACN and purified by Prep-HPLC to obtain compound T-202-1 (14mg, 33%).

10 ESI-MS m/z: 973 (M/2).

Preparation of compound T-202-2

- To a solution of compound T-202-1 (14mg, 0.0072mmol) in THF (0.20mL) and MeOH (0.05mL) and H₂O (0.05mL) was treated with LiOH (4.5mg, 0.1086mmol) at -25 °C and stirred for 6 hours. After the reaction was completed, the mixture was quenched with 2N HCl (adjust pH.2) and concentrated under reduced pressure to dryness organic solvents. The residue was diluted with H₂O and ACN and purified by Prep-HPLC to obtain compound T-202-2 (6.5mg, 63%).


ESI-MS m/z: 825 (M/2).

Preparation of compound T-202

- 20 To a solution of compound T-202-2 (6.5mg, 0.0039mmol), Mal-1 (1.72 mg, 0.0043mmol) in anhydrous DMSO (0.3 mL) at room temperature under N₂ nitrogen atmosphere was treated with CuBr (5.6 mg, 0.0393mmol) and stirred for 3 hours. The reaction mixture was purified by Prep-HPLC to obtain compound T-202 (5.8mg, 72%).

ESI-MS m/z: 1025 (M/2).


25

Example 108: *Preparation of Compound T-203*

Compound T-203 was synthesized in a way similar method of Example 107.

Yield 83%

5 ESI-MS m/z : 1017.19 ($M^+/2$), 2033.98 (M^+)


Example 109: *Preparation of Compound T-204*

To a solution of compound T-201-3 (4.6 mg, 0.0027 mmol), L-9 (0.83 mg, 0.0013 mmol) in DMSO (0.4 mL) at room temperature under N_2 nitrogen atmosphere was treated with CuBr (0.54 mg, 0.0038 mmol) and stirred for 1 hour. The reaction mixture was purified by Prep-HPLC to obtain compound T-204 (3.79 mg, 50.5%).

10

ESI-MS m/z: 1982.38 ($M^+/2$), 1321.94 ($M^+/3$), 991.85 ($M^+/4$).


Example 110: Preparation of Compound T-141



5 Compound T-141 was synthesized via a similar synthetic route as described in Example
99(55%).


ESI-MS m/z: 775.17 ($M^+/2+1$), 1548.67 (M^+)

Example 111: Preparation of Compound T-142




Compound T-142 was obtained by performing a reaction in a similar method as described in document US 16,472,983.

Example 112: *Preparation of Compound T-143*



Compound T-143 was obtained by performing a reaction in a similar method as described in document US 16,472,983.

Example 113: *Preparation of Compound T-144*

Compound T-144 was obtained by performing a reaction in a similar method as described in document US 11,996,009.

Example 114: *Reduction/Oxidation of Antibodies for Conjugation*

Cysteine engineered monoclonal antibodies were reduced with about a 20 folds excess of TCEP (tris(2-carboxyethyl) phosphine hydrochloride in 4 mM Tris-HCl pH 7.3 with 1 mM EDTA for 1 hours at 37 °C. In another way, Cysteine engineered monoclonal antibodies (B7H3, DLL3, HER2) were reduced with about a 5000 folds excess of L-Cysteine in 20 mM sodium phosphate pH 6.5 for 1 hours at 37 °C. The reduced thiomab was diluted and loaded onto a PD-10 column or vivaspin (MWCO, 30kDa) in PBS, pH 6.5 and eluted with 20 mM PBS. The eluted reduced thiomab was stored at 4 °C overnight for effective refolding.

The thiol/Ab value was checked by determining the reduced antibody concentration from the absorbance at 280 nm of the solution and the thiol concentration by reaction with DTNB (Aldrich, CAS No D8130) and determination of the absorbance at 412 nm.

Example 115: *Conjugation Method 1: (Thiomab conjugation)*

Stock solution of linker-toxin was made up in dimethylsulfoxide (DMSO) at concentrations of 1-3 mM. To a solution of the reduced antibody in 20mM sodium phosphate (pH 6.5) was added about 1.5-2.5 molar excess relative to cysteines per antibody of a linker toxin, such as T-2-AB~T-6-AB, T-10-AB, T-107-AB~ T-113-AB with a thiol reactive functional group such as maleimide. The conjugation reaction was allowed to proceed at 40 °C for 1 h. The antibody-drug conjugate was purified from excess unreacted linker-toxin using PD-10 column and immediately buffer exchanged in a 50mM borate buffer (pH 8.5-9.2) using Vivaspin (MWCO, 30kDa). The resulting solution was incubated at 37 °C for 22 h. The resulting solution was cooled, buffer-exchanged into PBS (pH 6.5-7.3), and purified by

HIC in order to remove any impurities. Final sample was concentrated to 5~10 mg/ml protein, and checked for DAR using the HIC and/or RP-HPLC conditions.

Example 116: Conjugation Method 2: (Random conjugation)

5 Antibody dissolved in PBS at pH6.5-7.3 was treated with 10 molar excess of TCEP (tris(2-carboxyethyl) phosphine) hydrochloride in 4 mM Tris pH 7.3 with 1 mM EDTA. After incubation at 37 °C for 1h, the resulting mixture and linker-toxin (8-10 molar excess relative to antibody) were mixed together in DMSO containing up to 5% v/v of 4 mM Tris buffer, 1 mM EDTA, pH 7.3. After the reaction was incubated for 1h at 40 °C, the buffer was
10 exchanged by elution over PD-10 column and Vivaspin (MWCO, 30kDa) and eluted with PBS at pH 6.5.

Example 117: Conjugation Method 3: (2-step conjugation method)

15 A solution of cysteine-engineered antibody (1-3mmol in buffer system, pH6.5) was diluted with PBS buffer, pH7.4. DMSO was added followed by a solution of linker-toxin (T-7 of Example 36) in DMSO. The final concentration of DMA was 4-10%. The resulting mixture was agitated gently for 3 hours at room temperature. Hydroxylamine (8.86 µL, 1,500 mmol) was added to the resulting mixture and incubated at 37 °C for 8 hours to block a reversible deconjugation reaction. The conjugation mixture was loaded and eluted through PD-10
20 column to remove excess drug-linker intermediate and other impurities. (US20110003969)

Example 118: Reduction/Oxidation of Antibodies for Conjugation

25 Cysteine engineered monoclonal antibodies were reduced with about a 20 folds excess of TCEP (tris(2-carboxyethyl) phosphine hydrochloride in PBS buffer pH 7.4 with 10 mM EDTA for 1 hour at 37 °C. The reduced thiomab was diluted and loaded onto a PD-10 column or vivaspin (MWCO, 30kDa) in PBS, pH 7.4 and eluted with PBS, pH 7.4. To oxidize the reduced thiomab antibody (B7H3, DLL3, HER2), process 5 equivalents of DHAA relative to the antibody concentration at 37 °C for 2 hours. The thiol/Ab value was checked by determining the reduced antibody concentration from the absorbance at 280 nm
30 of the solution and the thiol concentration by reaction with DTNB (Aldrich, CAS No D8130) and determination of the absorbance at 412 nm. The refolding ratio was checked by determining using RP-HPLC analysis (~94%).

Example 119: *Conjugation Method 4: (Thiomab conjugation)*

Stock solution of linker-toxin was made up in 50% dimethylacetamide (DMA) at concentrations of 5 mM. The solution of the reduced thiomab antibody were mixed together in DMA containing up to 10% v/v of 50 mM Borate buffer, pH 8.6 with 5mM EDTA. After
5 linker-toxin (T-18, T-131, T-136, T-137) was added about 6.0 molar excess relative to cysteines per antibody. The conjugation reaction was allowed to proceed at 37 °C for 1 hour or 30 °C for 3 hours. After that, added N-acetyl-L-Cysteine (6.0 molar excess relative to antibody) and incubated for 0.5 hour at RT. The antibody-drug conjugate was purified from excess unreacted linker-toxin using PD-10 column and immediately buffer exchanged in a
10 formulation buffer using Vivaspin (MWCO, 30kDa). Final sample was concentrated to 5~10 mg/ml protein, and checked for DAR and monomer% using the HIC, RP and/or SEC-HPLC conditions.

Example 120: *Conjugation Method 5: (Random conjugation)*

15 Antibody was treated with 3 molar excess of TCEP (tris(2-carboxyethyl) phosphine) hydrochloride in PBS pH 7.4 with 5 mM EDTA. After incubation at 37 °C for 2 hours, the resulting mixture and linker-toxin (4.6-5.5 molar excess relative to antibody) were mixed together in DMSO containing up to 10% v/v of 30 mM Borate buffer, pH 8.8. After the reaction was incubated for 2 hours at 37 °C, added N-acetyl-L-Cysteine (4.6-5.5 molar excess
20 relative to antibody) and incubated for 0.5 hour at RT. After that, the buffer was exchanged by elution over PD-10 column and Vivaspin (MWCO, 30kDa) and eluted with PBS at pH 6.5.

Example 121: *Purification of Antibody-Drug Conjugates*

25 The antibody-drug conjugate obtained from the conjugation method above was purified by HIC column (Proteomix HIC Butyl-NP5, 21.2 x 150 mm, 5 µm). The gradient was generated using 1.5 M ammonium sulfate in 50 mM sodium phosphate at pH 7.0 as mobile phase A and 5 % acetonitrile in 50 mM sodium phosphate at pH 7.0 as mobile phase B. The conjugate was eluted from the column using a gradient from 10 to 100 % B in 20min.
30 The average DAR values for intact antibody-drug conjugates were analyzed using HIC method.

Example 122: *In Vitro* Analysis of Protein-Drug Conjugates

The conjugates were evaluated on JIMT-1, Calu-6, CHO-K1, CCRF- CEM Raji, NCI-H69, NCI-N87 cancer cells. Cancer cells were seeded in 96-well plates at a density of 2,000 to 4,000 cells per well in 100 μ L of medium, and cultured for 6 or 24 hours. The ADCs were treated by serial dilutions of 1:3~1:10 from 50 nM to 0.0003 nM, The series of compound dilutions in DMSO were added to triplicate wells of 96-well plates at 50 μ L per well. All assays were performed in triplicate and the results were obtained in three independent experiments. The plates were incubated for 6 days at 37 °C in a humidified 5% CO₂-in-air atmosphere. Cell viability was determined by the MTT assay. 15uL of 3-(4,5-dimethylthiazol-2-yl)-2,5-phenyltetrazolium bromide (MTT) dye, dissolved in PBS buffer solution (5 mg/mL), or 15 μ L of 4-(3-[4-Iodophenyl]-2-[4-nitro-phenyl]-2H-5-tetrazolio)-1,3-benzene sulfonate (WST-1) was added to each well of the plates. The formazans formed by reduction of the MTT dye by mitochondrial oxidoreductases in the living cells were dissolved in DMSO, the formazans measured using the absorbance at 450nm or 550 nm. IC₅₀ was generated using a sigmoidal dose-response nonlinear regression curve fit (GraphPad software Inc.).

Table 8: In Vitro activity of selected conjugates; conjugates contain two drugs per antibody

IC ₅₀ (nM) $\pm$ SD					
ADC	JIMT-1	Calu-6	Raji	CCRF-CEM	CHO-K1
T-2-AB	0.010 $\pm$ 0.004	N/A	N/A	N/A	2.103 $\pm$ 0.449
T-3-AB	0.007 $\pm$ 0.003	N/A	N/A	N/A	N/A
T-4-AB	0.023 $\pm$ 0.013	0.038 $\pm$ 0.004	8.540 $\pm$ 1.188	2.837 $\pm$ 0.115	34.10 $\pm$ 7.370
T-5-AB	0.016 $\pm$ 0.003	0.024 $\pm$ 0.004	N/A	N/A	N/A
T-6-AB	0.023 $\pm$ 0.006	0.044 $\pm$ 0.006	10.94 $\pm$ 1.837	11.42 $\pm$ 1.978	100~500
T-8-AB	0.036 $\pm$ 0.002	0.044 $\pm$ 0.003	>250	76.31 $\pm$ 10.95	N/A
T-9-AB	0.015 $\pm$ 0.007	0.049 $\pm$ 0.008	3.075 $\pm$ 0.605	4.563 $\pm$ 0.707	N/A
T-10-AB	0.019 $\pm$ 0.004	0.066 $\pm$ 0.005	211.1 $\pm$ 34.95	45.05 $\pm$ 3.124	N/A
T-11-AB	0.042 $\pm$ 0.004	0.027 $\pm$ 0.001	6.896 $\pm$ 1.240	7.610 $\pm$ 0.512	N/A

T-12-AB	0.072±0.016	0.291±0.033	>250	197.2±41.11	N/A
T-13-AB	0.029±0.023	0.093±0.018	5.253±0.453	8.932±1.144	N/A
T-14-AB	0.020±0.009	0.066±0.007	272.2±17.64	62.09±0.430	N/A
T-15-AB	0.017±0.005	0.069±0.008	47.38±2.636	22.73±2.480	N/A
T-102-AB	0.009±0.002	0.096±0.004	N/A	12.54±0.590	14.60±1.69
T-103-AB	0.44±0.31	0.14±0.01	N/A	N/A	N/A
T-104-AB	0.20±0.09	0.075±0.001	5.63	5.84±0.52	N/A
T-110-AB	0.070±0.003	0.265±0.011	N/A	3.726±0.072	14.19±0.110
T-111-AB	0.085±0.006	N/A	N/A	N/A	N/A
T-112-AB	0.081±0.002	0.053±0.005	N/A	3.368±0.057	8.935±0.683
T-113-AB	0.101±0.009	0.061±0.001	N/A	N/A	N/A
T-115-AB	0.114±0.008	0.092±0.009	N/A	N/A	N/A
T-116-AB	0.32±0.22	1.16±0.22	500-1000	989±50	N/A
T-117-AB	0.30±0.13	1.62±0.19	500-1000	1006±29	N/A
T-118-AB	0.007±0.001	0.019±0.004	1.64±0.38	1.830±0.102	N/A
T-119-AB	0.010±0.002	0.075±0.004	35.2±1.6	41.26±9.70	N/A
T-120-AB	0.030±0.007	0.071±0.023	6.14±0.65	2.57±0.39	N/A
T-121-AB	0.029±0.006	0.864±0.232	152.9±30.3	136.4±27.4	N/A
T-122-AB	0.051±0.005	1.70±0.74	169.9±67.5	137.4±38.0	N/A
T-123-AB	0.037±0.002	1.943±0.874	404.7±73.9	343.9±9.1	N/A
T-124-AB	0.034±0.006	2.98±1.20	328.9±1.0	306.5±66.10	N/A
T-125-AB	0.034±0.002	2.634±1.387	376.4±32.4	342.4±16.29	N/A
AB: Cysteine-engineered antibody (B7H3 Y107 A121C)					

Table 9: In Vitro activity of selected conjugates

ADC (DAR)	IC ₅₀ (nM) ±SD	
	Calu-6	CCRF-CEM
T-127-AB (1.8)	1.375±0.639	343.1±44.67
T-129-AB (1.8)	5.417±1.386	N/A
T-132-AB (3.3)	0.324±0.017	107.2±64.70
T-133-AB (3.2)	0.327±0.105	N/A
T-134-AB (3.3)	0.281±0.147	N/A
T-135-AB (3.7)	0.343	N/A
T-137-AB (1.7)	0.555±0.072	820.6±346.8
AB: Cysteine-engineered antibody (B7H3 Y107 A121C)		

Table 10: In Vitro activity of selected conjugates

ADC (DAR)	IC ₅₀ (nM) ±SD		
	NCI-H69	CHO-K1	NCI-N87
T-103-AB1 (~6)	0.018 ± 0.010	N/A	13.244 ± 4.540

T-117-AB1 (1.8)	0.06 ± 0.02	N/A	50.7 ± 45.9
T-17-AB2 (1.8)	0.05 ± 0.02	N/A	365 ± 138
T-124-AB2 (1.8)	0.04 ± 0.03	N/A	N/A
T-125-AB2 (1.8)	0.12 ± 0.12	N/A	55.4 ± 54.9
T-126-AB2 (1.9)	0.21 ± 0.05	N/A	452 ± 471
T-135-AB2 (3.6)	0.03 ± 0.01	N/A	N/A
T-1-AB3 (2.0)	N/A	5.479	0.024±0.006
T-2-AB3 (1.6)	N/A	16.53 ±1.710	0.017 ±0.001
T-3-AB3 (1.8)	N/A	131.0±73.28	0.087±0.020
T-109-AB3 (1.8)	N/A	N/A	0.147 ±0.017
T-116-AB3 (2.0)	N/A	159.8±22.91	0.208±0.043
T-117-AB3 (1.8)	N/A	148.7±19.60	0.322±0.178
AB1: Antibody (DLL3 SA4717)			
AB2: Cysteine-engineered antibody (DLL3 V205C)			
AB3: Cysteine-engineered antibody (HER2 A114C)			

Example 123: *In Vivo Efficacy*

In vivo efficacy studies were performed in a target-expressing xenograft model using the JIMT-1 cell line. The human breast cancer JIMT-1 xenograft was established in 6-week-old female BALB/c nude mice by implanting 5×10^6 cells subcutaneously (SC) into their right flanks. When group mean tumor volumes reached approximately $150 \pm 20 \text{ mm}^3$, mice were randomized into groups to receive test agents (ADCs) or vehicle control (PBS). ADCs or PBS were administered intravenously (IV) by tail vein injection (6.4 mL/kg). Tumors were measured twice weekly with calipers, with tumor volumes calculated as: (length x length x width)/2. Single-dose administration of ADCs (T-2-AB, T-3-AB and T-4-AB) resulted in a decrease in tumor growth of JIMT-1 breast cancer xenografts. Dose-dependent antitumor activity was observed following single-dose administration of T-4 AB at 0.3 and 1.2 mg/kg. These results were shown in Figure 1A. Dose-dependent antitumor activity was observed

following single-dose administration of T-103-AB at 3.6 and 14.4 mg/kg. These results were shown in Figure 1B.

Example 124: Plasma Stability

Each compound A, B, C, D and methyl phenyl sulfone used as a standard material were dissolved in DMSO to make a concentration of 10 mM. Then, each of human plasma (Biochemed 752PR-SC-PMG), mouse plasma (Biochemed 029-APSC-MP) and rat plasma (Biochemed 031-APSC-MP) were mixed with the compound and MPS to make a final concentration of 100 μ M (final 3% DMSO). The resulting plasma mixtures were incubated at 37°C water bath. Aliquots were taken before the reaction and on 1 day, 2 days, 4 days, and 7 days after the reaction, wherein each aliquot was 100 μ L. To quench the reaction, two-fold volumes of acetonitrile was added, followed by brief vortexing, and centrifugation for plasma protein precipitation. Each supernatant obtained after centrifugation was collected and analyzed by HPLC. The compound A, B, C and D were detected and quantitated in the mouse and human plasma for up to 7 days (> 95%). This study demonstrated the excellent stability of glyco-substituted toxins-linker conjugates in plasma.

Results of plasma stability of glyco-substituted toxin-linker conjugates are shown in Fig. 2A and Fig. 2B. Data marked A or C are for unsubstituted toxin-linker conjugates, where data marked B or D are for glyco-substituted toxins-linker conjugates.

Example 125: Cellular Uptake

Cellular uptake study was performed via a similar method as described in Example 119.

Results of cellular uptake studies for duocarmycin payloads which were either unsubstituted or substituted with glyco groups are shown in the table below.

Table 11: In Vitro activity of selected conjugates; conjugates contain two drugs per antibody

ADC	IC ₅₀ (nM) $\pm$ SD		TI (CHO-K1/JIMT-1)
	JIMT-1 (positive)	CHO-K1 (negative)	
T-101-AB	0.007 $\pm$ 0.001	2.59 $\pm$ 0.24	370
T-102-AB	0.009 $\pm$ 0.002	14.60 $\pm$.69	1622.22

Table 12: In Vitro activity of selected conjugates; conjugates contain two drugs per antibody

ADC	IC ₅₀ (nM) ±SD		TI (CCRF-CEM/JIMT-1)
	JIMT-1	CCRF-CEM	
T-104-AB	0.20±0.09	5.84±0.52	29.20
T-103-AB	0.44±0.31	34.2±0.8	77.73
T-116-AB	0.32±0.22	989±50	3090.63
T-117-AB	0.30±0.13	1006±29	3353.33

5

INCORPORATION BY REFERENCE

All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

10


EQUIVALENTS

While specific embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the disclosure will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.


15

We claim:

1. A drug conjugate comprising a compound represented by formula (VII) or (VIII) and a linker group:



(VII); or



(VIII);

or a pharmaceutically acceptable salt thereof;

wherein:

A is a heterocycle;

each $R^{a'}$ and $R^{b'}$ are independently halogen, amino, hydroxyl, acetyl, hydroxyalkyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

two geminal $R^{b'}$ are optionally taken together to form an oxo or $=CH_2$; or two $R^{b'}$, together with the intervening atoms, optionally complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

$R^{c'}$ is sulfonate, sulfate, hydroxyl, amino, or thiol;

$R^{d'}$ is $-L''$ -Gly, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

provided that at least one $R^{c'}$ is sulfonate or sulfate, or at least one $R^{d'}$ is $-L''$ -Gly;

$R^{e'}$ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

m is an integer selected from 0-3;

n is an integer selected from 0-8, as valency permits;

ring Cy is selected from aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

$==$ is a single bond or a double bond;

X' is halogen;

X'' is -NR-, -S-, or -O-;

R is hydrogen or alkyl;

each R^{a''} and R^{b''} are independently halogen, amino, hydroxyl, alkoxy, acetyl, hydroxyalkyl, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or -(L''')_r-X''-Gly;

d is an integer selected from 0-4;

r is an integer from 0-1;

each L''' is a bond or a linker,

R^{e''} is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

p is an integer selected from 0-4;

DBD is a DNA binding domain;


L'' is a bond or a linker; and

Gly is a monosaccharide, disaccharide, or oligosaccharide.

2. The drug conjugate of claim 1, wherein each L''' is a C₁₀-C₁₀₀ linear or branched, saturated, or unsaturated alkylene moiety, optionally comprising one or more double bonds and/or triple bonds.

3. The drug conjugate of claim 1, wherein each p and each d are independently an integer from 0-1.


4. The drug conjugate of claim 1, wherein the compound is represented by Formula (VII):



or a pharmaceutically acceptable salt thereof.

5. The drug conjugate of of any one of claims 1-4, wherein A is 5- to 6-membered heterocycle.

6. The drug conjugate of any one of claims 1-5, wherein $R^{c'}$ is hydroxyl.
7. The drug conjugate of any one of claims 1-6, wherein $R^{d'}$ is hydrogen, C_{1-6} alkyl, C_{3-10} cycloalkyl, 3- to 10-membered heterocycloalkyl, C_{6-10} aryl, or 5- to 10-membered heteroaryl.
8. The drug conjugate of claim 7, wherein $R^{d'}$ is L''-Gly.
9. The drug conjugate of claim 4, wherein the compound is selected from:



or a pharmaceutically acceptable salt thereof;
wherein $\equiv$ is a single bond or a double bond.


10. The drug conjugate of any one of claims 1-9, wherein $R^{a'}$ is halogen, amino, hydroxyl, alkoxy, cyano, nitro, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 4- to 10-membered heterocycloalkyl, C_{6-10} aryl, or 5- to 10-membered heteroaryl.
11. The drug conjugate of any one of claims 1-10, wherein two geminal $R^{b'}$ are taken together to form $=CH_2$.
12. The drug conjugate of any one of claims 1-10, wherein two $R^{b'}$, together with the intervening atoms, complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
13. The drug conjugate of claim 12, wherein two $R^{b'}$, together with the intervening atoms, complete an aryl or heteroaryl.
14. The drug conjugate of claim 12, wherein two $R^{b'}$, together with the intervening atoms, complete an aryl.

15. The drug conjugate of any one of claims 1-14, wherein $R^{e'}$ is hydrogen, C_{1-6} alkyl, C_{3-10} cycloalkyl, 3- to 10-membered heterocycloalkyl, C_{6-10} aryl, or 5- to 10-membered heteroaryl.

16. The drug conjugate of claim 15, wherein $R^{e'}$ is hydrogen, C_{1-6} alkyl, or C_{3-10} cycloalkyl.


17. The drug conjugate of claim 16, wherein $R^{e'}$ is hydrogen.

18. The drug conjugate of claim 4 or 9, wherein the compound is selected from:



or a pharmaceutically acceptable salt thereof.

19. The drug conjugate of claim 1, wherein the compound is represented by Formula (VIII):





or a pharmaceutically acceptable salt thereof.

20. The drug conjugate of claim 19, wherein Cy is phenyl.


21. The drug conjugate of claim 19, wherein Cy is pyrrolidine or pyrrole.

22. The drug conjugate of claim 19, wherein the compound is represented by Formula (VIIIa) or (VIIIb):



or a pharmaceutically acceptable salt thereof.

23. The drug conjugate of any one of claims 19-22, wherein the DBD-(L''')_r-X''-Gly unit is selected from:



or a pharmaceutically acceptable salt thereof;

wherein:

Y'' is C or N;

X'' is selected from -NR-, -S-, or -O-;

R is hydrogen or alkyl;

r is an integer from 0-1;


each R^{b''} is independently halogen, amino, hydroxyl, acetyl, hydroxyalkyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or -(L''')_r-X''-Gly;

R^k is alkyl, preferably C_1 - C_3 alkyl;


q is an integer selected from 0-3; and

$\equiv$ is a single bond or a double bond.


24. The drug conjugate of any one of claims 19-23, wherein the compound is represented by Formula (VIIIc), (VIIId), (VIIIe), or (VIIIf):




(VIIIc);



(VIIId);



(VIIIe);









(VIIIf);


or a pharmaceutically acceptable salt thereof.

25. The drug conjugate of any one of claims 19-24, wherein:

each R^{a''} is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and each R^{b''} is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, C₁₋₆ alkyl, heteroalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 4- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl.


26. The drug conjugate of any one of claims 19-25, wherein X' is Cl.
27. The drug conjugate of any one of claims 19-26, wherein X' is Br.
28. The drug conjugate of any one of claims 19-27, wherein Y'' is C.
29. The drug conjugate of any one of claims 19-27, wherein Y'' is N.
30. The drug conjugate of any one of claims 19-29, wherein R^{e''} is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
31. The drug conjugate of claim 30, wherein R^{e''} is hydrogen, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl.
32. The drug conjugate of claim 31, wherein R^{e''} is hydrogen, C₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl.
33. The drug conjugate of claim 32, wherein R^{e''} is hydrogen.
34. The drug conjugate of claim 19, wherein the compound is selected from:





or a pharmaceutically acceptable salt thereof.

35. The drug conjugate of any one of claims 19-34, wherein L''' is a bond.
36. The drug conjugate of any one of claims 19-34, wherein L''' is a linker selected from




wherein:

R^a is hydrogen, halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and

each R^b is independently hydrogen, halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and h is an integer selected from 0-4, as valency permits.


37. The drug conjugate of claim 36, wherein L''' is



38. The drug conjugate of any one of claims 1-37, wherein Gly is a monosaccharide.


39. The drug conjugate of claim 38, wherein Gly is a monosaccharide selected from glucose, glucuronic acid, fucose, and galactose.

40. The drug conjugate of claim 39, wherein Gly is



optionally wherein 1 or more of the –OH groups is masked by a protecting group.


41. The drug conjugate of claim 40, wherein Gly is



42. The drug conjugate of any one of claims 1-37, wherein Gly is a disaccharide.


43. The drug conjugate of claim 42, wherein Gly is a disaccharide comprising glucose, glucuronic acid, fucose, galactose, or a combination thereof.

44. The drug conjugate of claim 43, wherein Gly is




optionally wherein 1 or more of the $-OH$ groups is masked by a protecting group.


45. The drug conjugate of claim 44, wherein Gly is




46. The drug conjugate of any one of claims 1-45, wherein X'' is coupled to Gly at the anomeric position.

47. The drug conjugate of any one of claims 1-46, represented by formula (IX), (X), or (XI):





(X); or



(XI);

or a pharmaceutically acceptable salt thereof;

wherein:

Z' is a coupling group;

Ar is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

Y' is $-(CR^{b_2})_yN(R^a)-$, $-(CR^{b_2})_yO-$, or $-(CR^{b_2})_yS-$, positioned such that the N, O, or S atom is attached to TG if y is 1;

TG is a triggering group that, when activated, generates an N, O, or S atom capable of reacting with the SO_2 to displace $(Q)_q-(L')_w$ and form a 5- to 6-membered ring including X- SO_2 and the intervening atoms of Ar;

X is $-O-$, $-C(R^b)_2-$, or $-N(R^c)-$;

L' is a spacer moiety that if present, is attached to the SO_2 via a heteroatom selected from O, S, and N, and is selected such that cleavage of the bond between L' and SO_2 promotes release of the active agent;

w is an integer selected from 0-1;

r is an integer from 0-1;

Z^2 is a linking group;

Z^3 is a linking group;


R^a , R^b and R^c are each independently hydrogen, or lower alkyl;

y is an integer selected from 0-1;

t is an integer from 1-5; and

e is an integer from 1-5.

48. The drug conjugate of claim 47, wherein Z^3 is selected from:



wherein:

X^5 is $-O-$ or $-NR^x-$;


Y^1 is CR^y , or N ;

R^x and R^y are each independently hydrogen or C_{1-6} alkyl;

each b is independently an integer from 1-3; and


c is an integer from 1-5.

49. The drug conjugate of claim 48, wherein Z^3 is selected from:



50. The drug conjugate of claim 47, wherein Z^2 is methylene.

51. The drug conjugate of claim 47, wherein Z^2 is



wherein:


Y^5 is CR^{Y1} or N, provided that only one Y^5 is N;

R^{Y1} is H, hydroxyl, amino, amido, or $(CH_2)_y(R^{Y1a})$;


R^{Y1a} is amino (*e.g.*, secondary or tertiary amino), aryl (*e.g.*, phenyl), or heteroaryl; and

y is an integer having a value of 1 to about 10.

52. The drug conjugate of claim 51, where Z^2 is



53. The drug conjugate of claim 47, wherein Z^2 is



wherein:

Y^6 is CR^{Y2} or N;


R^{Y2} is H or alkyl, preferably lower alkyl;

R^{Z2} is $(CH_2)_z R^{Z2a}$;

R^{Z2a} is amino (preferably tertiary amino), aryl (*e.g.*, phenyl), or heteroaryl; and

z is an integer having a value of 0 to about 10.

54. The drug conjugate of claim 53, where Z^2 is




55. The drug conjugate of any one of claims 47-54, wherein Ar is aryl.

56. The drug conjugate of claim 55, wherein Ar is C_{6-10} aryl.

57. The drug conjugate of claim 56, wherein Ar is phenyl.


58. The drug conjugate of any one of claims 47-54, wherein Ar is heteroaryl.

59. The drug conjugate of claim 58, wherein Ar is 5- to 10-membered heteroaryl.
60. The drug conjugate of any one of claims 47-59, wherein Y' is $-(CR^b)_yN(R^a)-$ or $-(CR^b)_yO-$.
61. The drug conjugate of claim 60, wherein Y' is $-(CR^b)_yO-$.
62. The drug conjugate of claim 60 or 61, wherein y is 0.
63. The drug conjugate of claim 60 or 61, wherein y is 1.
64. The drug conjugate of any one of claims 47-63, wherein X is $-O-$ or $-N(R^c)-$.
65. The drug conjugate of claim 64, wherein X is $-O-$.
66. The drug conjugate of any one of claims 47-65, wherein L' is the spacer moiety, and forms an $-O-$, an $-OC(O)-$, an $-OC(O)O-$, a $-NHC(O)O-$, or an $-OC(O)NH-$ linkage including the heteroatom of the active agent.
67. The drug conjugate of any one of claims 47-66, wherein TG is a monosaccharide.
68. The drug conjugate of claim 67, wherein TG is a monosaccharide selected from glucose, glucuronic acid, fucose, and galactose.
69. The drug conjugate of claim 68, wherein TG is



optionally wherein 1 or more of the $-OH$ groups is masked by a protecting group.


70. The drug conjugate of claim 69, wherein TG is



71. The drug conjugate of any one of claims 47-66, wherein TG is a disaccharide.


72. The drug conjugate of claim 71, wherein TG is a disaccharide comprising glucose, glucuronic acid, fucose, galactose, or a combination thereof.

73. The drug conjugate of claim 72, wherein TG is




optionally wherein 1 or more of the -OH groups is masked with a protecting group.








74. The drug conjugate of claim 73, wherein TG is




75. The drug conjugate of any one of claims 47-74, wherein Y' is coupled to TG at the anomeric position.

76. The conjugate of any one of claims 47-75, wherein Z' is selected from







wherein:

R^{za} is H or methyl;


R^{zb} is $-OH$, $=O$, or $=NHOH$;

m and n are each independently an integer selected from 1-10;

x is an integer selected from 1-2;




----- a single bond or a double bond; and

Z'' is selected from



77. A targeted drug conjugate comprising the drug conjugate of any one of claims 1-76 and a TM (a targeting moiety).








78. The targeted drug conjugate of claim 77, represented by formula (XII), (XIII) or (XIV):





or a pharmaceutically acceptable salt thereof;
wherein TM is a targeting moiety.

79. The targeted drug conjugate of claim 78, wherein Z' is selected from







80. The targeted drug conjugate of any one of claims 77-79, wherein the TM is a nanoparticle, an immunoglobulin, a nucleic acid, a protein, an oligopeptide, a polypeptide, an antibody, a fragment of an antigenic polypeptide, or a repebody.


81. The targeted drug conjugate of claim 80, wherein the TM is an antibody selected from an intact polyclonal antibody, an intact monoclonal antibody, an antibody fragment, a single chain Fv (scFv) mutant, a multispecific antibody, a bispecific antibody, a chimeric antibody, a humanized antibody, a human antibody, a fusion protein comprising an antigenic determinant portion of an antibody, and other modified immunoglobulin molecules comprising antigen recognition sites.

82. The targeted drug conjugate of claim 80, wherein the antibody is selected from Muromonab-CD3, Abciximab, Rituximab, Daclizumab, Palivizumab, Infliximab, Trastuzumab (herceptin), Etanercept, Basiliximab, Gemtuzumab ozogamicin, Alemtuzumab, Ibritumomab tiuxetan, Adalimumab, Alefacept, Omalizumab, Efalizumab, Tositumomab-I¹³¹, Cetuximab, Bevacizumab, Natalizumab, Ranibizumab, Panitumumab, Eculizumab, Rilonacept, Certolizumab pegol, Romiplostim, AMG-531, CNTO-148, CNTO-1275, ABT-874, LEA-29Y, Belimumab, TACI-Ig, Second generation anti-CD20, ACZ-885, Tocilizumab, Atlizumab, Mepolizumab, Pertuzumab, Humax CD20, Tremelimumab (CP-675 206), Ticilimumab, MDX-010, IDEC-114, Inotuzumab ozogamycin, HuMax EGFR, Aflibercept, HuMax-CD4, Ala-Ala, ChAglyCD3, TRX4, Catumaxomab, IGN101, MT-201, Pregovomab, CH-14.18, WX-G250, AMG-162, AAB-001, Motavizumab, MEDI-524, Efumgumab, Aurograb, Raxibacumab, Third generation anti-CD20, LY2469298, and Veltuzumab.

83. A drug conjugate comprising an active agent and a linking group; wherein the active agent is substituted with a polar group.

84. The drug conjugate of claim 83, wherein the polar group is selected from a saccharide, sulfate, or sulfonate.

85. The drug conjugate of claim 83, having the structure of Formula (I):



or a pharmaceutically acceptable salt thereof;

wherein:

Z' is a coupling group;

Ar is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

Y' is $-(\text{CR}^b)_y\text{N}(\text{R}^a)-$, $-(\text{CR}^b)_y\text{O}-$, or $-(\text{CR}^b)_y\text{S}-$, positioned such that the N, O, or S atom is attached to TG if y is 1;

TG is a triggering group that, when activated, generates an N, O, or S atom capable of reacting with the SO_2 to displace $(Q)_q(\text{L}')_w$ and form a 5- to 6-membered ring including $\text{X}-\text{SO}_2$ and the intervening atoms of Ar;

X is $-\text{O}-$, $-\text{C}(\text{R}^b)_2-$, or $-\text{N}(\text{R}^c)-$;

L' is a spacer moiety that if present, is attached to the SO_2 via a heteroatom selected from O, S, and N, and is selected such that cleavage of the bond between L' and SO_2 promotes release of the active agent;

each Q is independently an active agent substituted with a saccharide, a sulfate, or a sulfonate;

q is an integer selected from 1 to 3;

w and y are each independently 0 or 1; and

R^a , R^b and R^c are each independently hydrogen or C_{1-6} alkyl; or two R^b , together with the atom to which they are attached, complete a 3- to 5-membered ring;

provided that when w is 0, q is 1.


86. The drug conjugate of claim 85, wherein each Q is independently selected from a chemotherapeutic agent substituted with a saccharide, a sulfate, or a sulfonate or a toxin substituted with a saccharide, a sulfate, or a sulfonate.

87. The drug conjugate of claim 86, wherein the active agent is a chemotherapeutic agent substituted with a saccharide, a sulfate, or a sulfonate.

88. The drug conjugate of claim 85, wherein each Q is independently selected from an immunomodulatory compound substituted with a saccharide, a sulfate, or a sulfonate, an anticancer agent substituted with a saccharide, a sulfate, or a sulfonate, an antiviral agent substituted with a saccharide, a sulfate, or a sulfonate, an antibacterial agent substituted with a saccharide, a sulfate, or a sulfonate, an antifungal agent substituted with a saccharide, a sulfate, or a sulfonate, or an antiparasitic agent substituted with a saccharide, a sulfate, or a sulfonate, and an amanitin substituted with a saccharide, a sulfate, or a sulfonate.

89. The drug conjugate of claim 86, wherein each Q is independently selected from a benzodiazepine substituted with a saccharide, a sulfate, or a sulfonate, a duocarmycin substituted with a saccharide, a sulfate, or a sulfonate, an auristatin substituted with a saccharide, a sulfate, or a sulfonate, a tubulysine substituted with a saccharide, a sulfate, or a sulfonate, SN-38 substituted with a saccharide, a sulfate, or a sulfonate, PNU substituted with a saccharide, a sulfate, or a sulfonate, or an exatecan substituted with a saccharide, a sulfate, or a sulfonate.

90. The drug conjugate of claim 89, wherein each Q is independently represented by:



wherein:

Z^2 is a linking group;


Z^3 is a linking group;

t is an integer from 1-5;


e is an integer from 1-5; and

each Q' is independently a modified benzodiazepine.

91. The drug conjugate of claim 90, wherein each Q' is independently represented by formula (IIa) or (IIb):



(IIa); or



(IIb);

or a pharmaceutically acceptable salt thereof;

wherein:

each A is a heterocycle;

each R^{a'} is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl (preferably lower alkyl), alkenyl, alkynyl, cycloalkyl, aryl, or a heterocyclic ring, preferably a five- or six-membered ring; optionally, fused to or substituted with one or more aryl or heteroaryl rings;

each R^{b'} is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or a heterocyclic ring, preferably a five- or six-membered ring; optionally, fused to or substituted with one or more aryl or heteroaryl rings;

or two geminal R^{b'} are optionally taken together to form an oxo or =CH₂; or two R^{b'}, together with the intervening atoms, optionally complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with one or more of R^{f'}

each R^{f'} is independently halogen, hydroxyl, -O-Gly, cyano, nitro, alkyl, haloalkyl, cycloalkyl, carboxyl, amino, aminoalkyl (-CH₂NH₂, -CH₂NH(Me), or -CH₂N(Me)₂), aryl, or heteroaryl;

R^{c'} is sulfonate, sulfate, hydroxyl, amino, or thiol;

R^{d'} is -L''-Gly, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

provided that at least one R^{c'} is sulfonate or sulfate, or at least one R^{d'} is -L''-Gly;


L'' is a bond or a linker;

m is an integer selected from 0-3;


n is an integer selected from 0-8, as valency permits; and

Gly is glycosyl, preferably a monosaccharide, disaccharide, or oligosaccharide.

92. The drug conjugate of claim 90 or 91, wherein the drug conjugate is represented by Formula (IIIa) or (IIIb):




(IIIa); or



(IIIb);

or a pharmaceutically acceptable salt thereof.

93. The drug conjugate of any one of claims 90-92, wherein A is 5- to 6-membered heterocycle.
94. The drug conjugate of any one of claims 90-93, wherein R^{c'} is hydroxyl.
95. The drug conjugate of any one of claims 90-93, wherein R^{c'} is sulfonate or sulfate.
96. The drug conjugate of any one of claims 90-93, wherein R^{d'} is -L"-Gly.
97. The drug conjugate of any one of claims 90-93, wherein R^{d'} is hydrogen.
98. The drug conjugate of claim 90, wherein each Q' is independently selected from:



or a pharmaceutically acceptable salt thereof;

wherein $\equiv$ is a single bond or a double bond.

99. The drug conjugate of any one of claims 90-98, wherein R^{a'} is halogen, amino, hydroxyl, alkoxy, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 4- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl.

100. The drug conjugate of any one of claims 90-99, wherein one R^{b'} is alkyl or two geminal R^{b'} are taken together to form an alkenyl group.


101. The drug conjugate of any one of claims 90-99, wherein two R^{b'}, together with the intervening atoms, complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; preferably wherein the aryl or heteroaryl is a 6-membered aryl or heteroaryl, optionally substituted with one or more R^f.


102. The drug conjugate of claim 101, wherein two $R^{b'}$, together with the intervening atoms, complete an aryl or heteroaryl; preferably wherein the aryl or heteroaryl is a 6-membered aryl or heteroaryl, optionally substituted with one or more R^f .

103. The drug conjugate of claim 101, wherein two $R^{b'}$, together with the intervening atoms, complete an aryl.

104. The drug conjugate of claim 101, wherein two $R^{b'}$, together with the intervening atoms, complete a heteroaryl.

105. The drug conjugate of claim 90 or 98, wherein each Q' is independently selected from:






or a pharmaceutically acceptable salt thereof;

wherein $\equiv$ is a single bond or a double bond; and

wherein g is an integer from 0-4.

106. The drug conjugate of any one of claims 90-105, wherein Z^3 is selected from:



wherein:

X^5 is -O- or -NR^x-;


Y^1 is CR^y, or N;

R^y is hydrogen or C₁₋₆ alkyl;


each b is independently an integer from 1-3; and

c is an integer from 1-5.

107. The drug conjugate of claim 106, wherein Z^3 is selected from:



108. The drug conjugate of any one of claims 90-105, wherein Z^2 is methylene.





109. The drug conjugate of any one of claims 90-105, wherein Z^2 is ,
wherein:


Y^5 is CR^{Y1} or N, provided that only one Y^5 is N;




R^{Y1} is H, hydroxyl, amino, amido, or $(CH_2)_z(R^{Y1a})$;

R^{Y1a} is amino (*e.g.*, secondary or tertiary amino), aryl (*e.g.*, phenyl), or heteroaryl; and


z is an integer having a value of 1 to about 10.

110. The drug conjugate of claim 109, where Z^2 is , ,
, or .

111. The drug conjugate of any one of claims 90-105, wherein Z^2 is , wherein:
 Y^6 is CR^{Y2} or N;
 R^{Y2} is H or alkyl, preferably lower alkyl;
 R^{Z2} is $(CH_2)_zR^{Z2a}$;
 R^{Z2a} is amino (preferably tertiary amino), aryl (*e.g.*, phenyl), or heteroaryl; and
 z is an integer having a value of 0 to about 10.

112. The drug conjugate of claim 111, where Z^2 is , , or
.

113. The drug conjugate of claim 89, wherein each Q is independently a group of Formula (IV):



or a pharmaceutically acceptable salt thereof;

wherein:

ring Cy is selected from aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

== is a single bond or a double bond;

X' is halogen;

X'' is selected from -NR-, -S-, or -O-;

each R^{a''} and R^{b''} are independently halogen, amino, hydroxyl, alkoxy, acetyl, hydroxyalkyl, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or -(L''')_r-X''-Gly;

p is an integer selected from 0-4;

d is an integer selected from 0-4;

r is an integer from 0-1;

DBD is a DNA binding domain;

each L''' is a bond or a linker and

Gly is a monosaccharide, disaccharide, or oligosaccharide.


114. The drug conjugate of claim 113, wherein each L''' is a C₁₀-C₁₀₀ linear or branched, saturated, or unsaturated alkylene moiety, optionally comprising one or more double bonds and/or triple bonds.

115. The drug conjugate of claim 113, wherein each p and each d are independently an integer from 0-1.


116. The drug conjugate of claim 113, wherein Cy is phenyl.

117. The drug conjugate of claim 113, wherein Cy is pyrrolidine or pyrrole.

118. The drug conjugate of any one of claims 113-117, wherein each Q is independently a group of Formula (IVa) or (IVb):




(IVa);



(IVb);

or a pharmaceutically acceptable salt thereof.

119. The drug conjugate of any one of claims 113-118, wherein the DBD-(L''')_r-X''-Gly unit is selected from:



or a pharmaceutically acceptable salt thereof;

wherein:

Y'' is C or N;

X'' is selected from -NR-, -S-, or -O-;

R is hydrogen or alkyl;


each $R^{b''}$ is independently halogen, amino, hydroxyl, acetyl, hydroxyalkyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or $-(L''')_r-X''-Gly$;

R^k is alkyl or hydroxyalkyl, preferably C_1 - C_3 alkyl;


q is an integer selected from 0-3; and

$==$ is a single bond or a double bond.


120. The drug conjugate of claim 119, wherein each Q is independently selected from a group of Formula (IVc), (IVd), (IVe), (IVf), (IVg), (IVh), (IVi), or (IVj):




(IVc);




(IVd);




(IVe);




(IVf);




(IVg);



(IVh);




(IVi);




(IVj);

or a pharmaceutically acceptable salt thereof.


121. The drug conjugate of claim 120, wherein each Q is independently selected from a group of Formula (IVc), (IVd), (IVe), or (IVf):




(IVc);



(IVd);




(IVe);



(IVf);

or a pharmaceutically acceptable salt thereof.


122. The drug conjugate of any one of claims 113-121, wherein the drug conjugate is represented by Formula (V):




(V);

or a pharmaceutically acceptable salt thereof.

123. The drug conjugate of claim 122, wherein Cy is phenyl.
124. The drug conjugate of claim 122, wherein Cy is selected from pyrrolidine or pyrrole.
125. The drug conjugate of claim 122, wherein the drug conjugate is represented by Formula (Va) or (Vb):




(Va);



(Vb);

or a pharmaceutically acceptable salt thereof.

126. The drug conjugate of any one of claims 122-125, wherein the $DBD-(L''')_r-X''-Gly$ unit is selected from:



or a pharmaceutically acceptable salt thereof;

wherein:

Y'' is C or N;


each $R^{b''}$ is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;


R^k is alkyl or hydroxyalkyl, preferably C_1 - C_3 alkyl;

q is an integer selected from 0-3; and


$==$ is a single bond or a double bond.

127. The drug conjugate of claim 126, wherein the drug conjugate is selected from a group of Formula (Vc), (Vd), (Ve), or (Vf):






(Vd);




(Ve);




(Vf);

or a pharmaceutically acceptable salt thereof.

128. The drug conjugate of claim 127, wherein the drug conjugate is represented by formula (Vc) or (Vd):



(Vc); or



(Vd);

or a pharmaceutically acceptable salt thereof.





129. The drug conjugate of any one of claims 113-128, wherein:


each $R^{a''}$ is independently hydrogen, halogen, amino, hydroxyl, alkoxy, acetyl, hydroxyalkyl, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or $-(L''')_r-X''-Gly$; and

each $R^{b''}$ is independently hydrogen, halogen, amino, hydroxyl, alkoxy, acetyl, hydroxyalkyl, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or $-(L''')_r-X''-Gly$.

130. The drug conjugate of any one of claims 113-129, wherein X' is Cl.

131. The drug conjugate of any one of claims 113-129, wherein X' is Br.
132. The drug conjugate of any one of claims 113-131, wherein Y'' is C.
133. The drug conjugate of any one of claims 113-131, wherein Y'' is N.
134. The drug conjugate of any one of claims 113-133, wherein Q is selected from:






or a pharmaceutically acceptable salt thereof.

135. The drug conjugate of any one of claims 113-134, wherein L''' is a bond.


136. The drug conjugate of any one of claims 113-134, wherein L''' is a linker selected from



wherein:

$R^{a''''}$ is independently hydrogen, halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and each $R^{b''''}$ is independently hydrogen, halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and h is an integer selected from 0-4, as valency permits.


137. The drug conjugate of claim 136, wherein $L^{''''}$ is



138. The drug conjugate of any one of claims 91-137, wherein Gly is a monosaccharide.


139. The drug conjugate of claim 138, wherein Gly is a monosaccharide selected from glucose, glucuronic acid, fucose, and galactose.

140. The drug conjugate of claim 139, wherein Gly is



optionally wherein 1 or more of the –OH groups is masked by a protecting group.


141. The drug conjugate of claim 140, wherein Gly is



142. The drug conjugate of any one of claims 91-137, wherein Gly is a disaccharide.


143. The drug conjugate of claim 142, wherein Gly is a disaccharide comprising glucose, glucuronic acid, fucose, galactose, or a combination thereof.

144. The drug conjugate of claim 143, wherein Gly is




optionally wherein 1 or more of the –OH groups is masked by a protecting group.

145. The drug conjugate of claim 144, wherein Gly is



146. The drug conjugate of any one of claims 90-145, wherein X'' or L'' is coupled to Gly at the anomeric position.
147. The drug conjugate of any one of claims 85-146, wherein Ar is aryl.
148. The drug conjugate of claim 147, wherein Ar is C₆₋₁₀ aryl.
149. The drug conjugate of claim 148, wherein Ar is phenyl.
150. The drug conjugate of any one of claims 85-145, wherein Ar is heteroaryl.
151. The drug conjugate of claim 150, wherein Ar is 5- to 10-membered heteroaryl.
152. The drug conjugate of any one of claims 85-151, wherein Y' is -(CR^b₂)_yN(R^a)- or -(CR^b₂)_yO-.
153. The drug conjugate of claim 152, wherein Y' is -(CR^b₂)_yO-.
154. The drug conjugate of claim 152 or 153, wherein y is 0 or 1.
155. The drug conjugate of claim 152 or 153, wherein y is 1.
156. The drug conjugate of any one of claims 85-155, wherein X is -O-, -C(R^b)₂-, or -N(R^c)-.
157. The drug conjugate of claim 156, wherein X is -O-.
158. The drug conjugate of any one of claims 85-157, wherein L' is a spacer moiety, and forms an -O-, an -OC(O)-, an -OC(O)O- or an -OC(O)NH- linkage including the heteroatom of the active agent.
159. The drug conjugate of claim 158, wherein Q-(L')_w- is selected from



wherein:

X^4 is absent or forms an -O-, an -OC(O)-, an -OC(O)O- or an -OC(O)NH- linkage including the heteroatom of Q;

X^1 is -O- or -NR^a-;

R^a is hydrogen or alkyl;

X^2 is -O-, -OC(O)-, -OC(O)O- or -OC(O)NH-;

X^3 is -OC(=O)-;


w' is an integer having a value of 1-5;

R⁹ and R¹⁰ are each independently hydrogen, alkyl, aryl, or heteroaryl, wherein alkyl, aryl, and heteroaryl are unsubstituted or substituted with one or more substituents, *e.g.*, selected from alkyl, -(CH₂)_uNH₂, -(CH₂)_uNR^{u1}R^{u2}, and -(CH₂)_uSO₂R^{u3};

R^{u1}, R^{u2}, and R^{u3} are each independently hydrogen, alkyl, aryl, or heteroaryl; and

u is an integer having a value of 1-10.


160. The drug conjugate of claim 159, wherein Q-(L')_w- is



161. The drug conjugate of any one of claims 85-160, wherein TG is a monosaccharide.


162. The drug conjugate of claim 161, wherein TG is a monosaccharide selected from glucose, glucuronic acid, fucose, and galactose.

163. The drug conjugate of claim 162, wherein TG is



optionally wherein 1 or more of the –OH groups is masked by a protecting group.


164. The drug conjugate of claim 163, wherein TG is



165. The drug conjugate of any one of claims 85-160, wherein TG is a disaccharide.


166. The drug conjugate of claim 165, wherein TG is a disaccharide comprising glucose, glucuronic acid, fucose, galactose, or a combination thereof.

167. The drug conjugate of claim 166, wherein TG is




optionally wherein 1 or more of the –OH groups is masked by a protecting group.


168. The drug conjugate of claim 167, wherein TG is




169. The drug conjugate of any one of claims 85-168, wherein L' is coupled to TG at the anomeric position.

170. The drug conjugate of any one of claims 85-169, wherein Z' is selected from









wherein:

R^{za} is H or methyl;

R^{zb} is $-OH$, $=O$, or $=NHOH$;


n and m are each independently integer selected from 1-10;

x is integer selected from 1-2;


$\sim$ represents the bond between Z' and the drug conjugate;



----- a single bond or a double bond; and



Z'' is selected from







171. The drug conjugate of claim 85, wherein the drug conjugate is selected from




























or a pharmaceutically acceptable salt thereof.


172. A pharmaceutical composition comprising the drug conjugate of any one of claims 1-171.








173. A targeted drug conjugate of Formula (VI), comprising a TM (targeting moiety) conjugated to the drug conjugate of any one of claims 85-171:




wherein TM is a targeting moiety.

174. The conjugate of claim 173, wherein Z' is selected from







wherein

R^{za} is H or methyl;

R^{zb} is $-OH$, $=O$, or $=NOH$;

----- a single bond or a double bond;


n and m are each independently an integer selected from 1-10;

x is an integer selected from 1-2;


a" represents the bond between Z' and the drug conjugate;

b" represents the bond between Z' and TM; and

Z'' is selected from



175. A targeted drug conjugate of Formula (VIb) comprising a TM (targeting moiety) conjugated to the drug conjugate of claim 83 or 84:



wherein:

TM is a targeting moiety;

R is hydrogen or a hydroxy protection group;

X is -C(O)-, -NH-, -O-, or -S-;

Q is an active agent substituted with a saccharide, a sulfonate, or a sulfate;

T is $B' \cdots U1 \cdots (CH_2CH_2X_3)_{p4} \cdots (CH_2)_{p3} \cdots Wa_4 \cdots Q_2 \cdots Wa_3 \cdots W_1 \cdots$;

n is an integer selected from 0 or 1;

Y is hydrogen, haloC₁-C₈alkyl, halogen, cyano or nitro; z is an integer selected from 1-3, and

Y may be the same or different from each other, if z is an integer of not less than 2;

z1 is an integer selected from 0 or 1;

W₁ is $W_{a2} \cdots (CH_2)_{a1} \cdots W_{b1} \cdots Q_1 \cdots$;

W₂ is $W_{a4} \cdots Q_2 \cdots W_{a3} \cdots$;

W_{a1} and W_{a2} are each independently -NH-, -C(=O)-, or -CH₂-;

W_{a3} and W_{a4} are each independently -NH-, -C(=O)-, -CH₂-, -C(=O)NH-, -NHC(=O)-, or triazolylenes;

W_{b1} is an amide bond or triazolylenes;

L is an amino acid, peptide, or amide bond as a linker connecting W_{a2} and Z;

Z is a single bond, -W_{a5}-(CH₂)_{a2}-W_{b2}-(CH₂)_{a3}-W_{a6}-, or -W_{a7}-(CH₂)_{a4}-CR'R''-X'''-;

R' is C₁-C₈alkyl or TM-W_{a8}-Q₃-W_{c1}-(CH₂)_{a5}-;

R'' is TM-W_{a8}-Q₃-W_{c1}-(CH₂)_{a5}-;

Q₁ and Q₃ are each independently -(CH₂)_{a6}-(X₁CH₂CH₂)_{b1}-(CH₂)_{a7}-;

X₁ and X₃ are each independently -O-, -S-, -NH-, or -CH₂-;

X''' is -NHC(=O)-(CH₂)_{a8}-W_{a9}- or -C(=O)NH-(CH₂)_{a8}-W_{a9}-;

W_{a5}, W_{a6}, W_{a7}, W_{a8}, and W_{a9} are each independently -NH-, -C(=O)-, or -CH₂-;

W_{b2} is an amide bond or triazolylenes;

W_{c1} is -NHC(=O)- or -C(=O)NH-;

Q₂ is a saturated or unsaturated alkylene, which is linear or branched with a carbon number of 1 to 50, satisfying any one of (i) to (iii) below;


- (iv) at least one -CH₂- in the alkylene is substituted with one or more heteroatoms selected from -NH-, -C(=O)-, -O-, and -S-;
- (v) at least one arylene or heteroarylene is included in the alkylene;
- (vi) the alkylene is further substituted with one or more selected from the group consisting of C₁-C₂₀ alkyl, C₆-C₂₀ aryl, C₁-C₈ alkyl, -(CH₂)_{s1}COOR₃, -(CH₂)_{s1}COR₃, -(CH₂)_{s2}CONR₄R₅, and -(CH₂)_{s2}NR₄R₅;

arylene or heteroarylene of (ii) above may be further substituted with nitro;

R₃, R₄, and R₅ are each independently hydrogen or C₁-C₁₅ alkyl;

X₂ is -O-, -S-, -NH-, or -CH₂-;

U₁ is bound to B' in the position of asterisk (*) with a linking group selected from the following structures:



R is C₁-C₁₀ alkyl, C₆-C₂₀ aryl or C₂-C₂₀ heteroaryl;


TM and B' are each independently a ligand or a protein having properties selectively targeting a particular organ with a drug, a tissue or a cell, that is, properties binding to a receptor;

a1, a2, a3, a4, a5, a6, a8, b1, p1, p2, p3 and p4 are each independently an integer selected from 1-10;

a7, y, s1, s2 and s4 are each independently an integer selected from 0-10; and

R₁ and R₂ are each independently hydrogen, C₁-C₈ alkyl or C₃-C₈ cycloalkyl.

176. A targeted drug conjugate of Formula (VIc) comprising a TM (targeting moiety) conjugated to the drug conjugate of claim 83 or 84:



wherein:

TM is a targeting moiety;

G is a glucuronic acid moiety or a derivative thereof;

Q is an active agent substituted with a saccharide, a sulfonate or a sulfate;

W is an electron withdrawing group;


Z is hydrogen, C₁-C₈ alkyl, halogen, cyano, or nitro;

n is an integer selected from 1-3, and when n is an integer of 2 or more, each of the Z(s) are the same as or different from each other;

L is a linker connecting TM and W; and

R₁ and R₂ are each independently hydrogen, C₁-C₈ alkyl, or C₃-C₈ cycloalkyl.

177. A targeted drug conjugate of Formula (VId) comprising a TM (targeting moiety) conjugated to the drug conjugate of claim 83 or 84:



wherein TM is a targeting moiety;

L₁ is ligand moiety;


Q is an active agent substituted with a saccharide, a sulfonate or a sulfate;

-A_a-W_w-Y_y- is linker moiety;

A is an optional stretcher moiety;

a is an integer selected from 0-3;

each W is independently a glucuronide unit having one of the formula:



Su is a sugar moiety;

each R is independently hydrogen, halogen, -CN, or -NO₂;

w is an integer selected from 1-2;

Y is an optional self-immolative spacer moiety;

y is an integer selected from 0-2; and

p is an integer selected from 1-20.


178. The conjugate of claim 173-177, wherein the TM is a nanoparticle, an immunoglobulin, a nucleic acid, a protein, an oligopeptide, a polypeptide, an antibody, a fragment of an antigenic polypeptide, or a rebody.

179. The conjugate of claim 178, wherein the TM is an antibody selected from an intact polyclonal antibody, an intact monoclonal antibody, an antibody fragment, a single chain Fv (scFv) mutant, a multispecific antibody, a bispecific antibody, a chimeric antibody, a humanized antibody, a human antibody, a fusion protein comprising an antigenic determinant portion of an antibody, and other modified immunoglobulin molecules comprising antigen recognition sites.

180. The conjugate of claim 179, wherein the antibody is selected from Muromonab-CD3, Abciximab, Rituximab, Daclizumab, Palivizumab, Infliximab, Trastuzumab (herceptin), Etanercept, Basiliximab, Gemtuzumab ozogamicin, Alemtuzumab, Ibritumomab tiuxetan, Adalimumab, Alefacept, Omalizumab, Efalizumab, Tositumomab-I¹³¹, Cetuximab, Bevacizumab, Natalizumab, Ranibizumab, Panitumumab, Eculizumab, Rilonacept, Certolizumab pegol, Romiplostim, AMG-531, CNTO-148, CNTO-1275, ABT-874, LEA-29Y, Belimumab, TACI-Ig, Second generation anti-CD20, ACZ-885, Tocilizumab, Atlizumab, Mepolizumab, Pertuzumab, Humax CD20, Tremelimumab (CP-675 206), Ticilimumab, MDX-010, IDEC-114, Inotuzumab ozogamycin, HuMax EGFR, Aflibercept, HuMax-CD4, Ala-Ala, ChAglyCD3, TRX4, Catumaxomab, IGN101, MT-201, Pregovomab, CH-14.18, WX-G250, AMG-162, AAB-001, Motavizumab, MEDI-524, Efumgumab, Aurograb, Raxibacumab, Third generation anti-CD20, LY2469298, and Veltuzumab.

181. A pharmaceutical composition comprising the targeted drug conjugate of any one of claims 173-180.

182. A compound represented by Formula (VII) or (VIII):



or a pharmaceutically acceptable salt thereof;

wherein:

A is a heterocycle;

each R^{a'} and R^{b'} are independently halogen, amino, hydroxyl, acetyl, hydroxyalkyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

two geminal R^{b'} are optionally taken together to form an oxo or =CH₂; or two R^{b'}, together with the intervening atoms, optionally complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^{c'} is sulfonate, sulfate, hydroxyl, amino, or thiol;

R^{d'} is -L''-Gly, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

provided that at least one R^{c'} is sulfonate or sulfate, or at least one R^{d'} is -L''-Gly;

R^{e'} is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

m is an integer selected from 0-3;

n is an integer selected from 0-8, as valency permits;

ring Cy is selected from aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

=== is a single bond or a double bond;

X' is halogen;

X'' is -NR-, -S-, or -O-;

each R^{a''} and R^{b''} are independently halogen, amino, hydroxyl, alkoxy, acetyl, hydroxyalkyl, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or -(L''')_r-X''-Gly;

d is an integer selected from 0-4;

r is an integer selected from 0-1;

each L''' is a bond or a linker,

R^{e''} is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

p is an integer selected from 0-4;

DBD is a DNA binding domain;


L'' is a bond or a linker; and

Gly is a monosaccharide, disaccharide, or oligosaccharide.

183. A compound of claim 182, wherein each L''' is a C₁₀-C₁₀₀ linear or branched, saturated, or unsaturated alkylene moiety, optionally comprising one or more double bonds and/or triple bonds.

184. A compound of claim 182, wherein each p and each d are independently an integer from 0-1.

185. The compound of claim 182, represented by formula (VII):



(VII);

or a pharmaceutically acceptable salt thereof.


186. The compound of any one of claims 182-185, wherein A is 5- to 6-membered heterocycle.

187. The compound of any one of claims 182-186, wherein R^{c'} is hydroxyl.

188. The compound of any one of claims 182-187, wherein R^{d'} is hydrogen, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl.

189. The compound of claim 188, wherein R^{d'} is L''-Gly.

190. The compound of claim 185, wherein the compound is selected from:



or a pharmaceutically acceptable salt thereof;

wherein == is a single bond or a double bond.

191. The compound of any one of claims 182-190, wherein R^{a'} is halogen, amino, hydroxyl, alkoxy, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 4- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl.

192. The compound of any one of claims 182-191, wherein two geminal R^{b'} are taken together to form =CH₂.

193. The compound of any one of claims 182-191, wherein two R^{b'}, together with the intervening atoms, complete a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

194. The compound of claim 193, wherein two R^{b'}, together with the intervening atoms, complete an aryl or heteroaryl.


195. The compound of claim 193, wherein two R^{b'}, together with the intervening atoms, complete an aryl.

196. The compound of any one of claims 182-195, wherein R^{e'} is hydrogen, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl.

197. The compound of claim 196, wherein R^{e'} is hydrogen, C₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl.


198. The compound of claim 197, wherein R^{e'} is hydrogen.

199. The compound of claim 185 or 190, wherein the compound is selected from:



or a pharmaceutically acceptable salt thereof.

200. The compound of claim 182, represented by formula (VIII):





or a pharmaceutically acceptable salt thereof.

201. The compound of claim 200, wherein Cy is phenyl.


202. The compound of claim 200, wherein Cy is pyrrolidine or pyrrole.

203. The compound of claim 200, having the structure of Formula **(VIIIa)** or **(VIIIb)**:



or a pharmaceutically acceptable salt thereof.

204. The compound of any one of claims 200-203, wherein the DBD-(L''')-X''-Gly unit is selected from:



or a pharmaceutically acceptable salt thereof;

wherein:

Y'' is C or N;

X'' is selected from $-NR-$, $-S-$, or $-O-$;

R is hydrogen or alkyl;

r is an integer from 0-1;


each $R^{b''}$ is independently halogen, amino, hydroxyl, acetyl, hydroxyalkyl, alkoxy, cyano, nitro, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or $-(L''')_r-X''-Gly$;

R^k is alkyl, preferably C_1-C_3 alkyl;

q is an integer selected from 0-3; and


$==$ is a single bond or a double bond.

205. The compound of any one of claims 200-204, having the structure of Formula (VIIIc), (VIIId), (VIIIe), or (VIIIf):




(VIIIc);

(VIIIId);



(VIIIe);



(VIIIf);

or a pharmaceutically acceptable salt thereof.

206. The compound of any one of claims 200-205, wherein:

each $R^{a''}$ is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, alkenyl, alkynyl, =O, carboxyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
each $R^{b''}$ is independently halogen, amino, hydroxyl, alkoxy, cyano, nitro, C_{1-6} alkyl, heteroalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, 4- to 10-membered heterocycloalkyl, C_{6-10} aryl, or 5- to 10-membered heteroaryl.

207. The compound of any one of claims 200-206, wherein X' is Cl.

208. The compound of any one of claims 200-207, wherein X' is Br.

209. The compound of any one of claims 200-208, wherein Y'' is C.

210. The compound of any one of claims 200-208, wherein Y'' is N.





211. The compound of any one of claims 200-210, wherein $R^{e''}$ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.


212. The compound of claim 211, wherein R^{'''} is hydrogen, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, 3- to 10-membered heterocycloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl.

213. The compound of claim 212, wherein R^{'''} is hydrogen, C₁₋₆ alkyl, or C₃₋₁₀ cycloalkyl.

214. The compound of claim 213, wherein R^{'''} is hydrogen.

215. The compound of claim 200, wherein the compound is selected from:






or a pharmaceutically acceptable salt thereof.

216. The compound of any one of claims 200-215, wherein L''' is a bond.

217. The compound of any one of claims 200-215, wherein L''' is a linker selected from



wherein:

$R^{b''''}$ is hydrogen, halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl, alkenyl, alkynyl,


$=O$, carboxyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and

each $R^{b''''}$ is independently hydrogen, halogen, amino, hydroxyl, alkoxy, cyano, nitro, alkyl,

heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and

h is an integer selected from 0-4, as valency permits.


218. The compound of claim 217, wherein $L^{b''''}$ is



219. The compound of any one of claims 182-218, wherein Gly is a monosaccharide.


220. The compound of claim 219, wherein Gly is a monosaccharide selected from glucose, glucuronic acid, fucose, and galactose.

221. The compound of claim 220, wherein Gly is



optionally wherein 1 or more of the $-OH$ groups is masked by a protecting group.


222. The compound of claim 221, wherein Gly is



223. The compound of any one of claims 182-218, wherein Gly is a disaccharide.


224. The compound of claim 223, wherein Gly is a disaccharide comprising glucose, glucuronic acid, fucose, galactose, or a combination thereof.

225. The compound of claim 224, wherein Gly is



optionally wherein 1 or more of the –OH groups is masked by a protecting group.


226. The compound of claim 225, wherein Gly is




227. The compound of any one of claims 182-226, wherein X'' is coupled to Gly at the anomeric position.

228. A drug conjugate comprising the compound of any one of claims 182-227 and a linker group.


229. The drug conjugate of claim 228, represented by formula (IX), (X), or (XI):



(IX);



(X); or



(XI);

or a pharmaceutically acceptable salt thereof;

wherein:

Z' is a coupling group;

Ar is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

Y' is $-(CR^b)_yN(R^a)-$, $-(CR^b)_yO-$, or $-(CR^b)_yS-$, positioned such that the N, O, or S atom is attached to TG if y is 1;

TG is a triggering group that, when activated, generates an N, O, or S atom capable of reacting with the SO_2 to displace $(Q)_q-(L')_w$ and form a 5- to 6-membered ring including $X-SO_2$ and the intervening atoms of Ar;

X is $-O-$, $-C(R^b)_2-$, or $-N(R^c)-$;

L' is a spacer moiety that if present, is attached to the SO_2 via a heteroatom selected from O, S, and N, and is selected such that cleavage of the bond between L' and SO_2 promotes release of the active agent;

w is an integer selected from 0-1;

r is an integer from 0-1;

Z^2 is a linking group;

Z^3 is a linking group;


R^a , R^b and R^c are each independently hydrogen, or lower alkyl;

y is an integer selected from 0-1;

t is an integer from 1-5; and

e is an integer from 1-5.

230. The drug conjugate of claim 229, wherein Z^3 is selected from:



wherein:

X^5 is $-O-$ or $-NR^x-$;


Y^1 is CR^y , or N;

R^x and R^y are each independently hydrogen or C_{1-6} alkyl;

each b is independently an integer from 1-3; and


c is an integer from 1-5.

231. The drug conjugate of claim 230, wherein Z^3 is selected from:



232. The drug conjugate of claim 229, wherein Z^2 is methylene.

233. The drug conjugate of claim 229, wherein Z^2 is



wherein:


Y^5 is CR^{Y1} or N, provided that only one Y^5 is N;

R^{Y1} is H, hydroxyl, amino, amido, or $(CH_2)_y(R^{Y1a})$;


R^{Y1a} is amino (*e.g.*, secondary or tertiary amino), aryl (*e.g.*, phenyl), or heteroaryl; and

y is an integer having a value of 1 to about 10.

234. The drug conjugate of claim 233, where Z^2 is



235. The drug conjugate of claim 229, wherein Z^2 is



wherein:

Y^6 is CR^{Y2} or N;


R^{Y2} is H or alkyl, preferably lower alkyl;

R^{Z2} is $(CH_2)_zR^{Z2a}$;

R^{Z2a} is amino (preferably tertiary amino), aryl (*e.g.*, phenyl), or heteroaryl; and

z is an integer having a value of 0 to about 10.

236. The drug conjugate of claim 235, where Z^2 is



237. The drug conjugate of any one of claims 229-236, wherein Ar is aryl.

238. The drug conjugate of claim 237, wherein Ar is C₆₋₁₀ aryl.

239. The drug conjugate of claim 238, wherein Ar is phenyl.

240. The drug conjugate of any one of claims 229-236, wherein Ar is heteroaryl.

241. The drug conjugate of claim 240, wherein Ar is 5- to 10-membered heteroaryl.

242. The drug conjugate of any one of claims 229-241, wherein Y' is $-(CR^{b_2})_yN(R^a)-$ or $-(CR^{b_2})_yO-$.

243. The drug conjugate of claim 242, wherein Y' is $-(CR^{b_2})_yO-$.

244. The drug conjugate of claim 242 or 243, wherein y is 0.

245. The drug conjugate of claim 242 or 243, wherein y is 1.

246. The drug conjugate of any one of claims 229-245, wherein X is $-O-$ or $-N(R^c)-$.


247. The drug conjugate of claim 246, wherein X is $-O-$.

248. The drug conjugate of any one of claims 229-247, wherein L' is a spacer moiety, and forms an $-O-$, an $-OC(O)-$, an $-OC(O)O-$, a $-NHC(O)O-$, or an $-OC(O)NH-$ linkage including the heteroatom of the active agent.

249. The drug conjugate of any one of claims 229-248, wherein TG is a monosaccharide.


250. The drug conjugate of claim 249, wherein TG is a monosaccharide selected from glucose, glucuronic acid, fucose, and galactose.

251. The drug conjugate of claim 250, wherein TG is



optionally wherein 1 or more of the –OH groups is masked by a protecting group.


252. The drug conjugate of claim 251, wherein TG is



253. The drug conjugate of any one of claims 229-254, wherein TG is a disaccharide.


254. The drug conjugate of claim 253, wherein TG is a disaccharide comprising glucose, glucuronic acid, fucose, galactose, or a combination thereof.

255. The drug conjugate of claim 254, wherein TG is




optionally wherein 1 or more of the –OH groups is masked with a protecting group.


256. The drug conjugate of claim 255, wherein TG is



257. The drug conjugate of any one of claims 229-256, wherein Y' is coupled to TG at the anomeric position.

258. The conjugate of any one of claims 229-257, wherein Z' is selected from








m and n are each integer selected from 1-10;

x is integer selected from 1-2;



----- a single bond or a double bond; and


Z'' is selected from



259. A targeted drug conjugate comprising the drug conjugate of any one of claims 228-258 and a TM (a targeting moiety).

260. The targeted drug conjugate of claim 259, represented by formula (XII), (XIII) or (XIV):








or a pharmaceutically acceptable salt thereof;

wherein TM is a targeting moiety.

261. The targeted drug conjugate of claim 260, wherein Z' is selected from







R^{za} is H or methyl;

R^{zb} is $-OH$, $=O$, or $=NOH$;

n and m are each independently integer selected from 1-10;


x is integer selected from 1-2;

----- a single bond or a double bond;

a'' represents the bond between Z' and the drug conjugate;

b'' represents the bond between Z' and TM; and

Z'' is selected from



262. The targeted drug conjugate of any one of claims 259-261, wherein the TM is a nanoparticle, an immunoglobulin, a nucleic acid, a protein, an oligopeptide, a polypeptide, an antibody, a fragment of an antigenic polypeptide, or a rebody.

263. The targeted drug conjugate of claim 262, wherein the TM is an antibody selected from an intact polyclonal antibody, an intact monoclonal antibody, an antibody fragment, a single chain Fv (scFv) mutant, a multispecific antibody, a bispecific antibody, a chimeric antibody, a humanized antibody, a human antibody, a fusion protein comprising an antigenic determinant portion of an antibody, and other modified immunoglobulin molecules comprising antigen recognition sites.

264. The targeted drug conjugate of claim 262, wherein the antibody is selected from Muromonab-CD3, Abciximab, Rituximab, Daclizumab, Palivizumab, Infliximab, Trastuzumab (herceptin), Etanercept, Basiliximab, Gemtuzumab ozogamicin, Alemtuzumab, Ibritumomab tiuxetan, Adalimumab, Alefacept, Omalizumab, Efalizumab, Tositumomab-I¹³¹, Cetuximab, Bevacizumab, Natalizumab, Ranibizumab, Panitumumab, Eculizumab, Rilonacept, Certolizumab pegol, Romiplostim, AMG-531, CNTO-148, CNTO-1275, ABT-874, LEA-29Y, Belimumab, TACI-Ig, Second generation anti-CD20, ACZ-885, Tocilizumab, Atlizumab, Mepolizumab, Pertuzumab, Humax CD20, Tremelimumab (CP-675 206), Ticilimumab, MDX-010, IDEC-114, Inotuzumab ozogamycin, HuMax EGFR, Aflibercept, HuMax-CD4, Ala-Ala, ChAglyCD3, TRX4, Catumaxomab, IGN101, MT-201, Pregovomab, CH-14.18, WX-G250, AMG-162, AAB-001, Motavizumab, MEDI-524,

Efungumab, Aurograb, Raxibacumab, Third generation anti-CD20, LY2469298, and Veltuzumab.

265. A method of treating a cancer, comprising administering the compound, the drug conjugate, the targeted drug conjugate, or the pharmaceutically composition of any one of claims 1-264 to a subject in need thereof.

266. The method of claim 265, wherein the cancer is selected from leukemia, lymphoma, breast cancer, colon cancer, ovarian cancer, bladder cancer, prostate cancer, glioma, lung cancer, bronchial cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, urinary bladder cancer, kidney cancer, renal pelvis cancer, oral cavity cancer, pharynx cancer, uterine corpus cancer, or melanoma.

267. A method of treating an autoimmune diseases or an inflammatory disease, comprising administering the compound, the drug conjugate, the targeted drug conjugate, or the pharmaceutically composition of any one of claims 1-264 to a subject in need thereof.

268. The method of claim 267, wherein the autoimmune diseases or the inflammatory disease is selected from B-cell mediated autoimmune diseases or inflammatory diseases, for example, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP), Waldenstrom's hypergammaglobulinaemia, Sjogren's syndrome, multiple sclerosis (MS), or lupus nephritis.

Fig. 1A




Fig. 1B




Fig. 2A





Fig. 2B



INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2022/000772

A. CLASSIFICATION OF SUBJECT MATTER

A61K 47/60(2017.01)i; A61K 47/68(2017.01)i; A61P 35/00(2006.01)i; C07D 403/04(2006.01)i; C07D 471/04(2006.01)i; C07H 3/04(2006.01)i; C07H 3/02(2006.01)i; C07H 17/00(2006.01)i; C07D 495/14(2006.01)i; C07D 487/04(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K 47/60(2017.01); A61K 47/65(2017.01); A61K 47/68(2017.01); C07C 317/02(2006.01); C07C 317/06(2006.01)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models
Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal), STN(Registry, CAplus) & Keywords: antibody drug conjugate, polar group, cancer, linker

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97-44000 A2 (PANORAMA RESEARCH, INC.) 27 November 1997 (1997-11-27) page 17, lines 3-21; example 23; figure 9	1-3,19-23,34,83,84, 182-184,200-204,215
Y		113-118
A		4,5,9,18,85-92,98, 105,171,175-177, 185,186,190,199
X	KR 10-2021-0068591 A (INTOCELL, INC.) 09 June 2021 (2021-06-09) claims 1, 33; paragraphs [0064], [0425], [0426]; example 67	1,4,5,9,18,83-9 2,98,105,182,18 5,186,190,199
Y		113-118

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"D" document cited by the applicant in the international application	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"E" earlier application or patent but published on or after the international filing date	"&" document member of the same patent family
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 May 2023

Date of mailing of the international search report

23 May 2023

Name and mailing address of the ISA/KR

**Korean Intellectual Property Office
189 Cheongsa-ro, Seo-gu, Daejeon
35208, Republic of Korea**

Authorized officer

HEO, Joo Hyung

Facsimile No. +82-42-481-8578

Telephone No. +82-42-481-5373

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2022/000772**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2014-080251 A1 (HANGZHOU DAC BIOTECH CO., LTD.) 30 May 2014 (2014-05-30) claims 1, 5; figure 19-t	1,4,5,9,18,83,8 4,98,105,182,18 5,186,190,199
A	KR 10-2020-0107837 A (LEGOCHEM BIOSCIENCES, INC. et al.) 16 September 2020 (2020-09-16) the whole document	1-5,9,18-23,34,83- 92,98,105,113-118, 171,175-177,182- 186,190,199-204,215
A	KR 10-2019-0064619 A (MEDIMMUNE LIMITED) 10 June 2019 (2019-06-10) the whole document	1-5,9,18-23,34,83- 92,98,105,113-118, 171,175-177,182- 186,190,199-204,215

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2022/000772

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **265-268**
because they relate to subject matter not required to be searched by this Authority, namely:

Claims 265-268 pertain to methods for treatment of the human body by surgery or therapy as well as diagnostic methods (PCT Article 17(2)(a)(i) and Rule 39.1(iv)).
2. ☒ Claims Nos.: **8, 13, 14, 16, 17, 31-33, 37, 39-41, 43-45, 48-54, 56, 57, 59, 61, 65, 68-70, 72-74, 78, 79, 81, 82, 102-104, 107, 110, 112, 120, 121, 123-125, 127, 128, 137, 139-141, 143-145, 148, 149, 151, 153, 157, 159, 160, 162-164, 166-168, 174, 179, 180, 189, 194, 195, 197, 198, 212-214, 218, 220-222, 224-226, 229-236, 238, 239, 241, 243, 247, 250-252, 254-256, 260, 261, 263, 264, 266, 268**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claims 8, 13, 14, 16, 17, 31-33, 37, 39-41, 43-45, 48-54, 56, 57, 59, 61, 65, 68-70, 72-74, 78, 79, 81, 82, 102-104, 107, 110, 112, 120, 121, 123-125, 127, 128, 137, 139-141, 143-145, 148, 149, 151, 153, 157, 159, 160, 162-164, 166-168, 174, 179, 180, 189, 194, 195, 197, 198, 212-214, 218, 220-222, 224-226, 229-236, 238, 239, 241, 243, 247, 250-252, 254-256, 260, 261, 263, 264, 266, 268 are regarded to be unclear because they refer to claims which do not comply with PCT Rule 6.4(a).
3. ☒ Claims Nos.: **6, 7, 10-12, 15, 24-30, 35, 36, 38, 42, 46, 47, 55, 58, 60, 62-64, 66, 67, 71, 75-77, 80, 93-97, 99-101, 106, 108, 109, 111, 119, 122, 126, 129-136, 138, 142, 146, 147, 150, 152, 154-156, 158, 161, 165, 169, 170, 172, 173, 178, 181, 187, 188, 191-193, 196, 205-211, 216, 217, 219, 223, 227, 228, 237, 240, 242, 244-246, 248, 249, 253, 257-259, 262, 265, 267**
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/IB2022/000772

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)			Publication date (day/month/year)
WO	97-44000	A2	27 November 1997	AU	3217097	A	09 December 1997
				CN	1165303	C	08 September 2004
				CN	1219841	A	16 June 1999
				EP	0918752	A2	02 June 1999
				JP	2000-511893	A	12 September 2000
				US	5843937	A	01 December 1998
				WO	97-44000	A3	31 December 1997
KR	10-2021-0068591	A	09 June 2021	AU	2019-370859	A1	13 May 2021
				AU	2019-370859	A1	07 May 2020
				BR	112021008354	A2	03 August 2021
				CA	3118026	A1	07 May 2020
				CN	112930350	A	08 June 2021
				CN	113929707	A	14 January 2022
				EA	202191180	A1	21 September 2021
				EP	3873912	A2	08 September 2021
				IL	282530	A	30 June 2021
				JP	2022-510505	A	26 January 2022
				US	2022-0009946	A1	13 January 2022
				WO	2020-089687	A2	07 May 2020
				WO	2020-089687	A3	11 June 2020
WO	2014-080251	A1	30 May 2014	AU	2012-395148	A1	21 May 2015
				AU	2012-395148	B2	27 October 2016
				CA	2891280	A1	30 May 2014
				CA	2891280	C	20 March 2018
				CN	105849086	A	10 August 2016
				CN	105849086	B	31 July 2018
				EP	2922818	A1	30 September 2015
				EP	2922818	B1	05 September 2018
				ES	2701076	T3	20 February 2019
				JP	2016-501859	A	21 January 2016
				JP	6133431	B2	24 May 2017
				US	10131682	B2	20 November 2018
				US	2015-0250896	A1	10 September 2015
KR	10-2020-0107837	A	16 September 2020	AU	2020-233532	A1	16 September 2021
				CA	3129581	A1	10 September 2020
				CN	112135638	A	25 December 2020
				EP	3936150	A1	12 January 2022
				IL	285953	A	31 October 2021
				JP	2022-522547	A	20 April 2022
				KR	10-2503143	B1	24 February 2023
				SG	11202108550	A	29 September 2021
				US	2022-0339291	A1	27 October 2022
				WO	2020-180121	A1	10 September 2020
KR	10-2019-0064619	A	10 June 2019	AU	2017-343793	A1	18 April 2019
				AU	2017-343793	B2	10 October 2019
				BR	112019007612	A2	02 July 2019
				CA	3039832	A1	19 April 2018
				CA	3039832	C	05 May 2020
				CL	2019000992	A1	23 September 2019

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/IB2022/000772

Patent document cited in search report	Publication date (day/month/year)	Patent family member(s)	Publication date (day/month/year)
	CN	109843335 A	04 June 2019
	CN	109843335 B	30 July 2021
	CO	2019003709 A2	28 June 2019
	DK	3525830 T3	31 May 2021
	EA	038662 B1	30 September 2021
	EA	201990615 A1	30 August 2019
	EP	3525830 A1	21 August 2019
	EP	3525830 B1	10 March 2021
	ES	2874699 T3	05 November 2021
	HR	P20210868 T1	09 July 2021
	HU	E054461 T2	28 September 2021
	IL	265919 A	30 June 2019
	IL	265919 B	30 June 2020
	JP	2020-503250 A	30 January 2020
	JP	6678821 B2	08 April 2020
	KR	10-2253480 B1	18 May 2021
	LT	3525830 T	25 June 2021
	MX	2019004292 A	14 October 2019
	NZ	752526 A	31 July 2020
	PL	3525830 T3	27 September 2021
	PT	3525830 T	07 June 2021
	RS	61925 B1	30 June 2021
	SI	3525830 T1	31 August 2021
	US	10799595 B2	13 October 2020
	US	2019-0282705 A1	19 September 2019
	WO	2018-069490 A1	19 April 2018
	ZA	201902081 B	27 November 2019